,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,2021 ESG Action Report People.,"('Business_Model_Resilience', 0.48298048973083496)","('Systemic_Risk_Management', 0.07725781947374344)","('Human_Rights_And_Community_Relations', 0.061602652072906494)","('NON-ESG', 0.48298048973083496)","('NON-ESG', 0.07725781947374344)","('NON-ESG', 0.061602652072906494)"
Line 2,Passion.,"('Director_Removal', 0.06350527703762054)","('Supply_Chain_Management', 0.06275934725999832)","('Water_And_Wastewater_Management', 0.061495836824178696)","('NON-ESG', 0.06350527703762054)","('NON-ESG', 0.06275934725999832)","('NON-ESG', 0.061495836824178696)"
Line 3,Possibilities.,"('Ecological_Impacts', 0.1122550517320633)","('Competitive_Behavior', 0.08426161855459213)","('Business_Model_Resilience', 0.06524256616830826)","('NON-ESG', 0.1122550517320633)","('NON-ESG', 0.08426161855459213)","('NON-ESG', 0.06524256616830826)"
Line 4,"2021 ESG Action Report 3 A Message from Our Chairman and CEO I am tremendously proud to introduce our 2021 Environment, Social & Governance (ESG) Action Report.","('Human_Rights_And_Community_Relations', 0.43127208948135376)","('Management_Of_Legal_And_Regulatory_Framework', 0.1737564206123352)","('Business_Model_Resilience', 0.07927412539720535)","('NON-ESG', 0.43127208948135376)","('NON-ESG', 0.1737564206123352)","('NON-ESG', 0.07927412539720535)"
Line 5,This report reflects how we work with integrity and intention to advance patient health and a sustainable business that will deliver for our stakeholders for years to come.,"('Access_And_Affordability', 0.6593821048736572)","('Employee_Health_And_Safety', 0.06815531104803085)","('Human_Rights_And_Community_Relations', 0.03326861932873726)","(['Access to Healthcare'], 0.6593821048736572)","('NON-ESG', 0.06815531104803085)","('NON-ESG', 0.03326861932873726)"
Line 6,"Powered by 50,000 employees around the globe, it is the responsibility and the privilege of everyone at AbbVie to support our communities, better our society and help the patients of today and tomorrow.","('Human_Rights_And_Community_Relations', 0.5392780303955078)","('Access_And_Affordability', 0.14256899058818817)","('Employee_Engagement_Inclusion_And_Diversity', 0.08101483434438705)","([], 0.5392780303955078)","('NON-ESG', 0.14256899058818817)","('NON-ESG', 0.08101483434438705)"
Line 7,"Since AbbVie was founded in 2013, we have worked to help patients suffering from a wide range of diseases and conditions.","('Access_And_Affordability', 0.5856298804283142)","('Employee_Health_And_Safety', 0.15971297025680542)","('Critical_Incident_Risk_Management', 0.03447667881846428)","(['Access to Healthcare'], 0.5856298804283142)","('NON-ESG', 0.15971297025680542)","('NON-ESG', 0.03447667881846428)"
Line 8,"In 2020, our mission grew in scope and ability with the acquisition of Allergan and this past year was our first full year operating as a new combined company.","('Business_Model_Resilience', 0.5652129650115967)","('Systemic_Risk_Management', 0.07653737813234329)","('Product_Design_And_Lifecycle_Management', 0.05703572556376457)","(['Human Capital Development', 'Innovation Management'], 0.5652129650115967)","('NON-ESG', 0.07653737813234329)","('NON-ESG', 0.05703572556376457)"
Line 9,"Today, we are better positioned for continued growth with leadership positions across the key therapeutic areas of immunology, oncology, neuroscience and eye care, and aesthetics.","('Employee_Engagement_Inclusion_And_Diversity', 0.1852295845746994)","('Access_And_Affordability', 0.16987253725528717)","('Business_Model_Resilience', 0.09868963807821274)","('NON-ESG', 0.1852295845746994)","('NON-ESG', 0.16987253725528717)","('NON-ESG', 0.09868963807821274)"
Line 10,We have a proven track record of developing new innovative medicines that have made a remarkable impact for patients and will continue to change lives for years to come.,"('Customer_Welfare', 0.2303210347890854)","('Selling_Practices_And_Product_Labeling', 0.15563556551933289)","('Access_And_Affordability', 0.12412051856517792)","('NON-ESG', 0.2303210347890854)","('NON-ESG', 0.15563556551933289)","('NON-ESG', 0.12412051856517792)"
Line 11,"Since our inception, we have achieved more than 21 major product or indication approvals.","('Product_Quality_And_Safety', 0.3236936330795288)","('Competitive_Behavior', 0.1509159952402115)","('Selling_Practices_And_Product_Labeling', 0.11942608654499054)","('NON-ESG', 0.3236936330795288)","('NON-ESG', 0.1509159952402115)","('NON-ESG', 0.11942608654499054)"
Line 12,"Through our pipeline of promising therapies, we anticipate the potential approval of more than a dozen new products or major indications over the next two years.","('Customer_Welfare', 0.39511170983314514)","('Selling_Practices_And_Product_Labeling', 0.18205399811267853)","('Product_Design_And_Lifecycle_Management', 0.13596230745315552)","('NON-ESG', 0.39511170983314514)","('NON-ESG', 0.18205399811267853)","('NON-ESG', 0.13596230745315552)"
Line 13,These important milestones have the potential to help millions of additional patients.,"('Access_And_Affordability', 0.7887495756149292)","('Critical_Incident_Risk_Management', 0.03401733189821243)","('Human_Rights_And_Community_Relations', 0.024213971570134163)","(['Access to Healthcare'], 0.7887495756149292)","('NON-ESG', 0.03401733189821243)","('NON-ESG', 0.024213971570134163)"
Line 14,"In addition to our medicines, we continued to deliver on our commitment to society.","('Human_Rights_And_Community_Relations', 0.7942304015159607)","('Access_And_Affordability', 0.030271250754594803)","('Ecological_Impacts', 0.020244082435965538)","([], 0.7942304015159607)","('NON-ESG', 0.030271250754594803)","('NON-ESG', 0.020244082435965538)"
Line 15,"Together with our nonprofit partners, we advanced health and educational opportunities for underserved communities through our philanthropic commitments and continued to address the impact of COVID-19 through humanitarian support and employee volunteering efforts.","('Access_And_Affordability', 0.944710910320282)","('Critical_Incident_Risk_Management', 0.005077119916677475)","('Product_Quality_And_Safety', 0.00495348172262311)","(['Access to Healthcare'], 0.944710910320282)","('NON-ESG', 0.005077119916677475)","('NON-ESG', 0.00495348172262311)"
Line 16,"Through our patient assistance programs, we provided free medicines in the United States to more than 170,000 patients who were experiencing financial need.","('Access_And_Affordability', 0.8487547636032104)","('Energy_Management', 0.015545174479484558)","('Critical_Incident_Risk_Management', 0.015215128660202026)","(['Access to Healthcare'], 0.8487547636032104)","('NON-ESG', 0.015545174479484558)","('NON-ESG', 0.015215128660202026)"
Line 17,"Reaffirming our commitment to environmental sustainability, we committed to join the Science Based Targets Initiative (SBTi) to contribute to climate action by advancing our science-based emission targets.","('Physical_Impacts_Of_Climate_Change', 0.8067834973335266)","('Business_Model_Resilience', 0.050499651581048965)","('GHG_Emissions', 0.03811086341738701)","([], 0.8067834973335266)","('NON-ESG', 0.050499651581048965)","('NON-ESG', 0.03811086341738701)"
Line 18,"In our 10th year as an independent company, I am grateful for our employees and our partners, and what we have done together to help patients and contribute to society over the past decade.","('Access_And_Affordability', 0.376820832490921)","('Human_Rights_And_Community_Relations', 0.35277247428894043)","('Employee_Health_And_Safety', 0.02685067057609558)","('NON-ESG', 0.376820832490921)","('NON-ESG', 0.35277247428894043)","('NON-ESG', 0.02685067057609558)"
Line 19,I am confident in the future as we continue our mission to advance science and make a remarkable impact on peoples lives.,"('Access_And_Affordability', 0.22276754677295685)","('Human_Rights_And_Community_Relations', 0.20984581112861633)","('Ecological_Impacts', 0.08739154785871506)","('NON-ESG', 0.22276754677295685)","('NON-ESG', 0.20984581112861633)","('NON-ESG', 0.08739154785871506)"
Line 20,"Sincerely, Richard A.","('Business_Ethics', 0.18516620993614197)","('Director_Removal', 0.09160415828227997)","('Management_Of_Legal_And_Regulatory_Framework', 0.07050612568855286)","('NON-ESG', 0.18516620993614197)","('NON-ESG', 0.09160415828227997)","('NON-ESG', 0.07050612568855286)"
Line 21,Gonzalez Chairman and CEO Table of Contents Company Overview 6 Our Business 7 Our Approach to ESG 7 Our ESG Framework 8 Our Material Drivers 8 Board and Executive Oversight of ESG 10 Our ESG Council 11 Environmental 12 Environmental Sustainability 13 Social 20 Product Innovation 21 Product Quality and Safety 24 Patient Health and Engagement 25 Patient Access and Affordability 30 Human Capital Management 33 Community & Partner Engagement and Impact 42 Governance 48 Corporate Governance 48 Business Ethics 50 Supply Chain Sustainability 55 Looking Ahead 58 Indexes 60 UN Sustainable Development Goals 60 SASB Index: Biotechnology & Pharmaceuticals 644 2021 ESG Action Report 2021 ESG Action Report 5 Disclaimer and Looking Forward Statements The information and opinions contained in this report are provided as of the date of this report and are subject to change without notice.,"('Business_Ethics', 0.26909029483795166)","('Business_Model_Resilience', 0.1277528703212738)","('Product_Design_And_Lifecycle_Management', 0.1251836121082306)","('NON-ESG', 0.26909029483795166)","('NON-ESG', 0.1277528703212738)","('NON-ESG', 0.1251836121082306)"
Line 22,Gonzalez Chairman and CEO Table of Contents Company Overview 6 Our Business 7 Our Approach to ESG 7 Our ESG Framework 8 Our Material Drivers 8 Board and Executive Oversight of ESG 10 Our ESG Council 11 Environmental 12 Environmental Sustainability 13 Social 20 Product Innovation 21 Product Quality and Safety 24 Patient Health and Engagement 25 Patient Access and Affordability 30 Human Capital Management 33 Community & Partner Engagement and Impact 42 Governance 48 Corporate Governance 48 Business Ethics 50 Supply Chain Sustainability 55 Looking Ahead 58 Indexes 60 UN Sustainable Development Goals 60 SASB Index: Biotechnology & Pharmaceuticals 644 2021 ESG Action Report 2021 ESG Action Report 5 Disclaimer and Looking Forward Statements The information and opinions contained in this report are provided as of the date of this report and are subject to change without notice.,"('Supply_Chain_Management', 0.9058079719543457)","('Product_Design_And_Lifecycle_Management', 0.01905275322496891)","('Business_Model_Resilience', 0.014271118678152561)","([], 0.9058079719543457)","('NON-ESG', 0.01905275322496891)","('NON-ESG', 0.014271118678152561)"
Line 23,AbbVie does not undertake to update or revise any such statements.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8325631022453308)","('Business_Ethics', 0.033144257962703705)","('Director_Removal', 0.018475446850061417)","([], 0.8325631022453308)","('NON-ESG', 0.033144257962703705)","('NON-ESG', 0.018475446850061417)"
Line 24,Company goals are aspirational and not guarantees or promises that all goals will be met.,"('Business_Model_Resilience', 0.20824141800403595)","('Business_Ethics', 0.15214495360851288)","('Director_Removal', 0.10453362762928009)","('NON-ESG', 0.20824141800403595)","('NON-ESG', 0.15214495360851288)","('NON-ESG', 0.10453362762928009)"
Line 25,Certain statistics and metrics relating to ESG matters are estimates and may be based on assumptions or developing standards.,"('Management_Of_Legal_And_Regulatory_Framework', 0.5162004232406616)","('Systemic_Risk_Management', 0.1182781383395195)","('Business_Ethics', 0.05360271409153938)","([], 0.5162004232406616)","('NON-ESG', 0.1182781383395195)","('NON-ESG', 0.05360271409153938)"
Line 26,"This report may contain or incorporate by reference public information not separately reviewed, approved, or endorsed by AbbVie and no representation, warranty, or undertaking is made by AbbVie as to the accuracy, reasonableness, or completeness of such information.","('Management_Of_Legal_And_Regulatory_Framework', 0.42327386140823364)","('Customer_Privacy', 0.22228308022022247)","('Data_Security', 0.049577176570892334)","('NON-ESG', 0.42327386140823364)","('NON-ESG', 0.22228308022022247)","('NON-ESG', 0.049577176570892334)"
Line 27,Inclusion of information in this report is not an indication that the subject or information is material to AbbVies business or operating results.,"('Business_Model_Resilience', 0.27627116441726685)","('Customer_Privacy', 0.16676881909370422)","('Management_Of_Legal_And_Regulatory_Framework', 0.0691920667886734)","('NON-ESG', 0.27627116441726685)","('NON-ESG', 0.16676881909370422)","('NON-ESG', 0.0691920667886734)"
Line 28,This report is not intended to create legal rights or obligations.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8881064057350159)","('Human_Rights_And_Community_Relations', 0.027996549382805824)","('Director_Removal', 0.010082627646625042)","([], 0.8881064057350159)","('NON-ESG', 0.027996549382805824)","('NON-ESG', 0.010082627646625042)"
Line 29,"Some statements in this report are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.","('Management_Of_Legal_And_Regulatory_Framework', 0.9488513469696045)","('Business_Ethics', 0.011226575821638107)","('Director_Removal', 0.004042234271764755)","([], 0.9488513469696045)","('NON-ESG', 0.011226575821638107)","('NON-ESG', 0.004042234271764755)"
Line 30,"The words ""believe,"" ""expect,"" ""anticipate,"" ""project"" and similar expressions, among others, generally identify forward-looking statements.","('Business_Model_Resilience', 0.4087185859680176)","('Competitive_Behavior', 0.10688053071498871)","('Systemic_Risk_Management', 0.06254420429468155)","('NON-ESG', 0.4087185859680176)","('NON-ESG', 0.10688053071498871)","('NON-ESG', 0.06254420429468155)"
Line 31,AbbVie cautions that these forward- looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.,"('Systemic_Risk_Management', 0.8464556932449341)","('Competitive_Behavior', 0.02416948787868023)","('Business_Model_Resilience', 0.021189147606492043)","([], 0.8464556932449341)","('NON-ESG', 0.02416948787868023)","('NON-ESG', 0.021189147606492043)"
Line 32,"Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc (""Allergan""), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19.","('Competitive_Behavior', 0.8462516069412231)","('Systemic_Risk_Management', 0.04490872472524643)","('Business_Model_Resilience', 0.01892116293311119)","([], 0.8462516069412231)","('NON-ESG', 0.04490872472524643)","('NON-ESG', 0.01892116293311119)"
Line 33,"Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc (""Allergan""), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19.","('Systemic_Risk_Management', 0.5881146192550659)","('Physical_Impacts_Of_Climate_Change', 0.0684649646282196)","('Business_Model_Resilience', 0.04229779541492462)","([], 0.5881146192550659)","('NON-ESG', 0.0684649646282196)","('NON-ESG', 0.04229779541492462)"
Line 34,"Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, ""Risk Factors,"" of AbbVie's 2021 Annual Report on Form 10- K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q.","('Competitive_Behavior', 0.6271917819976807)","('Systemic_Risk_Management', 0.2044765055179596)","('Business_Model_Resilience', 0.042934395372867584)","([], 0.6271917819976807)","('NON-ESG', 0.2044765055179596)","('NON-ESG', 0.042934395372867584)"
Line 35,"AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.6 2021 ESG Action Report 2021 ESG Action Report 7 AbbVies mission is to discover and deliver innovative medicines and products that solve serious health issues and enhance peoples lives today and address the medical challenges of tomorrow.","('Product_Quality_And_Safety', 0.1709240972995758)","('Access_And_Affordability', 0.16323322057724)","('Product_Design_And_Lifecycle_Management', 0.162637859582901)","('NON-ESG', 0.1709240972995758)","('NON-ESG', 0.16323322057724)","('NON-ESG', 0.162637859582901)"
Line 36,"We strive to have a remarkable impact on peoples lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, and virology in addition to products and services across our aesthetics portfolio.","('Customer_Welfare', 0.36479511857032776)","('Product_Design_And_Lifecycle_Management', 0.09252320975065231)","('Access_And_Affordability', 0.08274442702531815)","('NON-ESG', 0.36479511857032776)","('NON-ESG', 0.09252320975065231)","('NON-ESG', 0.08274442702531815)"
Line 37,"Our state-of- the-art research, development and manufacturing centers across the world allow us to move the best ideas forward faster and deliver transformative change.","('Business_Model_Resilience', 0.418526828289032)","('Product_Design_And_Lifecycle_Management', 0.13456782698631287)","('Supply_Chain_Management', 0.06948982924222946)","('NON-ESG', 0.418526828289032)","('NON-ESG', 0.13456782698631287)","('NON-ESG', 0.06948982924222946)"
Line 38,"Our global headquarters is in North Chicago, IL, United States.","('Business_Model_Resilience', 0.5302293300628662)","('Employee_Engagement_Inclusion_And_Diversity', 0.05493222177028656)","('Product_Design_And_Lifecycle_Management', 0.05486138537526131)","(['Human Capital Development', 'Innovation Management'], 0.5302293300628662)","('NON-ESG', 0.05493222177028656)","('NON-ESG', 0.05486138537526131)"
Line 39,"We pride ourselves on a long tradition of strong corporate governance and financial controls, led by our board of directors.","('Director_Removal', 0.5042938590049744)","('Business_Model_Resilience', 0.09881612658500671)","('Business_Ethics', 0.06907399743795395)","(['Business Ethics'], 0.5042938590049744)","('NON-ESG', 0.09881612658500671)","('NON-ESG', 0.06907399743795395)"
Line 40,They play an active and vital role in overseeing our strategic direction and our performance against all objectives on behalf of our stakeholders.,"('Business_Model_Resilience', 0.4996189475059509)","('Director_Removal', 0.07468724250793457)","('Human_Rights_And_Community_Relations', 0.07303768396377563)","('NON-ESG', 0.4996189475059509)","('NON-ESG', 0.07468724250793457)","('NON-ESG', 0.07303768396377563)"
Line 41,More details on our board and approach to Corporate Governance can be found in the Corporate Governance section of this report and our 2022 Proxy Statement.,"('Management_Of_Legal_And_Regulatory_Framework', 0.6841453909873962)","('Business_Ethics', 0.04643520340323448)","('Director_Removal', 0.0456017330288887)","([], 0.6841453909873962)","('NON-ESG', 0.04643520340323448)","('NON-ESG', 0.0456017330288887)"
Line 42,"This past year was our first full year operating as a new combined company since our acquisition of Allergan plc (Allergan) on May 8, 2020.","('Business_Model_Resilience', 0.47389480471611023)","('Systemic_Risk_Management', 0.10159953683614731)","('Product_Design_And_Lifecycle_Management', 0.05225498974323273)","('NON-ESG', 0.47389480471611023)","('NON-ESG', 0.10159953683614731)","('NON-ESG', 0.05225498974323273)"
Line 43,"As such, KPIs contained in this report are reflective of this combined organization unless otherwise noted.","('Systemic_Risk_Management', 0.2415320724248886)","('Management_Of_Legal_And_Regulatory_Framework', 0.14393684267997742)","('Business_Model_Resilience', 0.10114704817533493)","('NON-ESG', 0.2415320724248886)","('NON-ESG', 0.14393684267997742)","('NON-ESG', 0.10114704817533493)"
Line 44,Previous years KPIs inclusive of only AbbVie data can be found in previous editions of AbbVies ESG Action Report.,"('Systemic_Risk_Management', 0.41818076372146606)","('Business_Model_Resilience', 0.18065564334392548)","('Management_Of_Legal_And_Regulatory_Framework', 0.11071877926588058)","('NON-ESG', 0.41818076372146606)","('NON-ESG', 0.18065564334392548)","('NON-ESG', 0.11071877926588058)"
Line 45,Our Business Transforming lives We inspire hope and transform lives every day.,"('Business_Model_Resilience', 0.47165900468826294)","('Human_Rights_And_Community_Relations', 0.11458170413970947)","('Employee_Engagement_Inclusion_And_Diversity', 0.07369495183229446)","('NON-ESG', 0.47165900468826294)","('NON-ESG', 0.11458170413970947)","('NON-ESG', 0.07369495183229446)"
Line 46,"We make decisions based on our deep caring and compassion for people, delivering a lasting impact to our patients, their families, our employees and the community.","('Human_Rights_And_Community_Relations', 0.6428695321083069)","('Access_And_Affordability', 0.11075122654438019)","('Employee_Health_And_Safety', 0.062154773622751236)","([], 0.6428695321083069)","('NON-ESG', 0.11075122654438019)","('NON-ESG', 0.062154773622751236)"
Line 47,Acting with integrity We strive to always do the right thing.,"('Business_Ethics', 0.7007937431335449)","('Human_Rights_And_Community_Relations', 0.03972595930099487)","('Director_Removal', 0.03928074240684509)","(['Business Ethics'], 0.7007937431335449)","('NON-ESG', 0.03972595930099487)","('NON-ESG', 0.03928074240684509)"
Line 48,"With uncompromising integrity at the heart of everything we do, we pursue the highest standards in quality, compliance, safety and performance.","('Product_Quality_And_Safety', 0.48121681809425354)","('Employee_Health_And_Safety', 0.24586394429206848)","('Business_Ethics', 0.06450699269771576)","('NON-ESG', 0.48121681809425354)","('NON-ESG', 0.24586394429206848)","('NON-ESG', 0.06450699269771576)"
Line 49,Driving innovation We innovate relentlessly in everything we do to tackle unmet needs.,"('Product_Design_And_Lifecycle_Management', 0.3807099163532257)","('Business_Model_Resilience', 0.25600093603134155)","('Supply_Chain_Management', 0.07777974009513855)","('NON-ESG', 0.3807099163532257)","('NON-ESG', 0.25600093603134155)","('NON-ESG', 0.07777974009513855)"
Line 50,We invest in the discovery and development of new medicines and healthcare approaches for a healthier world.,"('Access_And_Affordability', 0.25103479623794556)","('Customer_Welfare', 0.20483671128749847)","('Product_Design_And_Lifecycle_Management', 0.11924982070922852)","('NON-ESG', 0.25103479623794556)","('NON-ESG', 0.20483671128749847)","('NON-ESG', 0.11924982070922852)"
Line 51,"Embracing diversity and inclusion We treat everyone equally, with dignity and respect.","('Employee_Engagement_Inclusion_And_Diversity', 0.9687512516975403)","('Human_Rights_And_Community_Relations', 0.0035086863208562136)","('Employee_Health_And_Safety', 0.00294649344868958)","(['Talent Attraction & Retention'], 0.9687512516975403)","('NON-ESG', 0.0035086863208562136)","('NON-ESG', 0.00294649344868958)"
Line 52,"Around the world, our employees embrace diverse backgrounds and perspectives, which allows us all to achieve our best.","('Employee_Engagement_Inclusion_And_Diversity', 0.974953830242157)","('Human_Rights_And_Community_Relations', 0.002038989681750536)","('Employee_Health_And_Safety', 0.0018464504973962903)","(['Talent Attraction & Retention'], 0.974953830242157)","('NON-ESG', 0.002038989681750536)","('NON-ESG', 0.0018464504973962903)"
Line 53,Serving the community We are proud to serve and support the community and do our part to protect the environment.,"('Ecological_Impacts', 0.7922113537788391)","('Human_Rights_And_Community_Relations', 0.10132606327533722)","('Water_And_Wastewater_Management', 0.018982289358973503)","([], 0.7922113537788391)","('NON-ESG', 0.10132606327533722)","('NON-ESG', 0.018982289358973503)"
Line 54,We make a remarkable impact that's felt within healthcare and beyond.,"('Business_Model_Resilience', 0.38703566789627075)","('Human_Rights_And_Community_Relations', 0.11169039458036423)","('Access_And_Affordability', 0.06929540634155273)","('NON-ESG', 0.38703566789627075)","('NON-ESG', 0.11169039458036423)","('NON-ESG', 0.06929540634155273)"
Line 55,AbbVie is a research-driven biopharmaceutical company that takes on the toughest health challenges.,"('Employee_Health_And_Safety', 0.9060214757919312)","('Product_Quality_And_Safety', 0.01191913615912199)","('Product_Design_And_Lifecycle_Management', 0.01145593635737896)","(['Health Outcome Contribution'], 0.9060214757919312)","('NON-ESG', 0.01191913615912199)","('NON-ESG', 0.01145593635737896)"
Line 56,But we do more than treat diseaseswe embrace the responsibility of making a remarkable impact on peoples lives through the innovative medicines and solutions we create together.,"('Access_And_Affordability', 0.3163532316684723)","('Selling_Practices_And_Product_Labeling', 0.1134844496846199)","('Customer_Welfare', 0.1100197583436966)","('NON-ESG', 0.3163532316684723)","('NON-ESG', 0.1134844496846199)","('NON-ESG', 0.1100197583436966)"
Line 57,"This is driven by our compassion for people, commitment to innovation and inclusion, service to the community and uncompromising integrity.","('Human_Rights_And_Community_Relations', 0.9171516299247742)","('Employee_Engagement_Inclusion_And_Diversity', 0.010893630795180798)","('Employee_Health_And_Safety', 0.007878829725086689)","([], 0.9171516299247742)","('NON-ESG', 0.010893630795180798)","('NON-ESG', 0.007878829725086689)"
Line 58,"At AbbVie, we care deeply for patients, customers and their caregivers, our employees and our communities.","('Access_And_Affordability', 0.6930335760116577)","('Human_Rights_And_Community_Relations', 0.06772445142269135)","('Employee_Health_And_Safety', 0.050767891108989716)","(['Access to Healthcare'], 0.6930335760116577)","('NON-ESG', 0.06772445142269135)","('NON-ESG', 0.050767891108989716)"
Line 59,"We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety and performance.","('Product_Quality_And_Safety', 0.5642395615577698)","('Employee_Health_And_Safety', 0.26761239767074585)","('Product_Design_And_Lifecycle_Management', 0.017553279176354408)","(['Product Quality & Recall Management'], 0.5642395615577698)","('NON-ESG', 0.26761239767074585)","('NON-ESG', 0.017553279176354408)"
Line 60,"We invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare solutions for a healthier world.","('Product_Design_And_Lifecycle_Management', 0.2574629783630371)","('Access_And_Affordability', 0.20960105955600739)","('Customer_Welfare', 0.08603861927986145)","('NON-ESG', 0.2574629783630371)","('NON-ESG', 0.20960105955600739)","('NON-ESG', 0.08603861927986145)"
Line 61,"Globally, our employees represent diverse backgrounds and perspectives, and our company values treating everyone with dignity and respectwhich we believe allows us to achieve our best.","('Employee_Engagement_Inclusion_And_Diversity', 0.9579383730888367)","('Human_Rights_And_Community_Relations', 0.007816257886588573)","('Employee_Health_And_Safety', 0.003942854702472687)","(['Talent Attraction & Retention'], 0.9579383730888367)","('NON-ESG', 0.007816257886588573)","('NON-ESG', 0.003942854702472687)"
Line 62,"We proudly do our part, serving and supporting our communities and protecting the environment so we can make a lasting impact on healthcare and beyond.","('Human_Rights_And_Community_Relations', 0.7788001894950867)","('Ecological_Impacts', 0.0946277603507042)","('Access_And_Affordability', 0.017037618905305862)","([], 0.7788001894950867)","('NON-ESG', 0.0946277603507042)","('NON-ESG', 0.017037618905305862)"
Line 63,"As a research-driven global biopharmaceutical company, we apply the same high standards and rigor to the medicines and solutions we pursue, to how we operate our business.","('Competitive_Behavior', 0.15750236809253693)","('Product_Quality_And_Safety', 0.1418747454881668)","('Systemic_Risk_Management', 0.12766030430793762)","('NON-ESG', 0.15750236809253693)","('NON-ESG', 0.1418747454881668)","('NON-ESG', 0.12766030430793762)"
Line 64,"We recognize that our company and our industry hold a unique opportunity to make a real difference in peoples lives, but it's not just the breakthroughs we achieve that matter, its also the paths we take to achieve them.","('Business_Model_Resilience', 0.5007134079933167)","('Employee_Engagement_Inclusion_And_Diversity', 0.10409668833017349)","('Human_Rights_And_Community_Relations', 0.06421512365341187)","(['Human Capital Development', 'Innovation Management'], 0.5007134079933167)","('NON-ESG', 0.10409668833017349)","('NON-ESG', 0.06421512365341187)"
Line 65,We are advancing ESG initiatives that contribute to the sustainable growth of our company so that we can create positive impact for generations to come.,"('Business_Model_Resilience', 0.7352191209793091)","('Systemic_Risk_Management', 0.04977937415242195)","('Human_Rights_And_Community_Relations', 0.02343067154288292)","(['Human Capital Development', 'Innovation Management'], 0.7352191209793091)","('NON-ESG', 0.04977937415242195)","('NON-ESG', 0.02343067154288292)"
Line 66,"Our leaders are stewards of our ESG mission, and our people are committed to ensuring our research, innovations and collaborations put impact for people, communities and our world first.","('Human_Rights_And_Community_Relations', 0.8575947284698486)","('Access_And_Affordability', 0.020403264090418816)","('Employee_Engagement_Inclusion_And_Diversity', 0.017724964767694473)","([], 0.8575947284698486)","('NON-ESG', 0.020403264090418816)","('NON-ESG', 0.017724964767694473)"
Line 67,"We evaluate our efforts relative to external frameworks such as the Dow Jones Sustainability Index (DJSI), the Task Force on Climate-Related Financial Disclosures (TCFD), the United Nations Sustainability Development Goals (UN SDGs) and the Sustainability Accounting Standards Board (SASB).","('Physical_Impacts_Of_Climate_Change', 0.7554110288619995)","('Business_Model_Resilience', 0.09228391200304031)","('Systemic_Risk_Management', 0.027173057198524475)","([], 0.7554110288619995)","('NON-ESG', 0.09228391200304031)","('NON-ESG', 0.027173057198524475)"
Line 68,Our SASB Index performance is included as an appendix at the end of this report.,"('Systemic_Risk_Management', 0.5426648259162903)","('Business_Model_Resilience', 0.1857140064239502)","('Supply_Chain_Management', 0.03418312594294548)","([], 0.5426648259162903)","('NON-ESG', 0.1857140064239502)","('NON-ESG', 0.03418312594294548)"
Line 69,Acting responsibly is ingrained in everything we do.,"('Business_Model_Resilience', 0.19791719317436218)","('Human_Rights_And_Community_Relations', 0.12566785514354706)","('Product_Design_And_Lifecycle_Management', 0.08903411775827408)","('NON-ESG', 0.19791719317436218)","('NON-ESG', 0.12566785514354706)","('NON-ESG', 0.08903411775827408)"
Line 70,"It is how we drive a long-term, sustainable business that makes a genuine and lasting positive impact for patients, employees and communities.","('Human_Rights_And_Community_Relations', 0.8533923625946045)","('Access_And_Affordability', 0.03566174581646919)","('Employee_Health_And_Safety', 0.01239392813295126)","([], 0.8533923625946045)","('NON-ESG', 0.03566174581646919)","('NON-ESG', 0.01239392813295126)"
Line 71,"In 2021, we enhanced our ESG framework and governance while delivering sustainable solutions that improve the health of our business and society.","('Business_Model_Resilience', 0.31858503818511963)","('Management_Of_Legal_And_Regulatory_Framework', 0.21606658399105072)","('Human_Rights_And_Community_Relations', 0.12945058941841125)","('NON-ESG', 0.31858503818511963)","('NON-ESG', 0.21606658399105072)","('NON-ESG', 0.12945058941841125)"
Line 72,"Our Approach to ESGCompany Overview Our Principles8 2021 ESG Action Report 2021 ESG Action Report 9 Our Materiality MapImportance to stakeholders Impact to AbbVieCommunity & Partner Engagement and ImpactSupply Chain SustainabilityHuman Capital Management Employee Recruiting, Development & Retention Equity, Equality, Diversity & InclusionProduct Innovation Product Quality & Safety Patient Health & Engagement Patient Access & Patient AffordabilityBusiness Ethics Environmental SustainabilityEnvironmental Social Governance Categories VERY HIGH HIGH MODERATEOur ESG Framework is built around three foundational pillars that align with our enterprise goals and principles.","('Employee_Engagement_Inclusion_And_Diversity', 0.8578798174858093)","('Access_And_Affordability', 0.021237598732113838)","('Product_Quality_And_Safety', 0.015836939215660095)","(['Talent Attraction & Retention'], 0.8578798174858093)","('NON-ESG', 0.021237598732113838)","('NON-ESG', 0.015836939215660095)"
Line 73,"Our Approach to ESGCompany Overview Our Principles8 2021 ESG Action Report 2021 ESG Action Report 9 Our Materiality MapImportance to stakeholders Impact to AbbVieCommunity & Partner Engagement and ImpactSupply Chain SustainabilityHuman Capital Management Employee Recruiting, Development & Retention Equity, Equality, Diversity & InclusionProduct Innovation Product Quality & Safety Patient Health & Engagement Patient Access & Patient AffordabilityBusiness Ethics Environmental SustainabilityEnvironmental Social Governance Categories VERY HIGH HIGH MODERATEOur ESG Framework is built around three foundational pillars that align with our enterprise goals and principles.","('Management_Of_Legal_And_Regulatory_Framework', 0.5033055543899536)","('Business_Model_Resilience', 0.09859839826822281)","('Human_Rights_And_Community_Relations', 0.07066502422094345)","([], 0.5033055543899536)","('NON-ESG', 0.09859839826822281)","('NON-ESG', 0.07066502422094345)"
Line 74,"These have been developed based on an analysis of our material issues, considering the topics of most interest and relevance to our company and our stakeholdersincluding our patients, patient organizations, employees, investors, regulators and government, payers and providers, suppliers and nonprofit partners.","('Management_Of_Legal_And_Regulatory_Framework', 0.5808402299880981)","('Human_Rights_And_Community_Relations', 0.0632542222738266)","('Access_And_Affordability', 0.04370756074786186)","([], 0.5808402299880981)","('NON-ESG', 0.0632542222738266)","('NON-ESG', 0.04370756074786186)"
Line 75,Collaboration with stakeholders is critical to our success.,"('Human_Rights_And_Community_Relations', 0.6595393419265747)","('Management_Of_Legal_And_Regulatory_Framework', 0.05527138710021973)","('Business_Model_Resilience', 0.04782599210739136)","([], 0.6595393419265747)","('NON-ESG', 0.05527138710021973)","('NON-ESG', 0.04782599210739136)"
Line 76,"We strive to create value by building engaging, long-term relationships with each of our partners and stakeholders.","('Human_Rights_And_Community_Relations', 0.4488941431045532)","('Business_Model_Resilience', 0.23322826623916626)","('Employee_Engagement_Inclusion_And_Diversity', 0.04059640318155289)","('NON-ESG', 0.4488941431045532)","('NON-ESG', 0.23322826623916626)","('NON-ESG', 0.04059640318155289)"
Line 77,"Through these relationships, we engage in regular dialogue to understand evolving needs, interests and expectations of AbbVie.","('Human_Rights_And_Community_Relations', 0.5166122913360596)","('Management_Of_Legal_And_Regulatory_Framework', 0.18322846293449402)","('Business_Model_Resilience', 0.038082730025053024)","([], 0.5166122913360596)","('NON-ESG', 0.18322846293449402)","('NON-ESG', 0.038082730025053024)"
Line 78,"From these interactions, we develop our understanding of meaningful issues and identify additional opportunities to improve and make an impact.","('Human_Rights_And_Community_Relations', 0.7680553197860718)","('Management_Of_Legal_And_Regulatory_Framework', 0.04898801073431969)","('Access_And_Affordability', 0.023651542142033577)","([], 0.7680553197860718)","('NON-ESG', 0.04898801073431969)","('NON-ESG', 0.023651542142033577)"
Line 79,"We discover and deliver innovative medicines that solve serious health issues and enhance peoples lives by pushing the boundaries of innovation, putting people and patients first, creating high-quality therapeutic solutions and ensuring their safety, efficacy and accessibility.","('Product_Quality_And_Safety', 0.4859653115272522)","('Selling_Practices_And_Product_Labeling', 0.13093119859695435)","('Customer_Welfare', 0.11710009723901749)","('NON-ESG', 0.4859653115272522)","('NON-ESG', 0.13093119859695435)","('NON-ESG', 0.11710009723901749)"
Line 80,We unlock the full potential of diverse and talented teams and partnersto deliver today and into the future.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9220197200775146)","('Human_Rights_And_Community_Relations', 0.007589221466332674)","('Business_Model_Resilience', 0.006905743386596441)","(['Talent Attraction & Retention'], 0.9220197200775146)","('NON-ESG', 0.007589221466332674)","('NON-ESG', 0.006905743386596441)"
Line 81,"We do this by attracting and retaining the best talent, embracing diversity of thought and through collaboration.","('Employee_Engagement_Inclusion_And_Diversity', 0.9530402421951294)","('Human_Rights_And_Community_Relations', 0.0034839340951293707)","('Employee_Health_And_Safety', 0.0031978152692317963)","(['Talent Attraction & Retention'], 0.9530402421951294)","('NON-ESG', 0.0034839340951293707)","('NON-ESG', 0.0031978152692317963)"
Line 82,"We know that when we unlock the full potential of our people and our partners, we accelerate innovation, enhance peoples lives, and meet our business objectives.","('Business_Model_Resilience', 0.45479923486709595)","('Product_Design_And_Lifecycle_Management', 0.19062647223472595)","('Employee_Engagement_Inclusion_And_Diversity', 0.058318957686424255)","('NON-ESG', 0.45479923486709595)","('NON-ESG', 0.19062647223472595)","('NON-ESG', 0.058318957686424255)"
Line 83,We innovate with integrity and intention to advance long-term patient health and business resiliency.,"('Business_Model_Resilience', 0.9093875288963318)","('Physical_Impacts_Of_Climate_Change', 0.010928156785666943)","('Product_Design_And_Lifecycle_Management', 0.010221116244792938)","(['Human Capital Development', 'Innovation Management'], 0.9093875288963318)","('NON-ESG', 0.010928156785666943)","('NON-ESG', 0.010221116244792938)"
Line 84,"We ensure that we are prepared for the future by operating a sustainable, agile business model and governance structure that anticipates and evolves in a dynamic industry and society.","('Management_Of_Legal_And_Regulatory_Framework', 0.38980162143707275)","('Business_Model_Resilience', 0.2515667974948883)","('Human_Rights_And_Community_Relations', 0.054964568465948105)","('NON-ESG', 0.38980162143707275)","('NON-ESG', 0.2515667974948883)","('NON-ESG', 0.054964568465948105)"
Line 85,We are unwavering in assuring supply of innovative medicines to patients and life- enhancing products to customers.,"('Product_Design_And_Lifecycle_Management', 0.38390693068504333)","('Customer_Welfare', 0.24487537145614624)","('Selling_Practices_And_Product_Labeling', 0.14061787724494934)","('NON-ESG', 0.38390693068504333)","('NON-ESG', 0.24487537145614624)","('NON-ESG', 0.14061787724494934)"
Line 86,Product innovation We strive to make a remarkable impact on patients and drive sustainable growth by consistently discovering and delivering innovative medicines that address serious health issues and enhance peoples lives.,"('Product_Design_And_Lifecycle_Management', 0.3271002173423767)","('Customer_Welfare', 0.21718278527259827)","('Product_Quality_And_Safety', 0.12385321408510208)","('NON-ESG', 0.3271002173423767)","('NON-ESG', 0.21718278527259827)","('NON-ESG', 0.12385321408510208)"
Line 87,Patient access and patient affordability We believe everyone who needs our medicines should be able to get them.,"('Access_And_Affordability', 0.8615254759788513)","('Energy_Management', 0.011576932854950428)","('Critical_Incident_Risk_Management', 0.011394145898520947)","(['Access to Healthcare'], 0.8615254759788513)","('NON-ESG', 0.011576932854950428)","('NON-ESG', 0.011394145898520947)"
Line 88,Human capital management We believe purposeful work drives meaningful change.,"('Business_Model_Resilience', 0.7248663306236267)","('Systemic_Risk_Management', 0.03633119538426399)","('Supply_Chain_Management', 0.025671331211924553)","(['Human Capital Development', 'Innovation Management'], 0.7248663306236267)","('NON-ESG', 0.03633119538426399)","('NON-ESG', 0.025671331211924553)"
Line 89,We nurture diverse talent to solve the most complex health challenges and create remarkable impact in peoples lives.,"('Employee_Health_And_Safety', 0.3376097083091736)","('Access_And_Affordability', 0.2787499725818634)","('Human_Rights_And_Community_Relations', 0.11795398592948914)","('NON-ESG', 0.3376097083091736)","('NON-ESG', 0.2787499725818634)","('NON-ESG', 0.11795398592948914)"
Line 90,"We also prioritize Environmental Sustainability within and beyond AbbVie to support our patients, people and the planet.","('Human_Rights_And_Community_Relations', 0.3240126073360443)","('Product_Design_And_Lifecycle_Management', 0.1132633239030838)","('Ecological_Impacts', 0.08628488332033157)","('NON-ESG', 0.3240126073360443)","('NON-ESG', 0.1132633239030838)","('NON-ESG', 0.08628488332033157)"
Line 91,"We are focused on reducing our environmental footprint, growing sustainability through inspiring innovation and engaging our workforce to steward the same.","('Product_Design_And_Lifecycle_Management', 0.32590946555137634)","('Business_Model_Resilience', 0.19247277081012726)","('Supply_Chain_Management', 0.09172584861516953)","('NON-ESG', 0.32590946555137634)","('NON-ESG', 0.19247277081012726)","('NON-ESG', 0.09172584861516953)"
Line 92,Patient health and engagement We continuously strive to improve health outcomes for patients around the world.,"('Access_And_Affordability', 0.38165026903152466)","('Employee_Health_And_Safety', 0.3282831013202667)","('Critical_Incident_Risk_Management', 0.046335477381944656)","('NON-ESG', 0.38165026903152466)","('NON-ESG', 0.3282831013202667)","('NON-ESG', 0.046335477381944656)"
Line 93,"Product quality and safety We are committed to delivering safe and effective, quality products and medicines through robust quality systems.","('Product_Quality_And_Safety', 0.8771931529045105)","('Product_Design_And_Lifecycle_Management', 0.03490861877799034)","('Selling_Practices_And_Product_Labeling', 0.015689730644226074)","(['Product Quality & Recall Management'], 0.8771931529045105)","('NON-ESG', 0.03490861877799034)","('NON-ESG', 0.015689730644226074)"
Line 94,Business ethics We act with integrity in everything we do.,"('Business_Ethics', 0.9678126573562622)","('Competitive_Behavior', 0.00298354122787714)","('Customer_Privacy', 0.0024432954378426075)","(['Business Ethics'], 0.9678126573562622)","('NON-ESG', 0.00298354122787714)","('NON-ESG', 0.0024432954378426075)"
Line 95,Our ESG PillarsOur ESG Framework Our Material Drivers* *Our material drivers are based on a 2020 materiality assessment.,"('Business_Model_Resilience', 0.30556243658065796)","('Systemic_Risk_Management', 0.165605366230011)","('Management_Of_Legal_And_Regulatory_Framework', 0.1274283081293106)","('NON-ESG', 0.30556243658065796)","('NON-ESG', 0.165605366230011)","('NON-ESG', 0.1274283081293106)"
Line 96,The board of directors has oversight responsibility for the company and administers this responsibility both directly and with assistance from its committees.,"('Director_Removal', 0.7293434143066406)","('Management_Of_Legal_And_Regulatory_Framework', 0.07843916118144989)","('Business_Ethics', 0.02321241796016693)","(['Business Ethics'], 0.7293434143066406)","('NON-ESG', 0.07843916118144989)","('NON-ESG', 0.02321241796016693)"
Line 97,"Our directors have backgrounds that, when combined, provide a portfolio of experience and knowledge that serve AbbVies governance and strategic needs.","('Director_Removal', 0.3150894343852997)","('Business_Model_Resilience', 0.2625907361507416)","('Employee_Engagement_Inclusion_And_Diversity', 0.09475139528512955)","('NON-ESG', 0.3150894343852997)","('NON-ESG', 0.2625907361507416)","('NON-ESG', 0.09475139528512955)"
Line 98,"Director nominees are considered based on a range of criteria including broad-based business knowledge and relationships, prominence and excellent reputations in their primary fields of endeavor, as well as a global business perspective and commitment to good corporate citizenship.","('Director_Removal', 0.23765330016613007)","('Employee_Engagement_Inclusion_And_Diversity', 0.20667169988155365)","('Business_Model_Resilience', 0.1877790242433548)","('NON-ESG', 0.23765330016613007)","('NON-ESG', 0.20667169988155365)","('NON-ESG', 0.1877790242433548)"
Line 99,They demonstrate experience and ability that is relevant to the boards oversight role with respect to AbbVies business and affairs.,"('Management_Of_Legal_And_Regulatory_Framework', 0.5741251707077026)","('Director_Removal', 0.18634766340255737)","('Business_Ethics', 0.04861195757985115)","([], 0.5741251707077026)","('NON-ESG', 0.18634766340255737)","('NON-ESG', 0.04861195757985115)"
Line 100,"Board and Executive Oversight of ESG 10 2021 ESG Action Report 2021 ESG Action Report 11 In 2021, we were honored to have received some of the most prestigious ratings and rankings in our industry.","('Management_Of_Legal_And_Regulatory_Framework', 0.41311389207839966)","('Director_Removal', 0.13180452585220337)","('Business_Ethics', 0.09334100782871246)","('NON-ESG', 0.41311389207839966)","('NON-ESG', 0.13180452585220337)","('NON-ESG', 0.09334100782871246)"
Line 101,To date we have received more than 40 Top Employer Great Place to Work and Top Employer rankings globally.,"('Labor_Practices', 0.43597444891929626)","('Supply_Chain_Management', 0.10798642039299011)","('Employee_Engagement_Inclusion_And_Diversity', 0.08942649513483047)","('NON-ESG', 0.43597444891929626)","('NON-ESG', 0.10798642039299011)","('NON-ESG', 0.08942649513483047)"
Line 102,"In 2021, we enhanced our ESG oversight and governance with the establishment of an ESG Council.","('Management_Of_Legal_And_Regulatory_Framework', 0.7079697251319885)","('Director_Removal', 0.05533470958471298)","('Human_Rights_And_Community_Relations', 0.03787855803966522)","([], 0.7079697251319885)","('NON-ESG', 0.05533470958471298)","('NON-ESG', 0.03787855803966522)"
Line 103,"The ESG Council ensures strategic, enterprise-aligned delivery on AbbVies ESG Framework.","('Business_Model_Resilience', 0.7003549337387085)","('Systemic_Risk_Management', 0.04636211693286896)","('Management_Of_Legal_And_Regulatory_Framework', 0.03489352762699127)","(['Human Capital Development', 'Innovation Management'], 0.7003549337387085)","('NON-ESG', 0.04636211693286896)","('NON-ESG', 0.03489352762699127)"
Line 104,"Chaired by our Vice Chairman, External Affairs and Chief Legal Officer and composed of senior cross- functional leaders, the ESG Councils purpose is to champion business sustainability and mitigate business risks by monitoring, reviewing and recommending actions in support of our ESG framework and strategy.","('Systemic_Risk_Management', 0.6112046241760254)","('Business_Model_Resilience', 0.25028857588768005)","('Physical_Impacts_Of_Climate_Change', 0.037852656096220016)","([], 0.6112046241760254)","('NON-ESG', 0.25028857588768005)","('NON-ESG', 0.037852656096220016)"
Line 105,The ESG Council meets at minimum once per quarter and maintains sub-committees aligned to AbbVies material topics.,"('Management_Of_Legal_And_Regulatory_Framework', 0.7313446998596191)","('Director_Removal', 0.03460020199418068)","('Ecological_Impacts', 0.029523376375436783)","([], 0.7313446998596191)","('NON-ESG', 0.03460020199418068)","('NON-ESG', 0.029523376375436783)"
Line 106,"In 2021, we established an ESG Team, which reports to the Vice President of Corporate Responsibility.","('Business_Model_Resilience', 0.43722569942474365)","('Human_Rights_And_Community_Relations', 0.11535901576280594)","('Systemic_Risk_Management', 0.07669030129909515)","('NON-ESG', 0.43722569942474365)","('NON-ESG', 0.11535901576280594)","('NON-ESG', 0.07669030129909515)"
Line 107,The ESG Team focuses on supporting AbbVies ESG strategy and the ESG Council.,"('Business_Model_Resilience', 0.4666150212287903)","('Systemic_Risk_Management', 0.12276460230350494)","('Management_Of_Legal_And_Regulatory_Framework', 0.05805405229330063)","('NON-ESG', 0.4666150212287903)","('NON-ESG', 0.12276460230350494)","('NON-ESG', 0.05805405229330063)"
Line 108,"With this governance in place, we are well- positioned to recognize ESG opportunities and advance our ESG objectives.","('Business_Model_Resilience', 0.6559412479400635)","('Systemic_Risk_Management', 0.13196773827075958)","('Employee_Engagement_Inclusion_And_Diversity', 0.02018001861870289)","(['Human Capital Development', 'Innovation Management'], 0.6559412479400635)","('NON-ESG', 0.13196773827075958)","('NON-ESG', 0.02018001861870289)"
Line 109,Our ESG Council DiversityInc.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9566302299499512)","('Business_Model_Resilience', 0.003615252673625946)","('Human_Rights_And_Community_Relations', 0.0032022034283727407)","(['Talent Attraction & Retention'], 0.9566302299499512)","('NON-ESG', 0.003615252673625946)","('NON-ESG', 0.0032022034283727407)"
Line 110,"Top 50 Companies for Diversity Top 15 FORTUNE 100 Best Companies to Work For Included for four consecutive years Great Place to Work Worlds Best Workplaces Included for five consecutive years Human Rights Campaign Corporate Equality Index Scored 100% for six consecutive years Seramount ""100 Best Companies"" Workplace & Diversity Dow Jones Sustainability World Index Dow Jones Sustainability North America Index EcoVadis Corporate Social Responsibility Assessment Gold Medal FTSE4Good Index S&P 500 ESG Index AbbVie ranked on the 2021 Purpose Power IndexEnvironment, Social and Governance Civic 50 3BL Media ""100 Best Corporate Citizens"" PEOPLE Companies That Care Bioethics International Good Pharma Scorecard for clinical trial transparency Tied for firstCitizenship FORTUNE 100 FORTUNE Worlds Most Admired CompaniesBusiness PerformanceExternal Recognitions ESG Governance Board of Directors Chairman and CEO ESG TeamExecutive Sponsor & ESG Council Chair Vice Chairman, External Affairs and Chief Legal Officer ESG Council VP, Corporate Governance Legal VP, Corporate Responsibility, Brand, & Communications VP, Tax & Treasury VP, Internal Audit VP, Talent VP, Chief Ethics & Compliance Officer VP, Central Services VP, Quality Assurance VP, Regulatory Affairs and R&D Quality Assurance SVP, R&D Chief Operating Officer VP, Corporate Strategy VP, Global Market Access & Pricing VP, Commercial Operations & Patient Services The board of directors, through its committees, prioritizes and reviews ESG topics, material drivers and enterprise risks and discusses them with our senior management on a regular basis.","('Employee_Engagement_Inclusion_And_Diversity', 0.8969414234161377)","('Human_Rights_And_Community_Relations', 0.026911558583378792)","('Employee_Health_And_Safety', 0.01515379548072815)","(['Talent Attraction & Retention'], 0.8969414234161377)","('NON-ESG', 0.026911558583378792)","('NON-ESG', 0.01515379548072815)"
Line 111,"Top 50 Companies for Diversity Top 15 FORTUNE 100 Best Companies to Work For Included for four consecutive years Great Place to Work Worlds Best Workplaces Included for five consecutive years Human Rights Campaign Corporate Equality Index Scored 100% for six consecutive years Seramount ""100 Best Companies"" Workplace & Diversity Dow Jones Sustainability World Index Dow Jones Sustainability North America Index EcoVadis Corporate Social Responsibility Assessment Gold Medal FTSE4Good Index S&P 500 ESG Index AbbVie ranked on the 2021 Purpose Power IndexEnvironment, Social and Governance Civic 50 3BL Media ""100 Best Corporate Citizens"" PEOPLE Companies That Care Bioethics International Good Pharma Scorecard for clinical trial transparency Tied for firstCitizenship FORTUNE 100 FORTUNE Worlds Most Admired CompaniesBusiness PerformanceExternal Recognitions ESG Governance Board of Directors Chairman and CEO ESG TeamExecutive Sponsor & ESG Council Chair Vice Chairman, External Affairs and Chief Legal Officer ESG Council VP, Corporate Governance Legal VP, Corporate Responsibility, Brand, & Communications VP, Tax & Treasury VP, Internal Audit VP, Talent VP, Chief Ethics & Compliance Officer VP, Central Services VP, Quality Assurance VP, Regulatory Affairs and R&D Quality Assurance SVP, R&D Chief Operating Officer VP, Corporate Strategy VP, Global Market Access & Pricing VP, Commercial Operations & Patient Services The board of directors, through its committees, prioritizes and reviews ESG topics, material drivers and enterprise risks and discusses them with our senior management on a regular basis.","('Business_Ethics', 0.9277003407478333)","('Systemic_Risk_Management', 0.017529573291540146)","('Management_Of_Legal_And_Regulatory_Framework', 0.007352692075073719)","(['Business Ethics'], 0.9277003407478333)","('NON-ESG', 0.017529573291540146)","('NON-ESG', 0.007352692075073719)"
Line 112,"Top 50 Companies for Diversity Top 15 FORTUNE 100 Best Companies to Work For Included for four consecutive years Great Place to Work Worlds Best Workplaces Included for five consecutive years Human Rights Campaign Corporate Equality Index Scored 100% for six consecutive years Seramount ""100 Best Companies"" Workplace & Diversity Dow Jones Sustainability World Index Dow Jones Sustainability North America Index EcoVadis Corporate Social Responsibility Assessment Gold Medal FTSE4Good Index S&P 500 ESG Index AbbVie ranked on the 2021 Purpose Power IndexEnvironment, Social and Governance Civic 50 3BL Media ""100 Best Corporate Citizens"" PEOPLE Companies That Care Bioethics International Good Pharma Scorecard for clinical trial transparency Tied for firstCitizenship FORTUNE 100 FORTUNE Worlds Most Admired CompaniesBusiness PerformanceExternal Recognitions ESG Governance Board of Directors Chairman and CEO ESG TeamExecutive Sponsor & ESG Council Chair Vice Chairman, External Affairs and Chief Legal Officer ESG Council VP, Corporate Governance Legal VP, Corporate Responsibility, Brand, & Communications VP, Tax & Treasury VP, Internal Audit VP, Talent VP, Chief Ethics & Compliance Officer VP, Central Services VP, Quality Assurance VP, Regulatory Affairs and R&D Quality Assurance SVP, R&D Chief Operating Officer VP, Corporate Strategy VP, Global Market Access & Pricing VP, Commercial Operations & Patient Services The board of directors, through its committees, prioritizes and reviews ESG topics, material drivers and enterprise risks and discusses them with our senior management on a regular basis.","('Management_Of_Legal_And_Regulatory_Framework', 0.4056713581085205)","('Business_Ethics', 0.22916175425052643)","('Director_Removal', 0.09213843196630478)","('NON-ESG', 0.4056713581085205)","('NON-ESG', 0.22916175425052643)","('NON-ESG', 0.09213843196630478)"
Line 113,"Top 50 Companies for Diversity Top 15 FORTUNE 100 Best Companies to Work For Included for four consecutive years Great Place to Work Worlds Best Workplaces Included for five consecutive years Human Rights Campaign Corporate Equality Index Scored 100% for six consecutive years Seramount ""100 Best Companies"" Workplace & Diversity Dow Jones Sustainability World Index Dow Jones Sustainability North America Index EcoVadis Corporate Social Responsibility Assessment Gold Medal FTSE4Good Index S&P 500 ESG Index AbbVie ranked on the 2021 Purpose Power IndexEnvironment, Social and Governance Civic 50 3BL Media ""100 Best Corporate Citizens"" PEOPLE Companies That Care Bioethics International Good Pharma Scorecard for clinical trial transparency Tied for firstCitizenship FORTUNE 100 FORTUNE Worlds Most Admired CompaniesBusiness PerformanceExternal Recognitions ESG Governance Board of Directors Chairman and CEO ESG TeamExecutive Sponsor & ESG Council Chair Vice Chairman, External Affairs and Chief Legal Officer ESG Council VP, Corporate Governance Legal VP, Corporate Responsibility, Brand, & Communications VP, Tax & Treasury VP, Internal Audit VP, Talent VP, Chief Ethics & Compliance Officer VP, Central Services VP, Quality Assurance VP, Regulatory Affairs and R&D Quality Assurance SVP, R&D Chief Operating Officer VP, Corporate Strategy VP, Global Market Access & Pricing VP, Commercial Operations & Patient Services The board of directors, through its committees, prioritizes and reviews ESG topics, material drivers and enterprise risks and discusses them with our senior management on a regular basis.","('Systemic_Risk_Management', 0.937080442905426)","('Business_Model_Resilience', 0.012230560183525085)","('Physical_Impacts_Of_Climate_Change', 0.007362403906881809)","([], 0.937080442905426)","('NON-ESG', 0.012230560183525085)","('NON-ESG', 0.007362403906881809)"
Line 114,"These committees include the Nomination & Governance, Public Policy, Audit, and Compensation committee.","('Management_Of_Legal_And_Regulatory_Framework', 0.9139893651008606)","('Business_Ethics', 0.018230874091386795)","('Director_Removal', 0.009248699061572552)","([], 0.9139893651008606)","('NON-ESG', 0.018230874091386795)","('NON-ESG', 0.009248699061572552)"
Line 115,Each board member sits on one or more committees and brings their collective expertise to carry out board initiatives and oversight responsibilities.,"('Director_Removal', 0.6505902409553528)","('Management_Of_Legal_And_Regulatory_Framework', 0.10411304980516434)","('Employee_Engagement_Inclusion_And_Diversity', 0.0213369969278574)","(['Business Ethics'], 0.6505902409553528)","('NON-ESG', 0.10411304980516434)","('NON-ESG', 0.0213369969278574)"
Line 116,"Examples of this oversight involving ESG topics include: (1) reviewing results of the biennial all employee survey, (2) oversight of the companys equity, equality, diversity and inclusion strategy, (3) oversight of employee health and safety data and priorities, and (4) reviewing the companys commitments to pay equity, environmental sustainability efforts, ethics and compliance, risk management and other priorities.","('Employee_Engagement_Inclusion_And_Diversity', 0.8842113614082336)","('Employee_Health_And_Safety', 0.03898996859788895)","('Business_Ethics', 0.009515178389847279)","(['Talent Attraction & Retention'], 0.8842113614082336)","('NON-ESG', 0.03898996859788895)","('NON-ESG', 0.009515178389847279)"
Line 117,"Further, our executive officers also prioritize ESG topics as a strategic focus and significant importance to the business.","('Business_Model_Resilience', 0.7755370140075684)","('Director_Removal', 0.0374503917992115)","('Product_Design_And_Lifecycle_Management', 0.024701286107301712)","(['Human Capital Development', 'Innovation Management'], 0.7755370140075684)","('NON-ESG', 0.0374503917992115)","('NON-ESG', 0.024701286107301712)"
Line 118,"In 2021, our executive officers maintained a formal goal to protect AbbVies reputation across a range of ESG topics aligned to our long-term company strategy and ESG framework.","('Business_Model_Resilience', 0.7296318411827087)","('Systemic_Risk_Management', 0.10201046615839005)","('Business_Ethics', 0.015779687091708183)","(['Human Capital Development', 'Innovation Management'], 0.7296318411827087)","('NON-ESG', 0.10201046615839005)","('NON-ESG', 0.015779687091708183)"
Line 119,The ESG goal was weighted 10% within the short- term incentive program for each executive officer.,"('Director_Removal', 0.320423424243927)","('Management_Of_Legal_And_Regulatory_Framework', 0.20254570245742798)","('Business_Model_Resilience', 0.11890628188848495)","('NON-ESG', 0.320423424243927)","('NON-ESG', 0.20254570245742798)","('NON-ESG', 0.11890628188848495)"
Line 120,"As part of this ESG goal category, all senior leaders, including executive officers, commit to executing our Equity, Equality, Diversity and Inclusion (EEDI) strategy.","('Employee_Engagement_Inclusion_And_Diversity', 0.9733297228813171)","('Human_Rights_And_Community_Relations', 0.002252743812277913)","('Employee_Health_And_Safety', 0.0020101526752114296)","(['Talent Attraction & Retention'], 0.9733297228813171)","('NON-ESG', 0.002252743812277913)","('NON-ESG', 0.0020101526752114296)"
Line 121,"AbbVies executive officers have specific areas of focus for driving the companys framework, and together, the executives goals cover all of AbbVies ESG material drivers.","('Business_Model_Resilience', 0.5181146264076233)","('Director_Removal', 0.104396291077137)","('Employee_Engagement_Inclusion_And_Diversity', 0.060889095067977905)","(['Human Capital Development', 'Innovation Management'], 0.5181146264076233)","('NON-ESG', 0.104396291077137)","('NON-ESG', 0.060889095067977905)"
Line 122,"These goals are quantitative (e.g., reducing carbon emissions using a specific target) and qualitative (e.g., maintaining status as a top employer) in nature.","('GHG_Emissions', 0.7990387082099915)","('Management_Of_Legal_And_Regulatory_Framework', 0.0450899675488472)","('Air_Quality', 0.03559570014476776)","(['Operational Eco-Efficiency'], 0.7990387082099915)","('NON-ESG', 0.0450899675488472)","('NON-ESG', 0.03559570014476776)"
Line 123,12 2021 ESG Action Report 2021 ESG Action Report 13 Environmental We recognize that a business built on sustainable practices will be a long-lasting business.,"('Business_Model_Resilience', 0.41026851534843445)","('Product_Design_And_Lifecycle_Management', 0.2456357479095459)","('Supply_Chain_Management', 0.06025535985827446)","('NON-ESG', 0.41026851534843445)","('NON-ESG', 0.2456357479095459)","('NON-ESG', 0.06025535985827446)"
Line 124,"Our strategy is focused on reducing our environmental footprint, growing sustainably through inspiring innovation, and engaging our workforce to steward the same.","('Business_Model_Resilience', 0.3439652919769287)","('Employee_Engagement_Inclusion_And_Diversity', 0.15533389151096344)","('Product_Design_And_Lifecycle_Management', 0.10604944825172424)","('NON-ESG', 0.3439652919769287)","('NON-ESG', 0.15533389151096344)","('NON-ESG', 0.10604944825172424)"
Line 125,"We have set ambitious, long-term targets that put this strategy into practice.","('Business_Model_Resilience', 0.7354811429977417)","('Physical_Impacts_Of_Climate_Change', 0.029786452651023865)","('Systemic_Risk_Management', 0.023434754461050034)","(['Human Capital Development', 'Innovation Management'], 0.7354811429977417)","('NON-ESG', 0.029786452651023865)","('NON-ESG', 0.023434754461050034)"
Line 126,Climate change has a direct impact on human health.,"('Physical_Impacts_Of_Climate_Change', 0.9457882046699524)","('Critical_Incident_Risk_Management', 0.007359721232205629)","('Business_Model_Resilience', 0.005747148301452398)","([], 0.9457882046699524)","('NON-ESG', 0.007359721232205629)","('NON-ESG', 0.005747148301452398)"
Line 127,"As a company taking on the toughest health challenges, we must play our part in mitigating the impacts of climate change.","('Physical_Impacts_Of_Climate_Change', 0.9489301443099976)","('Business_Model_Resilience', 0.010461725294589996)","('Supply_Chain_Management', 0.004578021354973316)","([], 0.9489301443099976)","('NON-ESG', 0.010461725294589996)","('NON-ESG', 0.004578021354973316)"
Line 128,"In 2021, AbbVie surpassed its 2025 emissions reduction target of 25%, four years ahead of schedule.","('GHG_Emissions', 0.5022122263908386)","('Air_Quality', 0.29549625515937805)","('Energy_Management', 0.06754946708679199)","(['Operational Eco-Efficiency'], 0.5022122263908386)","('NON-ESG', 0.29549625515937805)","('NON-ESG', 0.06754946708679199)"
Line 129,"We accomplished this by increasing our investment in renewable sources, decreasing our Scope 2 emissions.","('GHG_Emissions', 0.717259407043457)","('Energy_Management', 0.10960695892572403)","('Air_Quality', 0.03561360388994217)","(['Operational Eco-Efficiency'], 0.717259407043457)","('NON-ESG', 0.10960695892572403)","('NON-ESG', 0.03561360388994217)"
Line 130,"Furthermore, AbbVie has implemented energy efficiency measures, which decreased both our Scope 1 and Scope 2 emissions.","('Energy_Management', 0.9749910831451416)","('Air_Quality', 0.0034227296710014343)","('Management_Of_Legal_And_Regulatory_Framework', 0.0029489712323993444)","(['Operational Eco-Efficiency'], 0.9749910831451416)","('NON-ESG', 0.0034227296710014343)","('NON-ESG', 0.0029489712323993444)"
Line 131,"For example, we completed the replacement of our cogeneration system at our site in Barceloneta, Puerto Rico.","('Management_Of_Legal_And_Regulatory_Framework', 0.17735408246517181)","('Access_And_Affordability', 0.14612135291099548)","('Energy_Management', 0.09699176251888275)","('NON-ESG', 0.17735408246517181)","('NON-ESG', 0.14612135291099548)","('NON-ESG', 0.09699176251888275)"
Line 132,"We committed to joining the Science Based Targets initiative (SBTi) in 2021 and setting ambitious science-based emissions reduction targets to support limiting global temperature rise to no more than 1.5C above pre-industrial levels, in line with the Paris Climate Agreement and the 2018 Intergovernmental Panel on Climate Change.","('Physical_Impacts_Of_Climate_Change', 0.8333925008773804)","('GHG_Emissions', 0.06518427282571793)","('Business_Model_Resilience', 0.020696459338068962)","([], 0.8333925008773804)","('NON-ESG', 0.06518427282571793)","('NON-ESG', 0.020696459338068962)"
Line 133,Working with the SBTi allows us to access expert resources that support us on our journey to meaningfully reduce our climate impact and provide external assessment and validation of our approach and target.,"('Physical_Impacts_Of_Climate_Change', 0.9349061250686646)","('Business_Model_Resilience', 0.017015816643834114)","('GHG_Emissions', 0.005670900456607342)","([], 0.9349061250686646)","('NON-ESG', 0.017015816643834114)","('NON-ESG', 0.005670900456607342)"
Line 134,"We intend to formally announce our SBTi- approved science-based targets in 2022, using 2021 as our baseline year.","('Management_Of_Legal_And_Regulatory_Framework', 0.3796774744987488)","('GHG_Emissions', 0.21949008107185364)","('Selling_Practices_And_Product_Labeling', 0.0483703650534153)","('NON-ESG', 0.3796774744987488)","('NON-ESG', 0.21949008107185364)","('NON-ESG', 0.0483703650534153)"
Line 135,"Environmental Sustainability2021 Highlights Surpassed 2025 target of reduction in carbon emissions since 2015 baseline25% of waste diverted from landfill92% winning ideas from the SPARK Innovation Accelerator13 of electricity purchased from renewable sources32% 2021 Achieved2025 Target2035 Target Reduce absolute carbon emissions (Scope 1 and Scope 2 market-based) vs. 2015 baseline1 -26% -25% -50% Increase percentage of electricity purchased from renewable sources (excluding leased commercial offices)+32% +50% +100% Reduce absolute water withdrawal (including non-contact cooling water) vs. 2015 baseline1 +14% -20% -50% Reduce absolute total hazardous and non-hazardous waste generated (excluding construction and demolition waste) vs. 2015 baseline1,2 -14% -20% - Achieve and maintain combined recycling rate for hazardous and non- hazardous waste (excluding construction and demolition waste)42% 50% - Achieve zero waste to landfill (excluding leased offices) 92% - 100%14 2021 ESG Action Report 2021 ESG Action Report 15 We continuously evaluate the impact of climate change on our business, particularly in terms of potential supply disruption.","('Energy_Management', 0.6751798987388611)","('GHG_Emissions', 0.09506296366453171)","('Air_Quality', 0.08208181709051132)","(['Operational Eco-Efficiency'], 0.6751798987388611)","('NON-ESG', 0.09506296366453171)","('NON-ESG', 0.08208181709051132)"
Line 136,"Environmental Sustainability2021 Highlights Surpassed 2025 target of reduction in carbon emissions since 2015 baseline25% of waste diverted from landfill92% winning ideas from the SPARK Innovation Accelerator13 of electricity purchased from renewable sources32% 2021 Achieved2025 Target2035 Target Reduce absolute carbon emissions (Scope 1 and Scope 2 market-based) vs. 2015 baseline1 -26% -25% -50% Increase percentage of electricity purchased from renewable sources (excluding leased commercial offices)+32% +50% +100% Reduce absolute water withdrawal (including non-contact cooling water) vs. 2015 baseline1 +14% -20% -50% Reduce absolute total hazardous and non-hazardous waste generated (excluding construction and demolition waste) vs. 2015 baseline1,2 -14% -20% - Achieve and maintain combined recycling rate for hazardous and non- hazardous waste (excluding construction and demolition waste)42% 50% - Achieve zero waste to landfill (excluding leased offices) 92% - 100%14 2021 ESG Action Report 2021 ESG Action Report 15 We continuously evaluate the impact of climate change on our business, particularly in terms of potential supply disruption.","('Waste_And_Hazardous_Materials_Management', 0.9851694107055664)","('Data_Security', 0.0010816722642630339)","('Water_And_Wastewater_Management', 0.0010187055449932814)","([], 0.9851694107055664)","('NON-ESG', 0.0010816722642630339)","('NON-ESG', 0.0010187055449932814)"
Line 137,"Environmental Sustainability2021 Highlights Surpassed 2025 target of reduction in carbon emissions since 2015 baseline25% of waste diverted from landfill92% winning ideas from the SPARK Innovation Accelerator13 of electricity purchased from renewable sources32% 2021 Achieved2025 Target2035 Target Reduce absolute carbon emissions (Scope 1 and Scope 2 market-based) vs. 2015 baseline1 -26% -25% -50% Increase percentage of electricity purchased from renewable sources (excluding leased commercial offices)+32% +50% +100% Reduce absolute water withdrawal (including non-contact cooling water) vs. 2015 baseline1 +14% -20% -50% Reduce absolute total hazardous and non-hazardous waste generated (excluding construction and demolition waste) vs. 2015 baseline1,2 -14% -20% - Achieve and maintain combined recycling rate for hazardous and non- hazardous waste (excluding construction and demolition waste)42% 50% - Achieve zero waste to landfill (excluding leased offices) 92% - 100%14 2021 ESG Action Report 2021 ESG Action Report 15 We continuously evaluate the impact of climate change on our business, particularly in terms of potential supply disruption.","('Supply_Chain_Management', 0.4233552813529968)","('Physical_Impacts_Of_Climate_Change', 0.4180186092853546)","('Systemic_Risk_Management', 0.023345910012722015)","('NON-ESG', 0.4233552813529968)","('NON-ESG', 0.4180186092853546)","('NON-ESG', 0.023345910012722015)"
Line 138,"To ensure continued access to medicines and to mitigate supply risks, we conduct climate risk assessments and implement adaptation projects.","('Supply_Chain_Management', 0.9302464723587036)","('Physical_Impacts_Of_Climate_Change', 0.01368074119091034)","('Water_And_Wastewater_Management', 0.005874434020370245)","([], 0.9302464723587036)","('NON-ESG', 0.01368074119091034)","('NON-ESG', 0.005874434020370245)"
Line 139,Climate risk is integrated into our enterprise risk management process.,"('Physical_Impacts_Of_Climate_Change', 0.9337341785430908)","('Business_Model_Resilience', 0.015987977385520935)","('Systemic_Risk_Management', 0.006643044296652079)","([], 0.9337341785430908)","('NON-ESG', 0.015987977385520935)","('NON-ESG', 0.006643044296652079)"
Line 140,We partnered with S&P Global Trucost in 2020 to perform a climate risk assessment for physical risks.,"('Physical_Impacts_Of_Climate_Change', 0.9463969469070435)","('Business_Model_Resilience', 0.009398046880960464)","('GHG_Emissions', 0.006956365890800953)","([], 0.9463969469070435)","('NON-ESG', 0.009398046880960464)","('NON-ESG', 0.006956365890800953)"
Line 141,The analysis focused on extreme weather impacts today and other climate impacts out to 2050.,"('Physical_Impacts_Of_Climate_Change', 0.8345314264297485)","('Business_Model_Resilience', 0.07934554666280746)","('GHG_Emissions', 0.009070232510566711)","([], 0.8345314264297485)","('NON-ESG', 0.07934554666280746)","('NON-ESG', 0.009070232510566711)"
Line 142,"The risk assessment encompassed 100 global sites and locations including all manufacturing, R&D, warehouse locations, along with select global offices.","('Business_Model_Resilience', 0.3030718266963959)","('Systemic_Risk_Management', 0.19076085090637207)","('Supply_Chain_Management', 0.15497736632823944)","('NON-ESG', 0.3030718266963959)","('NON-ESG', 0.19076085090637207)","('NON-ESG', 0.15497736632823944)"
Line 143,"It also included the top 35 locations of our critical suppliers, the top 20 locations for our third-party logistic warehouses and nine of our global third-party data centers.","('Supply_Chain_Management', 0.9198431372642517)","('Waste_And_Hazardous_Materials_Management', 0.00862368568778038)","('Water_And_Wastewater_Management', 0.007192033808678389)","([], 0.9198431372642517)","('NON-ESG', 0.00862368568778038)","('NON-ESG', 0.007192033808678389)"
Line 144,Details from this assessment were included in our 2021 CDP Climate submission.,"('Physical_Impacts_Of_Climate_Change', 0.5370070338249207)","('GHG_Emissions', 0.11921297758817673)","('Business_Model_Resilience', 0.07420270144939423)","([], 0.5370070338249207)","('NON-ESG', 0.11921297758817673)","('NON-ESG', 0.07420270144939423)"
Line 145,"AbbVie also conducts general assessments on the physical impact of climate change, including our upstream and downstream operations and stakeholders.","('Physical_Impacts_Of_Climate_Change', 0.940618097782135)","('Business_Model_Resilience', 0.01608743704855442)","('GHG_Emissions', 0.005543888546526432)","([], 0.940618097782135)","('NON-ESG', 0.01608743704855442)","('NON-ESG', 0.005543888546526432)"
Line 146,"In our continuous effort to adapt to climate risk, we updated the physical features of our Barceloneta, Puerto Rico site in preparation for stronger hurricanes in the future.","('Physical_Impacts_Of_Climate_Change', 0.8863239884376526)","('Business_Model_Resilience', 0.03897571563720703)","('GHG_Emissions', 0.011861851438879967)","([], 0.8863239884376526)","('NON-ESG', 0.03897571563720703)","('NON-ESG', 0.011861851438879967)"
Line 147,"Our roofs have been designed and reinforced to withstand a Category 5 hurricane, and our cogeneration system has recently been replaced to ensure that we can self-generate power in the event that an engine is damaged.","('Physical_Impacts_Of_Climate_Change', 0.5760402679443359)","('Critical_Incident_Risk_Management', 0.1407892405986786)","('Air_Quality', 0.0527174212038517)","([], 0.5760402679443359)","('NON-ESG', 0.1407892405986786)","('NON-ESG', 0.0527174212038517)"
Line 148,"To further improve our resiliency, we are in the process of installing on-site emergency power generators at our sites in Branchburg, New Jersey, and Waco, Texas, and have commissioned and installed an on-site emergency generator at our new R&D site in South San Francisco, California, in preparation for future wildfire-related outages.","('Critical_Incident_Risk_Management', 0.971863865852356)","('Employee_Health_And_Safety', 0.003964088391512632)","('Air_Quality', 0.0035921758972108364)","([], 0.971863865852356)","('NON-ESG', 0.003964088391512632)","('NON-ESG', 0.0035921758972108364)"
Line 149,AbbVie actively seeks to reduce the energy and water we consume and the waste we generate around the world.,"('Waste_And_Hazardous_Materials_Management', 0.9772230982780457)","('Water_And_Wastewater_Management', 0.0024832095950841904)","('Product_Design_And_Lifecycle_Management', 0.0019400280434638262)","([], 0.9772230982780457)","('NON-ESG', 0.0024832095950841904)","('NON-ESG', 0.0019400280434638262)"
Line 150,"We monitor our operations to ensure that the manufacturing, use and disposal of our medicines do not adversely affect the environment or human health.","('Employee_Health_And_Safety', 0.3508463203907013)","('Product_Design_And_Lifecycle_Management', 0.13111938536167145)","('Product_Quality_And_Safety', 0.10224638879299164)","('NON-ESG', 0.3508463203907013)","('NON-ESG', 0.13111938536167145)","('NON-ESG', 0.10224638879299164)"
Line 151,We operate robust environmental and energy management systems that support the integrity of our environmental sustainability strategy.,"('Business_Model_Resilience', 0.3136970102787018)","('Ecological_Impacts', 0.19511298835277557)","('Physical_Impacts_Of_Climate_Change', 0.07180120050907135)","('NON-ESG', 0.3136970102787018)","('NON-ESG', 0.19511298835277557)","('NON-ESG', 0.07180120050907135)"
Line 152,"Our determined efforts to reduce carbon emissions are being achieved largely through investment in technology, infrastructure and processes that increase energy efficiency and use cleaner energy sources.","('Energy_Management', 0.9474390149116516)","('Air_Quality', 0.009447051212191582)","('GHG_Emissions', 0.008520073257386684)","(['Operational Eco-Efficiency'], 0.9474390149116516)","('NON-ESG', 0.009447051212191582)","('NON-ESG', 0.008520073257386684)"
Line 153,We increased the amount of renewable electricity that we purchase to over 30% globally in 2021 and are on track to meet our 2025 target of increasing renewable energy sourcing to 50%.,"('Energy_Management', 0.974553644657135)","('Management_Of_Legal_And_Regulatory_Framework', 0.004182310774922371)","('Product_Design_And_Lifecycle_Management', 0.0026890623848885298)","(['Operational Eco-Efficiency'], 0.974553644657135)","('NON-ESG', 0.004182310774922371)","('NON-ESG', 0.0026890623848885298)"
Line 154,"We continue to expand the use of electric and hybrid vehicles in our fleets, as well as explore other opportunities to reduce emissions.","('Energy_Management', 0.5331758856773376)","('Air_Quality', 0.2556016445159912)","('GHG_Emissions', 0.0740678533911705)","(['Operational Eco-Efficiency'], 0.5331758856773376)","('NON-ESG', 0.2556016445159912)","('NON-ESG', 0.0740678533911705)"
Line 155,"For example, of the new vehicles that were introduced in our UK fleet, 95% were electric or hybrid, and over 30% of all the new vehicles introduced in our Western Europe fleet were electric or hybrid.","('Energy_Management', 0.6435108184814453)","('Product_Design_And_Lifecycle_Management', 0.10144802182912827)","('Management_Of_Legal_And_Regulatory_Framework', 0.042952198535203934)","(['Operational Eco-Efficiency'], 0.6435108184814453)","('NON-ESG', 0.10144802182912827)","('NON-ESG', 0.042952198535203934)"
Line 156,"In 2021, we replaced all steam boilers at our manufacturing site in Campo Verde, Italy.","('Energy_Management', 0.7842469215393066)","('Product_Design_And_Lifecycle_Management', 0.0476493276655674)","('Supply_Chain_Management', 0.016573715955018997)","(['Operational Eco-Efficiency'], 0.7842469215393066)","('NON-ESG', 0.0476493276655674)","('NON-ESG', 0.016573715955018997)"
Line 157,"The new boilers have increased efficiency to over 90% and are significantly more efficient than the previous units, which were at least 30 years old.","('Energy_Management', 0.947736918926239)","('Management_Of_Legal_And_Regulatory_Framework', 0.0074434345588088036)","('Air_Quality', 0.006380149163305759)","(['Operational Eco-Efficiency'], 0.947736918926239)","('NON-ESG', 0.0074434345588088036)","('NON-ESG', 0.006380149163305759)"
Line 158,Fourteen of our manufacturing sites have achieved ISO 14001 certification for environmental management systems and 12 have ISO 50001 certification for effective energy management systems.,"('Product_Design_And_Lifecycle_Management', 0.8045110106468201)","('Product_Quality_And_Safety', 0.04088541865348816)","('Energy_Management', 0.028915973380208015)","([], 0.8045110106468201)","('NON-ESG', 0.04088541865348816)","('NON-ESG', 0.028915973380208015)"
Line 159,"Our Westport, Ireland site is the newest site to receive the ISO 50001 certification.","('Product_Quality_And_Safety', 0.3501608073711395)","('Product_Design_And_Lifecycle_Management', 0.2724655270576477)","('Management_Of_Legal_And_Regulatory_Framework', 0.05134057253599167)","('NON-ESG', 0.3501608073711395)","('NON-ESG', 0.2724655270576477)","('NON-ESG', 0.05134057253599167)"
Line 160,"Our Branchburg, New Jersey; Waco, Texas; and Wyandotte, Michigan sites were awarded Energy Star Certification in 2021, and AbbVie was named the U.","('Management_Of_Legal_And_Regulatory_Framework', 0.17452894151210785)","('Product_Design_And_Lifecycle_Management', 0.14908692240715027)","('Product_Quality_And_Safety', 0.14269593358039856)","('NON-ESG', 0.17452894151210785)","('NON-ESG', 0.14908692240715027)","('NON-ESG', 0.14269593358039856)"
Line 161,S. Environmental Protection Agencys (EPA) ENERGY STAR Partner of the Year for our performance in 2021.,"('Management_Of_Legal_And_Regulatory_Framework', 0.4877123236656189)","('Ecological_Impacts', 0.21330177783966064)","('GHG_Emissions', 0.05768328905105591)","('NON-ESG', 0.4877123236656189)","('NON-ESG', 0.21330177783966064)","('NON-ESG', 0.05768328905105591)"
Line 162,"1 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('Business_Model_Resilience', 0.37769728899002075)","('Product_Design_And_Lifecycle_Management', 0.08301235735416412)","('Physical_Impacts_Of_Climate_Change', 0.07872799783945084)","('NON-ESG', 0.37769728899002075)","('NON-ESG', 0.08301235735416412)","('NON-ESG', 0.07872799783945084)"
Line 163,The numbers listed above include both AbbVie and Allergan data versus our targets.,"('Data_Security', 0.2683030366897583)","('Customer_Privacy', 0.1831716150045395)","('Systemic_Risk_Management', 0.1713901162147522)","('NON-ESG', 0.2683030366897583)","('NON-ESG', 0.1831716150045395)","('NON-ESG', 0.1713901162147522)"
Line 164,"2 Includes waste disposed of in the following manner: beneficial use, recycled, composted, treated, incinerated with energy recovery and incinerated without energy recovery.","('Waste_And_Hazardous_Materials_Management', 0.9838176965713501)","('Water_And_Wastewater_Management', 0.0015869889175519347)","('Data_Security', 0.0011651378590613604)","([], 0.9838176965713501)","('NON-ESG', 0.0015869889175519347)","('NON-ESG', 0.0011651378590613604)"
Line 165,"AbbVie Environmental Targets Reducing Our Footprint Energy and Carbon AbbVie is committed to understanding our climate risks, disclosing those risks and doing our part to mitigate the impacts of climate change by reducing our carbon footprint.","('Physical_Impacts_Of_Climate_Change', 0.9418744444847107)","('Business_Model_Resilience', 0.015982022508978844)","('Systemic_Risk_Management', 0.005360318813472986)","([], 0.9418744444847107)","('NON-ESG', 0.015982022508978844)","('NON-ESG', 0.005360318813472986)"
Line 166,"In early 2022, we committed to publicly disclosing environmental information in the TCFD framework.","('Management_Of_Legal_And_Regulatory_Framework', 0.1540830284357071)","('Customer_Privacy', 0.12829862534999847)","('Ecological_Impacts', 0.08241716772317886)","('NON-ESG', 0.1540830284357071)","('NON-ESG', 0.12829862534999847)","('NON-ESG', 0.08241716772317886)"
Line 167,Our TCFD report is available on our website .,"('Management_Of_Legal_And_Regulatory_Framework', 0.7237337827682495)","('GHG_Emissions', 0.0793854370713234)","('Systemic_Risk_Management', 0.022907055914402008)","([], 0.7237337827682495)","('NON-ESG', 0.0793854370713234)","('NON-ESG', 0.022907055914402008)"
Line 168,"The SPARK Innovation Accelerator is an incubator for employee-driven ideas that accelerate our efforts to reduce energy consumption, water use and waste.","('Energy_Management', 0.7754459977149963)","('Water_And_Wastewater_Management', 0.09650981426239014)","('Waste_And_Hazardous_Materials_Management', 0.01970500871539116)","(['Operational Eco-Efficiency'], 0.7754459977149963)","('NON-ESG', 0.09650981426239014)","('NON-ESG', 0.01970500871539116)"
Line 169,"In 2021, colleagues from 37 global sites submitted over 200 innovative ideas.","('Competitive_Behavior', 0.21280540525913239)","('Product_Design_And_Lifecycle_Management', 0.16756369173526764)","('Business_Model_Resilience', 0.11747975647449493)","('NON-ESG', 0.21280540525913239)","('NON-ESG', 0.16756369173526764)","('NON-ESG', 0.11747975647449493)"
Line 170,Thirteen winning ideas will be implemented by November 2022.,"('Management_Of_Legal_And_Regulatory_Framework', 0.5593100190162659)","('Business_Model_Resilience', 0.0909271314740181)","('Ecological_Impacts', 0.04057563841342926)","([], 0.5593100190162659)","('NON-ESG', 0.0909271314740181)","('NON-ESG', 0.04057563841342926)"
Line 171,"Two 2021 Winning Ideas: In North Chicago, a team of scientists built a dashboard to identify facilities that close fume hoods and those who leave them openallowing energy to escape, like an open window.","('Air_Quality', 0.557648777961731)","('Critical_Incident_Risk_Management', 0.11162940412759781)","('Energy_Management', 0.09446895867586136)","([], 0.557648777961731)","('NON-ESG', 0.11162940412759781)","('NON-ESG', 0.09446895867586136)"
Line 172,"By making this data visible, the team is influencing positive change and as a result, AbbVie saved almost 15,000 kilowatt hours of energy globally in 2021.","('Energy_Management', 0.9785857200622559)","('Management_Of_Legal_And_Regulatory_Framework', 0.002176510402932763)","('Air_Quality', 0.001962153473868966)","(['Operational Eco-Efficiency'], 0.9785857200622559)","('NON-ESG', 0.002176510402932763)","('NON-ESG', 0.001962153473868966)"
Line 173,A team of colleagues in the United States collaborated to understand the quantity of printed sales materials not being used due to the pandemic and the impact of the shift to virtual engagement of healthcare professionals.,"('Product_Design_And_Lifecycle_Management', 0.2791181802749634)","('Supply_Chain_Management', 0.22098897397518158)","('Selling_Practices_And_Product_Labeling', 0.09667231142520905)","('NON-ESG', 0.2791181802749634)","('NON-ESG', 0.22098897397518158)","('NON-ESG', 0.09667231142520905)"
Line 174,Their work identified an opportunity to reduce printed sales material waste by 31 metric tons each year.,"('Waste_And_Hazardous_Materials_Management', 0.9819489121437073)","('Water_And_Wastewater_Management', 0.001500876503996551)","('Air_Quality', 0.0014827819541096687)","([], 0.9819489121437073)","('NON-ESG', 0.001500876503996551)","('NON-ESG', 0.0014827819541096687)"
Line 175,The team looks forward to executing on their plan in 2022 and beyond.,"('Business_Model_Resilience', 0.36812612414360046)","('Physical_Impacts_Of_Climate_Change', 0.19295871257781982)","('Management_Of_Legal_And_Regulatory_Framework', 0.07187411189079285)","('NON-ESG', 0.36812612414360046)","('NON-ESG', 0.19295871257781982)","('NON-ESG', 0.07187411189079285)"
Line 176,"Task Force on Climate- Related Financial Disclosures (TCFD) Inspiring Innovation 16 2021 ESG Action Report 2021 ESG Action Report 17 2021 Change in absolute carbon emissions vs. 2015 baseline (Scope 1 and Scope 2, market based) [2025 target: -25%]1-26% Achieved Target Percentage of electricity purchased from renewable sources (excluding leased facilities) [2025 target: 50%]32% 2021 Absolute Scope 1 GHG Emissions (Metric Tons CO2e) 367,954 Scope 1 Stationary Combustion GHG Emissions (MT) 259,456 Scope 1 Mobile Combustion GHG Emissions (MT) 97,076 Scope 1 Fugitive GHG Emissions (MT) 5,501 Scope 1 Office Activities GHG Emissions (MT) 5,921 Absolute Scope 2 Location Based GHG Emissions (Metric Tons CO2e) 330,946 Absolute Scope 2 Market Based GHG Emissions (Metric Tons CO2e) 256,708 Scope 2 Purchased Electricity GHG Emissions (MT) 204,918 Scope 2 Purchased Steam GHG Emissions (MT) 25,649 Scope 2 Purchased Chilled Water GHG Emissions (MT) 26,141 Scope 1 & 2 GHG Intensity (Metric Tons CO2e /$million revenue) 11.12 Scope 1 & 2 Absolute Non-Carbon Emissions (in Metric Tons) (CH4, N20, HFC and Other) 7,016 CH4 (MT) 501 N2O (MT) 1,014 HFC (MT) 29 Other (MT) 5,472 Absolute Energy Consumption (MWH) 2,654,868 Natural Gas (MWH) 1,000,684 LNG, LPG & Propane (MWH) 338,459 #2 Fuel Oil (MWH) 51,985 #6 Fuel Oil (MWH) 0 Jet Kerosene (MWH) 22,698 Motor Fuel Gasoline/Diesel (MWH) 354,507 Purchased Electricity & Utilities (Steam & Chilled Water) (MWH) 886,5351 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('GHG_Emissions', 0.9666599035263062)","('Air_Quality', 0.005110336933284998)","('Ecological_Impacts', 0.0035525141283869743)","(['Operational Eco-Efficiency'], 0.9666599035263062)","('NON-ESG', 0.005110336933284998)","('NON-ESG', 0.0035525141283869743)"
Line 177,"Task Force on Climate- Related Financial Disclosures (TCFD) Inspiring Innovation 16 2021 ESG Action Report 2021 ESG Action Report 17 2021 Change in absolute carbon emissions vs. 2015 baseline (Scope 1 and Scope 2, market based) [2025 target: -25%]1-26% Achieved Target Percentage of electricity purchased from renewable sources (excluding leased facilities) [2025 target: 50%]32% 2021 Absolute Scope 1 GHG Emissions (Metric Tons CO2e) 367,954 Scope 1 Stationary Combustion GHG Emissions (MT) 259,456 Scope 1 Mobile Combustion GHG Emissions (MT) 97,076 Scope 1 Fugitive GHG Emissions (MT) 5,501 Scope 1 Office Activities GHG Emissions (MT) 5,921 Absolute Scope 2 Location Based GHG Emissions (Metric Tons CO2e) 330,946 Absolute Scope 2 Market Based GHG Emissions (Metric Tons CO2e) 256,708 Scope 2 Purchased Electricity GHG Emissions (MT) 204,918 Scope 2 Purchased Steam GHG Emissions (MT) 25,649 Scope 2 Purchased Chilled Water GHG Emissions (MT) 26,141 Scope 1 & 2 GHG Intensity (Metric Tons CO2e /$million revenue) 11.12 Scope 1 & 2 Absolute Non-Carbon Emissions (in Metric Tons) (CH4, N20, HFC and Other) 7,016 CH4 (MT) 501 N2O (MT) 1,014 HFC (MT) 29 Other (MT) 5,472 Absolute Energy Consumption (MWH) 2,654,868 Natural Gas (MWH) 1,000,684 LNG, LPG & Propane (MWH) 338,459 #2 Fuel Oil (MWH) 51,985 #6 Fuel Oil (MWH) 0 Jet Kerosene (MWH) 22,698 Motor Fuel Gasoline/Diesel (MWH) 354,507 Purchased Electricity & Utilities (Steam & Chilled Water) (MWH) 886,5351 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('GHG_Emissions', 0.9622567296028137)","('Air_Quality', 0.007574915885925293)","('Ecological_Impacts', 0.004137663170695305)","(['Operational Eco-Efficiency'], 0.9622567296028137)","('NON-ESG', 0.007574915885925293)","('NON-ESG', 0.004137663170695305)"
Line 178,"Task Force on Climate- Related Financial Disclosures (TCFD) Inspiring Innovation 16 2021 ESG Action Report 2021 ESG Action Report 17 2021 Change in absolute carbon emissions vs. 2015 baseline (Scope 1 and Scope 2, market based) [2025 target: -25%]1-26% Achieved Target Percentage of electricity purchased from renewable sources (excluding leased facilities) [2025 target: 50%]32% 2021 Absolute Scope 1 GHG Emissions (Metric Tons CO2e) 367,954 Scope 1 Stationary Combustion GHG Emissions (MT) 259,456 Scope 1 Mobile Combustion GHG Emissions (MT) 97,076 Scope 1 Fugitive GHG Emissions (MT) 5,501 Scope 1 Office Activities GHG Emissions (MT) 5,921 Absolute Scope 2 Location Based GHG Emissions (Metric Tons CO2e) 330,946 Absolute Scope 2 Market Based GHG Emissions (Metric Tons CO2e) 256,708 Scope 2 Purchased Electricity GHG Emissions (MT) 204,918 Scope 2 Purchased Steam GHG Emissions (MT) 25,649 Scope 2 Purchased Chilled Water GHG Emissions (MT) 26,141 Scope 1 & 2 GHG Intensity (Metric Tons CO2e /$million revenue) 11.12 Scope 1 & 2 Absolute Non-Carbon Emissions (in Metric Tons) (CH4, N20, HFC and Other) 7,016 CH4 (MT) 501 N2O (MT) 1,014 HFC (MT) 29 Other (MT) 5,472 Absolute Energy Consumption (MWH) 2,654,868 Natural Gas (MWH) 1,000,684 LNG, LPG & Propane (MWH) 338,459 #2 Fuel Oil (MWH) 51,985 #6 Fuel Oil (MWH) 0 Jet Kerosene (MWH) 22,698 Motor Fuel Gasoline/Diesel (MWH) 354,507 Purchased Electricity & Utilities (Steam & Chilled Water) (MWH) 886,5351 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('Energy_Management', 0.6756109595298767)","('GHG_Emissions', 0.1842726469039917)","('Air_Quality', 0.04420686513185501)","(['Operational Eco-Efficiency'], 0.6756109595298767)","('NON-ESG', 0.1842726469039917)","('NON-ESG', 0.04420686513185501)"
Line 179,"Task Force on Climate- Related Financial Disclosures (TCFD) Inspiring Innovation 16 2021 ESG Action Report 2021 ESG Action Report 17 2021 Change in absolute carbon emissions vs. 2015 baseline (Scope 1 and Scope 2, market based) [2025 target: -25%]1-26% Achieved Target Percentage of electricity purchased from renewable sources (excluding leased facilities) [2025 target: 50%]32% 2021 Absolute Scope 1 GHG Emissions (Metric Tons CO2e) 367,954 Scope 1 Stationary Combustion GHG Emissions (MT) 259,456 Scope 1 Mobile Combustion GHG Emissions (MT) 97,076 Scope 1 Fugitive GHG Emissions (MT) 5,501 Scope 1 Office Activities GHG Emissions (MT) 5,921 Absolute Scope 2 Location Based GHG Emissions (Metric Tons CO2e) 330,946 Absolute Scope 2 Market Based GHG Emissions (Metric Tons CO2e) 256,708 Scope 2 Purchased Electricity GHG Emissions (MT) 204,918 Scope 2 Purchased Steam GHG Emissions (MT) 25,649 Scope 2 Purchased Chilled Water GHG Emissions (MT) 26,141 Scope 1 & 2 GHG Intensity (Metric Tons CO2e /$million revenue) 11.12 Scope 1 & 2 Absolute Non-Carbon Emissions (in Metric Tons) (CH4, N20, HFC and Other) 7,016 CH4 (MT) 501 N2O (MT) 1,014 HFC (MT) 29 Other (MT) 5,472 Absolute Energy Consumption (MWH) 2,654,868 Natural Gas (MWH) 1,000,684 LNG, LPG & Propane (MWH) 338,459 #2 Fuel Oil (MWH) 51,985 #6 Fuel Oil (MWH) 0 Jet Kerosene (MWH) 22,698 Motor Fuel Gasoline/Diesel (MWH) 354,507 Purchased Electricity & Utilities (Steam & Chilled Water) (MWH) 886,5351 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('Business_Model_Resilience', 0.31365880370140076)","('Systemic_Risk_Management', 0.1077670231461525)","('Physical_Impacts_Of_Climate_Change', 0.09445156157016754)","('NON-ESG', 0.31365880370140076)","('NON-ESG', 0.1077670231461525)","('NON-ESG', 0.09445156157016754)"
Line 180,The numbers listed above include both AbbVie and Allergan data versus our targets.,"('Data_Security', 0.2683030366897583)","('Customer_Privacy', 0.1831716150045395)","('Systemic_Risk_Management', 0.1713901162147522)","('NON-ESG', 0.2683030366897583)","('NON-ESG', 0.1831716150045395)","('NON-ESG', 0.1713901162147522)"
Line 181,This table includes new KPIs added to 2021 ESG Action Report.,"('Systemic_Risk_Management', 0.4838895797729492)","('Business_Model_Resilience', 0.19310328364372253)","('Management_Of_Legal_And_Regulatory_Framework', 0.07584341615438461)","('NON-ESG', 0.4838895797729492)","('NON-ESG', 0.19310328364372253)","('NON-ESG', 0.07584341615438461)"
Line 182,"2021 was the first full year that Allergan data was integrated into AbbVie, and the data provided is reflective of such.","('Customer_Privacy', 0.1755763441324234)","('Data_Security', 0.17340707778930664)","('Systemic_Risk_Management', 0.15277248620986938)","('NON-ESG', 0.1755763441324234)","('NON-ESG', 0.17340707778930664)","('NON-ESG', 0.15277248620986938)"
Line 183,"Key Performance Indicators: Carbon Emissions and Renewable Energy Key Performance Indicators: Carbon Emissions and Renewable Energy Absolute Values Integrating sustainability into AbbVies design, planning and development processes allows AbbVie to make progress toward our environmental targets, but also supports sustainable growth well into the future.","('Energy_Management', 0.44133445620536804)","('GHG_Emissions', 0.2253800332546234)","('Management_Of_Legal_And_Regulatory_Framework', 0.11119451373815536)","('NON-ESG', 0.44133445620536804)","('NON-ESG', 0.2253800332546234)","('NON-ESG', 0.11119451373815536)"
Line 184,"In 2021, we released refreshed Global Facility Design Guidelines to our facility designers and engineers across the globe.","('Product_Design_And_Lifecycle_Management', 0.20061945915222168)","('Business_Model_Resilience', 0.12552401423454285)","('Supply_Chain_Management', 0.08042722195386887)","('NON-ESG', 0.20061945915222168)","('NON-ESG', 0.12552401423454285)","('NON-ESG', 0.08042722195386887)"
Line 185,"These guidelines include over 100 sustainable design concepts that can be incorporated in new construction, upgrades and retrofits.","('Product_Design_And_Lifecycle_Management', 0.7003053426742554)","('Energy_Management', 0.07475073635578156)","('Business_Model_Resilience', 0.03839154914021492)","([], 0.7003053426742554)","('NON-ESG', 0.07475073635578156)","('NON-ESG', 0.03839154914021492)"
Line 186,"Most of our design concepts were integrated into our new R&D facility located in South San Francisco, a certified LEED Platinum building.","('Product_Design_And_Lifecycle_Management', 0.5807613134384155)","('Business_Model_Resilience', 0.06616809219121933)","('Product_Quality_And_Safety', 0.05944807827472687)","([], 0.5807613134384155)","('NON-ESG', 0.06616809219121933)","('NON-ESG', 0.05944807827472687)"
Line 187,"The building, opened in 2021, includes energy efficient lighting and lighting controls as well as a rainwater harvesting system.","('Water_And_Wastewater_Management', 0.6196305155754089)","('Energy_Management', 0.20624203979969025)","('GHG_Emissions', 0.023692695423960686)","([], 0.6196305155754089)","('NON-ESG', 0.20624203979969025)","('NON-ESG', 0.023692695423960686)"
Line 188,"Designing for Sustainability Access to clean water is crucial for human health, and we are committed to using water responsibly and doing our part to protect this vital resource.","('Water_And_Wastewater_Management', 0.97210294008255)","('Ecological_Impacts', 0.0038471492007374763)","('GHG_Emissions', 0.002929029753431678)","([], 0.97210294008255)","('NON-ESG', 0.0038471492007374763)","('NON-ESG', 0.002929029753431678)"
Line 189,We have set an ambitious goal to halve our absolute water withdrawal by 2035 compared to our 2015 baseline.,"('Water_And_Wastewater_Management', 0.9744775891304016)","('GHG_Emissions', 0.003643756965175271)","('Ecological_Impacts', 0.0021441050339490175)","([], 0.9744775891304016)","('NON-ESG', 0.003643756965175271)","('NON-ESG', 0.0021441050339490175)"
Line 190,"To achieve this goal, we focus our efforts on reducing our total global water consumption and investing in innovative technologies that allow us to use water more efficiently.","('Water_And_Wastewater_Management', 0.9749759435653687)","('Energy_Management', 0.003067025914788246)","('GHG_Emissions', 0.0026858875062316656)","([], 0.9749759435653687)","('NON-ESG', 0.003067025914788246)","('NON-ESG', 0.0026858875062316656)"
Line 191,"In Barceloneta, Puerto Rico, we have reduced water consumption at the site by over 250,000 cubic meters annually.","('Water_And_Wastewater_Management', 0.9724517464637756)","('Energy_Management', 0.004260309971868992)","('GHG_Emissions', 0.002976607298478484)","([], 0.9724517464637756)","('NON-ESG', 0.004260309971868992)","('NON-ESG', 0.002976607298478484)"
Line 192,"Through a reverse osmosis system in our on-site wastewater treatment plant, treated wastewater is further purified via reverse osmosis and used for non-manufacturing purposes at the site.","('Water_And_Wastewater_Management', 0.9613862037658691)","('Waste_And_Hazardous_Materials_Management', 0.00597811583429575)","('Energy_Management', 0.0037898803129792213)","([], 0.9613862037658691)","('NON-ESG', 0.00597811583429575)","('NON-ESG', 0.0037898803129792213)"
Line 193,"Water 18 2021 ESG Action Report 2021 ESG Action Report 19 A grant made by Allergan, an AbbVie company, brought environmental revitalization to Electronic City in Bangalore, India.","('Ecological_Impacts', 0.25339871644973755)","('Business_Model_Resilience', 0.14197738468647003)","('Water_And_Wastewater_Management', 0.1053672656416893)","('NON-ESG', 0.25339871644973755)","('NON-ESG', 0.14197738468647003)","('NON-ESG', 0.1053672656416893)"
Line 194,"Lake Bingipura, a 28.2-acre body of water, was previously treated as a municipal dump yard.","('Water_And_Wastewater_Management', 0.9225630164146423)","('Waste_And_Hazardous_Materials_Management', 0.016359668225049973)","('Ecological_Impacts', 0.015857534483075142)","([], 0.9225630164146423)","('NON-ESG', 0.016359668225049973)","('NON-ESG', 0.015857534483075142)"
Line 195,"The contamination and human encroachment resulted in reduced water capacity, blocked water channels, the death of flora and fauna and the spread of disease to the community.","('Water_And_Wastewater_Management', 0.838132381439209)","('Ecological_Impacts', 0.09975998848676682)","('GHG_Emissions', 0.008361599408090115)","([], 0.838132381439209)","('NON-ESG', 0.09975998848676682)","('NON-ESG', 0.008361599408090115)"
Line 196,"Employee volunteers revived the lake ecologically using time-tested and sustainable techniques, making use of an Allergan contribution.","('Ecological_Impacts', 0.9694878458976746)","('Water_And_Wastewater_Management', 0.004519656766206026)","('GHG_Emissions', 0.0040800441056489944)","([], 0.9694878458976746)","('NON-ESG', 0.004519656766206026)","('NON-ESG', 0.0040800441056489944)"
Line 197,"The rejuvenation has doubled the water capacity and brings safe drinking water to more than 5,000 people across four villages.","('Water_And_Wastewater_Management', 0.9745116233825684)","('Energy_Management', 0.003159046871587634)","('GHG_Emissions', 0.0018702137749642134)","([], 0.9745116233825684)","('NON-ESG', 0.003159046871587634)","('NON-ESG', 0.0018702137749642134)"
Line 198,The treated water that flows out supports up to 75 acres of agricultural land.,"('Water_And_Wastewater_Management', 0.972051739692688)","('Waste_And_Hazardous_Materials_Management', 0.0031257267110049725)","('Energy_Management', 0.0022598605137318373)","([], 0.972051739692688)","('NON-ESG', 0.0031257267110049725)","('NON-ESG', 0.0022598605137318373)"
Line 199,Native plant species have been planted and are already proving to support the return of birds and other local fauna.,"('Ecological_Impacts', 0.9715179800987244)","('GHG_Emissions', 0.0034719964023679495)","('Water_And_Wastewater_Management', 0.0028952928259968758)","([], 0.9715179800987244)","('NON-ESG', 0.0034719964023679495)","('NON-ESG', 0.0028952928259968758)"
Line 200,"Environmental Revitalization 2021 Change in absolute water withdrawal vs. 2015 baseline (includes non-contact cooling water)1,2,3+14% Change in absolute water consumption vs. 2015 baseline (excludes non-contact cooling water)1,2,3-13% Absolute total water consumption (million cubic meters)35.22 2021 Reduce absolute total hazardous and non-hazardous waste generated (excluding construction and demolition waste) vs. 2015 baseline [2025 Target: -20%]1,2 -14% Combined recycling rate for hazardous and non-hazardous waste (excluding construction and demolition)42% Percentage of global waste diverted from landfills (annually) (excluding construction and demolition) 92% Absolute total hazardous and non-hazardous waste generated (excluding construction and demolition waste) (1,000 Metric Tons)3 36.9 1 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('Waste_And_Hazardous_Materials_Management', 0.9732807874679565)","('Water_And_Wastewater_Management', 0.006258506793528795)","('Product_Design_And_Lifecycle_Management', 0.0015903994208201766)","([], 0.9732807874679565)","('NON-ESG', 0.006258506793528795)","('NON-ESG', 0.0015903994208201766)"
Line 201,"Environmental Revitalization 2021 Change in absolute water withdrawal vs. 2015 baseline (includes non-contact cooling water)1,2,3+14% Change in absolute water consumption vs. 2015 baseline (excludes non-contact cooling water)1,2,3-13% Absolute total water consumption (million cubic meters)35.22 2021 Reduce absolute total hazardous and non-hazardous waste generated (excluding construction and demolition waste) vs. 2015 baseline [2025 Target: -20%]1,2 -14% Combined recycling rate for hazardous and non-hazardous waste (excluding construction and demolition)42% Percentage of global waste diverted from landfills (annually) (excluding construction and demolition) 92% Absolute total hazardous and non-hazardous waste generated (excluding construction and demolition waste) (1,000 Metric Tons)3 36.9 1 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('Waste_And_Hazardous_Materials_Management', 0.9848758578300476)","('Water_And_Wastewater_Management', 0.0012189035769551992)","('Data_Security', 0.0011780165368691087)","([], 0.9848758578300476)","('NON-ESG', 0.0012189035769551992)","('NON-ESG', 0.0011780165368691087)"
Line 202,The numbers listed above include both AbbVie and Allergan data versus our targets.,"('Data_Security', 0.2683030366897583)","('Customer_Privacy', 0.1831716150045395)","('Systemic_Risk_Management', 0.1713901162147522)","('NON-ESG', 0.2683030366897583)","('NON-ESG', 0.1831716150045395)","('NON-ESG', 0.1713901162147522)"
Line 203,Figures exclude two R&D facilities which were not included in the 2015 baseline.,"('Supply_Chain_Management', 0.3499170243740082)","('Business_Model_Resilience', 0.18714269995689392)","('Systemic_Risk_Management', 0.15758073329925537)","('NON-ESG', 0.3499170243740082)","('NON-ESG', 0.18714269995689392)","('NON-ESG', 0.15758073329925537)"
Line 204,2 Non-contact cooling water is returned to the source in the same amount and with the same quality as was withdrawn.,"('Water_And_Wastewater_Management', 0.9063835740089417)","('Energy_Management', 0.02740311250090599)","('Waste_And_Hazardous_Materials_Management', 0.011648111045360565)","([], 0.9063835740089417)","('NON-ESG', 0.02740311250090599)","('NON-ESG', 0.011648111045360565)"
Line 205,The increase weve seen in our non-contact cooling water use is generally due to seasonal variations in source water temperature.,"('Water_And_Wastewater_Management', 0.9731872081756592)","('Energy_Management', 0.0037868903018534184)","('Waste_And_Hazardous_Materials_Management', 0.0019930643029510975)","([], 0.9731872081756592)","('NON-ESG', 0.0037868903018534184)","('NON-ESG', 0.0019930643029510975)"
Line 206,"3 Represents new KPI added to 2021 ESG Action Report.1 In 2021, AbbVie performed a recalculation exercise of the metrics for our Environmental Sustainability targets and our 2015 baseline.","('Business_Model_Resilience', 0.5856273174285889)","('Physical_Impacts_Of_Climate_Change', 0.07036419957876205)","('Supply_Chain_Management', 0.04542695730924606)","(['Human Capital Development', 'Innovation Management'], 0.5856273174285889)","('NON-ESG', 0.07036419957876205)","('NON-ESG', 0.04542695730924606)"
Line 207,The numbers listed above include both AbbVie and Allergan data versus our targets.,"('Data_Security', 0.2683030366897583)","('Customer_Privacy', 0.1831716150045395)","('Systemic_Risk_Management', 0.1713901162147522)","('NON-ESG', 0.2683030366897583)","('NON-ESG', 0.1831716150045395)","('NON-ESG', 0.1713901162147522)"
Line 208,"2 Includes waste disposed of in the following manner: beneficial use, recycled, composted, treated, incinerated with energy recovery and incinerated without energy recovery.","('Waste_And_Hazardous_Materials_Management', 0.9838176965713501)","('Water_And_Wastewater_Management', 0.0015869889175519347)","('Data_Security', 0.0011651378590613604)","([], 0.9838176965713501)","('NON-ESG', 0.0015869889175519347)","('NON-ESG', 0.0011651378590613604)"
Line 209,3 Represents new KPI added to 2021 ESG Action Report.,"('Systemic_Risk_Management', 0.24924249947071075)","('Business_Model_Resilience', 0.2207707166671753)","('Management_Of_Legal_And_Regulatory_Framework', 0.16603565216064453)","('NON-ESG', 0.24924249947071075)","('NON-ESG', 0.2207707166671753)","('NON-ESG', 0.16603565216064453)"
Line 210,"Key Performance Indicators: WaterKey Performance Indicators: WasteAs a pharmaceutical company, we recognize the importance of minimizing waste and using appropriate disposal methods for both hazardous and non-hazardous waste alike.","('Waste_And_Hazardous_Materials_Management', 0.9852181077003479)","('Water_And_Wastewater_Management', 0.0011230449890717864)","('Data_Security', 0.0010549393482506275)","([], 0.9852181077003479)","('NON-ESG', 0.0011230449890717864)","('NON-ESG', 0.0010549393482506275)"
Line 211,"Whenever possible, we avoid landfills and continuously evaluate opportunities to reduce, reuse and recycle our waste materials.","('Waste_And_Hazardous_Materials_Management', 0.9830920100212097)","('Water_And_Wastewater_Management', 0.0014703604392707348)","('Data_Security', 0.0011652259854599833)","([], 0.9830920100212097)","('NON-ESG', 0.0014703604392707348)","('NON-ESG', 0.0011652259854599833)"
Line 212,"In 2016, we set a goal to send zero waste to landfill by 2035.","('Waste_And_Hazardous_Materials_Management', 0.98311448097229)","('Water_And_Wastewater_Management', 0.0016268834006041288)","('Air_Quality', 0.0013370889937505126)","([], 0.98311448097229)","('NON-ESG', 0.0016268834006041288)","('NON-ESG', 0.0013370889937505126)"
Line 213,"To ensure proper management, we characterize our waste streams to determine waste classification and proper disposal methods and ensure our employees are fully aware of correct classification and procedures.","('Waste_And_Hazardous_Materials_Management', 0.9850622415542603)","('Water_And_Wastewater_Management', 0.0012034327955916524)","('Data_Security', 0.0010536228073760867)","([], 0.9850622415542603)","('NON-ESG', 0.0012034327955916524)","('NON-ESG', 0.0010536228073760867)"
Line 214,Waste management training is provided to AbbVie employees and contract workers before they undertake any responsibility for hazardous waste management activities.,"('Waste_And_Hazardous_Materials_Management', 0.9850425124168396)","('Employee_Health_And_Safety', 0.0010761365992948413)","('Data_Security', 0.0010686845052987337)","([], 0.9850425124168396)","('NON-ESG', 0.0010761365992948413)","('NON-ESG', 0.0010686845052987337)"
Line 215,We routinely audit the procedures and practices of third-party waste management providers to ensure our waste is responsibly managed and disposed.,"('Waste_And_Hazardous_Materials_Management', 0.9845755100250244)","('Water_And_Wastewater_Management', 0.001402606489136815)","('Data_Security', 0.001148243434727192)","([], 0.9845755100250244)","('NON-ESG', 0.001402606489136815)","('NON-ESG', 0.001148243434727192)"
Line 216,"For example, our Sligo-Manorhamilton, Ireland site continues to make significant reductions in their generation of hazardous waste.","('Waste_And_Hazardous_Materials_Management', 0.9844580292701721)","('Data_Security', 0.001178611651994288)","('Water_And_Wastewater_Management', 0.0011702864430844784)","([], 0.9844580292701721)","('NON-ESG', 0.001178611651994288)","('NON-ESG', 0.0011702864430844784)"
Line 217,They previously installed an on- site wastewater treatment unit that has decreased their hazardous waste by over 60% in the past two years.,"('Waste_And_Hazardous_Materials_Management', 0.9800412058830261)","('Water_And_Wastewater_Management', 0.0037229289300739765)","('Air_Quality', 0.0014856812776997685)","([], 0.9800412058830261)","('NON-ESG', 0.0037229289300739765)","('NON-ESG', 0.0014856812776997685)"
Line 218,Our Global Packaging Design for Recovery approach focuses on creating designs for our package material and finished package to facilitate diversion from the landfill.,"('Product_Design_And_Lifecycle_Management', 0.9440370202064514)","('Waste_And_Hazardous_Materials_Management', 0.007936373353004456)","('Selling_Practices_And_Product_Labeling', 0.005353342276066542)","([], 0.9440370202064514)","('NON-ESG', 0.007936373353004456)","('NON-ESG', 0.005353342276066542)"
Line 219,This approach also accounts for how we ship our products by optimizing our transportation-related packaging and working with our suppliers to do the same.,"('Product_Design_And_Lifecycle_Management', 0.9656211733818054)","('Selling_Practices_And_Product_Labeling', 0.003330366685986519)","('Supply_Chain_Management', 0.0029645469039678574)","([], 0.9656211733818054)","('NON-ESG', 0.003330366685986519)","('NON-ESG', 0.0029645469039678574)"
Line 220,"One example comes from a packaging format change for MAVYRET (for 84 count monthly tablet packs), where weve seen a greenhouse gas equivalent reduction of 98% and a recycling potential increase of 64% compared to the previously used packaging.","('GHG_Emissions', 0.8177809715270996)","('Energy_Management', 0.0323554091155529)","('Product_Design_And_Lifecycle_Management', 0.017633764073252678)","(['Operational Eco-Efficiency'], 0.8177809715270996)","('NON-ESG', 0.0323554091155529)","('NON-ESG', 0.017633764073252678)"
Line 221,"Waste 20 2021 ESG Action Report 2021 ESG Action Report 21 of management positions are held by women51% new product or indication approvals including indication expansions10 healthcare providers reached through independent education grants750 K+Since our launch in 2013, we have invested roughly $50 billion in research to discover, develop and deliver new medicines.","('Customer_Welfare', 0.21800455451011658)","('Access_And_Affordability', 0.11473497003316879)","('Competitive_Behavior', 0.10122071951627731)","('NON-ESG', 0.21800455451011658)","('NON-ESG', 0.11473497003316879)","('NON-ESG', 0.10122071951627731)"
Line 222,We target diseases with significant unmet need where we can improve the standard of care with innovative new therapies.,"('Access_And_Affordability', 0.4584929347038269)","('Customer_Welfare', 0.08342938125133514)","('Systemic_Risk_Management', 0.051417239010334015)","('NON-ESG', 0.4584929347038269)","('NON-ESG', 0.08342938125133514)","('NON-ESG', 0.051417239010334015)"
Line 223,We are constantly working to create solutions that go beyond simply treating the illness.,"('Employee_Health_And_Safety', 0.8561749458312988)","('Product_Quality_And_Safety', 0.02300279587507248)","('Access_And_Affordability', 0.019036373123526573)","(['Health Outcome Contribution'], 0.8561749458312988)","('NON-ESG', 0.02300279587507248)","('NON-ESG', 0.019036373123526573)"
Line 224,"Our innovation strives to have a positive impact on patients lives, on society and on science itself.","('Access_And_Affordability', 0.313859760761261)","('Human_Rights_And_Community_Relations', 0.09146888554096222)","('Business_Model_Resilience', 0.0690901130437851)","('NON-ESG', 0.313859760761261)","('NON-ESG', 0.09146888554096222)","('NON-ESG', 0.0690901130437851)"
Line 225,Product Innovation 2021 Highlights donated to disaster relief organizations$1.,"('Critical_Incident_Risk_Management', 0.581419825553894)","('Product_Design_And_Lifecycle_Management', 0.10207457095384598)","('Energy_Management', 0.06070893257856369)","([], 0.581419825553894)","('NON-ESG', 0.10207457095384598)","('NON-ESG', 0.06070893257856369)"
Line 226,2MU.,"('Data_Security', 0.32676756381988525)","('Customer_Privacy', 0.06659352034330368)","('Labor_Practices', 0.05397927388548851)","('NON-ESG', 0.32676756381988525)","('NON-ESG', 0.06659352034330368)","('NON-ESG', 0.05397927388548851)"
Line 227,S.,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 228,"patients provided medicine at no cost through our patient assistance programs170K+ raised during the employee giving campaign with AbbVie Foundation matching$23.7 MWe approach our science with an unrelenting spirit to deliver medicines that improve lives, inspiring hope and confidence for patients to live a brighter today and tomorrow.","('Access_And_Affordability', 0.8613771200180054)","('Human_Rights_And_Community_Relations', 0.019168904051184654)","('Employee_Health_And_Safety', 0.011021437123417854)","(['Access to Healthcare'], 0.8613771200180054)","('NON-ESG', 0.019168904051184654)","('NON-ESG', 0.011021437123417854)"
Line 229,This requires both dedicated innovations to address unmet needs and extensive investment in research and development.,"('Access_And_Affordability', 0.3141815662384033)","('Product_Design_And_Lifecycle_Management', 0.14303705096244812)","('Supply_Chain_Management', 0.05442652106285095)","('NON-ESG', 0.3141815662384033)","('NON-ESG', 0.14303705096244812)","('NON-ESG', 0.05442652106285095)"
Line 230,"To be successful, we must also understand what matters most to patients.","('Access_And_Affordability', 0.5206789374351501)","('Human_Rights_And_Community_Relations', 0.06433053314685822)","('Employee_Engagement_Inclusion_And_Diversity', 0.04340975731611252)","(['Access to Healthcare'], 0.5206789374351501)","('NON-ESG', 0.06433053314685822)","('NON-ESG', 0.04340975731611252)"
Line 231,We empathize with and work to understand the experiences of people living with diseases so that we can meet their specialized needs.,"('Access_And_Affordability', 0.6254987716674805)","('Human_Rights_And_Community_Relations', 0.12085111439228058)","('Employee_Health_And_Safety', 0.05380334332585335)","(['Access to Healthcare'], 0.6254987716674805)","('NON-ESG', 0.12085111439228058)","('NON-ESG', 0.05380334332585335)"
Line 232,"We partner with patients, patient advocacy groups and healthcare providers to understand the individual experience, define meaningful outcomes and pioneer new methods to measure them in accurate and relevant ways.","('Access_And_Affordability', 0.5925378203392029)","('Human_Rights_And_Community_Relations', 0.11171387881040573)","('Employee_Health_And_Safety', 0.055794570595026016)","(['Access to Healthcare'], 0.5925378203392029)","('NON-ESG', 0.11171387881040573)","('NON-ESG', 0.055794570595026016)"
Line 233,"We continue to enhance our efforts to ensure we are innovating for all patients, regardless of their race or ethnicity.","('Employee_Engagement_Inclusion_And_Diversity', 0.9741674065589905)","('Human_Rights_And_Community_Relations', 0.0019318402046337724)","('Customer_Privacy', 0.0018760553793981671)","(['Talent Attraction & Retention'], 0.9741674065589905)","('NON-ESG', 0.0019318402046337724)","('NON-ESG', 0.0018760553793981671)"
Line 234,Innovation in science is at the heart of our commitment to patient health and well-being.,"('Access_And_Affordability', 0.4772864878177643)","('Employee_Health_And_Safety', 0.18943926692008972)","('Human_Rights_And_Community_Relations', 0.03753841668367386)","('NON-ESG', 0.4772864878177643)","('NON-ESG', 0.18943926692008972)","('NON-ESG', 0.03753841668367386)"
Line 235,"Our responsibility starts with discovering and developing novel medicines and treatment approaches that make a real-world impact, and since 2013 we have achieved 21 major product or indication approvals.","('Selling_Practices_And_Product_Labeling', 0.4200238585472107)","('Customer_Welfare', 0.2215723842382431)","('Product_Design_And_Lifecycle_Management', 0.05172933638095856)","('NON-ESG', 0.4200238585472107)","('NON-ESG', 0.2215723842382431)","('NON-ESG', 0.05172933638095856)"
Line 236,"In 2021, the U.","('Management_Of_Legal_And_Regulatory_Framework', 0.33352944254875183)","('Competitive_Behavior', 0.10759539902210236)","('Business_Model_Resilience', 0.07077011466026306)","('NON-ESG', 0.33352944254875183)","('NON-ESG', 0.10759539902210236)","('NON-ESG', 0.07077011466026306)"
Line 237,S. Food and Drug Administration approved new products QULIPTA and VUITY and the European Commission approved a new indication for SKYRIZI.,"('Selling_Practices_And_Product_Labeling', 0.30728110671043396)","('Customer_Welfare', 0.30392688512802124)","('Product_Quality_And_Safety', 0.1427593231201172)","('NON-ESG', 0.30728110671043396)","('NON-ESG', 0.30392688512802124)","('NON-ESG', 0.1427593231201172)"
Line 238,We regularly work with strategic partners to amplify the impact of our scientific progress.,"('Ecological_Impacts', 0.2634339928627014)","('Management_Of_Legal_And_Regulatory_Framework', 0.15973086655139923)","('Business_Model_Resilience', 0.10942461341619492)","('NON-ESG', 0.2634339928627014)","('NON-ESG', 0.15973086655139923)","('NON-ESG', 0.10942461341619492)"
Line 239,"Whether through collaborations with smaller biotech companies, teaming up with universities or joining forces with other pharmaceutical companies around the world, partnerships are a powerful path to scientific discovery and patient success.","('Access_And_Affordability', 0.16140179336071014)","('Competitive_Behavior', 0.1571580022573471)","('Customer_Welfare', 0.10798373073339462)","('NON-ESG', 0.16140179336071014)","('NON-ESG', 0.1571580022573471)","('NON-ESG', 0.10798373073339462)"
Line 240,"In 2021, AbbVie embarked on several new partnerships, including: an eye care collaboration with REGENXBIO, an oncology agreement with Caribou Biosciences on the development of new CAR-T cell therapies and an extension of our collaboration with the University of Chicago to support preclinical oncology research.","('Access_And_Affordability', 0.36223503947257996)","('Customer_Welfare', 0.13527989387512207)","('Employee_Engagement_Inclusion_And_Diversity', 0.053560834378004074)","('NON-ESG', 0.36223503947257996)","('NON-ESG', 0.13527989387512207)","('NON-ESG', 0.053560834378004074)"
Line 241,"Our collaboration with Calico, a division of Alphabet, now twice renewed, focuses on advancing research and development in age-related diseases including neurodegeneration and cancer.","('Employee_Engagement_Inclusion_And_Diversity', 0.19957590103149414)","('Access_And_Affordability', 0.19888348877429962)","('Employee_Health_And_Safety', 0.1052635908126831)","('NON-ESG', 0.19957590103149414)","('NON-ESG', 0.19888348877429962)","('NON-ESG', 0.1052635908126831)"
Line 242,"Innovating for Patients Designed to reduce pain and discomfort for those living with arthritis, limited mobility and chronic pain, AbbVie updated the packaging of RINVOQ, a joint pain medication.","('Employee_Health_And_Safety', 0.9075911045074463)","('Employee_Engagement_Inclusion_And_Diversity', 0.00992543064057827)","('Product_Design_And_Lifecycle_Management', 0.007837070152163506)","(['Health Outcome Contribution'], 0.9075911045074463)","('NON-ESG', 0.00992543064057827)","('NON-ESG', 0.007837070152163506)"
Line 243,"The easy-to-open RINVOQ bottle design includes a cap with a wide, easy-to-grip texture and an embedded tool that punctures the foil liner, both of which simplify medication access.","('Product_Design_And_Lifecycle_Management', 0.6680697798728943)","('Customer_Welfare', 0.10804116725921631)","('Selling_Practices_And_Product_Labeling', 0.044039126485586166)","([], 0.6680697798728943)","('NON-ESG', 0.10804116725921631)","('NON-ESG', 0.044039126485586166)"
Line 244,Our innovative design was awarded the Arthritis Foundation's Ease of Use Commendation.,"('Product_Design_And_Lifecycle_Management', 0.8850260376930237)","('Product_Quality_And_Safety', 0.013288221322000027)","('Energy_Management', 0.010463783517479897)","([], 0.8850260376930237)","('NON-ESG', 0.013288221322000027)","('NON-ESG', 0.010463783517479897)"
Line 245,"Innovating with Patient Experience in Mind Social22 2021 ESG Action Report 2021 ESG Action Report 23 Neglected tropical diseases (NTDs), together with widespread tropical diseases such as malaria and tuberculosis, impact over one billion people globally.","('Physical_Impacts_Of_Climate_Change', 0.20925989747047424)","('Systemic_Risk_Management', 0.18000921607017517)","('Employee_Health_And_Safety', 0.08083660155534744)","('NON-ESG', 0.20925989747047424)","('NON-ESG', 0.18000921607017517)","('NON-ESG', 0.08083660155534744)"
Line 246,"These diseases, which disproportionately affect people in low- and middle-income countries, are detrimental to both public health globally and economic well-being locally.","('Access_And_Affordability', 0.5855162143707275)","('Employee_Health_And_Safety', 0.12481211125850677)","('Human_Rights_And_Community_Relations', 0.058111175894737244)","(['Access to Healthcare'], 0.5855162143707275)","('NON-ESG', 0.12481211125850677)","('NON-ESG', 0.058111175894737244)"
Line 247,"Combating NTDs requires input, commitment and collaboration between a wide range of dedicated partners.","('Human_Rights_And_Community_Relations', 0.1854637861251831)","('Management_Of_Legal_And_Regulatory_Framework', 0.09103254973888397)","('Competitive_Behavior', 0.07647014409303665)","('NON-ESG', 0.1854637861251831)","('NON-ESG', 0.09103254973888397)","('NON-ESG', 0.07647014409303665)"
Line 248,"Thats why we were one of the original signatories to the London Declaration on Neglected Tropical Diseases, a collaborative global partnership that aims to eliminate or control 10 NTDs.","('Access_And_Affordability', 0.15380239486694336)","('Physical_Impacts_Of_Climate_Change', 0.1468326449394226)","('Systemic_Risk_Management', 0.09595080465078354)","('NON-ESG', 0.15380239486694336)","('NON-ESG', 0.1468326449394226)","('NON-ESG', 0.09595080465078354)"
Line 249,"Hundreds of AbbVie scientists have donated 180,000 pro bono hours over the past 10 years to help find solutions for these persistent global public health challenges.","('Access_And_Affordability', 0.28029879927635193)","('Critical_Incident_Risk_Management', 0.12538522481918335)","('Employee_Health_And_Safety', 0.10243958234786987)","('NON-ESG', 0.28029879927635193)","('NON-ESG', 0.12538522481918335)","('NON-ESG', 0.10243958234786987)"
Line 250,"AbbVies Executive Council on Neglected Diseases coordinates our innovative technologies, diverse compounds for screening and scientific expertise.","('Access_And_Affordability', 0.5864132642745972)","('Ecological_Impacts', 0.047805000096559525)","('Systemic_Risk_Management', 0.039962176233530045)","(['Access to Healthcare'], 0.5864132642745972)","('NON-ESG', 0.047805000096559525)","('NON-ESG', 0.039962176233530045)"
Line 251,"We collaborate with partners to conduct preclinical and early clinical development and testing, and clinical trials that can lead to new treatments in NTDs including in onchocerciasis, Chagas disease, and leishmaniasis.","('Access_And_Affordability', 0.16104534268379211)","('Product_Quality_And_Safety', 0.13636329770088196)","('Customer_Welfare', 0.1328991800546646)","('NON-ESG', 0.16104534268379211)","('NON-ESG', 0.13636329770088196)","('NON-ESG', 0.1328991800546646)"
Line 252,We also offer a 10-week summer internship program for chemistry students working on NTD-related research.,"('Employee_Engagement_Inclusion_And_Diversity', 0.5225778222084045)","('Labor_Practices', 0.13764864206314087)","('Access_And_Affordability', 0.04670644551515579)","(['Talent Attraction & Retention'], 0.5225778222084045)","('NON-ESG', 0.13764864206314087)","('NON-ESG', 0.04670644551515579)"
Line 253,"One of our most promising NTD programs is ABBV-4083, or flubentylosin, which is currently in Phase 2.","('Customer_Welfare', 0.3717723488807678)","('GHG_Emissions', 0.12404957413673401)","('Selling_Practices_And_Product_Labeling', 0.07962559163570404)","('NON-ESG', 0.3717723488807678)","('NON-ESG', 0.12404957413673401)","('NON-ESG', 0.07962559163570404)"
Line 254,"The goal of the program is to treat parasitic disease onchocerciasis (river blindness), which impacts over 17 million people99% of which are in Africa.","('Employee_Health_And_Safety', 0.6480953097343445)","('Access_And_Affordability', 0.08279543370008469)","('Employee_Engagement_Inclusion_And_Diversity', 0.04713192954659462)","(['Health Outcome Contribution'], 0.6480953097343445)","('NON-ESG', 0.08279543370008469)","('NON-ESG', 0.04713192954659462)"
Line 255,"In partnership with the Drugs for Neglected Diseases initiative (DNDi), we were able to build two clinical sites in the rural areas of the Democratic Republic of Congo (DRC), enrolling roughly 80% of our Phase 2 trial.","('Access_And_Affordability', 0.7003381252288818)","('Human_Rights_And_Community_Relations', 0.03641251474618912)","('Product_Quality_And_Safety', 0.02511710673570633)","(['Access to Healthcare'], 0.7003381252288818)","('NON-ESG', 0.03641251474618912)","('NON-ESG', 0.02511710673570633)"
Line 256,The over 400 scientists working pro-bono to develop this river blindness treatment reflects both scientific excellence and our commitment to society.,"('Access_And_Affordability', 0.33006367087364197)","('Employee_Health_And_Safety', 0.1633511781692505)","('Product_Quality_And_Safety', 0.06632401794195175)","('NON-ESG', 0.33006367087364197)","('NON-ESG', 0.1633511781692505)","('NON-ESG', 0.06632401794195175)"
Line 257,A documentary on our work with the DNDi can be found on Vox.com.,"('Management_Of_Legal_And_Regulatory_Framework', 0.17720703780651093)","('Business_Model_Resilience', 0.15963192284107208)","('Human_Rights_And_Community_Relations', 0.12522514164447784)","('NON-ESG', 0.17720703780651093)","('NON-ESG', 0.15963192284107208)","('NON-ESG', 0.12522514164447784)"
Line 258,"In 2021, we celebrated the 10-year anniversary of the Tuberculosis Drug Accelerator (TBDA), an innovative partnership with other pharmaceutical companies, academics, and healthcare advocacy organizations.","('Access_And_Affordability', 0.22684940695762634)","('Management_Of_Legal_And_Regulatory_Framework', 0.10404755920171738)","('Competitive_Behavior', 0.103591687977314)","('NON-ESG', 0.22684940695762634)","('NON-ESG', 0.10404755920171738)","('NON-ESG', 0.103591687977314)"
Line 259,"The partnerships mission is to discover and develop drug candidates to support affordable, shorter and safer drug regimens that can achieve rapid, durable cures.","('Customer_Welfare', 0.292041152715683)","('Product_Quality_And_Safety', 0.13207639753818512)","('Access_And_Affordability', 0.12474823743104935)","('NON-ESG', 0.292041152715683)","('NON-ESG', 0.13207639753818512)","('NON-ESG', 0.12474823743104935)"
Line 260,"AbbVie has been an active participant with the TBDA, providing crucial compounds from our library, expertise in medicinal and computational chemistry, pharmacokinetics, assay development and screening, drug safety and toxicology studies to the challenges of anti-TB drug discovery and development.","('Product_Quality_And_Safety', 0.5239946842193604)","('Customer_Welfare', 0.08893612772226334)","('Competitive_Behavior', 0.07818975299596786)","(['Product Quality & Recall Management'], 0.5239946842193604)","('NON-ESG', 0.08893612772226334)","('NON-ESG', 0.07818975299596786)"
Line 261,"To effectively serve the populations living with the diseases that we study and for whom we create solutions, it is imperative to design inclusive clinical research programs with equitable access for patients and physicians.","('Access_And_Affordability', 0.7790495753288269)","('Employee_Engagement_Inclusion_And_Diversity', 0.032328128814697266)","('Customer_Welfare', 0.02457224391400814)","(['Access to Healthcare'], 0.7790495753288269)","('NON-ESG', 0.032328128814697266)","('NON-ESG', 0.02457224391400814)"
Line 262,"To do so, we have established a dedicated team that is fostering a data- driven approach to ensure AbbVie-sponsored clinical trials are diverse, equitable and inclusive.","('Employee_Engagement_Inclusion_And_Diversity', 0.9238665103912354)","('Access_And_Affordability', 0.008140486665070057)","('Business_Model_Resilience', 0.006864770781248808)","(['Talent Attraction & Retention'], 0.9238665103912354)","('NON-ESG', 0.008140486665070057)","('NON-ESG', 0.006864770781248808)"
Line 263,We hired AbbVies first Director of Clinical Trial Diversity & Inclusion in 2020 to lead this critical work.,"('Employee_Engagement_Inclusion_And_Diversity', 0.964205265045166)","('Employee_Health_And_Safety', 0.0034756602253764868)","('Human_Rights_And_Community_Relations', 0.002567921532317996)","(['Talent Attraction & Retention'], 0.964205265045166)","('NON-ESG', 0.0034756602253764868)","('NON-ESG', 0.002567921532317996)"
Line 264,"The responsibility of the role has since been expanded to foster an emphasis on patient centricity, ensuring even greater intentionality in the inclusion of patient insights into clinical trial planning.","('Competitive_Behavior', 0.238982692360878)","('Access_And_Affordability', 0.16079361736774445)","('Business_Model_Resilience', 0.08109068125486374)","('NON-ESG', 0.238982692360878)","('NON-ESG', 0.16079361736774445)","('NON-ESG', 0.08109068125486374)"
Line 265,"This teams focus is to build foundational capabilities that will enable a sustainable and systematic approach to clinical trial diversity, patient centricity and the patient experience at every phase of our clinical development work.","('Access_And_Affordability', 0.2090136706829071)","('Competitive_Behavior', 0.11791513115167618)","('Customer_Welfare', 0.10434213280677795)","('NON-ESG', 0.2090136706829071)","('NON-ESG', 0.11791513115167618)","('NON-ESG', 0.10434213280677795)"
Line 266,"We have a comprehensive strategy to support the improvement of representation in our clinical trials through inclusive clinical protocols that incorporate diversity into the clinical drug development process, to address unmet needs and strive toward the best possible outcomes.","('Employee_Engagement_Inclusion_And_Diversity', 0.9407074451446533)","('Customer_Welfare', 0.006200630217790604)","('Business_Model_Resilience', 0.005397445056587458)","(['Talent Attraction & Retention'], 0.9407074451446533)","('NON-ESG', 0.006200630217790604)","('NON-ESG', 0.005397445056587458)"
Line 267,"Some of the ways we are beginning to bridge gaps with diverse communities to advance clinical trial diversity include: Selecting strategic site locations that ensure we connect to a community of potential participants Empowering trial sites to meet the needs of diverse populations by bridging gaps between researchers, staff and patients and ensuring that sites are equipped to lead trials effectively Opening a two-way dialogue with potential participants to listen and understand their perspectives, and to leverage these learnings to enhance our drug development process Building relationships with community health advocates and leaders to reach more diverse patients Expanding our investigator pool by creating training for investigators and clinical research staff and developing a pathway for the next generation of AbbVie researchers Establishing clear KPIs for collecting and interpreting data, so we can benchmark and track our progressClinical research is a key component of developing new medicines.","('Employee_Engagement_Inclusion_And_Diversity', 0.8387960195541382)","('Customer_Welfare', 0.020830417051911354)","('Access_And_Affordability', 0.02030172012746334)","(['Talent Attraction & Retention'], 0.8387960195541382)","('NON-ESG', 0.020830417051911354)","('NON-ESG', 0.02030172012746334)"
Line 268,"Some of the ways we are beginning to bridge gaps with diverse communities to advance clinical trial diversity include: Selecting strategic site locations that ensure we connect to a community of potential participants Empowering trial sites to meet the needs of diverse populations by bridging gaps between researchers, staff and patients and ensuring that sites are equipped to lead trials effectively Opening a two-way dialogue with potential participants to listen and understand their perspectives, and to leverage these learnings to enhance our drug development process Building relationships with community health advocates and leaders to reach more diverse patients Expanding our investigator pool by creating training for investigators and clinical research staff and developing a pathway for the next generation of AbbVie researchers Establishing clear KPIs for collecting and interpreting data, so we can benchmark and track our progressClinical research is a key component of developing new medicines.","('Access_And_Affordability', 0.2636309862136841)","('Employee_Engagement_Inclusion_And_Diversity', 0.15490132570266724)","('Customer_Welfare', 0.14300157129764557)","('NON-ESG', 0.2636309862136841)","('NON-ESG', 0.15490132570266724)","('NON-ESG', 0.14300157129764557)"
Line 269,"Every year, tens of thousands of people worldwide participate in clinical trials of potential AbbVie medicines.","('Competitive_Behavior', 0.19597256183624268)","('Customer_Welfare', 0.1534186154603958)","('Selling_Practices_And_Product_Labeling', 0.09347765892744064)","('NON-ESG', 0.19597256183624268)","('NON-ESG', 0.1534186154603958)","('NON-ESG', 0.09347765892744064)"
Line 270,We require all our clinical studies to be conducted in a manner consistent with the ethical principles outlined in the World Medical Associations Declaration of Helsinki and to adhere to applicable standards set by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).,"('Management_Of_Legal_And_Regulatory_Framework', 0.16974776983261108)","('Product_Quality_And_Safety', 0.16307926177978516)","('Access_And_Affordability', 0.10764850676059723)","('NON-ESG', 0.16974776983261108)","('NON-ESG', 0.16307926177978516)","('NON-ESG', 0.10764850676059723)"
Line 271,"This includes adherence to Good Clinical Practice, Good Laboratory Practice and Good Manufacturing Practice standards, all of which provide assurance that the rights, safety, well-being and ethical treatment of trial participants are protected.","('Product_Quality_And_Safety', 0.9086883068084717)","('Employee_Health_And_Safety', 0.012861216440796852)","('Business_Ethics', 0.009128652513027191)","(['Product Quality & Recall Management'], 0.9086883068084717)","('NON-ESG', 0.012861216440796852)","('NON-ESG', 0.009128652513027191)"
Line 272,"We share comprehensive information regarding our processes on our website regardless of outcome, while protecting patient confidentiality and sharing the results of all clinical trials, with health authorities and on publicly available registries including, but not limited to, the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, the U.","('Customer_Privacy', 0.45301663875579834)","('Business_Ethics', 0.23777998983860016)","('Data_Security', 0.0919332504272461)","('NON-ESG', 0.45301663875579834)","('NON-ESG', 0.23777998983860016)","('NON-ESG', 0.0919332504272461)"
Line 273,S. Food and Drug Administration (FDA).,"('Management_Of_Legal_And_Regulatory_Framework', 0.4621313214302063)","('Product_Quality_And_Safety', 0.11750368773937225)","('Selling_Practices_And_Product_Labeling', 0.06804869323968887)","('NON-ESG', 0.4621313214302063)","('NON-ESG', 0.11750368773937225)","('NON-ESG', 0.06804869323968887)"
Line 274,"Beyond safety, we aim to make our clinical trials as effective as possible.","('Product_Quality_And_Safety', 0.6853235960006714)","('Customer_Welfare', 0.042963720858097076)","('Competitive_Behavior', 0.04219774901866913)","(['Product Quality & Recall Management'], 0.6853235960006714)","('NON-ESG', 0.042963720858097076)","('NON-ESG', 0.04219774901866913)"
Line 275,"This includes new technologies to increase efficiency of process, broadening the diversity of study populations, accelerating recruitment, reducing cost and continually improving the patient experience.","('Employee_Engagement_Inclusion_And_Diversity', 0.4980323016643524)","('Access_And_Affordability', 0.13885697722434998)","('Customer_Welfare', 0.0715320035815239)","('NON-ESG', 0.4980323016643524)","('NON-ESG', 0.13885697722434998)","('NON-ESG', 0.0715320035815239)"
Line 276,"Through our clinical development process, we gather actionable insights that allows us to make patient-centric decisions.","('Competitive_Behavior', 0.20308053493499756)","('Business_Model_Resilience', 0.12308579683303833)","('Customer_Welfare', 0.10349158197641373)","('NON-ESG', 0.20308053493499756)","('NON-ESG', 0.12308579683303833)","('NON-ESG', 0.10349158197641373)"
Line 277,"R&D for Neglected Tropical Diseases Diversity in Clinical Trials Clinical Trials 2021 Adjusted Investment in Research and Development1$6.5B New product or indication approvals including indication expansions 10 Number of programs granted a designation by at least one major regulatory authority to expedite development or review7 Percent of compounds in late-stage clinical development with novel mechanism of action280% Number of FDA Breakthrough Therapy Designations32 Research hours donated to neglected tropical diseases, malaria and tuberculosis 14,307 1 Adjusted investment in Research and Development spend is a non-GAAP measure and excludes specified items of $0.4B compared to the as reported GAAP measure of $6.9B.","('Access_And_Affordability', 0.2411111444234848)","('Customer_Welfare', 0.15698190033435822)","('Competitive_Behavior', 0.06804125010967255)","('NON-ESG', 0.2411111444234848)","('NON-ESG', 0.15698190033435822)","('NON-ESG', 0.06804125010967255)"
Line 278,"R&D for Neglected Tropical Diseases Diversity in Clinical Trials Clinical Trials 2021 Adjusted Investment in Research and Development1$6.5B New product or indication approvals including indication expansions 10 Number of programs granted a designation by at least one major regulatory authority to expedite development or review7 Percent of compounds in late-stage clinical development with novel mechanism of action280% Number of FDA Breakthrough Therapy Designations32 Research hours donated to neglected tropical diseases, malaria and tuberculosis 14,307 1 Adjusted investment in Research and Development spend is a non-GAAP measure and excludes specified items of $0.4B compared to the as reported GAAP measure of $6.9B.","('Management_Of_Legal_And_Regulatory_Framework', 0.7637028694152832)","('Systemic_Risk_Management', 0.059797611087560654)","('Access_And_Affordability', 0.025835368782281876)","([], 0.7637028694152832)","('NON-ESG', 0.059797611087560654)","('NON-ESG', 0.025835368782281876)"
Line 279,"2 Indicates compounds considered ""first-in-class"" in the scientific community in phase III, phase II with registration potential, or in regulatory approval process.","('GHG_Emissions', 0.2950083613395691)","('Management_Of_Legal_And_Regulatory_Framework', 0.22818012535572052)","('Selling_Practices_And_Product_Labeling', 0.0742788091301918)","('NON-ESG', 0.2950083613395691)","('NON-ESG', 0.22818012535572052)","('NON-ESG', 0.0742788091301918)"
Line 280,"Not included are compounds considered best-in-class, new indications, new formulations, and new forms of delivery.","('Selling_Practices_And_Product_Labeling', 0.4935806691646576)","('Customer_Welfare', 0.1942259967327118)","('Product_Design_And_Lifecycle_Management', 0.11436600238084793)","('NON-ESG', 0.4935806691646576)","('NON-ESG', 0.1942259967327118)","('NON-ESG', 0.11436600238084793)"
Line 281,3 Represents new KPI added to 2021 ESG Action Report.,"('Systemic_Risk_Management', 0.24924249947071075)","('Business_Model_Resilience', 0.2207707166671753)","('Management_Of_Legal_And_Regulatory_Framework', 0.16603565216064453)","('NON-ESG', 0.24924249947071075)","('NON-ESG', 0.2207707166671753)","('NON-ESG', 0.16603565216064453)"
Line 282,"Key Performance Indicators: Research & Development24 2021 ESG Action Report 2021 ESG Action Report 25 At AbbVie, our patients are at the center of everything we do.","('Business_Model_Resilience', 0.3452138602733612)","('Systemic_Risk_Management', 0.14999093115329742)","('Human_Rights_And_Community_Relations', 0.07103067636489868)","('NON-ESG', 0.3452138602733612)","('NON-ESG', 0.14999093115329742)","('NON-ESG', 0.07103067636489868)"
Line 283,"At the core of our patient- centric philosophy is that all employees, both at AbbVie and those of our suppliers, aim to make a remarkable impact on patient lives by striving for excellence and getting it right the first time.","('Access_And_Affordability', 0.6336419582366943)","('Human_Rights_And_Community_Relations', 0.059653811156749725)","('Employee_Health_And_Safety', 0.043403543531894684)","(['Access to Healthcare'], 0.6336419582366943)","('NON-ESG', 0.059653811156749725)","('NON-ESG', 0.043403543531894684)"
Line 284,Product Quality and Safety We have robust systems in place to ensure the medicines we manufacture are of high quality and available when patients need them.,"('Product_Quality_And_Safety', 0.8680784702301025)","('Selling_Practices_And_Product_Labeling', 0.03196936845779419)","('Product_Design_And_Lifecycle_Management', 0.014376350678503513)","(['Product Quality & Recall Management'], 0.8680784702301025)","('NON-ESG', 0.03196936845779419)","('NON-ESG', 0.014376350678503513)"
Line 285,The AbbVie Quality Council oversees our quality strategy and direction across AbbVie.,"('Business_Ethics', 0.2840828001499176)","('Product_Quality_And_Safety', 0.22658684849739075)","('Management_Of_Legal_And_Regulatory_Framework', 0.082227423787117)","('NON-ESG', 0.2840828001499176)","('NON-ESG', 0.22658684849739075)","('NON-ESG', 0.082227423787117)"
Line 286,Our Quality Council is accountable directly to our CEO and is comprised of the heads of quality from R&D and Operations.,"('Director_Removal', 0.24637645483016968)","('Business_Ethics', 0.2319081574678421)","('Management_Of_Legal_And_Regulatory_Framework', 0.13623569905757904)","('NON-ESG', 0.24637645483016968)","('NON-ESG', 0.2319081574678421)","('NON-ESG', 0.13623569905757904)"
Line 287,"Within these two functions, we have Quality Assurance Groups to ensure a culture of quality is fully embedded throughout all our activities.","('Business_Ethics', 0.4955810308456421)","('Product_Quality_And_Safety', 0.16454336047172546)","('Systemic_Risk_Management', 0.042949192225933075)","('NON-ESG', 0.4955810308456421)","('NON-ESG', 0.16454336047172546)","('NON-ESG', 0.042949192225933075)"
Line 288,The values below outline our shared commitment to upholding the highest standards of quality every day.,"('Business_Ethics', 0.2126273512840271)","('Product_Quality_And_Safety', 0.132283017039299)","('Product_Design_And_Lifecycle_Management', 0.08310715109109879)","('NON-ESG', 0.2126273512840271)","('NON-ESG', 0.132283017039299)","('NON-ESG', 0.08310715109109879)"
Line 289,We all own quality.,"('Product_Design_And_Lifecycle_Management', 0.5019521713256836)","('Supply_Chain_Management', 0.058400172740221024)","('Business_Model_Resilience', 0.048954661935567856)","([], 0.5019521713256836)","('NON-ESG', 0.058400172740221024)","('NON-ESG', 0.048954661935567856)"
Line 290,Quality is everyones job; AbbVies mission is to deliver a consistent stream of innovative medicines and have a remarkable impact on peoples lives.,"('Access_And_Affordability', 0.311434805393219)","('Customer_Welfare', 0.17333927750587463)","('Selling_Practices_And_Product_Labeling', 0.10945229232311249)","('NON-ESG', 0.311434805393219)","('NON-ESG', 0.17333927750587463)","('NON-ESG', 0.10945229232311249)"
Line 291,We cannot do that without everyone prioritizing quality and compliance in all that we do.,"('Management_Of_Legal_And_Regulatory_Framework', 0.41742849349975586)","('Business_Ethics', 0.33912092447280884)","('Product_Quality_And_Safety', 0.04742245748639107)","('NON-ESG', 0.41742849349975586)","('NON-ESG', 0.33912092447280884)","('NON-ESG', 0.04742245748639107)"
Line 292,"Everyone has an important voice to ask questions, express concerns and raise observations on any quality matter.","('Management_Of_Legal_And_Regulatory_Framework', 0.40995341539382935)","('Human_Rights_And_Community_Relations', 0.1124705821275711)","('Business_Ethics', 0.08018819242715836)","('NON-ESG', 0.40995341539382935)","('NON-ESG', 0.1124705821275711)","('NON-ESG', 0.08018819242715836)"
Line 293,"In our culture of quality if you SEE something, SAY something, DO something.","('Business_Ethics', 0.2897472083568573)","('Director_Removal', 0.13692207634449005)","('Business_Model_Resilience', 0.06878968328237534)","('NON-ESG', 0.2897472083568573)","('NON-ESG', 0.13692207634449005)","('NON-ESG', 0.06878968328237534)"
Line 294,Our employees make the difference in providing the highest quality products and outstanding service to our patients.,"('Product_Design_And_Lifecycle_Management', 0.941157877445221)","('Product_Quality_And_Safety', 0.01184980757534504)","('Selling_Practices_And_Product_Labeling', 0.005340154282748699)","([], 0.941157877445221)","('NON-ESG', 0.01184980757534504)","('NON-ESG', 0.005340154282748699)"
Line 295,"If we focus on quality and flawless execution, compliance will follow.","('Business_Ethics', 0.6058294773101807)","('Systemic_Risk_Management', 0.07988758385181427)","('Business_Model_Resilience', 0.05254793167114258)","(['Business Ethics'], 0.6058294773101807)","('NON-ESG', 0.07988758385181427)","('NON-ESG', 0.05254793167114258)"
Line 296,"We empower all employees to be critical, constructive and uphold AbbVie to the highest standards of quality, every day.","('Business_Ethics', 0.26694512367248535)","('Product_Quality_And_Safety', 0.11673346161842346)","('Employee_Engagement_Inclusion_And_Diversity', 0.08291421830654144)","('NON-ESG', 0.26694512367248535)","('NON-ESG', 0.11673346161842346)","('NON-ESG', 0.08291421830654144)"
Line 297,AbbVie is an industry leader in quality.,"('Product_Quality_And_Safety', 0.23048999905586243)","('Supply_Chain_Management', 0.19228041172027588)","('Product_Design_And_Lifecycle_Management', 0.16904868185520172)","('NON-ESG', 0.23048999905586243)","('NON-ESG', 0.19228041172027588)","('NON-ESG', 0.16904868185520172)"
Line 298,"Our pride in product quality and commitment to patient safety are a powerful combination that motivates employees to stay vigilant, speak up and be part of the solution.","('Product_Quality_And_Safety', 0.7880902886390686)","('Product_Design_And_Lifecycle_Management', 0.05826219171285629)","('Employee_Health_And_Safety', 0.030329644680023193)","(['Product Quality & Recall Management'], 0.7880902886390686)","('NON-ESG', 0.05826219171285629)","('NON-ESG', 0.030329644680023193)"
Line 299,"The principles and structure of our integrated enterprise Quality Management System (QMS) are outlined in our Global Quality Manual, available to all our personnel.","('Business_Ethics', 0.3939379155635834)","('Product_Quality_And_Safety', 0.16395480930805206)","('Systemic_Risk_Management', 0.10004787147045135)","('NON-ESG', 0.3939379155635834)","('NON-ESG', 0.16395480930805206)","('NON-ESG', 0.10004787147045135)"
Line 300,The QMS complies with all applicable global standards and regulations (GxP) including the International Organization for Standardization (ISO).,"('Management_Of_Legal_And_Regulatory_Framework', 0.7595526576042175)","('Product_Quality_And_Safety', 0.08880514651536942)","('Director_Removal', 0.012123016640543938)","([], 0.7595526576042175)","('NON-ESG', 0.08880514651536942)","('NON-ESG', 0.012123016640543938)"
Line 301,"To ensure quality and regulatory compliance, AbbVie manufacturing sites receive both internal and external inspections and audits from major regulatory health authorities such as the U.","('Management_Of_Legal_And_Regulatory_Framework', 0.8143529295921326)","('Business_Ethics', 0.10610801726579666)","('Product_Quality_And_Safety', 0.012510028667747974)","([], 0.8143529295921326)","('NON-ESG', 0.10610801726579666)","('NON-ESG', 0.012510028667747974)"
Line 302,"S. FDA, the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.","('Management_Of_Legal_And_Regulatory_Framework', 0.8544799089431763)","('Competitive_Behavior', 0.021324727684259415)","('Business_Ethics', 0.017396878451108932)","([], 0.8544799089431763)","('NON-ESG', 0.021324727684259415)","('NON-ESG', 0.017396878451108932)"
Line 303,"In 2021, these audits had no findings resulting in production stoppages.","('Business_Ethics', 0.22914712131023407)","('Management_Of_Legal_And_Regulatory_Framework', 0.1361534744501114)","('Systemic_Risk_Management', 0.10523168742656708)","('NON-ESG', 0.22914712131023407)","('NON-ESG', 0.1361534744501114)","('NON-ESG', 0.10523168742656708)"
Line 304,"We take strong, proactive measures to assess and maintain the security of our supply chain, as described in the Supply Chain Sustainability section of this report.","('Supply_Chain_Management', 0.9482787847518921)","('Product_Design_And_Lifecycle_Management', 0.006271007005125284)","('Labor_Practices', 0.003676861524581909)","([], 0.9482787847518921)","('NON-ESG', 0.006271007005125284)","('NON-ESG', 0.003676861524581909)"
Line 305,Our Pharmacovigilance and Patient Safety teams identify potential safety issues and mitigate their impact on patients with an overall goal to improve the patient experience throughout the product lifecycle.,"('Product_Quality_And_Safety', 0.870449960231781)","('Product_Design_And_Lifecycle_Management', 0.032519180327653885)","('Employee_Health_And_Safety', 0.017576346173882484)","(['Product Quality & Recall Management'], 0.870449960231781)","('NON-ESG', 0.032519180327653885)","('NON-ESG', 0.017576346173882484)"
Line 306,"Over the course of 2021, at any given time, these teams were supporting approximately 250 studies and approximately 150 marketed products and devices.","('Product_Design_And_Lifecycle_Management', 0.945131242275238)","('Selling_Practices_And_Product_Labeling', 0.007331503089517355)","('Customer_Welfare', 0.006849270313978195)","([], 0.945131242275238)","('NON-ESG', 0.007331503089517355)","('NON-ESG', 0.006849270313978195)"
Line 307,"In 2021, these teams advanced research and forecasting pertaining to COVID-19, including the following projects: Completed a baseline manuscript for an observational cohort study of COVID-19 in Lake County, Illinois1 Evaluated the risk of severe COVID-19 outcomes in patients with immunology conditions2 Assessed patient characteristics and the risk of severe COVID-19 outcomes in cancer and Immune-mediated Inflammatory Disease patients Our Pharmacovigilance and Patient Safety teams also take action to address any risks of our medicines being counterfeited or diverted.","('Employee_Health_And_Safety', 0.3455132246017456)","('Product_Quality_And_Safety', 0.14422912895679474)","('Access_And_Affordability', 0.10679063946008682)","('NON-ESG', 0.3455132246017456)","('NON-ESG', 0.14422912895679474)","('NON-ESG', 0.10679063946008682)"
Line 308,"In 2021, these teams advanced research and forecasting pertaining to COVID-19, including the following projects: Completed a baseline manuscript for an observational cohort study of COVID-19 in Lake County, Illinois1 Evaluated the risk of severe COVID-19 outcomes in patients with immunology conditions2 Assessed patient characteristics and the risk of severe COVID-19 outcomes in cancer and Immune-mediated Inflammatory Disease patients Our Pharmacovigilance and Patient Safety teams also take action to address any risks of our medicines being counterfeited or diverted.","('Business_Ethics', 0.33598119020462036)","('Data_Security', 0.1812473088502884)","('Competitive_Behavior', 0.08381032943725586)","('NON-ESG', 0.33598119020462036)","('NON-ESG', 0.1812473088502884)","('NON-ESG', 0.08381032943725586)"
Line 309,"We regularly provide education and training to employees, healthcare providers and law enforcement officials in higher-risk geographies.","('Management_Of_Legal_And_Regulatory_Framework', 0.32188093662261963)","('Access_And_Affordability', 0.17862844467163086)","('Product_Quality_And_Safety', 0.07372090220451355)","('NON-ESG', 0.32188093662261963)","('NON-ESG', 0.17862844467163086)","('NON-ESG', 0.07372090220451355)"
Line 310,Our education covers the social and health risks of counterfeited and diverted medicines as well as common illicit trade practices and security protocols.,"('Business_Ethics', 0.453940749168396)","('Data_Security', 0.16884149610996246)","('Competitive_Behavior', 0.07443566620349884)","('NON-ESG', 0.453940749168396)","('NON-ESG', 0.16884149610996246)","('NON-ESG', 0.07443566620349884)"
Line 311,To learn more about our anti-counterfeiting measures please see the Governance section of this report.,"('Data_Security', 0.40839332342147827)","('Business_Ethics', 0.16177049279212952)","('Competitive_Behavior', 0.09424557536840439)","('NON-ESG', 0.40839332342147827)","('NON-ESG', 0.16177049279212952)","('NON-ESG', 0.09424557536840439)"
Line 312,Upholding the Highest Quality Standards 1 (Ryan D.,"('Business_Ethics', 0.36977413296699524)","('Competitive_Behavior', 0.11452192068099976)","('Product_Quality_And_Safety', 0.10561823099851608)","('NON-ESG', 0.36977413296699524)","('NON-ESG', 0.11452192068099976)","('NON-ESG', 0.10561823099851608)"
Line 313,"Kilapatrick, 2022) 2 (Y.","('Management_Of_Legal_And_Regulatory_Framework', 0.49554115533828735)","('Competitive_Behavior', 0.11803106963634491)","('Business_Ethics', 0.0563892163336277)","('NON-ESG', 0.49554115533828735)","('NON-ESG', 0.11803106963634491)","('NON-ESG', 0.0563892163336277)"
Line 314,"Ye, X .","('Competitive_Behavior', 0.24120654165744781)","('Business_Ethics', 0.14608342945575714)","('Labor_Practices', 0.07811617851257324)","('NON-ESG', 0.24120654165744781)","('NON-ESG', 0.14608342945575714)","('NON-ESG', 0.07811617851257324)"
Line 315,"Yue, W .","('Competitive_Behavior', 0.16457794606685638)","('Management_Of_Legal_And_Regulatory_Framework', 0.12232275307178497)","('GHG_Emissions', 0.10115011781454086)","('NON-ESG', 0.16457794606685638)","('NON-ESG', 0.12232275307178497)","('NON-ESG', 0.10115011781454086)"
Line 316,"Krueger, L .","('Ecological_Impacts', 0.3382089138031006)","('GHG_Emissions', 0.1394033282995224)","('Management_Of_Legal_And_Regulatory_Framework', 0.07978668808937073)","('NON-ESG', 0.3382089138031006)","('NON-ESG', 0.1394033282995224)","('NON-ESG', 0.07978668808937073)"
Line 317,"Wegrzyn, 2021) 2021 FDA Class I or FDA Class II Product Recalls 1Key Performance Indicator: Product Recalls This table includes a new KPI added to 2021 ESG Action Report.","('Product_Quality_And_Safety', 0.6100859045982361)","('Selling_Practices_And_Product_Labeling', 0.12391778081655502)","('Competitive_Behavior', 0.02846522629261017)","(['Product Quality & Recall Management'], 0.6100859045982361)","('NON-ESG', 0.12391778081655502)","('NON-ESG', 0.02846522629261017)"
Line 318,The KPI includes both Class I and Class II recalls.,"('Management_Of_Legal_And_Regulatory_Framework', 0.4700089693069458)","('Energy_Management', 0.07831209152936935)","('Product_Design_And_Lifecycle_Management', 0.04773026332259178)","('NON-ESG', 0.4700089693069458)","('NON-ESG', 0.07831209152936935)","('NON-ESG', 0.04773026332259178)"
Line 319,The identified 2021 recall involved a Class II voluntary recall.,"('Critical_Incident_Risk_Management', 0.33812305331230164)","('Product_Quality_And_Safety', 0.13795681297779083)","('Employee_Health_And_Safety', 0.1204415038228035)","('NON-ESG', 0.33812305331230164)","('NON-ESG', 0.13795681297779083)","('NON-ESG', 0.1204415038228035)"
Line 320,More information on this recall can be found on the FDA website .,"('Product_Quality_And_Safety', 0.2961975634098053)","('Critical_Incident_Risk_Management', 0.09562922269105911)","('Management_Of_Legal_And_Regulatory_Framework', 0.09224843978881836)","('NON-ESG', 0.2961975634098053)","('NON-ESG', 0.09562922269105911)","('NON-ESG', 0.09224843978881836)"
Line 321,26 2021 ESG Action Report 2021 ESG Action Report 27 Eliminating the hepatitis C virus (HCV) and relieving symptoms of other diseases will mean uniting all of us behind a collective effort to overcome the obstacles associated with the disease.,"('Systemic_Risk_Management', 0.18808357417583466)","('Employee_Health_And_Safety', 0.10319463908672333)","('Access_And_Affordability', 0.09862945973873138)","('NON-ESG', 0.18808357417583466)","('NON-ESG', 0.10319463908672333)","('NON-ESG', 0.09862945973873138)"
Line 322,"The hundreds of HCV elimination projects that AbbVie supports are forging partnerships that help concentrate our efforts, share learnings and scale what works.","('Access_And_Affordability', 0.38278594613075256)","('Management_Of_Legal_And_Regulatory_Framework', 0.06397774815559387)","('Human_Rights_And_Community_Relations', 0.05958900228142738)","('NON-ESG', 0.38278594613075256)","('NON-ESG', 0.06397774815559387)","('NON-ESG', 0.05958900228142738)"
Line 323,These are just a few of our efforts to date: Peer Motivation: People who inject drugs (PWIDs) are the largest identifiable high- risk population for HCV in Switzerland.,"('Access_And_Affordability', 0.28079739212989807)","('Customer_Welfare', 0.08694733679294586)","('Critical_Incident_Risk_Management', 0.07087676227092743)","('NON-ESG', 0.28079739212989807)","('NON-ESG', 0.08694733679294586)","('NON-ESG', 0.07087676227092743)"
Line 324,Our project here seeks to establish testing at drug treatment centers and launch peer programs to motivate PWIDs to seek screenings and care.,"('Access_And_Affordability', 0.7474692463874817)","('Product_Quality_And_Safety', 0.03723656013607979)","('Customer_Welfare', 0.03116699866950512)","(['Access to Healthcare'], 0.7474692463874817)","('NON-ESG', 0.03723656013607979)","('NON-ESG', 0.03116699866950512)"
Line 325,"Hep C A-L-E-R-T: A project in Romania is working to show that HCV elimination is possible through cost-effective, point-of- care testing using a rapid finger stick test in regional hospitals.","('Access_And_Affordability', 0.3154940903186798)","('Product_Quality_And_Safety', 0.1292913407087326)","('Customer_Welfare', 0.10600098222494125)","('NON-ESG', 0.3154940903186798)","('NON-ESG', 0.1292913407087326)","('NON-ESG', 0.10600098222494125)"
Line 326,"Road to the Cure: In Israel, an effort to map the most frequented locations of people who inject drugs is helping healthcare providers bring laboratory services and HCV treatment to places where these patients feel comfortable.","('Access_And_Affordability', 0.413155734539032)","('Customer_Welfare', 0.1127292737364769)","('Employee_Health_And_Safety', 0.07305304706096649)","('NON-ESG', 0.413155734539032)","('NON-ESG', 0.1127292737364769)","('NON-ESG', 0.07305304706096649)"
Line 327,Learning from Diabetes: New research shows that Australia must increase testing and improve linkage to care to eliminate HCV by 2030.,"('Access_And_Affordability', 0.26803961396217346)","('Customer_Welfare', 0.18101750314235687)","('Product_Quality_And_Safety', 0.07680929452180862)","('NON-ESG', 0.26803961396217346)","('NON-ESG', 0.18101750314235687)","('NON-ESG', 0.07680929452180862)"
Line 328,"To help, one Australian project is replicating a successful model of diabetes screening and treatment at Blacktown Hospital in Western Sydney to improve HCV awareness among at risk groups including people who inject drugs.","('Access_And_Affordability', 0.5155021548271179)","('Employee_Health_And_Safety', 0.10613460093736649)","('Product_Quality_And_Safety', 0.06720581650733948)","(['Access to Healthcare'], 0.5155021548271179)","('NON-ESG', 0.10613460093736649)","('NON-ESG', 0.06720581650733948)"
Line 329,Battling Hepatitis C Around the World Our independent healthcare grants increase access to continuing education and improve HCV awareness among at-risk groups including people who inject drugs.,"('Access_And_Affordability', 0.8110697269439697)","('Product_Quality_And_Safety', 0.029724903404712677)","('Customer_Welfare', 0.016576729714870453)","(['Access to Healthcare'], 0.8110697269439697)","('NON-ESG', 0.029724903404712677)","('NON-ESG', 0.016576729714870453)"
Line 330,"We support independent scientific and medical education programs that offer unbiased continuing education for experienced healthcare providers and scientists on current, new and emerging science.","('Access_And_Affordability', 0.6293505430221558)","('Employee_Engagement_Inclusion_And_Diversity', 0.047451816499233246)","('Management_Of_Legal_And_Regulatory_Framework', 0.03743230551481247)","(['Access to Healthcare'], 0.6293505430221558)","('NON-ESG', 0.047451816499233246)","('NON-ESG', 0.03743230551481247)"
Line 331,"By deepening provider knowledge, patients are better served and more positive outcomes are achieved.","('Access_And_Affordability', 0.6793115139007568)","('Human_Rights_And_Community_Relations', 0.03753483667969704)","('Customer_Welfare', 0.032970722764730453)","(['Access to Healthcare'], 0.6793115139007568)","('NON-ESG', 0.03753483667969704)","('NON-ESG', 0.032970722764730453)"
Line 332,Our grants also fund fellowships that increase capacity in under resourced fields and educate providers on medical advances and emerging therapies.,"('Access_And_Affordability', 0.8301573395729065)","('Product_Quality_And_Safety', 0.019149838015437126)","('Customer_Welfare', 0.01280179899185896)","(['Access to Healthcare'], 0.8301573395729065)","('NON-ESG', 0.019149838015437126)","('NON-ESG', 0.01280179899185896)"
Line 333,We prioritize grants to initiatives that focus on the reduction of healthcare disparities in underserved populations and those that advance inclusive patient care.,"('Access_And_Affordability', 0.9474131464958191)","('Critical_Incident_Risk_Management', 0.004802870098501444)","('Product_Quality_And_Safety', 0.004493890330195427)","(['Access to Healthcare'], 0.9474131464958191)","('NON-ESG', 0.004802870098501444)","('NON-ESG', 0.004493890330195427)"
Line 334,"Some of our funded initiatives have fostered telemedicine and telehealth, bridging geographic gaps.","('Management_Of_Legal_And_Regulatory_Framework', 0.4015345573425293)","('Access_And_Affordability', 0.1646348088979721)","('Systemic_Risk_Management', 0.05961333587765694)","('NON-ESG', 0.4015345573425293)","('NON-ESG', 0.1646348088979721)","('NON-ESG', 0.05961333587765694)"
Line 335,"In 2021, we reached nearly 700,000 patients and more than 750,000 healthcare providers through our independent healthcare grants.","('Access_And_Affordability', 0.7693447470664978)","('Energy_Management', 0.02799094095826149)","('Customer_Welfare', 0.023180533200502396)","(['Access to Healthcare'], 0.7693447470664978)","('NON-ESG', 0.02799094095826149)","('NON-ESG', 0.023180533200502396)"
Line 336,More information on areas we support through our independent healthcare grants and the most up-to-date grant application process can be found on our website .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8825749158859253)","('Access_And_Affordability', 0.033541735261678696)","('Human_Rights_And_Community_Relations', 0.009629402309656143)","([], 0.8825749158859253)","('NON-ESG', 0.033541735261678696)","('NON-ESG', 0.009629402309656143)"
Line 337,Our patient care and support helps patients reach their full treatment potential.,"('Access_And_Affordability', 0.8524234294891357)","('Human_Rights_And_Community_Relations', 0.013791169039905071)","('Employee_Engagement_Inclusion_And_Diversity', 0.013174166902899742)","(['Access to Healthcare'], 0.8524234294891357)","('NON-ESG', 0.013791169039905071)","('NON-ESG', 0.013174166902899742)"
Line 338,"We offer a wide range of country- specific, disease-state patient programs that provide meaningful, informative and empowering support to patients who have been prescribed AbbVie medicines.","('Access_And_Affordability', 0.6837678551673889)","('Customer_Welfare', 0.04620217904448509)","('Selling_Practices_And_Product_Labeling', 0.03860962390899658)","(['Access to Healthcare'], 0.6837678551673889)","('NON-ESG', 0.04620217904448509)","('NON-ESG', 0.03860962390899658)"
Line 339,"We also verify insurance coverage, help patients access financial assistance, and in specific situations, may dispense medicines directly to patients.","('Access_And_Affordability', 0.6941127777099609)","('Management_Of_Legal_And_Regulatory_Framework', 0.04425520822405815)","('Selling_Practices_And_Product_Labeling', 0.042866431176662445)","(['Access to Healthcare'], 0.6941127777099609)","('NON-ESG', 0.04425520822405815)","('NON-ESG', 0.042866431176662445)"
Line 340,"To learn more about the ways we make medicines more affordable to patients, please refer to the Patient Access and Affordability section of this report.","('Access_And_Affordability', 0.6614819765090942)","('Customer_Welfare', 0.054036643356084824)","('Selling_Practices_And_Product_Labeling', 0.0485905222594738)","(['Access to Healthcare'], 0.6614819765090942)","('NON-ESG', 0.054036643356084824)","('NON-ESG', 0.0485905222594738)"
Line 341,The support we provide patients increases their ability to access and use our medicines in a way that ensures successful outcomes.,"('Access_And_Affordability', 0.8242213726043701)","('Customer_Welfare', 0.018615463748574257)","('Human_Rights_And_Community_Relations', 0.017448071390390396)","(['Access to Healthcare'], 0.8242213726043701)","('NON-ESG', 0.018615463748574257)","('NON-ESG', 0.017448071390390396)"
Line 342,"For example, through our Nurse Ambassador program and through other support resources, we provide educational programs to patients that ensure they are empowered with the knowledge and resources to better understand their disease, treatment and the usage of their medicine.","('Access_And_Affordability', 0.7429021596908569)","('Product_Quality_And_Safety', 0.030160384252667427)","('Customer_Welfare', 0.02808835171163082)","(['Access to Healthcare'], 0.7429021596908569)","('NON-ESG', 0.030160384252667427)","('NON-ESG', 0.02808835171163082)"
Line 343,"To enhance the ways in which we support patients to use their prescribed medicines, we use learnings and tools from behavioral science such as teach-back, an established health literacy technique.","('Access_And_Affordability', 0.7535073161125183)","('Product_Quality_And_Safety', 0.037331849336624146)","('Customer_Welfare', 0.027545837685465813)","(['Access to Healthcare'], 0.7535073161125183)","('NON-ESG', 0.037331849336624146)","('NON-ESG', 0.027545837685465813)"
Line 344,"Teach-back helps us to better understand how patients interpret the information we share with them, which in turn allows us to further adapt our communications for clarity.","('Customer_Privacy', 0.5304521918296814)","('Access_And_Affordability', 0.058215729892253876)","('Management_Of_Legal_And_Regulatory_Framework', 0.045900922268629074)","([], 0.5304521918296814)","('NON-ESG', 0.058215729892253876)","('NON-ESG', 0.045900922268629074)"
Line 345,"Independent Healthcare Grants Patient SupportAt AbbVie, patients are at the heart of what we do: discovering and delivering life- changing medicines.","('Access_And_Affordability', 0.6820216774940491)","('Customer_Welfare', 0.0407567098736763)","('Product_Design_And_Lifecycle_Management', 0.031126027926802635)","(['Access to Healthcare'], 0.6820216774940491)","('NON-ESG', 0.0407567098736763)","('NON-ESG', 0.031126027926802635)"
Line 346,"We know that these transformative medicines only matter if they are safe, effective and accessible to everyone who needs them, when they need them.","('Access_And_Affordability', 0.6847341656684875)","('Selling_Practices_And_Product_Labeling', 0.03865446522831917)","('Customer_Welfare', 0.03767746314406395)","(['Access to Healthcare'], 0.6847341656684875)","('NON-ESG', 0.03865446522831917)","('NON-ESG', 0.03767746314406395)"
Line 347,"From drug discovery to development to working with partners to ensure our medicines are accessible and affordable, we offer a breadth of resources, so that people taking our medicines can feel empowered, informed and in control of their health.","('Access_And_Affordability', 0.6050846576690674)","('Customer_Welfare', 0.07522335648536682)","('Product_Quality_And_Safety', 0.036421842873096466)","(['Access to Healthcare'], 0.6050846576690674)","('NON-ESG', 0.07522335648536682)","('NON-ESG', 0.036421842873096466)"
Line 348,We amplify patients voices to ensure their concerns are heard and accounted for in our decision making worldwide.,"('Human_Rights_And_Community_Relations', 0.385888934135437)","('Management_Of_Legal_And_Regulatory_Framework', 0.11086554080247879)","('Access_And_Affordability', 0.08743929862976074)","('NON-ESG', 0.385888934135437)","('NON-ESG', 0.11086554080247879)","('NON-ESG', 0.08743929862976074)"
Line 349,"Patient Health and Engagement In 2021, AbbVies Immunology Complete Programs were recognized as one of the Most Valuable Patient Support or Access Programs as part of the WEGO Health Patient-Choice Awards.","('Access_And_Affordability', 0.8523916006088257)","('Employee_Health_And_Safety', 0.014245796017348766)","('Product_Quality_And_Safety', 0.014058372937142849)","(['Access to Healthcare'], 0.8523916006088257)","('NON-ESG', 0.014245796017348766)","('NON-ESG', 0.014058372937142849)"
Line 350,"In a time when many patients have delayed treatments and visits to providers due to the pandemic, AbbVies Immunology Complete Programs have provided the resources and support patients need.","('Access_And_Affordability', 0.47155293822288513)","('Critical_Incident_Risk_Management', 0.08097629249095917)","('Systemic_Risk_Management', 0.04543546587228775)","('NON-ESG', 0.47155293822288513)","('NON-ESG', 0.08097629249095917)","('NON-ESG', 0.04543546587228775)"
Line 351,"In 2021 alone, the programs helped more than 200,000 patients navigate their journeys living with several immune-mediated conditions like rheumatoid arthritis and psoriatic arthritismore than double the number of patients who were enrolled in the program before the COVID-19 pandemic.","('Employee_Health_And_Safety', 0.22680191695690155)","('Access_And_Affordability', 0.18198205530643463)","('Product_Quality_And_Safety', 0.0931084156036377)","('NON-ESG', 0.22680191695690155)","('NON-ESG', 0.18198205530643463)","('NON-ESG', 0.0931084156036377)"
Line 352,"Created to provide support at no cost, patients were prescribed HUMIRA, RINVOQ, or SKYRIZI; the programs are based on experience and evidence and intended to help patients access and adhere to their medications.","('Access_And_Affordability', 0.5010484457015991)","('Customer_Welfare', 0.08930116891860962)","('Selling_Practices_And_Product_Labeling', 0.06775230914354324)","(['Access to Healthcare'], 0.5010484457015991)","('NON-ESG', 0.08930116891860962)","('NON-ESG', 0.06775230914354324)"
Line 353,Rewarding Our Patient Support 28 2021 ESG Action Report 2021 ESG Action Report 29 The patient isand will always beat the heart of all the work we do.,"('Access_And_Affordability', 0.4283917248249054)","('Human_Rights_And_Community_Relations', 0.1799352914094925)","('Management_Of_Legal_And_Regulatory_Framework', 0.06716415286064148)","('NON-ESG', 0.4283917248249054)","('NON-ESG', 0.1799352914094925)","('NON-ESG', 0.06716415286064148)"
Line 354,"Without understanding the lived experience of people living with health conditions, including their wants, needs and goals, it is impossible to design, develop and deliver life-improving medicines for patients.","('Access_And_Affordability', 0.7074195742607117)","('Employee_Health_And_Safety', 0.09364274889230728)","('Human_Rights_And_Community_Relations', 0.03610498458147049)","(['Access to Healthcare'], 0.7074195742607117)","('NON-ESG', 0.09364274889230728)","('NON-ESG', 0.03610498458147049)"
Line 355,We partner with patient advocacy groups and rely on the valuable insights they share on the patient and caregiver experience.,"('Access_And_Affordability', 0.7398366332054138)","('Human_Rights_And_Community_Relations', 0.06922489404678345)","('Employee_Health_And_Safety', 0.029788726940751076)","(['Access to Healthcare'], 0.7398366332054138)","('NON-ESG', 0.06922489404678345)","('NON-ESG', 0.029788726940751076)"
Line 356,"We foster relationships with patient advocacy groups based on mutual trust, respect and shared goals, which reflect AbbVies transparent and ethical behavioral standards.","('Business_Ethics', 0.9052026271820068)","('Human_Rights_And_Community_Relations', 0.018355175852775574)","('Management_Of_Legal_And_Regulatory_Framework', 0.011078727431595325)","(['Business Ethics'], 0.9052026271820068)","('NON-ESG', 0.018355175852775574)","('NON-ESG', 0.011078727431595325)"
Line 357,"Together, we have a shared aim to improve patients lives.","('Access_And_Affordability', 0.7219958305358887)","('Employee_Health_And_Safety', 0.059275537729263306)","('Human_Rights_And_Community_Relations', 0.049183789640665054)","(['Access to Healthcare'], 0.7219958305358887)","('NON-ESG', 0.059275537729263306)","('NON-ESG', 0.049183789640665054)"
Line 358,Essential to early detection of diseases is awareness of and education on that disease.,"('Employee_Health_And_Safety', 0.19962361454963684)","('Access_And_Affordability', 0.19565299153327942)","('Product_Quality_And_Safety', 0.10200158506631851)","('NON-ESG', 0.19962361454963684)","('NON-ESG', 0.19565299153327942)","('NON-ESG', 0.10200158506631851)"
Line 359,The patient advocacy community enables us to garner diverse perspectives and to build a greater understanding of the experiences of our patients and the unique challenges of the patient journey from diagnosis to treatment.,"('Access_And_Affordability', 0.4290866553783417)","('Employee_Engagement_Inclusion_And_Diversity', 0.2078593522310257)","('Human_Rights_And_Community_Relations', 0.0960032194852829)","('NON-ESG', 0.4290866553783417)","('NON-ESG', 0.2078593522310257)","('NON-ESG', 0.0960032194852829)"
Line 360,This helps inform our decisions from drug development to packaging design and delivery.,"('Product_Design_And_Lifecycle_Management', 0.9155780076980591)","('Customer_Welfare', 0.015331852249801159)","('Selling_Practices_And_Product_Labeling', 0.013415849767625332)","([], 0.9155780076980591)","('NON-ESG', 0.015331852249801159)","('NON-ESG', 0.013415849767625332)"
Line 361,"Through these partnerships, AbbVie also contributes to patient and caregiver education specific to disease states and shares information about quality-of-life improvements.","('Access_And_Affordability', 0.8746466040611267)","('Product_Quality_And_Safety', 0.01629679463803768)","('Employee_Health_And_Safety', 0.015050718560814857)","(['Access to Healthcare'], 0.8746466040611267)","('NON-ESG', 0.01629679463803768)","('NON-ESG', 0.015050718560814857)"
Line 362,Our approach to partnering with patient advocacy groups is rooted in the foundations of three critically important guiding principles: 1.,"('Access_And_Affordability', 0.5936124920845032)","('Human_Rights_And_Community_Relations', 0.12499242275953293)","('Management_Of_Legal_And_Regulatory_Framework', 0.03587112948298454)","(['Access to Healthcare'], 0.5936124920845032)","('NON-ESG', 0.12499242275953293)","('NON-ESG', 0.03587112948298454)"
Line 363,Independence: The independence of patient advocacy groups will not be compromised.,"('Management_Of_Legal_And_Regulatory_Framework', 0.39821916818618774)","('Competitive_Behavior', 0.15421292185783386)","('Business_Ethics', 0.13059572875499725)","('NON-ESG', 0.39821916818618774)","('NON-ESG', 0.15421292185783386)","('NON-ESG', 0.13059572875499725)"
Line 364,We encourage PAGs to maintain relationships with a wide range of organizations and companies.,"('Business_Ethics', 0.19383399188518524)","('Management_Of_Legal_And_Regulatory_Framework', 0.1743478626012802)","('Business_Model_Resilience', 0.10683920234441757)","('NON-ESG', 0.19383399188518524)","('NON-ESG', 0.1743478626012802)","('NON-ESG', 0.10683920234441757)"
Line 365,2.,"('Competitive_Behavior', 0.15795664489269257)","('Customer_Welfare', 0.10852150619029999)","('Energy_Management', 0.08616163581609726)","('NON-ESG', 0.15795664489269257)","('NON-ESG', 0.10852150619029999)","('NON-ESG', 0.08616163581609726)"
Line 366,"Transparency: All support will be disclosed according to relevant laws, and patient advocacy groups will recognize company support through locally appropriate means.","('Business_Ethics', 0.8748285174369812)","('Management_Of_Legal_And_Regulatory_Framework', 0.06420900672674179)","('Data_Security', 0.005679572932422161)","(['Business Ethics'], 0.8748285174369812)","('NON-ESG', 0.06420900672674179)","('NON-ESG', 0.005679572932422161)"
Line 367,"Both AbbVie and patient advocacy groups will have final approval on all public uses of their respective names, logos and identifying symbols.","('Customer_Privacy', 0.2799537777900696)","('Management_Of_Legal_And_Regulatory_Framework', 0.08799631148576736)","('Employee_Engagement_Inclusion_And_Diversity', 0.08128217607736588)","('NON-ESG', 0.2799537777900696)","('NON-ESG', 0.08799631148576736)","('NON-ESG', 0.08128217607736588)"
Line 368,3.,"('Competitive_Behavior', 0.1465800553560257)","('Customer_Welfare', 0.10041514039039612)","('Product_Design_And_Lifecycle_Management', 0.07025990635156631)","('NON-ESG', 0.1465800553560257)","('NON-ESG', 0.10041514039039612)","('NON-ESG', 0.07025990635156631)"
Line 369,"Trust and Mutual Respect: Through a mutual and open understanding of each others policies, objectives and working practices, we will demonstrate respect for our partners as we each work toward common objectives and outcomes.","('Human_Rights_And_Community_Relations', 0.5063902735710144)","('Business_Ethics', 0.14027796685695648)","('Customer_Privacy', 0.05368456616997719)","([], 0.5063902735710144)","('NON-ESG', 0.14027796685695648)","('NON-ESG', 0.05368456616997719)"
Line 370,"When providing information on marketed and investigational medicines, AbbVie will do so in compliance with applicable local laws, regulations, policies and procedures.","('Selling_Practices_And_Product_Labeling', 0.3601604402065277)","('Management_Of_Legal_And_Regulatory_Framework', 0.2515536844730377)","('Access_And_Affordability', 0.09335947781801224)","('NON-ESG', 0.3601604402065277)","('NON-ESG', 0.2515536844730377)","('NON-ESG', 0.09335947781801224)"
Line 371,"Engagement with the Patient Community 2021 Grants, donations and/or sponsorships to healthcare and patient organizations ($ million) $155.4Key Performance Indicator: Support for Healthcare and Patient Organizations This table includes a new KPI added to the 2021 ESG Action Report.","('Management_Of_Legal_And_Regulatory_Framework', 0.4052315354347229)","('Access_And_Affordability', 0.23329097032546997)","('Human_Rights_And_Community_Relations', 0.16508178412914276)","('NON-ESG', 0.4052315354347229)","('NON-ESG', 0.23329097032546997)","('NON-ESG', 0.16508178412914276)"
Line 372,This KPI does not include AbbVie Foundation or Corporate philanthropic grants or donations.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8966053128242493)","('Business_Ethics', 0.012823560275137424)","('Director_Removal', 0.010487711988389492)","([], 0.8966053128242493)","('NON-ESG', 0.012823560275137424)","('NON-ESG', 0.010487711988389492)"
Line 373,See the Community & Partner Engagement and Impact section for more details on AbbVies philanthropic efforts.,"('Human_Rights_And_Community_Relations', 0.8589767217636108)","('Access_And_Affordability', 0.03608064353466034)","('Management_Of_Legal_And_Regulatory_Framework', 0.012211530469357967)","([], 0.8589767217636108)","('NON-ESG', 0.03608064353466034)","('NON-ESG', 0.012211530469357967)"
Line 374,"Patient Communication in Brazil Our Meaningful Conversations (Conversas Importantes) project ensures oncology providers are better able to communicate with patients about their disease, their options and clinical trials.","('Access_And_Affordability', 0.3965963125228882)","('Customer_Welfare', 0.08421377092599869)","('Competitive_Behavior', 0.06441085785627365)","('NON-ESG', 0.3965963125228882)","('NON-ESG', 0.08421377092599869)","('NON-ESG', 0.06441085785627365)"
Line 375,Disease Management and Education in Mexico Our Siente tu Libertad digital platform provides patients suffering from psoriasis with educational tools and tips on disease management and connects patients with dermatologists specializing in the disease.,"('Employee_Health_And_Safety', 0.3868506848812103)","('Access_And_Affordability', 0.10942672193050385)","('Product_Quality_And_Safety', 0.09042470157146454)","('NON-ESG', 0.3868506848812103)","('NON-ESG', 0.10942672193050385)","('NON-ESG', 0.09042470157146454)"
Line 376,Educating Providers and Patients Around the World30 2021 ESG Action Report 2021 ESG Action Report 31 AbbVies commitment to patients inspires a focus on innovation and a dedication to ensuring that patients who can benefit from AbbVies medicines have access to them.,"('Access_And_Affordability', 0.7487601637840271)","('Customer_Welfare', 0.03281007334589958)","('Product_Quality_And_Safety', 0.024817682802677155)","(['Access to Healthcare'], 0.7487601637840271)","('NON-ESG', 0.03281007334589958)","('NON-ESG', 0.024817682802677155)"
Line 377,"We commit to pursuing new ways to address patients most serious health issues, while expanding access and support for patients to improve lives today.","('Access_And_Affordability', 0.8615753650665283)","('Employee_Health_And_Safety', 0.020968351513147354)","('Human_Rights_And_Community_Relations', 0.016643885523080826)","(['Access to Healthcare'], 0.8615753650665283)","('NON-ESG', 0.020968351513147354)","('NON-ESG', 0.016643885523080826)"
Line 378,Science and innovation are the lifeblood of our company.,"('Business_Model_Resilience', 0.30012401938438416)","('Product_Design_And_Lifecycle_Management', 0.1303311437368393)","('Competitive_Behavior', 0.11855001747608185)","('NON-ESG', 0.30012401938438416)","('NON-ESG', 0.1303311437368393)","('NON-ESG', 0.11855001747608185)"
Line 379,We dedicate ourselves to addressing the worlds pressing health challenges by combining our experience in pioneering scientific breakthroughs with a focus on pursuing the best ideas in science.,"('Access_And_Affordability', 0.2811007797718048)","('Employee_Health_And_Safety', 0.18363679945468903)","('Product_Quality_And_Safety', 0.0760212317109108)","('NON-ESG', 0.2811007797718048)","('NON-ESG', 0.18363679945468903)","('NON-ESG', 0.0760212317109108)"
Line 380,We also recognize that innovative treatments can only make a difference if patients can access the medicines that they and their providers choose.,"('Access_And_Affordability', 0.48695430159568787)","('Customer_Welfare', 0.12014714628458023)","('Selling_Practices_And_Product_Labeling', 0.05769193917512894)","('NON-ESG', 0.48695430159568787)","('NON-ESG', 0.12014714628458023)","('NON-ESG', 0.05769193917512894)"
Line 381,"Innovation and access must work in tandem, which is why AbbVie commits to helping patients who need our medicines to get those medicines.","('Access_And_Affordability', 0.7289301156997681)","('Customer_Welfare', 0.04059585928916931)","('Selling_Practices_And_Product_Labeling', 0.023620296269655228)","(['Access to Healthcare'], 0.7289301156997681)","('NON-ESG', 0.04059585928916931)","('NON-ESG', 0.023620296269655228)"
Line 382,We keep our commitment to making a remarkable impact on patients at the center of how we operateincluding in how we approach the pricing of our medicines and the ways we work to increase access and support for patients throughout their treatment journey.,"('Access_And_Affordability', 0.7103950381278992)","('Customer_Welfare', 0.050611432641744614)","('Selling_Practices_And_Product_Labeling', 0.02538151852786541)","(['Access to Healthcare'], 0.7103950381278992)","('NON-ESG', 0.050611432641744614)","('NON-ESG', 0.02538151852786541)"
Line 383,"To achieve this, we assist qualified patients in the United States by making their co-pay less burdensome and by providing free medicine.","('Labor_Practices', 0.27287551760673523)","('Management_Of_Legal_And_Regulatory_Framework', 0.2282322347164154)","('Access_And_Affordability', 0.16871261596679688)","('NON-ESG', 0.27287551760673523)","('NON-ESG', 0.2282322347164154)","('NON-ESG', 0.16871261596679688)"
Line 384,"Across the world, we are at times able to provide patients with access to our medicines before they are formally approved for use by regulatory agencies on a compassionate use basis.","('Access_And_Affordability', 0.5422486662864685)","('Selling_Practices_And_Product_Labeling', 0.09656306356191635)","('Customer_Welfare', 0.056153491139411926)","(['Access to Healthcare'], 0.5422486662864685)","('NON-ESG', 0.09656306356191635)","('NON-ESG', 0.056153491139411926)"
Line 385,"We also donate medicines Patient Access and Affordability Within the United States, we provide co-pay assistance, regardless of income, to all patients with commercial insurance; most eligible patients pay $5-10 per month for their AbbVie medicines.","('Access_And_Affordability', 0.880851686000824)","('Management_Of_Legal_And_Regulatory_Framework', 0.012280194088816643)","('Product_Quality_And_Safety', 0.012272666208446026)","(['Access to Healthcare'], 0.880851686000824)","('NON-ESG', 0.012280194088816643)","('NON-ESG', 0.012272666208446026)"
Line 386,More than 90% of commercial patients utilize our co-pay assistance program.,"('Access_And_Affordability', 0.6837975978851318)","('Management_Of_Legal_And_Regulatory_Framework', 0.056522808969020844)","('Labor_Practices', 0.05375710129737854)","(['Access to Healthcare'], 0.6837975978851318)","('NON-ESG', 0.056522808969020844)","('NON-ESG', 0.05375710129737854)"
Line 387,"We also make donations to independent charitable foundations that provide co-pay assistance to patients in need, regardless of what type of therapy they are on.","('Access_And_Affordability', 0.8366872668266296)","('Management_Of_Legal_And_Regulatory_Framework', 0.032898418605327606)","('Human_Rights_And_Community_Relations', 0.01712130568921566)","(['Access to Healthcare'], 0.8366872668266296)","('NON-ESG', 0.032898418605327606)","('NON-ESG', 0.01712130568921566)"
Line 388,Patients in the United States without insurance or those with limited coverage for our medicines in the United States may be eligible to receive AbbVie medicines at no cost to them through myAbbVie Assist.,"('Access_And_Affordability', 0.5244103670120239)","('Management_Of_Legal_And_Regulatory_Framework', 0.14056256413459778)","('Product_Quality_And_Safety', 0.040461841970682144)","(['Access to Healthcare'], 0.5244103670120239)","('NON-ESG', 0.14056256413459778)","('NON-ESG', 0.040461841970682144)"
Line 389,The program serves as an important safety net and helps 99% of uninsured patients who seek our assistance.,"('Access_And_Affordability', 0.32404088973999023)","('Employee_Health_And_Safety', 0.26346108317375183)","('Product_Quality_And_Safety', 0.14223121106624603)","('NON-ESG', 0.32404088973999023)","('NON-ESG', 0.26346108317375183)","('NON-ESG', 0.14223121106624603)"
Line 390,"In 2021, AbbVie integrated products available under the Allergan Patient Assistance Program into myAbbVie Assist.","('Access_And_Affordability', 0.4831095039844513)","('Product_Quality_And_Safety', 0.07210948318243027)","('Employee_Health_And_Safety', 0.06366317719221115)","('NON-ESG', 0.4831095039844513)","('NON-ESG', 0.07210948318243027)","('NON-ESG', 0.06366317719221115)"
Line 391,"The income eligibility requirement for myAbbVie Assist is 600% of the Federal Poverty Level (FPL), or an income of less than $159,000 for a household of four people.","('Access_And_Affordability', 0.742611289024353)","('Human_Rights_And_Community_Relations', 0.04083705693483353)","('Employee_Engagement_Inclusion_And_Diversity', 0.02879517897963524)","(['Access to Healthcare'], 0.742611289024353)","('NON-ESG', 0.04083705693483353)","('NON-ESG', 0.02879517897963524)"
Line 392,"For patients who lost insurance coverage or for those facing financial hardship because of COVID-19, we continued to provide free AbbVie medicines for qualifying individuals in 2021.","('Management_Of_Legal_And_Regulatory_Framework', 0.4524480700492859)","('Access_And_Affordability', 0.2447415292263031)","('Systemic_Risk_Management', 0.046830251812934875)","('NON-ESG', 0.4524480700492859)","('NON-ESG', 0.2447415292263031)","('NON-ESG', 0.046830251812934875)"
Line 393,"In 2021, myAbbVie Assist supported over 170,000 patients in the United States To facilitate access to AbbVie medicines globally, we contribute to the World Intellectual Property Organizations Patent Information Initiative for Medicines (Pat-INFORMED) database.","('Competitive_Behavior', 0.59901362657547)","('Management_Of_Legal_And_Regulatory_Framework', 0.16201622784137726)","('Product_Quality_And_Safety', 0.029317336156964302)","([], 0.59901362657547)","('NON-ESG', 0.16201622784137726)","('NON-ESG', 0.029317336156964302)"
Line 394,"This database provides patent information on medicines for HIV/AIDS, cardiovascular diseases, diabetes, hepatitis C, oncology, respiratory conditions and other products on the WHO Essential Medicines List so that procurement agencies may easily find patent holders and communicate directly with companies selling medicines they need.","('Competitive_Behavior', 0.8519622683525085)","('Management_Of_Legal_And_Regulatory_Framework', 0.028102129697799683)","('Product_Quality_And_Safety', 0.011708594858646393)","([], 0.8519622683525085)","('NON-ESG', 0.028102129697799683)","('NON-ESG', 0.011708594858646393)"
Line 395,"We also have global medicine donation programs, in which we provide medicines for people who would have no other means of accessing them due to country-specific limitations and availability.","('Access_And_Affordability', 0.6217982769012451)","('Selling_Practices_And_Product_Labeling', 0.06275473535060883)","('Customer_Welfare', 0.0503801666200161)","(['Access to Healthcare'], 0.6217982769012451)","('NON-ESG', 0.06275473535060883)","('NON-ESG', 0.0503801666200161)"
Line 396,We have seven ongoing medicine donation partnerships with international non-governmental organizations providing assistance in low- and middle-income countries.,"('Access_And_Affordability', 0.7871041297912598)","('Human_Rights_And_Community_Relations', 0.057760920375585556)","('Management_Of_Legal_And_Regulatory_Framework', 0.028561288490891457)","(['Access to Healthcare'], 0.7871041297912598)","('NON-ESG', 0.057760920375585556)","('NON-ESG', 0.028561288490891457)"
Line 397,"We support requests for medical donations for pediatric health, mental health and HIV/AIDS, as well as access to surgical care by donating our general anesthesia treatment for use in free surgeries.","('Access_And_Affordability', 0.8218576908111572)","('Employee_Health_And_Safety', 0.021066639572381973)","('Product_Quality_And_Safety', 0.01843666471540928)","(['Access to Healthcare'], 0.8218576908111572)","('NON-ESG', 0.021066639572381973)","('NON-ESG', 0.01843666471540928)"
Line 398,"Furthermore, we donate medicines for use in disaster relief efforts and in response to humanitarian crises.","('Critical_Incident_Risk_Management', 0.9618200659751892)","('Physical_Impacts_Of_Climate_Change', 0.005401932168751955)","('Access_And_Affordability', 0.0035389878321439028)","([], 0.9618200659751892)","('NON-ESG', 0.005401932168751955)","('NON-ESG', 0.0035389878321439028)"
Line 399,"Since 2013, we have donated medicines for use in over 100 countries.","('Access_And_Affordability', 0.22438247501850128)","('Customer_Welfare', 0.16941383481025696)","('Selling_Practices_And_Product_Labeling', 0.15458324551582336)","('NON-ESG', 0.22438247501850128)","('NON-ESG', 0.16941383481025696)","('NON-ESG', 0.15458324551582336)"
Line 400,Patient Assistance Global Access to Medicines 1 Allergan Patient Assistance Program was integrated into myAbbVie Assist in 2021.,"('Access_And_Affordability', 0.8670825958251953)","('Critical_Incident_Risk_Management', 0.01239818800240755)","('Energy_Management', 0.012133777141571045)","(['Access to Healthcare'], 0.8670825958251953)","('NON-ESG', 0.01239818800240755)","('NON-ESG', 0.012133777141571045)"
Line 401,This number is inclusive of the integrated program.,"('Access_And_Affordability', 0.5483533143997192)","('Employee_Engagement_Inclusion_And_Diversity', 0.05752222612500191)","('Management_Of_Legal_And_Regulatory_Framework', 0.0470767505466938)","(['Access to Healthcare'], 0.5483533143997192)","('NON-ESG', 0.05752222612500191)","('NON-ESG', 0.0470767505466938)"
Line 402,Key Performance Indicator: Expanding Access to Our Medicines 2021 U.,"('Access_And_Affordability', 0.38274621963500977)","('Selling_Practices_And_Product_Labeling', 0.11991989612579346)","('Customer_Welfare', 0.08641152083873749)","('NON-ESG', 0.38274621963500977)","('NON-ESG', 0.11991989612579346)","('NON-ESG', 0.08641152083873749)"
Line 403,"S patients provided medicine at no cost through our patient assistance programs1170,162 At times, we can provide earlier access to treatment for people who are suffering from serious medical conditions and could potentially benefit from our medicines.","('Access_And_Affordability', 0.8020661473274231)","('Employee_Health_And_Safety', 0.037387665361166)","('Product_Quality_And_Safety', 0.02071920968592167)","(['Access to Healthcare'], 0.8020661473274231)","('NON-ESG', 0.037387665361166)","('NON-ESG', 0.02071920968592167)"
Line 404,"Through our compassionate use programs, AbbVie provides access to investigational drugs prior to regulatory approval for patients who suffer from serious or life-threatening illness, as determined on a case-by-case basis and implemented through programs subject to established regulatory pathways.","('Access_And_Affordability', 0.38835614919662476)","('Product_Quality_And_Safety', 0.1701551377773285)","('Management_Of_Legal_And_Regulatory_Framework', 0.078001469373703)","('NON-ESG', 0.38835614919662476)","('NON-ESG', 0.1701551377773285)","('NON-ESG', 0.078001469373703)"
Line 405,"Our compassionate use programs span a variety of medicines across oncology, immunology, neuroscience and other therapeutic areas.","('Customer_Welfare', 0.4282273054122925)","('Competitive_Behavior', 0.09214987605810165)","('Selling_Practices_And_Product_Labeling', 0.08193773031234741)","('NON-ESG', 0.4282273054122925)","('NON-ESG', 0.09214987605810165)","('NON-ESG', 0.08193773031234741)"
Line 406,"Additionally, we recognize that during launch of a new medicine, as payers evaluate the robust evidence generated by our clinical development programs, pending evaluation of potential value could delay or impact payer and health system reimbursement decisions.","('Management_Of_Legal_And_Regulatory_Framework', 0.8595858216285706)","('Business_Ethics', 0.03476801887154579)","('Competitive_Behavior', 0.0251566544175148)","([], 0.8595858216285706)","('NON-ESG', 0.03476801887154579)","('NON-ESG', 0.0251566544175148)"
Line 407,"To balance early access for patients with maturity and certainty of the data, we work to pursue alternative access agreements to encourage earlier coverage and reimbursement of new treatments, where appropriate.to international non-governmental organizations that are supporting people as part of medical missions and disaster and humanitarian crises.","('Critical_Incident_Risk_Management', 0.7198638916015625)","('Access_And_Affordability', 0.12990449368953705)","('Employee_Health_And_Safety', 0.023839598521590233)","([], 0.7198638916015625)","('NON-ESG', 0.12990449368953705)","('NON-ESG', 0.023839598521590233)"
Line 408,"To learn more about AbbVies approach to access to medicine, see Our Commitment to Access to Medicines on our website.","('Access_And_Affordability', 0.7575759887695312)","('Selling_Practices_And_Product_Labeling', 0.033380381762981415)","('Customer_Welfare', 0.02276206575334072)","(['Access to Healthcare'], 0.7575759887695312)","('NON-ESG', 0.033380381762981415)","('NON-ESG', 0.02276206575334072)"
Line 409,I cant begin to thank you enough for helping me another year.,"('Human_Rights_And_Community_Relations', 0.14065898954868317)","('Management_Of_Legal_And_Regulatory_Framework', 0.13226883113384247)","('Access_And_Affordability', 0.09618920087814331)","('NON-ESG', 0.14065898954868317)","('NON-ESG', 0.13226883113384247)","('NON-ESG', 0.09618920087814331)"
Line 410,My actual life depends on you.,"('Customer_Privacy', 0.17642301321029663)","('Competitive_Behavior', 0.12335680425167084)","('Business_Model_Resilience', 0.09679020941257477)","('NON-ESG', 0.17642301321029663)","('NON-ESG', 0.12335680425167084)","('NON-ESG', 0.09679020941257477)"
Line 411,I can now live like everyone else.,"('Employee_Engagement_Inclusion_And_Diversity', 0.22652755677700043)","('Business_Model_Resilience', 0.09688876569271088)","('Competitive_Behavior', 0.08973930031061172)","('NON-ESG', 0.22652755677700043)","('NON-ESG', 0.09688876569271088)","('NON-ESG', 0.08973930031061172)"
Line 412,Physically I can now function and do things.,"('Product_Design_And_Lifecycle_Management', 0.22478888928890228)","('Employee_Health_And_Safety', 0.13849356770515442)","('Customer_Welfare', 0.0691954493522644)","('NON-ESG', 0.22478888928890228)","('NON-ESG', 0.13849356770515442)","('NON-ESG', 0.0691954493522644)"
Line 413,"Financially, I can afford to come out of the house for a small treat, now and then!","('Management_Of_Legal_And_Regulatory_Framework', 0.3250812888145447)","('Systemic_Risk_Management', 0.11143619567155838)","('Access_And_Affordability', 0.0610603466629982)","('NON-ESG', 0.3250812888145447)","('NON-ESG', 0.11143619567155838)","('NON-ESG', 0.0610603466629982)"
Line 414,"Thank you.""","('Waste_And_Hazardous_Materials_Management', 0.0879942774772644)","('Product_Design_And_Lifecycle_Management', 0.08720160275697708)","('Customer_Privacy', 0.08082225918769836)","('NON-ESG', 0.0879942774772644)","('NON-ESG', 0.08720160275697708)","('NON-ESG', 0.08082225918769836)"
Line 415,"Patient using myAbbVie AssistRelieving the Burden One Patient at a Time 32 2021 ESG Action Report 2021 ESG Action Report 33 Our Health Economics and Outcomes Research (HEOR) team is a world-class leader in creating innovative, high- impact evidence that optimizes appropriate patient access to AbbVie products.","('Access_And_Affordability', 0.7236602902412415)","('Customer_Welfare', 0.04173342511057854)","('Product_Quality_And_Safety', 0.03455634415149689)","(['Access to Healthcare'], 0.7236602902412415)","('NON-ESG', 0.04173342511057854)","('NON-ESG', 0.03455634415149689)"
Line 416,"HEOR evidence helps payers, providers, policymakers and patients understand how medicines perform in the real world.","('Management_Of_Legal_And_Regulatory_Framework', 0.45527300238609314)","('Access_And_Affordability', 0.19599416851997375)","('Human_Rights_And_Community_Relations', 0.04484407231211662)","('NON-ESG', 0.45527300238609314)","('NON-ESG', 0.19599416851997375)","('NON-ESG', 0.04484407231211662)"
Line 417,"Using real-world evidence helps us to understand disease burden, treatment patterns, patient experience and product performance in settings and populations that are representative of everyday clinical practice.","('Access_And_Affordability', 0.2996457815170288)","('Employee_Health_And_Safety', 0.0853826254606247)","('Customer_Welfare', 0.08328757435083389)","('NON-ESG', 0.2996457815170288)","('NON-ESG', 0.0853826254606247)","('NON-ESG', 0.08328757435083389)"
Line 418,"Advancing Patient Care with Big Data At AbbVie, our culture is centered on the belief that how we work with each other and achieve results matters.","('Access_And_Affordability', 0.28934893012046814)","('Customer_Welfare', 0.09542571753263474)","('Employee_Engagement_Inclusion_And_Diversity', 0.06549160927534103)","('NON-ESG', 0.28934893012046814)","('NON-ESG', 0.09542571753263474)","('NON-ESG', 0.06549160927534103)"
Line 419,This steadfast focus continues to position AbbVie as an employer of choice.,"('Supply_Chain_Management', 0.14652012288570404)","('Competitive_Behavior', 0.092592753469944)","('Labor_Practices', 0.0874648317694664)","('NON-ESG', 0.14652012288570404)","('NON-ESG', 0.092592753469944)","('NON-ESG', 0.0874648317694664)"
Line 420,"In 2021, we were again listed as one of Fortune 100 Best Companies to Work For and a Great Place to Work Worlds Best Workplacesboth rankings determined by employees.","('Employee_Engagement_Inclusion_And_Diversity', 0.4138059616088867)","('Employee_Health_And_Safety', 0.16775467991828918)","('Product_Design_And_Lifecycle_Management', 0.0636027604341507)","('NON-ESG', 0.4138059616088867)","('NON-ESG', 0.16775467991828918)","('NON-ESG', 0.0636027604341507)"
Line 421,"AbbVie takes a holistic approach to the way we manage our human capital, focusing on Equity, Equality, Diversity and Inclusion (EEDI), professional and leadership development and employee well-being.","('Employee_Engagement_Inclusion_And_Diversity', 0.973540723323822)","('Human_Rights_And_Community_Relations', 0.002531803445890546)","('Employee_Health_And_Safety', 0.002436687471345067)","(['Talent Attraction & Retention'], 0.973540723323822)","('NON-ESG', 0.002531803445890546)","('NON-ESG', 0.002436687471345067)"
Line 422,This approach was demonstrated in 2021 as we worked to ensure a unified culture and workforce after our Allergan acquisition.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9361671209335327)","('Business_Model_Resilience', 0.007780743762850761)","('Employee_Health_And_Safety', 0.007299440447241068)","(['Talent Attraction & Retention'], 0.9361671209335327)","('NON-ESG', 0.007780743762850761)","('NON-ESG', 0.007299440447241068)"
Line 423,Human Capital Management Our HEOR researchers utilize big data to highlight patterns of care and generate evidence to support the real-world value of a new drug or technology.,"('Business_Model_Resilience', 0.32319796085357666)","('Systemic_Risk_Management', 0.28142687678337097)","('Competitive_Behavior', 0.13281820714473724)","('NON-ESG', 0.32319796085357666)","('NON-ESG', 0.28142687678337097)","('NON-ESG', 0.13281820714473724)"
Line 424,This big data falls into three broad buckets: 1.,"('Systemic_Risk_Management', 0.7004982233047485)","('Competitive_Behavior', 0.10299576073884964)","('Management_Of_Legal_And_Regulatory_Framework', 0.021340997889637947)","([], 0.7004982233047485)","('NON-ESG', 0.10299576073884964)","('NON-ESG', 0.021340997889637947)"
Line 425,"Clinical data, which helps evaluate a medicines safety and effectiveness 2.","('Product_Quality_And_Safety', 0.8842681646347046)","('Selling_Practices_And_Product_Labeling', 0.012272398918867111)","('Customer_Welfare', 0.011792867444455624)","(['Product Quality & Recall Management'], 0.8842681646347046)","('NON-ESG', 0.012272398918867111)","('NON-ESG', 0.011792867444455624)"
Line 426,"Economic and resource utilization (including inpatient admissions, emergency room visits, outpatient visits and other medical services) data, which is used to evaluate its economic value 3.","('Access_And_Affordability', 0.45576557517051697)","('Employee_Health_And_Safety', 0.10964887589216232)","('Critical_Incident_Risk_Management', 0.06776002794504166)","('NON-ESG', 0.45576557517051697)","('NON-ESG', 0.10964887589216232)","('NON-ESG', 0.06776002794504166)"
Line 427,"Patient experience data, which typically focuses on signs, symptoms and impacts that are important to patients Large and diverse data allows us to better understand the experience of patients often excluded from clinical trials, as well as evaluate treatment comparisons that may not have been made in a randomized controlled trial.","('Employee_Health_And_Safety', 0.6149368286132812)","('Access_And_Affordability', 0.07224707305431366)","('Product_Quality_And_Safety', 0.048309631645679474)","(['Health Outcome Contribution'], 0.6149368286132812)","('NON-ESG', 0.07224707305431366)","('NON-ESG', 0.048309631645679474)"
Line 428,"In addition, this data helps us understand healthcare resource utilization and potential cost offsets associated with therapies or interventions used in the real world.","('Energy_Management', 0.3225305378437042)","('Supply_Chain_Management', 0.17137478291988373)","('Access_And_Affordability', 0.16824258863925934)","('NON-ESG', 0.3225305378437042)","('NON-ESG', 0.17137478291988373)","('NON-ESG', 0.16824258863925934)"
Line 429,"When real-world data is put into context and complements data from clinical trials, a more comprehensive assessment and understanding of a treatment or disease, healthcare delivery and, ultimately, a persons experience of treatment is captured, all of which is used to advance patient care and access to treatment.","('Access_And_Affordability', 0.7418825626373291)","('Customer_Welfare', 0.031368475407361984)","('Human_Rights_And_Community_Relations', 0.022387394681572914)","(['Access to Healthcare'], 0.7418825626373291)","('NON-ESG', 0.031368475407361984)","('NON-ESG', 0.022387394681572914)"
Line 430,1.,"('Competitive_Behavior', 0.08736830949783325)","('Energy_Management', 0.08274902403354645)","('Management_Of_Legal_And_Regulatory_Framework', 0.0740576833486557)","('NON-ESG', 0.08736830949783325)","('NON-ESG', 0.08274902403354645)","('NON-ESG', 0.0740576833486557)"
Line 431,"Our Principles, which represent who we are and what we stand for: transforming lives, acting with integrity, driving innovation, embracing diversity and inclusion and serving the community.","('Employee_Engagement_Inclusion_And_Diversity', 0.967298150062561)","('Human_Rights_And_Community_Relations', 0.004440980032086372)","('Business_Model_Resilience', 0.0024394907522946596)","(['Talent Attraction & Retention'], 0.967298150062561)","('NON-ESG', 0.004440980032086372)","('NON-ESG', 0.0024394907522946596)"
Line 432,2.,"('Competitive_Behavior', 0.15795664489269257)","('Customer_Welfare', 0.10852150619029999)","('Energy_Management', 0.08616163581609726)","('NON-ESG', 0.15795664489269257)","('NON-ESG', 0.10852150619029999)","('NON-ESG', 0.08616163581609726)"
Line 433,"The Ways We Work, a core set of behaviors that provide clear expectations for all employees, reinforcing that how we achieve results matters.","('Employee_Engagement_Inclusion_And_Diversity', 0.4159640371799469)","('Human_Rights_And_Community_Relations', 0.08430168032646179)","('Competitive_Behavior', 0.07786662131547928)","('NON-ESG', 0.4159640371799469)","('NON-ESG', 0.08430168032646179)","('NON-ESG', 0.07786662131547928)"
Line 434,"Integrated into the entire talent journey, these behaviors form the basis for assessing performance, prioritizing development, and ultimately, rewarding employees.","('Employee_Engagement_Inclusion_And_Diversity', 0.9179757237434387)","('Employee_Health_And_Safety', 0.010957786813378334)","('Human_Rights_And_Community_Relations', 0.0064763715490698814)","(['Talent Attraction & Retention'], 0.9179757237434387)","('NON-ESG', 0.010957786813378334)","('NON-ESG', 0.0064763715490698814)"
Line 435,3.,"('Competitive_Behavior', 0.1465800553560257)","('Customer_Welfare', 0.10041514039039612)","('Product_Design_And_Lifecycle_Management', 0.07025990635156631)","('NON-ESG', 0.1465800553560257)","('NON-ESG', 0.10041514039039612)","('NON-ESG', 0.07025990635156631)"
Line 436,"Our Talent Philosophy, which guides how we lead and develop talent at AbbVie.","('Employee_Engagement_Inclusion_And_Diversity', 0.8860864639282227)","('Employee_Health_And_Safety', 0.0139653654769063)","('Business_Model_Resilience', 0.008014087565243244)","(['Talent Attraction & Retention'], 0.8860864639282227)","('NON-ESG', 0.0139653654769063)","('NON-ESG', 0.008014087565243244)"
Line 437,"Our workplace culture is built upon three fundamental guideposts: 34 2021 ESG Action Report 2021 ESG Action Report 35 Our five-year EEDI strategy, launched in 2019, focuses on several cornerstones of success: drive awareness & understanding; attract and source talent; develop and engage talent; and create connections and community.","('Employee_Engagement_Inclusion_And_Diversity', 0.922897219657898)","('Human_Rights_And_Community_Relations', 0.007403511554002762)","('Employee_Health_And_Safety', 0.006881916895508766)","(['Talent Attraction & Retention'], 0.922897219657898)","('NON-ESG', 0.007403511554002762)","('NON-ESG', 0.006881916895508766)"
Line 438,"We do this for our people, our patients and our business.","('Human_Rights_And_Community_Relations', 0.2754899561405182)","('Access_And_Affordability', 0.2463356852531433)","('Employee_Engagement_Inclusion_And_Diversity', 0.06426169723272324)","('NON-ESG', 0.2754899561405182)","('NON-ESG', 0.2463356852531433)","('NON-ESG', 0.06426169723272324)"
Line 439,Each of these strategic areas has specific objectives and associated initiatives and include implementation plans organized by business function and geography.,"('Business_Model_Resilience', 0.6619580388069153)","('Physical_Impacts_Of_Climate_Change', 0.033160023391246796)","('Product_Design_And_Lifecycle_Management', 0.029283585026860237)","(['Human Capital Development', 'Innovation Management'], 0.6619580388069153)","('NON-ESG', 0.033160023391246796)","('NON-ESG', 0.029283585026860237)"
Line 440,"The strategy and its implementation are driven and overseen by our CEO, Chief Equity Officer and the Executive Leadership team who set formal goals and are held accountable for our performance in this area.","('Business_Model_Resilience', 0.34528690576553345)","('Director_Removal', 0.22246886789798737)","('Management_Of_Legal_And_Regulatory_Framework', 0.052579477429389954)","('NON-ESG', 0.34528690576553345)","('NON-ESG', 0.22246886789798737)","('NON-ESG', 0.052579477429389954)"
Line 441,"Additionally, all AbbVie executives have equity, equality, diversity and inclusion related goals.","('Employee_Engagement_Inclusion_And_Diversity', 0.9729005098342896)","('Human_Rights_And_Community_Relations', 0.0023313763085752726)","('Employee_Health_And_Safety', 0.0022355527617037296)","(['Talent Attraction & Retention'], 0.9729005098342896)","('NON-ESG', 0.0023313763085752726)","('NON-ESG', 0.0022355527617037296)"
Line 442,See the Board and Executive Oversight of ESG section of this report to learn more about our executives ESG goals.,"('Director_Removal', 0.43935468792915344)","('Management_Of_Legal_And_Regulatory_Framework', 0.11203105747699738)","('Business_Model_Resilience', 0.08634744584560394)","('NON-ESG', 0.43935468792915344)","('NON-ESG', 0.11203105747699738)","('NON-ESG', 0.08634744584560394)"
Line 443,We are committed to consistently raising the bar when it comes to cultivating a diverse and inclusive workplace.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9678950309753418)","('Human_Rights_And_Community_Relations', 0.003571482840925455)","('Employee_Health_And_Safety', 0.002825833158567548)","(['Talent Attraction & Retention'], 0.9678950309753418)","('NON-ESG', 0.003571482840925455)","('NON-ESG', 0.002825833158567548)"
Line 444,"Our CEO, Richard Gonzalez, signed the CEO Action pledge to signal our commitment to advancing diversity and inclusion in our workplace, and we have joined Paradigm for Parity, which focuses on ensuring gender parity at the senior leadership level.","('Employee_Engagement_Inclusion_And_Diversity', 0.9760684967041016)","('Employee_Health_And_Safety', 0.002050652401521802)","('Human_Rights_And_Community_Relations', 0.001731226802803576)","(['Talent Attraction & Retention'], 0.9760684967041016)","('NON-ESG', 0.002050652401521802)","('NON-ESG', 0.001731226802803576)"
Line 445,"In recent years, AbbVies executive leadership has led our response to the United States racial justice movement and has overseen internal programs designed to ensure that AbbVie is attracting, retaining and developing diverse talent.","('Employee_Engagement_Inclusion_And_Diversity', 0.9707520008087158)","('Employee_Health_And_Safety', 0.0026984522119164467)","('Human_Rights_And_Community_Relations', 0.002203019568696618)","(['Talent Attraction & Retention'], 0.9707520008087158)","('NON-ESG', 0.0026984522119164467)","('NON-ESG', 0.002203019568696618)"
Line 446,"Cultivating a Diverse and Inclusive Workforce Equity, Equality, Diversity & Inclusion Strategic Priorities Awareness & Learning Removing Barriers & Obstacles Creating Differentiation Measuring & SustainingDrive Awareness & Understanding Instilling an inclusive mindset in all leaders and employeesAttract & Source Talent Proactively finding and engaging top talentDevelop & Engage Talent Creating opportunities for talent to thriveCreate Connections & Community Bringing people together to promote inclusion Annual Enterprise Initiatives Functional/Local Implementation PlansEquity Focusing on a culture of equity and inclusion through education, removing barriers, creating differentiation and measurement.","('Employee_Engagement_Inclusion_And_Diversity', 0.9760845303535461)","('Employee_Health_And_Safety', 0.0019382418831810355)","('Human_Rights_And_Community_Relations', 0.0017809408018365502)","(['Talent Attraction & Retention'], 0.9760845303535461)","('NON-ESG', 0.0019382418831810355)","('NON-ESG', 0.0017809408018365502)"
Line 447,"Cultivating a Diverse and Inclusive Workforce Equity, Equality, Diversity & Inclusion Strategic Priorities Awareness & Learning Removing Barriers & Obstacles Creating Differentiation Measuring & SustainingDrive Awareness & Understanding Instilling an inclusive mindset in all leaders and employeesAttract & Source Talent Proactively finding and engaging top talentDevelop & Engage Talent Creating opportunities for talent to thriveCreate Connections & Community Bringing people together to promote inclusion Annual Enterprise Initiatives Functional/Local Implementation PlansEquity Focusing on a culture of equity and inclusion through education, removing barriers, creating differentiation and measurement.","('Employee_Engagement_Inclusion_And_Diversity', 0.9524328708648682)","('Human_Rights_And_Community_Relations', 0.008390309289097786)","('Access_And_Affordability', 0.003865305334329605)","(['Talent Attraction & Retention'], 0.9524328708648682)","('NON-ESG', 0.008390309289097786)","('NON-ESG', 0.003865305334329605)"
Line 448,Equity is embedded in everything we do.,"('Competitive_Behavior', 0.2841351628303528)","('Systemic_Risk_Management', 0.16098250448703766)","('Business_Ethics', 0.13671739399433136)","('NON-ESG', 0.2841351628303528)","('NON-ESG', 0.16098250448703766)","('NON-ESG', 0.13671739399433136)"
Line 449,AbbVie affiliates around the world are implementing programs that resonate with their unique cultures and employee needs.,"('Employee_Engagement_Inclusion_And_Diversity', 0.834688127040863)","('Human_Rights_And_Community_Relations', 0.030157001689076424)","('Employee_Health_And_Safety', 0.017513012513518333)","(['Talent Attraction & Retention'], 0.834688127040863)","('NON-ESG', 0.030157001689076424)","('NON-ESG', 0.017513012513518333)"
Line 450,"In New Zealand, AbbVie made the decision to engage, understand and draw on Maori cultural perspectives within the organization.","('Employee_Engagement_Inclusion_And_Diversity', 0.483053982257843)","('Human_Rights_And_Community_Relations', 0.33448368310928345)","('Competitive_Behavior', 0.01873300038278103)","('NON-ESG', 0.483053982257843)","('NON-ESG', 0.33448368310928345)","('NON-ESG', 0.01873300038278103)"
Line 451,"The Maori, the indigenous Polynesian people of New Zealand, hold seats in Parliament and their language is an official language of the country.","('Employee_Engagement_Inclusion_And_Diversity', 0.44890376925468445)","('Human_Rights_And_Community_Relations', 0.338066965341568)","('Ecological_Impacts', 0.019341398030519485)","('NON-ESG', 0.44890376925468445)","('NON-ESG', 0.338066965341568)","('NON-ESG', 0.019341398030519485)"
Line 452,AbbVie New Zealands EEDI Committee and other leaders have actively elevated Maori inclusion by sponsoring language lessons and organizing visits to culturally significant venues.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9597160220146179)","('Human_Rights_And_Community_Relations', 0.00552097475156188)","('Employee_Health_And_Safety', 0.0027468986809253693)","(['Talent Attraction & Retention'], 0.9597160220146179)","('NON-ESG', 0.00552097475156188)","('NON-ESG', 0.0027468986809253693)"
Line 453,"We hosted a Maori Language Week, with live online quizzes, group singing, podcasts, playlists, Maori mindfulness exercises and our largest ever language lesson.","('Employee_Engagement_Inclusion_And_Diversity', 0.4763661026954651)","('Human_Rights_And_Community_Relations', 0.12409169971942902)","('Access_And_Affordability', 0.06388211995363235)","('NON-ESG', 0.4763661026954651)","('NON-ESG', 0.12409169971942902)","('NON-ESG', 0.06388211995363235)"
Line 454,"Meanwhile, innovative reimbursement proposals that prioritize Maori health needs have been initiated, along with insight- gathering Maori patient interviews across therapeutic areas.","('Management_Of_Legal_And_Regulatory_Framework', 0.40853065252304077)","('Access_And_Affordability', 0.11452335119247437)","('Business_Ethics', 0.09495312720537186)","('NON-ESG', 0.40853065252304077)","('NON-ESG', 0.11452335119247437)","('NON-ESG', 0.09495312720537186)"
Line 455,Global EEDI Efforts: A Look at New Zealand An important part of our EEDI strategy is to instill an inclusive mindset in all leaders and employees so that we realize the full value of our diverse workforce.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9741341471672058)","('Employee_Health_And_Safety', 0.002111301524564624)","('Human_Rights_And_Community_Relations', 0.0017473516054451466)","(['Talent Attraction & Retention'], 0.9741341471672058)","('NON-ESG', 0.002111301524564624)","('NON-ESG', 0.0017473516054451466)"
Line 456,"In 2021, we enhanced the EEDI content on our internal portal and launched new virtual inclusive learning programs, building out our EEDI curriculum and continuing to enhance our extensive library and toolkit.","('Access_And_Affordability', 0.5987603068351746)","('Employee_Engagement_Inclusion_And_Diversity', 0.06569769978523254)","('Management_Of_Legal_And_Regulatory_Framework', 0.04535474255681038)","(['Access to Healthcare'], 0.5987603068351746)","('NON-ESG', 0.06569769978523254)","('NON-ESG', 0.04535474255681038)"
Line 457,We also supported company-wide programming developed by our Employee Resource Groups to foster more awareness and understanding of diverse communities and perspectives.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9168155193328857)","('Human_Rights_And_Community_Relations', 0.03126430884003639)","('Access_And_Affordability', 0.0061590950936079025)","(['Talent Attraction & Retention'], 0.9168155193328857)","('NON-ESG', 0.03126430884003639)","('NON-ESG', 0.0061590950936079025)"
Line 458,"In 2021, we expanded our global listening sessions, giving employees an opportunity to share their experiences, ideas and thoughts on race, bias and inclusion.","('Employee_Engagement_Inclusion_And_Diversity', 0.9729053378105164)","('Human_Rights_And_Community_Relations', 0.002991539193317294)","('Employee_Health_And_Safety', 0.0021054763346910477)","(['Talent Attraction & Retention'], 0.9729053378105164)","('NON-ESG', 0.002991539193317294)","('NON-ESG', 0.0021054763346910477)"
Line 459,Several sessions allowed employees to develop a deeper understanding of current events impacting many of our employees.,"('Business_Model_Resilience', 0.18521253764629364)","('Human_Rights_And_Community_Relations', 0.12331600487232208)","('Employee_Engagement_Inclusion_And_Diversity', 0.09723283350467682)","('NON-ESG', 0.18521253764629364)","('NON-ESG', 0.12331600487232208)","('NON-ESG', 0.09723283350467682)"
Line 460,"At the same time, listening sessions gave the leadership and engagement teams a pulse on how our employees were thinking about those events and how we could best support them.","('Employee_Engagement_Inclusion_And_Diversity', 0.29258257150650024)","('Human_Rights_And_Community_Relations', 0.24054817855358124)","('Business_Model_Resilience', 0.0777423232793808)","('NON-ESG', 0.29258257150650024)","('NON-ESG', 0.24054817855358124)","('NON-ESG', 0.0777423232793808)"
Line 461,Our Black Business Network (BBN) Employee Resource Group led meaningful educational opportunities to bring greater awareness of EEDI to the AbbVie community and established differentiated programming for greater impact.,"('Employee_Engagement_Inclusion_And_Diversity', 0.7521585822105408)","('Access_And_Affordability', 0.09350153803825378)","('Employee_Health_And_Safety', 0.0297271478921175)","(['Talent Attraction & Retention'], 0.7521585822105408)","('NON-ESG', 0.09350153803825378)","('NON-ESG', 0.0297271478921175)"
Line 462,We also hosted notable external speakers to provide additional awareness and learning opportunities for all employees.,"('Employee_Engagement_Inclusion_And_Diversity', 0.7856922149658203)","('Access_And_Affordability', 0.04905019700527191)","('Employee_Health_And_Safety', 0.02007124572992325)","(['Talent Attraction & Retention'], 0.7856922149658203)","('NON-ESG', 0.04905019700527191)","('NON-ESG', 0.02007124572992325)"
Line 463,"AbbVie attracts, engages and hires diverse talent as part of its comprehensive talent strategy.","('Employee_Engagement_Inclusion_And_Diversity', 0.9629679322242737)","('Employee_Health_And_Safety', 0.0032885964028537273)","('Customer_Welfare', 0.0022115828469395638)","(['Talent Attraction & Retention'], 0.9629679322242737)","('NON-ESG', 0.0032885964028537273)","('NON-ESG', 0.0022115828469395638)"
Line 464,"Our proactive approach governs AbbVies strategy and is applied across all stages of the recruitment pipeline, from early career to executive leadership.","('Employee_Engagement_Inclusion_And_Diversity', 0.8503736853599548)","('Business_Model_Resilience', 0.037831272929906845)","('Director_Removal', 0.011848589405417442)","(['Talent Attraction & Retention'], 0.8503736853599548)","('NON-ESG', 0.037831272929906845)","('NON-ESG', 0.011848589405417442)"
Line 465,"Leveraging strategic partnerships with organizations and educational institutions, AbbVie continues to build a robust pool of diverse talent today and for years to come.","('Employee_Engagement_Inclusion_And_Diversity', 0.9499385356903076)","('Access_And_Affordability', 0.003918299917131662)","('Employee_Health_And_Safety', 0.003664926392957568)","(['Talent Attraction & Retention'], 0.9499385356903076)","('NON-ESG', 0.003918299917131662)","('NON-ESG', 0.003664926392957568)"
Line 466,"With an emphasis on our early career pipeline, a dedicated team of AbbVie relationship managers and recruiters have developed direct school partnerships with nine Historically Black Colleges and Universities (HBCUs) and Hispanic-Serving Institutions (HSIs).","('Employee_Engagement_Inclusion_And_Diversity', 0.9449832439422607)","('Access_And_Affordability', 0.005395866464823484)","('Customer_Welfare', 0.0045578256249427795)","(['Talent Attraction & Retention'], 0.9449832439422607)","('NON-ESG', 0.005395866464823484)","('NON-ESG', 0.0045578256249427795)"
Line 467,"Driving Awareness and Understanding Attracting and Sourcing Diverse Talent36 2021 ESG Action Report 2021 ESG Action Report 37 At AbbVie, we strive to ensure every employee is aware of, and has access to, opportunities for learning, growth and advancement.","('Employee_Engagement_Inclusion_And_Diversity', 0.9449735879898071)","('Access_And_Affordability', 0.004565350711345673)","('Employee_Health_And_Safety', 0.00409190496429801)","(['Talent Attraction & Retention'], 0.9449735879898071)","('NON-ESG', 0.004565350711345673)","('NON-ESG', 0.00409190496429801)"
Line 468,"Our thriving Executive Diversity Mentoring Program (EDMP) pairs high performing, diverse talent with AbbVie senior executive leaders for a one-on-one mentoring partnership over ten months.","('Employee_Engagement_Inclusion_And_Diversity', 0.9726715087890625)","('Employee_Health_And_Safety', 0.002077624201774597)","('Human_Rights_And_Community_Relations', 0.0018405826995149255)","(['Talent Attraction & Retention'], 0.9726715087890625)","('NON-ESG', 0.002077624201774597)","('NON-ESG', 0.0018405826995149255)"
Line 469,Mentees gain insight into executive-level thinking and engage in direct dialogue with successful AbbVie leaders.,"('Employee_Engagement_Inclusion_And_Diversity', 0.22338716685771942)","('Business_Model_Resilience', 0.1572607457637787)","('Director_Removal', 0.12702101469039917)","('NON-ESG', 0.22338716685771942)","('NON-ESG', 0.1572607457637787)","('NON-ESG', 0.12702101469039917)"
Line 470,EDMP accelerates the professional growth of our diverse workforce.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9707489609718323)","('Business_Model_Resilience', 0.0022260346449911594)","('Employee_Health_And_Safety', 0.0021014048252254725)","(['Talent Attraction & Retention'], 0.9707489609718323)","('NON-ESG', 0.0022260346449911594)","('NON-ESG', 0.0021014048252254725)"
Line 471,In the last year we have seen program participation increase 300%.,"('Access_And_Affordability', 0.21715959906578064)","('Management_Of_Legal_And_Regulatory_Framework', 0.21083374321460724)","('Human_Rights_And_Community_Relations', 0.07720493525266647)","('NON-ESG', 0.21715959906578064)","('NON-ESG', 0.21083374321460724)","('NON-ESG', 0.07720493525266647)"
Line 472,We also launched our Executive Sponsorship Program in 2021.,"('Employee_Engagement_Inclusion_And_Diversity', 0.2887817323207855)","('Management_Of_Legal_And_Regulatory_Framework', 0.17246054112911224)","('Access_And_Affordability', 0.08090529590845108)","('NON-ESG', 0.2887817323207855)","('NON-ESG', 0.17246054112911224)","('NON-ESG', 0.08090529590845108)"
Line 473,"This program builds upon our culture of mentorship, with an emphasis on equity, creating more pathways for talent of diverse backgrounds and experiences to be successful at AbbVie.","('Employee_Engagement_Inclusion_And_Diversity', 0.9620650410652161)","('Access_And_Affordability', 0.0032569447066634893)","('Employee_Health_And_Safety', 0.0030564083717763424)","(['Talent Attraction & Retention'], 0.9620650410652161)","('NON-ESG', 0.0032569447066634893)","('NON-ESG', 0.0030564083717763424)"
Line 474,"Like mentorship, our sponsorship program format is also based on a one-on-one partnership; however, sponsorship is driven by the leader.","('Employee_Engagement_Inclusion_And_Diversity', 0.3102012872695923)","('Access_And_Affordability', 0.2694464325904846)","('Employee_Health_And_Safety', 0.05449800565838814)","('NON-ESG', 0.3102012872695923)","('NON-ESG', 0.2694464325904846)","('NON-ESG', 0.05449800565838814)"
Line 475,We also provide expert coaching and guidance particularly for sponsors throughout their journey.,"('Access_And_Affordability', 0.43398207426071167)","('Management_Of_Legal_And_Regulatory_Framework', 0.1266869753599167)","('Employee_Engagement_Inclusion_And_Diversity', 0.06370814144611359)","('NON-ESG', 0.43398207426071167)","('NON-ESG', 0.1266869753599167)","('NON-ESG', 0.06370814144611359)"
Line 476,This program is a two-year commitment.,"('Access_And_Affordability', 0.5409080982208252)","('Employee_Engagement_Inclusion_And_Diversity', 0.08888567984104156)","('Product_Quality_And_Safety', 0.043804507702589035)","(['Access to Healthcare'], 0.5409080982208252)","('NON-ESG', 0.08888567984104156)","('NON-ESG', 0.043804507702589035)"
Line 477,"Our seven Employee Resource Groups (ERGs) are open to all employees, whether they identify as part of the represented group or as an ally.","('Employee_Engagement_Inclusion_And_Diversity', 0.5819734930992126)","('Employee_Health_And_Safety', 0.1062549278140068)","('Labor_Practices', 0.09126255661249161)","(['Talent Attraction & Retention'], 0.5819734930992126)","('NON-ESG', 0.1062549278140068)","('NON-ESG', 0.09126255661249161)"
Line 478,"These groups promote awareness of and appreciation for our diversity and create connections and opportunities for mentoring, professional development, talent attraction and networking.","('Employee_Engagement_Inclusion_And_Diversity', 0.9732166528701782)","('Employee_Health_And_Safety', 0.002199772512540221)","('Human_Rights_And_Community_Relations', 0.0018089330988004804)","(['Talent Attraction & Retention'], 0.9732166528701782)","('NON-ESG', 0.002199772512540221)","('NON-ESG', 0.0018089330988004804)"
Line 479,"Every year, the AbbVie Foundation provides each resource group with a $100,000 grant to distribute to nonprofit partners of their choice that align with their respective missions.","('Access_And_Affordability', 0.31679701805114746)","('Management_Of_Legal_And_Regulatory_Framework', 0.16623064875602722)","('Human_Rights_And_Community_Relations', 0.14708657562732697)","('NON-ESG', 0.31679701805114746)","('NON-ESG', 0.16623064875602722)","('NON-ESG', 0.14708657562732697)"
Line 480,"As of 2021, our ERGs included: AbbVie Pride AbbVie Veterans Ability at AbbVie AHORA Hispanic/Latino Asian Leadership Network Black Business Network Women Leaders in Action Learn more about our Employee Resource Groups at our website .","('Employee_Engagement_Inclusion_And_Diversity', 0.9703671932220459)","('Employee_Health_And_Safety', 0.0024198719765990973)","('Human_Rights_And_Community_Relations', 0.00240658363327384)","(['Talent Attraction & Retention'], 0.9703671932220459)","('NON-ESG', 0.0024198719765990973)","('NON-ESG', 0.00240658363327384)"
Line 481,"Developing and Engaging Diverse Talent Creating Connections and Community We continue to be recognized for our workplace and diversity efforts across the globe, which supports us in attracting and retaining top talent.","('Employee_Engagement_Inclusion_And_Diversity', 0.9755350351333618)","('Employee_Health_And_Safety', 0.0019888037350028753)","('Human_Rights_And_Community_Relations', 0.0016141313826665282)","(['Talent Attraction & Retention'], 0.9755350351333618)","('NON-ESG', 0.0019888037350028753)","('NON-ESG', 0.0016141313826665282)"
Line 482,"As a company, we are recognized in more than 40 locations as a great place to work and top employer.","('Employee_Health_And_Safety', 0.14321352541446686)","('Employee_Engagement_Inclusion_And_Diversity', 0.1388571858406067)","('Labor_Practices', 0.13602842390537262)","('NON-ESG', 0.14321352541446686)","('NON-ESG', 0.1388571858406067)","('NON-ESG', 0.13602842390537262)"
Line 483,"The recognitions we are most proud of in 2021 include: DiversityInc Top 50 Companies for Diversity Top 15 Seramount 100 Best Companies"" Human Rights Campaign Corporate Equality Index Scored 100% Disability:IN Disability Equality Index Scored 100% Recognized on the FORTUNE 100 Best Companies to Work For list for the fourth year in a row, moving up 29 spots Recognized on the Great Place to Work Worlds Best Workplaces list for the fifth year in a row, moving up 1 1 spots to number 4 External RecognitionIve really enjoyed being a part of Black Business Network (BBN) West.","('Employee_Engagement_Inclusion_And_Diversity', 0.9656447172164917)","('Employee_Health_And_Safety', 0.005050815176218748)","('Human_Rights_And_Community_Relations', 0.004082900937646627)","(['Talent Attraction & Retention'], 0.9656447172164917)","('NON-ESG', 0.005050815176218748)","('NON-ESG', 0.004082900937646627)"
Line 484,"The recognitions we are most proud of in 2021 include: DiversityInc Top 50 Companies for Diversity Top 15 Seramount 100 Best Companies"" Human Rights Campaign Corporate Equality Index Scored 100% Disability:IN Disability Equality Index Scored 100% Recognized on the FORTUNE 100 Best Companies to Work For list for the fourth year in a row, moving up 29 spots Recognized on the Great Place to Work Worlds Best Workplaces list for the fifth year in a row, moving up 1 1 spots to number 4 External RecognitionIve really enjoyed being a part of Black Business Network (BBN) West.","('Employee_Engagement_Inclusion_And_Diversity', 0.348210871219635)","('Business_Model_Resilience', 0.22937852144241333)","('Systemic_Risk_Management', 0.10786199569702148)","('NON-ESG', 0.348210871219635)","('NON-ESG', 0.22937852144241333)","('NON-ESG', 0.10786199569702148)"
Line 485,Everyone has been so warm and welcoming.,"('Employee_Engagement_Inclusion_And_Diversity', 0.12293338030576706)","('Employee_Health_And_Safety', 0.11472117900848389)","('Human_Rights_And_Community_Relations', 0.08666901290416718)","('NON-ESG', 0.12293338030576706)","('NON-ESG', 0.11472117900848389)","('NON-ESG', 0.08666901290416718)"
Line 486,"As a legacy Allergan employee, it has been a great opportunity to network and get to know colleagues in other business units that I would not interact with during the normal course of business.","('Employee_Engagement_Inclusion_And_Diversity', 0.2442200481891632)","('Customer_Privacy', 0.12930840253829956)","('Employee_Health_And_Safety', 0.10124441981315613)","('NON-ESG', 0.2442200481891632)","('NON-ESG', 0.12930840253829956)","('NON-ESG', 0.10124441981315613)"
Line 487,"BBN West, and ERGs in general, have the unique ability to expand your global view and give visibility to the greater organization, all while fostering a sense of community, connectivity and belonging.""","('Human_Rights_And_Community_Relations', 0.7368044257164001)","('Business_Model_Resilience', 0.05196749418973923)","('Employee_Engagement_Inclusion_And_Diversity', 0.04318098723888397)","([], 0.7368044257164001)","('NON-ESG', 0.05196749418973923)","('NON-ESG', 0.04318098723888397)"
Line 488,"Sharon Gomez, Senior District Manager 2021 Total employees 50,000 % women globally 55% % women in executive and board positions136% % women in VP and above positions236% % women in Director and Manager positions 51% % women in management positions351% % women in management positions in revenue-generating functions454% % women in STEM-related positions 59% % U.","('Employee_Engagement_Inclusion_And_Diversity', 0.7486374974250793)","('Director_Removal', 0.062076687812805176)","('Labor_Practices', 0.04683104529976845)","(['Talent Attraction & Retention'], 0.7486374974250793)","('NON-ESG', 0.062076687812805176)","('NON-ESG', 0.04683104529976845)"
Line 489,S. employees who are members of underrepresented populations 35% % U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9398064613342285)","('Labor_Practices', 0.008414285257458687)","('Employee_Health_And_Safety', 0.004246464930474758)","(['Talent Attraction & Retention'], 0.9398064613342285)","('NON-ESG', 0.008414285257458687)","('NON-ESG', 0.004246464930474758)"
Line 490,S. employees who are veterans 3% % U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.8478503227233887)","('Labor_Practices', 0.038702208548784256)","('Employee_Health_And_Safety', 0.016433846205472946)","(['Talent Attraction & Retention'], 0.8478503227233887)","('NON-ESG', 0.038702208548784256)","('NON-ESG', 0.016433846205472946)"
Line 491,S. employees who have disabilities 5% 1 Represents new KPI added to 2021 ESG Action Report.,"('Employee_Engagement_Inclusion_And_Diversity', 0.7483082413673401)","('Labor_Practices', 0.06022945046424866)","('Employee_Health_And_Safety', 0.03842221572995186)","(['Talent Attraction & Retention'], 0.7483082413673401)","('NON-ESG', 0.06022945046424866)","('NON-ESG', 0.03842221572995186)"
Line 492,"Includes VP-level and above, including women who are members of AbbVies Board of Directors.","('Director_Removal', 0.7370128631591797)","('Employee_Engagement_Inclusion_And_Diversity', 0.03539071977138519)","('Business_Model_Resilience', 0.02265608124434948)","(['Business Ethics'], 0.7370128631591797)","('NON-ESG', 0.03539071977138519)","('NON-ESG', 0.02265608124434948)"
Line 493,2 Does not include women who are members of AbbVies Board of Directors.,"('Director_Removal', 0.7463045716285706)","('Employee_Engagement_Inclusion_And_Diversity', 0.029554858803749084)","('Labor_Practices', 0.02400820702314377)","(['Business Ethics'], 0.7463045716285706)","('NON-ESG', 0.029554858803749084)","('NON-ESG', 0.02400820702314377)"
Line 494,3 Includes women in manager-level positions and above.,"('Employee_Engagement_Inclusion_And_Diversity', 0.4592154920101166)","('Director_Removal', 0.1603853553533554)","('Labor_Practices', 0.13422931730747223)","('NON-ESG', 0.4592154920101166)","('NON-ESG', 0.1603853553533554)","('NON-ESG', 0.13422931730747223)"
Line 495,"4 ""Revenue-generating functions means a position within AbbVies commercial organization.","('Management_Of_Legal_And_Regulatory_Framework', 0.29121750593185425)","('Competitive_Behavior', 0.21316857635974884)","('Systemic_Risk_Management', 0.08632039278745651)","('NON-ESG', 0.29121750593185425)","('NON-ESG', 0.21316857635974884)","('NON-ESG', 0.08632039278745651)"
Line 496,"Key Performance Indicators: EEDI 38 2021 ESG Action Report 2021 ESG Action Report 39 Share in total workforce (as % of total workforce)Share in all management positions (manager level and above as % of total management workforce) Asian 17% 21% Black or African American 6% 5% Hispanic/Latinx 9% 6% White 65% 66% Other (includes Native American/Alaska Native, Native Hawaiian/Other Pacific Islander and two or more races)3% 2% AbbVie publishes our EEO-1 U.","('Employee_Engagement_Inclusion_And_Diversity', 0.9737238883972168)","('Employee_Health_And_Safety', 0.0019580533262342215)","('Human_Rights_And_Community_Relations', 0.0019163156393915415)","(['Talent Attraction & Retention'], 0.9737238883972168)","('NON-ESG', 0.0019580533262342215)","('NON-ESG', 0.0019163156393915415)"
Line 497,S. workforce diversity data on our website .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9711039662361145)","('Employee_Health_And_Safety', 0.0025701536796987057)","('Customer_Privacy', 0.0017763716168701649)","(['Talent Attraction & Retention'], 0.9711039662361145)","('NON-ESG', 0.0025701536796987057)","('NON-ESG', 0.0017763716168701649)"
Line 498,U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.14571937918663025)","('Product_Design_And_Lifecycle_Management', 0.12332227826118469)","('Employee_Engagement_Inclusion_And_Diversity', 0.06306221336126328)","('NON-ESG', 0.14571937918663025)","('NON-ESG', 0.12332227826118469)","('NON-ESG', 0.06306221336126328)"
Line 499,S.,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 500,"Workforce by Race and Ethnicity At AbbVie, we believe in self-directed growth and development, where employees set the objectives that they want to achieve.","('Employee_Engagement_Inclusion_And_Diversity', 0.9759875535964966)","('Human_Rights_And_Community_Relations', 0.0017905146814882755)","('Employee_Health_And_Safety', 0.0016690889606252313)","(['Talent Attraction & Retention'], 0.9759875535964966)","('NON-ESG', 0.0017905146814882755)","('NON-ESG', 0.0016690889606252313)"
Line 501,We supplement this individualized approach with company-wide education and an investment in emerging leaders.,"('Employee_Engagement_Inclusion_And_Diversity', 0.48335179686546326)","('Access_And_Affordability', 0.1364162415266037)","('Business_Model_Resilience', 0.0450826957821846)","('NON-ESG', 0.48335179686546326)","('NON-ESG', 0.1364162415266037)","('NON-ESG', 0.0450826957821846)"
Line 502,"We also conduct annual Talent Management Reviews, driven from the organizational perspective and led by our leaders across all functions.","('Employee_Engagement_Inclusion_And_Diversity', 0.9520673155784607)","('Business_Model_Resilience', 0.0041917734779417515)","('Employee_Health_And_Safety', 0.003617189358919859)","(['Talent Attraction & Retention'], 0.9520673155784607)","('NON-ESG', 0.0041917734779417515)","('NON-ESG', 0.003617189358919859)"
Line 503,Our leaders play an essential role in bringing out the best in their teams.,"('Employee_Engagement_Inclusion_And_Diversity', 0.4149176776409149)","('Human_Rights_And_Community_Relations', 0.11822492629289627)","('Business_Model_Resilience', 0.06803713738918304)","('NON-ESG', 0.4149176776409149)","('NON-ESG', 0.11822492629289627)","('NON-ESG', 0.06803713738918304)"
Line 504,We offer live and virtual training resources on topics like inclusive leadership and defining expectations through our Leadership Essentials workshops.,"('Employee_Engagement_Inclusion_And_Diversity', 0.8626927733421326)","('Access_And_Affordability', 0.018361981958150864)","('Human_Rights_And_Community_Relations', 0.017369305714964867)","(['Talent Attraction & Retention'], 0.8626927733421326)","('NON-ESG', 0.018361981958150864)","('NON-ESG', 0.017369305714964867)"
Line 505,"This includes Leadership Expectations, which focuses on equipping new people leaders by defining our leadership practices and expectations; Leading Performance, which focuses on how leaders raise the bar on their own performance and that of their team; and Leading Teams, which helps leaders develop their strategy for inclusive leadership and keeping teams motivated.","('Employee_Engagement_Inclusion_And_Diversity', 0.5312090516090393)","('Human_Rights_And_Community_Relations', 0.07884500920772552)","('Business_Model_Resilience', 0.07681802660226822)","(['Talent Attraction & Retention'], 0.5312090516090393)","('NON-ESG', 0.07884500920772552)","('NON-ESG', 0.07681802660226822)"
Line 506,"For our identified key talent, which is determined based on performance and leadership potential, we have developed the AbbVie Executive Development Program (EDP).","('Employee_Engagement_Inclusion_And_Diversity', 0.9071044325828552)","('Business_Model_Resilience', 0.010498718358576298)","('Director_Removal', 0.008265835233032703)","(['Talent Attraction & Retention'], 0.9071044325828552)","('NON-ESG', 0.010498718358576298)","('NON-ESG', 0.008265835233032703)"
Line 507,This program includes a suite of live and virtual training resources that are focused entirely on leadership development.,"('Employee_Engagement_Inclusion_And_Diversity', 0.5245218873023987)","('Access_And_Affordability', 0.13344673812389374)","('Employee_Health_And_Safety', 0.05054352432489395)","(['Talent Attraction & Retention'], 0.5245218873023987)","('NON-ESG', 0.13344673812389374)","('NON-ESG', 0.05054352432489395)"
Line 508,"In 2021, nearly 800 employees participated in the EDP.","('Labor_Practices', 0.5417183041572571)","('Employee_Engagement_Inclusion_And_Diversity', 0.10719580203294754)","('Human_Rights_And_Community_Relations', 0.05627993121743202)","([], 0.5417183041572571)","('NON-ESG', 0.10719580203294754)","('NON-ESG', 0.05627993121743202)"
Line 509,"All employees use our Raise the Bar performance management process to establish expectations, tie goals to annual performance and ensure we are exemplifying the Ways We Workbehaviors expected of all employees regardless of level, role and geographic location.","('Employee_Engagement_Inclusion_And_Diversity', 0.8335935473442078)","('Business_Model_Resilience', 0.020602168515324593)","('Human_Rights_And_Community_Relations', 0.01746092550456524)","(['Talent Attraction & Retention'], 0.8335935473442078)","('NON-ESG', 0.020602168515324593)","('NON-ESG', 0.01746092550456524)"
Line 510,"Our two- way dialogue feedback check-ins, called Time to Talk, support performance, motivate development and build trust.","('Business_Model_Resilience', 0.16647040843963623)","('Human_Rights_And_Community_Relations', 0.15417079627513885)","('Business_Ethics', 0.1504371613264084)","('NON-ESG', 0.16647040843963623)","('NON-ESG', 0.15417079627513885)","('NON-ESG', 0.1504371613264084)"
Line 511,"The resulting ratings guide merit-based pay increases, and for those eligible, annual bonus payouts and long-term incentive stock grants.","('Labor_Practices', 0.9426859617233276)","('Management_Of_Legal_And_Regulatory_Framework', 0.008822493255138397)","('Director_Removal', 0.006453834008425474)","([], 0.9426859617233276)","('NON-ESG', 0.008822493255138397)","('NON-ESG', 0.006453834008425474)"
Line 512,"At AbbVie, we engage our employees on the topics that matter most to us and to reinforce the culture that we have developed together.","('Employee_Engagement_Inclusion_And_Diversity', 0.6298355460166931)","('Human_Rights_And_Community_Relations', 0.057628754526376724)","('Employee_Health_And_Safety', 0.0504922941327095)","(['Talent Attraction & Retention'], 0.6298355460166931)","('NON-ESG', 0.057628754526376724)","('NON-ESG', 0.0504922941327095)"
Line 513,"From volunteerism and employee wellness events to talent development and Employee Resource Groups, our employee engagement activities help to support our culture and drive employee retention.","('Employee_Engagement_Inclusion_And_Diversity', 0.9719797372817993)","('Employee_Health_And_Safety', 0.003350978484377265)","('Customer_Welfare', 0.0016895242733880877)","(['Talent Attraction & Retention'], 0.9719797372817993)","('NON-ESG', 0.003350978484377265)","('NON-ESG', 0.0016895242733880877)"
Line 514,"Our focus on amplifying our culture has generated positive results on performance, our reputation and the engagement of our leaders and employees.","('Employee_Engagement_Inclusion_And_Diversity', 0.6907747387886047)","('Human_Rights_And_Community_Relations', 0.04536834731698036)","('Business_Model_Resilience', 0.036387473344802856)","(['Talent Attraction & Retention'], 0.6907747387886047)","('NON-ESG', 0.04536834731698036)","('NON-ESG', 0.036387473344802856)"
Line 515,The results of our 2021 employee survey showed that our workforce is highly engaged and increasingly satisfied with our culture.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9381382465362549)","('Employee_Health_And_Safety', 0.009382952004671097)","('Labor_Practices', 0.008163860067725182)","(['Talent Attraction & Retention'], 0.9381382465362549)","('NON-ESG', 0.009382952004671097)","('NON-ESG', 0.008163860067725182)"
Line 516,"Our workforce also indicated that their managers are effective in leading their teams, which reinforces the important role leaders play in employee satisfaction and the strong talent development infrastructure AbbVie has in place to help leaders expand their people leadership skills.","('Employee_Engagement_Inclusion_And_Diversity', 0.9451705813407898)","('Employee_Health_And_Safety', 0.00683523528277874)","('Human_Rights_And_Community_Relations', 0.005340980365872383)","(['Talent Attraction & Retention'], 0.9451705813407898)","('NON-ESG', 0.00683523528277874)","('NON-ESG', 0.005340980365872383)"
Line 517,"We not only share enterprise employee survey results with our employees and board of directors, but also hold leaders accountable for sharing and actioning their own teams results among their employees.","('Employee_Engagement_Inclusion_And_Diversity', 0.3123719096183777)","('Director_Removal', 0.21430732309818268)","('Labor_Practices', 0.14114218950271606)","('NON-ESG', 0.3123719096183777)","('NON-ESG', 0.21430732309818268)","('NON-ESG', 0.14114218950271606)"
Line 518,"In 2021, in our first year as a fully integrated company, our internal employee survey found that 82% of our employees are engaged at work; they have pride, energy, optimism and a commitment to AbbVie.","('Employee_Engagement_Inclusion_And_Diversity', 0.5948084592819214)","('Employee_Health_And_Safety', 0.18545113503932953)","('Labor_Practices', 0.05294257774949074)","(['Talent Attraction & Retention'], 0.5948084592819214)","('NON-ESG', 0.18545113503932953)","('NON-ESG', 0.05294257774949074)"
Line 519,"Our award-winning, global Learn.","('Employee_Engagement_Inclusion_And_Diversity', 0.2619357705116272)","('Access_And_Affordability', 0.13318218290805817)","('Business_Model_Resilience', 0.07558633387088776)","('NON-ESG', 0.2619357705116272)","('NON-ESG', 0.13318218290805817)","('NON-ESG', 0.07558633387088776)"
Line 520,Develop.,"('Business_Model_Resilience', 0.15012292563915253)","('Product_Design_And_Lifecycle_Management', 0.12899670004844666)","('Employee_Engagement_Inclusion_And_Diversity', 0.10172994434833527)","('NON-ESG', 0.15012292563915253)","('NON-ESG', 0.12899670004844666)","('NON-ESG', 0.10172994434833527)"
Line 521,Perform.,"('Employee_Engagement_Inclusion_And_Diversity', 0.10616154223680496)","('Competitive_Behavior', 0.0836322158575058)","('Customer_Privacy', 0.0739956796169281)","('NON-ESG', 0.10616154223680496)","('NON-ESG', 0.0836322158575058)","('NON-ESG', 0.0739956796169281)"
Line 522,"(LDP) program offers webinars, online tools and mobile resources to all employees and puts skill and capability development on topics like resilience, decision making, empathy, innovation, inclusivity and influence at their fingertips.","('Business_Model_Resilience', 0.8112454414367676)","('Employee_Engagement_Inclusion_And_Diversity', 0.03331324830651283)","('Human_Rights_And_Community_Relations', 0.024088246747851372)","(['Human Capital Development', 'Innovation Management'], 0.8112454414367676)","('NON-ESG', 0.03331324830651283)","('NON-ESG', 0.024088246747851372)"
Line 523,These resources are refined each year in response to employee evaluations and other strategic priorities and are now available in six languages.,"('Management_Of_Legal_And_Regulatory_Framework', 0.228458434343338)","('Access_And_Affordability', 0.16461703181266785)","('Human_Rights_And_Community_Relations', 0.14300568401813507)","('NON-ESG', 0.228458434343338)","('NON-ESG', 0.16461703181266785)","('NON-ESG', 0.14300568401813507)"
Line 524,"As we integrated Allergan into AbbVie in 2021, we increased participation across our programs by 25%.","('Customer_Welfare', 0.3608121871948242)","('Access_And_Affordability', 0.07221479713916779)","('GHG_Emissions', 0.06101541593670845)","('NON-ESG', 0.3608121871948242)","('NON-ESG', 0.07221479713916779)","('NON-ESG', 0.06101541593670845)"
Line 525,We encourage each employee to define an annual learning and development objective for themselves and prioritize development opportunities to meet that objective.,"('Access_And_Affordability', 0.32671865820884705)","('Employee_Engagement_Inclusion_And_Diversity', 0.2809809446334839)","('Human_Rights_And_Community_Relations', 0.07376604527235031)","('NON-ESG', 0.32671865820884705)","('NON-ESG', 0.2809809446334839)","('NON-ESG', 0.07376604527235031)"
Line 526,Understanding our employees interests and goals allows us to offer highly relevant opportunities that contribute to their success and give them the resources they need to grow their careers and contribute to their fullest potential.,"('Employee_Engagement_Inclusion_And_Diversity', 0.8108797669410706)","('Human_Rights_And_Community_Relations', 0.028437111526727676)","('Access_And_Affordability', 0.021641748026013374)","(['Talent Attraction & Retention'], 0.8108797669410706)","('NON-ESG', 0.028437111526727676)","('NON-ESG', 0.021641748026013374)"
Line 527,"All employees also have access to a suite of career development resources that enable self-guided planning to define career interests, investigate job openings and identify opportunities for improvement.","('Employee_Engagement_Inclusion_And_Diversity', 0.8912128806114197)","('Access_And_Affordability', 0.019466856494545937)","('Employee_Health_And_Safety', 0.011342251673340797)","(['Talent Attraction & Retention'], 0.8912128806114197)","('NON-ESG', 0.019466856494545937)","('NON-ESG', 0.011342251673340797)"
Line 528,We also make training resources available to help employees evolve their Ways We Work behaviors.,"('Employee_Engagement_Inclusion_And_Diversity', 0.8393720388412476)","('Employee_Health_And_Safety', 0.04069751128554344)","('Labor_Practices', 0.015640633180737495)","(['Talent Attraction & Retention'], 0.8393720388412476)","('NON-ESG', 0.04069751128554344)","('NON-ESG', 0.015640633180737495)"
Line 529,"Developing Our People Leadership Development Performance Management Engaging Our Employees Learning40 2021 ESG Action Report 2021 ESG Action Report 41 2021 Overall turnover rate 11% Voluntary turnover rate 8% Number of new hires 8,000 Percentage of open positions filled by internal candidates 30% Employee engagement rate182% Percent of employees who indicate that AbbVie equips them well to perform in their role176% 2021 Recordable incident rate (per 200,000 hours worked)10.16 Lost time injuries frequency rate (per 200,000 hours worked)10.04 Number of work-related employee and contractor fatalities201 Source: Employee Survey, 2021.","('Employee_Health_And_Safety', 0.9785175919532776)","('Employee_Engagement_Inclusion_And_Diversity', 0.002795770298689604)","('Labor_Practices', 0.002072037197649479)","(['Health Outcome Contribution'], 0.9785175919532776)","('NON-ESG', 0.002795770298689604)","('NON-ESG', 0.002072037197649479)"
Line 530,"Developing Our People Leadership Development Performance Management Engaging Our Employees Learning40 2021 ESG Action Report 2021 ESG Action Report 41 2021 Overall turnover rate 11% Voluntary turnover rate 8% Number of new hires 8,000 Percentage of open positions filled by internal candidates 30% Employee engagement rate182% Percent of employees who indicate that AbbVie equips them well to perform in their role176% 2021 Recordable incident rate (per 200,000 hours worked)10.16 Lost time injuries frequency rate (per 200,000 hours worked)10.04 Number of work-related employee and contractor fatalities201 Source: Employee Survey, 2021.","('Labor_Practices', 0.5128381848335266)","('Employee_Health_And_Safety', 0.3789832592010498)","('Employee_Engagement_Inclusion_And_Diversity', 0.01892612688243389)","([], 0.5128381848335266)","('NON-ESG', 0.3789832592010498)","('NON-ESG', 0.01892612688243389)"
Line 531,1 Legacy Allergan data is excluded from this KPI.,"('Data_Security', 0.2622097432613373)","('Customer_Privacy', 0.18902850151062012)","('Systemic_Risk_Management', 0.0984337329864502)","('NON-ESG', 0.2622097432613373)","('NON-ESG', 0.18902850151062012)","('NON-ESG', 0.0984337329864502)"
Line 532,2 Represents new KPI added to 2021 ESG Action Report.,"('Systemic_Risk_Management', 0.24292130768299103)","('Business_Model_Resilience', 0.2147713154554367)","('Management_Of_Legal_And_Regulatory_Framework', 0.18765650689601898)","('NON-ESG', 0.24292130768299103)","('NON-ESG', 0.2147713154554367)","('NON-ESG', 0.18765650689601898)"
Line 533,Contractors only include those individuals who are contingent/temporary workers under AbbVies direct supervision.,"('Labor_Practices', 0.9699915051460266)","('Employee_Health_And_Safety', 0.0035881060175597668)","('Director_Removal', 0.0031760132405906916)","([], 0.9699915051460266)","('NON-ESG', 0.0035881060175597668)","('NON-ESG', 0.0031760132405906916)"
Line 534,"Key Performance Indicators: Talent Attraction, Retention and Development Key Performance Indicators: Workplace SafetyEnsuring the safety of our employees across our workplace is a cornerstone commitment to our employee community and human rights more broadly.","('Employee_Health_And_Safety', 0.6297017931938171)","('Employee_Engagement_Inclusion_And_Diversity', 0.11994610726833344)","('Human_Rights_And_Community_Relations', 0.09849861264228821)","(['Health Outcome Contribution'], 0.6297017931938171)","('NON-ESG', 0.11994610726833344)","('NON-ESG', 0.09849861264228821)"
Line 535,Our guiding philosophy is called Zero.,"('Competitive_Behavior', 0.2000870257616043)","('Business_Ethics', 0.16120578348636627)","('Human_Rights_And_Community_Relations', 0.11469113081693649)","('NON-ESG', 0.2000870257616043)","('NON-ESG', 0.16120578348636627)","('NON-ESG', 0.11469113081693649)"
Line 536,Believe It.,"('Business_Ethics', 0.11924604326486588)","('Employee_Engagement_Inclusion_And_Diversity', 0.08344632387161255)","('Business_Model_Resilience', 0.06727141886949539)","('NON-ESG', 0.11924604326486588)","('NON-ESG', 0.08344632387161255)","('NON-ESG', 0.06727141886949539)"
Line 537,Achieve It.,"('Product_Design_And_Lifecycle_Management', 0.17141129076480865)","('Business_Model_Resilience', 0.10434616357088089)","('Employee_Engagement_Inclusion_And_Diversity', 0.07221102714538574)","('NON-ESG', 0.17141129076480865)","('NON-ESG', 0.10434616357088089)","('NON-ESG', 0.07221102714538574)"
Line 538,"which reflects the core belief that every environmental, health and safety incident is preventable as we all adopt a preventative mindset.","('Critical_Incident_Risk_Management', 0.6828997731208801)","('Employee_Health_And_Safety', 0.26202499866485596)","('Air_Quality', 0.006759115029126406)","([], 0.6828997731208801)","('NON-ESG', 0.26202499866485596)","('NON-ESG', 0.006759115029126406)"
Line 539,"We provide comprehensive safety training for all employees, as it pertains to their workplace environment.","('Employee_Health_And_Safety', 0.9827934503555298)","('Critical_Incident_Risk_Management', 0.002658888464793563)","('Employee_Engagement_Inclusion_And_Diversity', 0.0017075652722269297)","(['Health Outcome Contribution'], 0.9827934503555298)","('NON-ESG', 0.002658888464793563)","('NON-ESG', 0.0017075652722269297)"
Line 540,"Additionally, 13 of our manufacturing sites are certified to the international standards for safety associated with ISO 45001.","('Product_Quality_And_Safety', 0.8508965373039246)","('Employee_Health_And_Safety', 0.05902884155511856)","('Product_Design_And_Lifecycle_Management', 0.012277876958251)","(['Product Quality & Recall Management'], 0.8508965373039246)","('NON-ESG', 0.05902884155511856)","('NON-ESG', 0.012277876958251)"
Line 541,"Since our launch as an independent company, we have been a Dow Jones Sustainability Index (DJSI) leader in occupational health and safety across the biotechnology industry, reflecting our commitment to continuously improving our best-in-class safety programs.","('Employee_Health_And_Safety', 0.970592200756073)","('Product_Quality_And_Safety', 0.0052284919656813145)","('Employee_Engagement_Inclusion_And_Diversity', 0.004001276567578316)","(['Health Outcome Contribution'], 0.970592200756073)","('NON-ESG', 0.0052284919656813145)","('NON-ESG', 0.004001276567578316)"
Line 542,"In 2021, we continued to demonstrate our commitment to our employees safety by expanding on Zero.","('Employee_Health_And_Safety', 0.9658311009407043)","('Employee_Engagement_Inclusion_And_Diversity', 0.008418421261012554)","('Product_Quality_And_Safety', 0.003686305833980441)","(['Health Outcome Contribution'], 0.9658311009407043)","('NON-ESG', 0.008418421261012554)","('NON-ESG', 0.003686305833980441)"
Line 543,Believe It.,"('Business_Ethics', 0.11924604326486588)","('Employee_Engagement_Inclusion_And_Diversity', 0.08344632387161255)","('Business_Model_Resilience', 0.06727141886949539)","('NON-ESG', 0.11924604326486588)","('NON-ESG', 0.08344632387161255)","('NON-ESG', 0.06727141886949539)"
Line 544,Achieve It.,"('Product_Design_And_Lifecycle_Management', 0.17141129076480865)","('Business_Model_Resilience', 0.10434616357088089)","('Employee_Engagement_Inclusion_And_Diversity', 0.07221102714538574)","('NON-ESG', 0.17141129076480865)","('NON-ESG', 0.10434616357088089)","('NON-ESG', 0.07221102714538574)"
Line 545,and rolling out our Think 5/Take 5 safety culture initiative.,"('Product_Quality_And_Safety', 0.5465552806854248)","('Employee_Health_And_Safety', 0.18815308809280396)","('Product_Design_And_Lifecycle_Management', 0.11255128681659698)","(['Product Quality & Recall Management'], 0.5465552806854248)","('NON-ESG', 0.18815308809280396)","('NON-ESG', 0.11255128681659698)"
Line 546,This initiative has been designed to empower employees across AbbVies manufacturing sites to take ownership of safety and promote the safest workplace possible.,"('Employee_Health_And_Safety', 0.9835694432258606)","('Employee_Engagement_Inclusion_And_Diversity', 0.002128207590430975)","('Critical_Incident_Risk_Management', 0.0013645938597619534)","(['Health Outcome Contribution'], 0.9835694432258606)","('NON-ESG', 0.002128207590430975)","('NON-ESG', 0.0013645938597619534)"
Line 547,Please see the Business Ethics section to find information on our human rights practices.,"('Human_Rights_And_Community_Relations', 0.685439944267273)","('Business_Ethics', 0.13284635543823242)","('Labor_Practices', 0.01983356848359108)","([], 0.685439944267273)","('NON-ESG', 0.13284635543823242)","('NON-ESG', 0.01983356848359108)"
Line 548,"At AbbVie, we are driven by the holistic well-being of our employees worldwide, offering them support through multiple programs, tools and resources.","('Human_Rights_And_Community_Relations', 0.5295498371124268)","('Access_And_Affordability', 0.1562039852142334)","('Employee_Health_And_Safety', 0.09891470521688461)","([], 0.5295498371124268)","('NON-ESG', 0.1562039852142334)","('NON-ESG', 0.09891470521688461)"
Line 549,"Our AbbVie Employee Assistance Program (EAP) steps in for employees when they need it most, aiding personal concerns and providing free, short-term counseling and referral services.","('Access_And_Affordability', 0.49928173422813416)","('Employee_Health_And_Safety', 0.2120804637670517)","('Human_Rights_And_Community_Relations', 0.06342414766550064)","('NON-ESG', 0.49928173422813416)","('NON-ESG', 0.2120804637670517)","('NON-ESG', 0.06342414766550064)"
Line 550,"As of April 2022, all employees globally, as well as their household members, have access to the EAP .","('Access_And_Affordability', 0.6559408903121948)","('Product_Quality_And_Safety', 0.04589744284749031)","('Labor_Practices', 0.026980280876159668)","(['Access to Healthcare'], 0.6559408903121948)","('NON-ESG', 0.04589744284749031)","('NON-ESG', 0.026980280876159668)"
Line 551,"Additionally, AbbVie Vitalityour approach to well- beingprovides resources that support the physical, mental, emotional, financial, workplace, and personal needs of our employees.","('Employee_Health_And_Safety', 0.4138360917568207)","('Human_Rights_And_Community_Relations', 0.1928575485944748)","('Access_And_Affordability', 0.11320748180150986)","('NON-ESG', 0.4138360917568207)","('NON-ESG', 0.1928575485944748)","('NON-ESG', 0.11320748180150986)"
Line 552,"Vitality offers access to fitness and health classes, financial planning, and mental health and caregiver support resources.","('Access_And_Affordability', 0.6750470995903015)","('Employee_Health_And_Safety', 0.12050768733024597)","('Employee_Engagement_Inclusion_And_Diversity', 0.033008676022291183)","(['Access to Healthcare'], 0.6750470995903015)","('NON-ESG', 0.12050768733024597)","('NON-ESG', 0.033008676022291183)"
Line 553,These programs ensure our employees can be their best selvesin and outside the workplace.,"('Human_Rights_And_Community_Relations', 0.24866174161434174)","('Employee_Engagement_Inclusion_And_Diversity', 0.20567049086093903)","('Employee_Health_And_Safety', 0.14643537998199463)","('NON-ESG', 0.24866174161434174)","('NON-ESG', 0.20567049086093903)","('NON-ESG', 0.14643537998199463)"
Line 554,"We also support employees through the AbbVie Foundation's Employee Assistance Program, which includes the Possibilities Scholarship Program and the Employee Relief Program.","('Employee_Health_And_Safety', 0.34242546558380127)","('Employee_Engagement_Inclusion_And_Diversity', 0.2987421452999115)","('Labor_Practices', 0.13215571641921997)","('NON-ESG', 0.34242546558380127)","('NON-ESG', 0.2987421452999115)","('NON-ESG', 0.13215571641921997)"
Line 555,Employee assistance is offered at two pivotal momentswhen a child goes to college and if a disaster or personal hardship strikes.,"('Employee_Health_And_Safety', 0.4607383608818054)","('Critical_Incident_Risk_Management', 0.20798802375793457)","('Access_And_Affordability', 0.1390087604522705)","('NON-ESG', 0.4607383608818054)","('NON-ESG', 0.20798802375793457)","('NON-ESG', 0.1390087604522705)"
Line 556,"In 2021, 261 scholarships were awarded to students in 20 countries as part of the AbbVie Possibilities Scholarship Program, and $1,455,784 was provided in financial assistance to employees in 17 countries and 26 states in the United States as part of the Employee Relief Program.","('Employee_Engagement_Inclusion_And_Diversity', 0.20241467654705048)","('Access_And_Affordability', 0.1784990280866623)","('Management_Of_Legal_And_Regulatory_Framework', 0.15501847863197327)","('NON-ESG', 0.20241467654705048)","('NON-ESG', 0.1784990280866623)","('NON-ESG', 0.15501847863197327)"
Line 557,"We support work-life well-being and flexibility to help our employees sustain high performance, productivity and engagement.","('Employee_Engagement_Inclusion_And_Diversity', 0.2869071066379547)","('Labor_Practices', 0.20736071467399597)","('Employee_Health_And_Safety', 0.20227187871932983)","('NON-ESG', 0.2869071066379547)","('NON-ESG', 0.20736071467399597)","('NON-ESG', 0.20227187871932983)"
Line 558,"We provide managers and their teams with tools, tips and guidelines on effectively managing team and individual flexibility in where and when people work.","('Employee_Engagement_Inclusion_And_Diversity', 0.1486261636018753)","('Director_Removal', 0.11839703470468521)","('Human_Rights_And_Community_Relations', 0.10013174265623093)","('NON-ESG', 0.1486261636018753)","('NON-ESG', 0.11839703470468521)","('NON-ESG', 0.10013174265623093)"
Line 559,Employees continue to indicate in the Employee Survey that their managers grant them enough flexibility to meet their personal/family responsibilities.,"('Employee_Engagement_Inclusion_And_Diversity', 0.27398380637168884)","('Human_Rights_And_Community_Relations', 0.2714020907878876)","('Labor_Practices', 0.1882258653640747)","('NON-ESG', 0.27398380637168884)","('NON-ESG', 0.2714020907878876)","('NON-ESG', 0.1882258653640747)"
Line 560,"During 2020 and 2021, AbbVie provided numerous resources that supported employees ability to work effectively during the COVID-19 pandemic, while managing their own well- being and caring for their families.","('Access_And_Affordability', 0.510499119758606)","('Employee_Health_And_Safety', 0.19986334443092346)","('Human_Rights_And_Community_Relations', 0.1191277951002121)","(['Access to Healthcare'], 0.510499119758606)","('NON-ESG', 0.19986334443092346)","('NON-ESG', 0.1191277951002121)"
Line 561,"These resources continue to remain in place and include caring for physical, emotional and financial health, collaborating with coworkers virtually, supporting managers to effectively lead and collaborate with their teams, virtual development opportunities and caregiver support services for working parents.","('Access_And_Affordability', 0.7621712684631348)","('Employee_Health_And_Safety', 0.09123663604259491)","('Human_Rights_And_Community_Relations', 0.02371073327958584)","(['Access to Healthcare'], 0.7621712684631348)","('NON-ESG', 0.09123663604259491)","('NON-ESG', 0.02371073327958584)"
Line 562,Protecting Our Workforce Enhancing Employee Well-Being Work-Life and Well-Being The first step to erasing the stigma of mental illness is awareness.,"('Employee_Health_And_Safety', 0.9272387027740479)","('Access_And_Affordability', 0.011951598338782787)","('Employee_Engagement_Inclusion_And_Diversity', 0.010081185027956963)","(['Health Outcome Contribution'], 0.9272387027740479)","('NON-ESG', 0.011951598338782787)","('NON-ESG', 0.010081185027956963)"
Line 563,"During National Mental Health Awareness month in May 2021, AbbVie continued to deliver on our promise to support the work-life well-being of every employee.","('Employee_Health_And_Safety', 0.7981215119361877)","('Access_And_Affordability', 0.05797562375664711)","('Human_Rights_And_Community_Relations', 0.02754220739006996)","(['Health Outcome Contribution'], 0.7981215119361877)","('NON-ESG', 0.05797562375664711)","('NON-ESG', 0.02754220739006996)"
Line 564,"We first ensured team members knew about the months significance by launching a comprehensive employee communications campaign, which included infographics showing the prevalence of mental illness around the world; mental health resources, including self-assessments and articles on how to talk about mental health; and live and on- demand virtual learning opportunities.","('Employee_Health_And_Safety', 0.8567124009132385)","('Product_Quality_And_Safety', 0.020256707444787025)","('Access_And_Affordability', 0.015213768929243088)","(['Health Outcome Contribution'], 0.8567124009132385)","('NON-ESG', 0.020256707444787025)","('NON-ESG', 0.015213768929243088)"
Line 565,"By encouraging employees to use the many resources AbbVie Vitality offers, we not only support our employees well- being, but contribute to increasing visibility about mental health on a larger scale.","('Employee_Health_And_Safety', 0.8968868851661682)","('Access_And_Affordability', 0.026860099285840988)","('Human_Rights_And_Community_Relations', 0.008878947235643864)","(['Health Outcome Contribution'], 0.8968868851661682)","('NON-ESG', 0.026860099285840988)","('NON-ESG', 0.008878947235643864)"
Line 566,Erasing the stigma of mental illness and supporting employee well-beingOur nonprofit partners are advancing health equity for communities and patients around the world through community programs that drive systems change.,"('Employee_Health_And_Safety', 0.799976646900177)","('Access_And_Affordability', 0.07032887637615204)","('Product_Quality_And_Safety', 0.01649373397231102)","(['Health Outcome Contribution'], 0.799976646900177)","('NON-ESG', 0.07032887637615204)","('NON-ESG', 0.01649373397231102)"
Line 567,"United Negro College Fund, Inc.","('Management_Of_Legal_And_Regulatory_Framework', 0.6445356607437134)","('Access_And_Affordability', 0.060987334698438644)","('Business_Ethics', 0.05479448661208153)","([], 0.6445356607437134)","('NON-ESG', 0.060987334698438644)","('NON-ESG', 0.05479448661208153)"
Line 568,"With AbbVie support, the United Negro College Fund (UNCF) launched the Healthcare Workforce Diversity Program, focused on preparing and motivating Black professionals to pursue a wide variety of careers in healthcare and ultimately reduce health disparities.","('Employee_Engagement_Inclusion_And_Diversity', 0.9749135971069336)","('Employee_Health_And_Safety', 0.0020873781759291887)","('Business_Model_Resilience', 0.0015074627008289099)","(['Talent Attraction & Retention'], 0.9749135971069336)","('NON-ESG', 0.0020873781759291887)","('NON-ESG', 0.0015074627008289099)"
Line 569,"In 2021, the program awarded 200 scholarships and provided wraparound support services to students.","('Access_And_Affordability', 0.6338244080543518)","('Management_Of_Legal_And_Regulatory_Framework', 0.0774088054895401)","('Employee_Engagement_Inclusion_And_Diversity', 0.04446607455611229)","(['Access to Healthcare'], 0.6338244080543518)","('NON-ESG', 0.0774088054895401)","('NON-ESG', 0.04446607455611229)"
Line 570,"In addition, UNCF established partnerships with 118 new institutions of higher learning, enabling the organization to reach more students and ensure they make it to and through college.","('Access_And_Affordability', 0.6771108508110046)","('Employee_Engagement_Inclusion_And_Diversity', 0.0609276257455349)","('Ecological_Impacts', 0.028378747403621674)","(['Access to Healthcare'], 0.6771108508110046)","('NON-ESG', 0.0609276257455349)","('NON-ESG', 0.028378747403621674)"
Line 571,University of Chicago Urban Health Initiative The Urban Health Initiative (UHI) is striving to promote health equity within Chicagos South Side community.,"('Access_And_Affordability', 0.4786067306995392)","('Employee_Health_And_Safety', 0.22410516440868378)","('Employee_Engagement_Inclusion_And_Diversity', 0.039195429533720016)","('NON-ESG', 0.4786067306995392)","('NON-ESG', 0.22410516440868378)","('NON-ESG', 0.039195429533720016)"
Line 572,"With AbbVie support, UHI launched the Liaisons in Care (LinC) program, which leverages the support of community health workers to advance access to care.","('Access_And_Affordability', 0.8830679059028625)","('Human_Rights_And_Community_Relations', 0.01954212598502636)","('Employee_Health_And_Safety', 0.016836071386933327)","(['Access to Healthcare'], 0.8830679059028625)","('NON-ESG', 0.01954212598502636)","('NON-ESG', 0.016836071386933327)"
Line 573,"The team of newly hired community health workers (CHWs) have engaged in over 1,100 patient visits, providing education around disease management and helping patients navigate food, transportation and housing.","('Access_And_Affordability', 0.6127092838287354)","('Employee_Health_And_Safety', 0.18226242065429688)","('Critical_Incident_Risk_Management', 0.03172747790813446)","(['Access to Healthcare'], 0.6127092838287354)","('NON-ESG', 0.18226242065429688)","('NON-ESG', 0.03172747790813446)"
Line 574,"Baylor College of Medicine International Pediatric AIDS Initiative AbbVie Foundation supports the Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI), which provides comprehensive HIV care, treatment, prevention, testing and psychosocial support for over 25,000 children and adults in Romania and Malawi.","('Access_And_Affordability', 0.7633060216903687)","('Employee_Health_And_Safety', 0.049330148845911026)","('Product_Quality_And_Safety', 0.028262222185730934)","(['Access to Healthcare'], 0.7633060216903687)","('NON-ESG', 0.049330148845911026)","('NON-ESG', 0.028262222185730934)"
Line 575,"Over the course of the partnership, BIPAIs programs have contributed to Romania and Malawi advancing towards 95-95-95 targets set by UNAIDS to end the AIDS epidemic by 2030.","('Access_And_Affordability', 0.29597949981689453)","('Human_Rights_And_Community_Relations', 0.16507737338542938)","('Critical_Incident_Risk_Management', 0.1549496352672577)","('NON-ESG', 0.29597949981689453)","('NON-ESG', 0.16507737338542938)","('NON-ESG', 0.1549496352672577)"
Line 576,"The COVID-19 pandemic presented Strengthening Healthcare Systems challenges to health services and staffing, however, BIPAI adapted their treatment approach, resulting in innovations that helped to maintain excellence in healthcare delivery.","('Access_And_Affordability', 0.5498756766319275)","('Critical_Incident_Risk_Management', 0.060599666088819504)","('Systemic_Risk_Management', 0.04656766727566719)","(['Access to Healthcare'], 0.5498756766319275)","('NON-ESG', 0.060599666088819504)","('NON-ESG', 0.04656766727566719)"
Line 577,Adherence and mortality rates have nearly returned to pre- pandemic levels and differentiated service delivery models adopted during the pandemic continue to be implemented.,"('Critical_Incident_Risk_Management', 0.3758234679698944)","('Physical_Impacts_Of_Climate_Change', 0.2035178691148758)","('Employee_Health_And_Safety', 0.06307072192430496)","('NON-ESG', 0.3758234679698944)","('NON-ESG', 0.2035178691148758)","('NON-ESG', 0.06307072192430496)"
Line 578,"AMPATH (Academic Model Providing Access to Healthcare) With support from AbbVie Foundation, AMPATH seeks to improve the health of hard-to-reach populations in western Kenya through an integrated care model that improves access to high quality care, addresses social determinants of health and leverages Kenyas goal to create a universal health coverage system.","('Access_And_Affordability', 0.8834047913551331)","('Employee_Health_And_Safety', 0.012826028279960155)","('Product_Quality_And_Safety', 0.010506199672818184)","(['Access to Healthcare'], 0.8834047913551331)","('NON-ESG', 0.012826028279960155)","('NON-ESG', 0.010506199672818184)"
Line 579,"In 2021, AMPATH supported approximately 70,000 participants in a program to help families in need of healthcare gain the financial capacity to access services.","('Access_And_Affordability', 0.9324071407318115)","('Human_Rights_And_Community_Relations', 0.008512269705533981)","('Critical_Incident_Risk_Management', 0.008199237287044525)","(['Access to Healthcare'], 0.9324071407318115)","('NON-ESG', 0.008512269705533981)","('NON-ESG', 0.008199237287044525)"
Line 580,"Partners In Health (PIH) Partners in Healths innovative community health programs are strengthening the capacity of healthcare providers and improving access to and quality of care for nearly 85,000 people in Chiapas, Mexico.","('Access_And_Affordability', 0.865615963935852)","('Human_Rights_And_Community_Relations', 0.019255291670560837)","('Critical_Incident_Risk_Management', 0.016512418165802956)","(['Access to Healthcare'], 0.865615963935852)","('NON-ESG', 0.019255291670560837)","('NON-ESG', 0.016512418165802956)"
Line 581,"In 2021, AbbVie Foundations support enabled PIH to serve an estimated 1,100 patients with chronic diseases and provided training and support to 90 community health workers and 25 health professionals.","('Employee_Health_And_Safety', 0.7528858184814453)","('Access_And_Affordability', 0.09963781386613846)","('Product_Quality_And_Safety', 0.020220303907990456)","(['Health Outcome Contribution'], 0.7528858184814453)","('NON-ESG', 0.09963781386613846)","('NON-ESG', 0.020220303907990456)"
Line 582,"PIH expanded a household screening visit program, where community health workers visit homes to provide preventative care and services to high-risk patients.","('Access_And_Affordability', 0.8123343586921692)","('Employee_Health_And_Safety', 0.052368976175785065)","('Critical_Incident_Risk_Management', 0.02662578411400318)","(['Access to Healthcare'], 0.8123343586921692)","('NON-ESG', 0.052368976175785065)","('NON-ESG', 0.02662578411400318)"
Line 583,"In 2021, PIH began to pilot a program that trains and empowers nurses and community health workers to take on more responsibilities to improve the health of patients with chronic diseases.","('Employee_Health_And_Safety', 0.8986133933067322)","('Access_And_Affordability', 0.029127391055226326)","('Critical_Incident_Risk_Management', 0.009904170408844948)","(['Health Outcome Contribution'], 0.8986133933067322)","('NON-ESG', 0.029127391055226326)","('NON-ESG', 0.009904170408844948)"
Line 584,"By strengthening the healthcare system, PIHtogether with the AbbVie Foundationis providing much needed care for patients and increasing access to primary healthcare in the region.","('Access_And_Affordability', 0.9288955926895142)","('Critical_Incident_Risk_Management', 0.009723519906401634)","('Employee_Health_And_Safety', 0.006112575065344572)","(['Access to Healthcare'], 0.9288955926895142)","('NON-ESG', 0.009723519906401634)","('NON-ESG', 0.006112575065344572)"
Line 585,"42 2021 ESG Action Report 2021 ESG Action Report 43 AbbVie is committed to providing a comprehensive total rewards package that is competitive in attracting, retaining and engaging the talent we need to drive our business growth.","('Competitive_Behavior', 0.6469716429710388)","('Business_Model_Resilience', 0.12985682487487793)","('Systemic_Risk_Management', 0.053937241435050964)","([], 0.6469716429710388)","('NON-ESG', 0.12985682487487793)","('NON-ESG', 0.053937241435050964)"
Line 586,"We offer employees a combination of robust and meaningful benefits, compensation and well-being programsincluding healthcare and retirement benefits, life and disability insurance, sick pay, medical leave and programs that support families.","('Labor_Practices', 0.9471030235290527)","('Employee_Engagement_Inclusion_And_Diversity', 0.011721103452146053)","('Employee_Health_And_Safety', 0.005630756728351116)","([], 0.9471030235290527)","('NON-ESG', 0.011721103452146053)","('NON-ESG', 0.005630756728351116)"
Line 587,Our well-rounded compensation programs include short-and long-term incentives designed to ensure we are competitive with our peers.,"('Competitive_Behavior', 0.82970130443573)","('Business_Ethics', 0.0302260909229517)","('Management_Of_Legal_And_Regulatory_Framework', 0.026240481063723564)","([], 0.82970130443573)","('NON-ESG', 0.0302260909229517)","('NON-ESG', 0.026240481063723564)"
Line 588,"Our industry-leading United States parental leave policies provide up to 12 weeks paid leave, which can be used incrementally and in phases.","('Labor_Practices', 0.9479881525039673)","('Employee_Health_And_Safety', 0.0063497587107121944)","('Director_Removal', 0.00457886653020978)","([], 0.9479881525039673)","('NON-ESG', 0.0063497587107121944)","('NON-ESG', 0.00457886653020978)"
Line 589,"In 2021, 27% of employees who took parental leave used the phase back option.","('Labor_Practices', 0.4734484553337097)","('Access_And_Affordability', 0.16431169211864471)","('Employee_Engagement_Inclusion_And_Diversity', 0.10010023415088654)","('NON-ESG', 0.4734484553337097)","('NON-ESG', 0.16431169211864471)","('NON-ESG', 0.10010023415088654)"
Line 590,An additional two weeks of paid leave is provided to parents that adopt or build their families through surrogacy.,"('Access_And_Affordability', 0.801033079624176)","('Employee_Engagement_Inclusion_And_Diversity', 0.0423356257379055)","('Human_Rights_And_Community_Relations', 0.023417750373482704)","(['Access to Healthcare'], 0.801033079624176)","('NON-ESG', 0.0423356257379055)","('NON-ESG', 0.023417750373482704)"
Line 591,"AbbVie provides additional support for new parents by including breastfeeding/lactation benefits such as lactation rooms in most of its global office locations, as well as educational materials and discounts on breast pumps for all employees through AbbVies Mothers at Work program.","('Access_And_Affordability', 0.6531021595001221)","('Employee_Health_And_Safety', 0.07289597392082214)","('Employee_Engagement_Inclusion_And_Diversity', 0.04928627610206604)","(['Access to Healthcare'], 0.6531021595001221)","('NON-ESG', 0.07289597392082214)","('NON-ESG', 0.04928627610206604)"
Line 592,AbbVie also provides on-site daycare centers at several locations.,"('Access_And_Affordability', 0.8331581950187683)","('Employee_Health_And_Safety', 0.03306951746344566)","('Critical_Incident_Risk_Management', 0.015384980477392673)","(['Access to Healthcare'], 0.8331581950187683)","('NON-ESG', 0.03306951746344566)","('NON-ESG', 0.015384980477392673)"
Line 593,Benefits AbbVie is committed to pay equity.,"('Management_Of_Legal_And_Regulatory_Framework', 0.35555845499038696)","('Labor_Practices', 0.18993687629699707)","('Access_And_Affordability', 0.07713533192873001)","('NON-ESG', 0.35555845499038696)","('NON-ESG', 0.18993687629699707)","('NON-ESG', 0.07713533192873001)"
Line 594,We conduct annual pay-equity analyses to ensure pay is equitable across genders and ethnicities among United States employees.,"('Labor_Practices', 0.6117464303970337)","('Employee_Engagement_Inclusion_And_Diversity', 0.30491557717323303)","('Human_Rights_And_Community_Relations', 0.007162643596529961)","([], 0.6117464303970337)","('NON-ESG', 0.30491557717323303)","('NON-ESG', 0.007162643596529961)"
Line 595,Giving back is an integral part of who we are.,"('Human_Rights_And_Community_Relations', 0.30918288230895996)","('Employee_Engagement_Inclusion_And_Diversity', 0.08630627393722534)","('Business_Model_Resilience', 0.0772257074713707)","('NON-ESG', 0.30918288230895996)","('NON-ESG', 0.08630627393722534)","('NON-ESG', 0.0772257074713707)"
Line 596,"Our giving culture is reflected in our philanthropy and the ways our employees support communities through philanthropic grants, donations, and volunteering all over the world.","('Management_Of_Legal_And_Regulatory_Framework', 0.24330434203147888)","('Human_Rights_And_Community_Relations', 0.23950284719467163)","('Access_And_Affordability', 0.11982933431863785)","('NON-ESG', 0.24330434203147888)","('NON-ESG', 0.23950284719467163)","('NON-ESG', 0.11982933431863785)"
Line 597,"AbbVie and AbbVie Foundations philanthropic giving focuses on three main areas: strengthening healthcare systems, supporting effective educational programs and building strong communities.","('Access_And_Affordability', 0.5115349888801575)","('Human_Rights_And_Community_Relations', 0.22675222158432007)","('Management_Of_Legal_And_Regulatory_Framework', 0.04571663588285446)","(['Access to Healthcare'], 0.5115349888801575)","('NON-ESG', 0.22675222158432007)","('NON-ESG', 0.04571663588285446)"
Line 598,"In 2021, AbbVie expanded our COVID-19 philanthropic support by enhancing access to vaccinations through employee volunteering and community engagement.","('Access_And_Affordability', 0.5620084404945374)","('Employee_Health_And_Safety', 0.13315676152706146)","('Product_Quality_And_Safety', 0.05464037507772446)","(['Access to Healthcare'], 0.5620084404945374)","('NON-ESG', 0.13315676152706146)","('NON-ESG', 0.05464037507772446)"
Line 599,We continued to advance our $50 million multi-year commitment to six racial equity partners and our $350 million commitment to nine partner organizations across the United States and Puerto Rico.,"('Management_Of_Legal_And_Regulatory_Framework', 0.2889614999294281)","('Access_And_Affordability', 0.10776917636394501)","('Employee_Engagement_Inclusion_And_Diversity', 0.09638786315917969)","('NON-ESG', 0.2889614999294281)","('NON-ESG', 0.10776917636394501)","('NON-ESG', 0.09638786315917969)"
Line 600,Community & Partner Engagement and Impact44 2021 ESG Action Report 2021 ESG Action Report 45 Our philanthropic investments advance equity in education by supporting nonprofits that address systemic barriers to advancement and empower marginalized students and young adults.,"('Human_Rights_And_Community_Relations', 0.3911820352077484)","('Access_And_Affordability', 0.3182609975337982)","('Employee_Engagement_Inclusion_And_Diversity', 0.05259491130709648)","('NON-ESG', 0.3911820352077484)","('NON-ESG', 0.3182609975337982)","('NON-ESG', 0.05259491130709648)"
Line 601,"These partners provide counseling and tutoring services, work to improve graduation rates and reduce dropout rates, strengthen college and career readiness for children K-12 and provide skills-based training.","('Employee_Engagement_Inclusion_And_Diversity', 0.5706629753112793)","('Access_And_Affordability', 0.23019380867481232)","('Customer_Welfare', 0.020998788997530937)","(['Talent Attraction & Retention'], 0.5706629753112793)","('NON-ESG', 0.23019380867481232)","('NON-ESG', 0.020998788997530937)"
Line 602,"Rebuilding North Chicago's Only Middle School One of our most impactful and meaningful contributions to education is our $40 million donation to support the construction of a new Neal Math & Science Academy, North Chicagos only middle school.","('Access_And_Affordability', 0.8378546833992004)","('Employee_Engagement_Inclusion_And_Diversity', 0.017146792262792587)","('Ecological_Impacts', 0.013314721174538136)","(['Access to Healthcare'], 0.8378546833992004)","('NON-ESG', 0.017146792262792587)","('NON-ESG', 0.013314721174538136)"
Line 603,"In 2021, construction began and the first students at the New Neal will enter its doors in the Fall of 2022.","('Employee_Engagement_Inclusion_And_Diversity', 0.4446049630641937)","('Access_And_Affordability', 0.11994116008281708)","('Waste_And_Hazardous_Materials_Management', 0.05368603765964508)","('NON-ESG', 0.4446049630641937)","('NON-ESG', 0.11994116008281708)","('NON-ESG', 0.05368603765964508)"
Line 604,"This new school, co-imagined and designed in partnership with the North Chicago community, will provide a modernized learning environment to improve student success, graduation rates and college and career readiness.","('Employee_Engagement_Inclusion_And_Diversity', 0.4989541172981262)","('Access_And_Affordability', 0.22605901956558228)","('Ecological_Impacts', 0.0249971691519022)","('NON-ESG', 0.4989541172981262)","('NON-ESG', 0.22605901956558228)","('NON-ESG', 0.0249971691519022)"
Line 605,Communities in Schools Communities in Schools (CIS) offers essential support services to provide low-income students an equitable opportunity to excel in the classroom and beyond.,"('Access_And_Affordability', 0.8055357336997986)","('Human_Rights_And_Community_Relations', 0.06656181812286377)","('Employee_Engagement_Inclusion_And_Diversity', 0.023869361728429794)","(['Access to Healthcare'], 0.8055357336997986)","('NON-ESG', 0.06656181812286377)","('NON-ESG', 0.023869361728429794)"
Line 606,"With AbbVies support, in the 2020-2021 school year CIS served over 74,000 students in 154 schools, including children in 16 Chicago public schools.","('Access_And_Affordability', 0.9076561331748962)","('Product_Quality_And_Safety', 0.008550952188670635)","('Human_Rights_And_Community_Relations', 0.008123159408569336)","(['Access to Healthcare'], 0.9076561331748962)","('NON-ESG', 0.008550952188670635)","('NON-ESG', 0.008123159408569336)"
Line 607,Year Up Year Up empowers young adults to achieve economic mobility by providing access to opportunity.,"('Access_And_Affordability', 0.43880271911621094)","('Employee_Engagement_Inclusion_And_Diversity', 0.2988679111003876)","('Human_Rights_And_Community_Relations', 0.06908153742551804)","('NON-ESG', 0.43880271911621094)","('NON-ESG', 0.2988679111003876)","('NON-ESG', 0.06908153742551804)"
Line 608,"Through Year Up's proven model, young adults gain technical and professional skills and real-world work experience.","('Employee_Engagement_Inclusion_And_Diversity', 0.679034411907196)","('Employee_Health_And_Safety', 0.057309839874506)","('Labor_Practices', 0.0539359487593174)","(['Talent Attraction & Retention'], 0.679034411907196)","('NON-ESG', 0.057309839874506)","('NON-ESG', 0.0539359487593174)"
Line 609,"In 2021, with AbbVies support, Year Up's locations in Boston, the Bay Area, Chicago and New York-New Jersey served more than 3,000 young adults.","('Access_And_Affordability', 0.5935509204864502)","('Employee_Engagement_Inclusion_And_Diversity', 0.17050278186798096)","('Customer_Welfare', 0.026856999844312668)","(['Access to Healthcare'], 0.5935509204864502)","('NON-ESG', 0.17050278186798096)","('NON-ESG', 0.026856999844312668)"
Line 610,City Year City Year aims to increase math and literacy support in low- income schools and among at-risk students.,"('Access_And_Affordability', 0.8884130120277405)","('Employee_Engagement_Inclusion_And_Diversity', 0.015102184377610683)","('Product_Quality_And_Safety', 0.011901205405592918)","(['Access to Healthcare'], 0.8884130120277405)","('NON-ESG', 0.015102184377610683)","('NON-ESG', 0.011901205405592918)"
Line 611,"In the 2020-2021 school year, AbbVies support enabled City Year to reach over 225,000 students across over 320 schools, including 17,000 students in Chicago and 7,000 in San Jose.","('Access_And_Affordability', 0.7348766922950745)","('Employee_Engagement_Inclusion_And_Diversity', 0.06252119690179825)","('Ecological_Impacts', 0.018810011446475983)","(['Access to Healthcare'], 0.7348766922950745)","('NON-ESG', 0.06252119690179825)","('NON-ESG', 0.018810011446475983)"
Line 612,"Effective Educational Programs The New Neal will help turn my dreams into reality.""","('Access_And_Affordability', 0.7150422930717468)","('Employee_Engagement_Inclusion_And_Diversity', 0.030873030424118042)","('Energy_Management', 0.024655796587467194)","(['Access to Healthcare'], 0.7150422930717468)","('NON-ESG', 0.030873030424118042)","('NON-ESG', 0.024655796587467194)"
Line 613,"Neal Math and Science Academy student at the 2021 groundbreaking ceremonySpotlight on Direct Reliefs Fund for Health EquityOur Racial Equity Commitment In 2020, AbbVie launched a $50 million, five-year commitment to six nonprofit partners advancing health and education equity in Black and historically marginalized communities.","('Employee_Engagement_Inclusion_And_Diversity', 0.47172811627388)","('Access_And_Affordability', 0.19371935725212097)","('Human_Rights_And_Community_Relations', 0.15931376814842224)","('NON-ESG', 0.47172811627388)","('NON-ESG', 0.19371935725212097)","('NON-ESG', 0.15931376814842224)"
Line 614,"In the year since we made this important philanthropic commitment, our partners have set the foundation for their programs and are accelerating measurable progress on health, education and workforce disparities.","('Employee_Engagement_Inclusion_And_Diversity', 0.7874372005462646)","('Access_And_Affordability', 0.07379427552223206)","('Human_Rights_And_Community_Relations', 0.02063773013651371)","(['Talent Attraction & Retention'], 0.7874372005462646)","('NON-ESG', 0.07379427552223206)","('NON-ESG', 0.02063773013651371)"
Line 615,Learn more about our first years impact on our website .,"('Business_Model_Resilience', 0.5498271584510803)","('Access_And_Affordability', 0.05219126120209694)","('Systemic_Risk_Management', 0.04137840121984482)","(['Human Capital Development', 'Innovation Management'], 0.5498271584510803)","('NON-ESG', 0.05219126120209694)","('NON-ESG', 0.04137840121984482)"
Line 616,The AbbVie Foundation seeded Direct Reliefs Fund for Health Equity with a $10 million commitment.,"('Access_And_Affordability', 0.5781941413879395)","('Management_Of_Legal_And_Regulatory_Framework', 0.09812111407518387)","('Systemic_Risk_Management', 0.04118521511554718)","(['Access to Healthcare'], 0.5781941413879395)","('NON-ESG', 0.09812111407518387)","('NON-ESG', 0.04118521511554718)"
Line 617,The initiative centers on improving care and addressing health inequities in Black and marginalized communities.,"('Human_Rights_And_Community_Relations', 0.8065664172172546)","('Access_And_Affordability', 0.07518009841442108)","('Employee_Engagement_Inclusion_And_Diversity', 0.022818248718976974)","([], 0.8065664172172546)","('NON-ESG', 0.07518009841442108)","('NON-ESG', 0.022818248718976974)"
Line 618,"The Fund is led by a team of advisors including co-chair Dr. Regina Benjamin, the 18th U.","('Management_Of_Legal_And_Regulatory_Framework', 0.3735395669937134)","('Director_Removal', 0.11303692311048508)","('Employee_Engagement_Inclusion_And_Diversity', 0.08231446892023087)","('NON-ESG', 0.3735395669937134)","('NON-ESG', 0.11303692311048508)","('NON-ESG', 0.08231446892023087)"
Line 619,S.,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 620,Surgeon General of the United States.,"('Management_Of_Legal_And_Regulatory_Framework', 0.2537992596626282)","('Director_Removal', 0.07648429274559021)","('Critical_Incident_Risk_Management', 0.07490307837724686)","('NON-ESG', 0.2537992596626282)","('NON-ESG', 0.07648429274559021)","('NON-ESG', 0.07490307837724686)"
Line 621,"In 2021, with AbbVies support, the Fund for Health Equity awarded $1.8 million to its first cohort of grantees of 10 community health organizations across the country.","('Access_And_Affordability', 0.5203027129173279)","('Human_Rights_And_Community_Relations', 0.2689675986766815)","('Critical_Incident_Risk_Management', 0.019786151126027107)","(['Access to Healthcare'], 0.5203027129173279)","('NON-ESG', 0.2689675986766815)","('NON-ESG', 0.019786151126027107)"
Line 622,"Some of the activities achieved by grantees include: Hiring key staff roles and increasing their ability to serve their community Convening community healthcare providers and advocates on the issues of health disparities Establishing a workforce training program for Black and Latinx providers Deploying health outreach buses and street medicine teams It took us a long time to create the issues we now have around health equity, and it's going to take a long time to fix them.","('Access_And_Affordability', 0.7376344203948975)","('Employee_Engagement_Inclusion_And_Diversity', 0.06471838802099228)","('Employee_Health_And_Safety', 0.034601252526044846)","(['Access to Healthcare'], 0.7376344203948975)","('NON-ESG', 0.06471838802099228)","('NON-ESG', 0.034601252526044846)"
Line 623,"Thats why having long term commitments, like the one AbbVies made, matter.""","('Business_Model_Resilience', 0.5873492956161499)","('Management_Of_Legal_And_Regulatory_Framework', 0.06704976409673691)","('Human_Rights_And_Community_Relations', 0.04711470380425453)","(['Human Capital Development', 'Innovation Management'], 0.5873492956161499)","('NON-ESG', 0.06704976409673691)","('NON-ESG', 0.04711470380425453)"
Line 624,"Dr. Byron Scott, M.","('Employee_Engagement_Inclusion_And_Diversity', 0.256855309009552)","('Access_And_Affordability', 0.1397445946931839)","('Management_Of_Legal_And_Regulatory_Framework', 0.0551009364426136)","('NON-ESG', 0.256855309009552)","('NON-ESG', 0.1397445946931839)","('NON-ESG', 0.0551009364426136)"
Line 625,"D., MBA, co-chair of the Fund for Health Equity and board director of Direct Relief and chair of its Medical Advisory Council46 2021 ESG Action Report 2021 ESG Action Report 47 We live in a time where young people have taken the brunt of this pandemic.","('Access_And_Affordability', 0.2862875759601593)","('Physical_Impacts_Of_Climate_Change', 0.16438066959381104)","('Critical_Incident_Risk_Management', 0.13336540758609772)","('NON-ESG', 0.2862875759601593)","('NON-ESG', 0.16438066959381104)","('NON-ESG', 0.13336540758609772)"
Line 626,Too many have not had an opportunity to keep up with their work due to the challenges of remote learning.,"('Access_And_Affordability', 0.34187570214271545)","('Employee_Engagement_Inclusion_And_Diversity', 0.08185825496912003)","('Supply_Chain_Management', 0.046037737280130386)","('NON-ESG', 0.34187570214271545)","('NON-ESG', 0.08185825496912003)","('NON-ESG', 0.046037737280130386)"
Line 627,"AbbVie has stepped up in this important moment.""","('Business_Model_Resilience', 0.17790937423706055)","('Access_And_Affordability', 0.16026335954666138)","('Human_Rights_And_Community_Relations', 0.08561143279075623)","('NON-ESG', 0.17790937423706055)","('NON-ESG', 0.16026335954666138)","('NON-ESG', 0.08561143279075623)"
Line 628,Marc H.,"('Competitive_Behavior', 0.23647069931030273)","('Management_Of_Legal_And_Regulatory_Framework', 0.08555939048528671)","('Ecological_Impacts', 0.08431053906679153)","('NON-ESG', 0.23647069931030273)","('NON-ESG', 0.08555939048528671)","('NON-ESG', 0.08431053906679153)"
Line 629,"Morial, Chief Executive Officer, National Urban League.","('Business_Model_Resilience', 0.2815878391265869)","('Employee_Engagement_Inclusion_And_Diversity', 0.09382864832878113)","('Human_Rights_And_Community_Relations', 0.06198088079690933)","('NON-ESG', 0.2815878391265869)","('NON-ESG', 0.09382864832878113)","('NON-ESG', 0.06198088079690933)"
Line 630,"Advisory CouncilServing our communities is core to AbbVies culture, and our employees around the world are committed to giving back.","('Employee_Engagement_Inclusion_And_Diversity', 0.19832372665405273)","('Director_Removal', 0.1831940859556198)","('Human_Rights_And_Community_Relations', 0.16394861042499542)","('NON-ESG', 0.19832372665405273)","('NON-ESG', 0.1831940859556198)","('NON-ESG', 0.16394861042499542)"
Line 631,We are consistently recognized as a company that delivers on its giving promises.,"('Human_Rights_And_Community_Relations', 0.1761346012353897)","('Business_Ethics', 0.15215463936328888)","('Business_Model_Resilience', 0.10795140266418457)","('NON-ESG', 0.1761346012353897)","('NON-ESG', 0.15215463936328888)","('NON-ESG', 0.10795140266418457)"
Line 632,"For the third consecutive year, AbbVie was honored by Great Place to Work and PEOPLE as one of the 2021 Companies That Care.","('Access_And_Affordability', 0.17299367487430573)","('Employee_Health_And_Safety', 0.1388099044561386)","('Human_Rights_And_Community_Relations', 0.11853939294815063)","('NON-ESG', 0.17299367487430573)","('NON-ESG', 0.1388099044561386)","('NON-ESG', 0.11853939294815063)"
Line 633,Our employee giving and matching program encourages employees to make charitable donations to eligible nonprofit organizations.,"('Management_Of_Legal_And_Regulatory_Framework', 0.4749301075935364)","('Access_And_Affordability', 0.16043679416179657)","('Labor_Practices', 0.047483161091804504)","('NON-ESG', 0.4749301075935364)","('NON-ESG', 0.16043679416179657)","('NON-ESG', 0.047483161091804504)"
Line 634,"The AbbVie Foundation matches those contributions dollar for dollar, up to $5,000 per employee per year.","('Management_Of_Legal_And_Regulatory_Framework', 0.5862756967544556)","('Human_Rights_And_Community_Relations', 0.055362503975629807)","('Director_Removal', 0.05293280631303787)","([], 0.5862756967544556)","('NON-ESG', 0.055362503975629807)","('NON-ESG', 0.05293280631303787)"
Line 635,"In 2021, nearly 20,000 employees in more than 50 countries raised $23.7 million for 11,400 nonprofits worldwide.","('Management_Of_Legal_And_Regulatory_Framework', 0.2809341251850128)","('Access_And_Affordability', 0.12415335327386856)","('Employee_Engagement_Inclusion_And_Diversity', 0.09309999644756317)","('NON-ESG', 0.2809341251850128)","('NON-ESG', 0.12415335327386856)","('NON-ESG', 0.09309999644756317)"
Line 636,"Two years ago, the AbbVie Foundation committed to matching employee donations 3:1 to civil rights nonprofits fostering racial equity.","('Employee_Engagement_Inclusion_And_Diversity', 0.9010935425758362)","('Human_Rights_And_Community_Relations', 0.025998737663030624)","('Access_And_Affordability', 0.009482061490416527)","(['Talent Attraction & Retention'], 0.9010935425758362)","('NON-ESG', 0.025998737663030624)","('NON-ESG', 0.009482061490416527)"
Line 637,"By the end of 2021, $1.6 million had been raised to advance racial equity.","('Employee_Engagement_Inclusion_And_Diversity', 0.9705083966255188)","('Human_Rights_And_Community_Relations', 0.0021594532299786806)","('Competitive_Behavior', 0.002023454988375306)","(['Talent Attraction & Retention'], 0.9705083966255188)","('NON-ESG', 0.0021594532299786806)","('NON-ESG', 0.002023454988375306)"
Line 638,"Every year, all AbbVie employees can use up to two days of paid work time to volunteer in the community.","('Labor_Practices', 0.5893206000328064)","('Employee_Health_And_Safety', 0.09754940122365952)","('Human_Rights_And_Community_Relations', 0.0850173607468605)","([], 0.5893206000328064)","('NON-ESG', 0.09754940122365952)","('NON-ESG', 0.0850173607468605)"
Line 639,"While the pandemic paused in-person volunteering in 2021, such as Week of Possibilities, our global week of community service event, our employees found creative ways to stay engaged with our communities.","('Human_Rights_And_Community_Relations', 0.35155147314071655)","('Employee_Health_And_Safety', 0.32328271865844727)","('Access_And_Affordability', 0.09329710900783539)","('NON-ESG', 0.35155147314071655)","('NON-ESG', 0.32328271865844727)","('NON-ESG', 0.09329710900783539)"
Line 640,"A few examples of employee volunteering in 2021: Over 200 AbbVie volunteers assembled and delivered over 1,500 math and learning kits for underserved students and teachers Nearly 600 AbbVie medical and non-medical volunteers in the Chicagoland area supported vaccination administration We partnered with Year Up to host virtual mock-interview events where AbbVie volunteers helped prepare 100+ young people for entry into the workforce Teams in Ireland initiated five beach clean ups across the countryAcross AbbVie, we run several pro bono programs so that our employees can donate their specialized skills, typically in areas advancing medicine and contributing to the research of curing devastating diseases in the developing world.","('Access_And_Affordability', 0.8733883500099182)","('Employee_Health_And_Safety', 0.024388669058680534)","('Human_Rights_And_Community_Relations', 0.01599963568150997)","(['Access to Healthcare'], 0.8733883500099182)","('NON-ESG', 0.024388669058680534)","('NON-ESG', 0.01599963568150997)"
Line 641,"A few examples of employee volunteering in 2021: Over 200 AbbVie volunteers assembled and delivered over 1,500 math and learning kits for underserved students and teachers Nearly 600 AbbVie medical and non-medical volunteers in the Chicagoland area supported vaccination administration We partnered with Year Up to host virtual mock-interview events where AbbVie volunteers helped prepare 100+ young people for entry into the workforce Teams in Ireland initiated five beach clean ups across the countryAcross AbbVie, we run several pro bono programs so that our employees can donate their specialized skills, typically in areas advancing medicine and contributing to the research of curing devastating diseases in the developing world.","('Access_And_Affordability', 0.5153194069862366)","('Employee_Health_And_Safety', 0.09056966006755829)","('Employee_Engagement_Inclusion_And_Diversity', 0.05389431118965149)","(['Access to Healthcare'], 0.5153194069862366)","('NON-ESG', 0.09056966006755829)","('NON-ESG', 0.05389431118965149)"
Line 642,"For more on our pro-bono work in neglected tropical diseases, please see the Product Innovation section of this report.","('Product_Design_And_Lifecycle_Management', 0.5229480862617493)","('Product_Quality_And_Safety', 0.12177015095949173)","('Customer_Welfare', 0.061526138335466385)","([], 0.5229480862617493)","('NON-ESG', 0.12177015095949173)","('NON-ESG', 0.061526138335466385)"
Line 643,"Through our legal pro bono program, approximately 15 AbbVie attorneys and legal staff have been working with the National Immigrant Justice Center (NIJC), a nonprofit that provides legal services to immigrants and asylum seekers, since 2018 by donating their time and skills to represent people seeking asylum in the United States on grounds of political and gender persecution.","('Employee_Engagement_Inclusion_And_Diversity', 0.8653672337532043)","('Human_Rights_And_Community_Relations', 0.019617129117250443)","('Access_And_Affordability', 0.0166410394012928)","(['Talent Attraction & Retention'], 0.8653672337532043)","('NON-ESG', 0.019617129117250443)","('NON-ESG', 0.0166410394012928)"
Line 644,We are proud to contribute to protecting human rights in this way.,"('Human_Rights_And_Community_Relations', 0.9593808054924011)","('Access_And_Affordability', 0.003923633135855198)","('Labor_Practices', 0.003217238001525402)","([], 0.9593808054924011)","('NON-ESG', 0.003923633135855198)","('NON-ESG', 0.003217238001525402)"
Line 645,"In 2021, we had four asylum victories through this work.","('Management_Of_Legal_And_Regulatory_Framework', 0.47127577662467957)","('Competitive_Behavior', 0.13380995392799377)","('Business_Ethics', 0.09882423281669617)","('NON-ESG', 0.47127577662467957)","('NON-ESG', 0.13380995392799377)","('NON-ESG', 0.09882423281669617)"
Line 646,We are actively connected with 10 clients still awaiting interviews.,"('Business_Ethics', 0.2449222356081009)","('Customer_Privacy', 0.15571452677249908)","('Business_Model_Resilience', 0.09817711263895035)","('NON-ESG', 0.2449222356081009)","('NON-ESG', 0.15571452677249908)","('NON-ESG', 0.09817711263895035)"
Line 647,"Employee Giving and Volunteering Expanding Vaccine Access in Underserved Communities Building Strong Communities 2021 Employee community volunteers (worldwide) 1,2451 Philanthropic Donations ($ millions)2$44.9 Students reached through education projects 387,879 Funds raised during employee giving campaign ($ millions) $23.7 Total amount donated to disaster relief organizations excluding product donations ($ millions) $1.2 1 In 2021, all AbbVie-organized in-person volunteering programs were paused due to COVID-19.","('Access_And_Affordability', 0.8967685699462891)","('Human_Rights_And_Community_Relations', 0.022816544398665428)","('Critical_Incident_Risk_Management', 0.010842401534318924)","(['Access to Healthcare'], 0.8967685699462891)","('NON-ESG', 0.022816544398665428)","('NON-ESG', 0.010842401534318924)"
Line 648,"Employee Giving and Volunteering Expanding Vaccine Access in Underserved Communities Building Strong Communities 2021 Employee community volunteers (worldwide) 1,2451 Philanthropic Donations ($ millions)2$44.9 Students reached through education projects 387,879 Funds raised during employee giving campaign ($ millions) $23.7 Total amount donated to disaster relief organizations excluding product donations ($ millions) $1.2 1 In 2021, all AbbVie-organized in-person volunteering programs were paused due to COVID-19.","('Management_Of_Legal_And_Regulatory_Framework', 0.2521440088748932)","('Customer_Privacy', 0.10266520828008652)","('Business_Ethics', 0.09772434830665588)","('NON-ESG', 0.2521440088748932)","('NON-ESG', 0.10266520828008652)","('NON-ESG', 0.09772434830665588)"
Line 649,"That included our annual global volunteering event, Week of Possibilities.","('Human_Rights_And_Community_Relations', 0.2507445514202118)","('Employee_Health_And_Safety', 0.22698402404785156)","('Employee_Engagement_Inclusion_And_Diversity', 0.19107414782047272)","('NON-ESG', 0.2507445514202118)","('NON-ESG', 0.22698402404785156)","('NON-ESG', 0.19107414782047272)"
Line 650,"As a result, our volunteering numbers are not in line with our historic volunteering efforts and reflect select, small scale volunteering opportunities only.","('Employee_Health_And_Safety', 0.33715763688087463)","('Employee_Engagement_Inclusion_And_Diversity', 0.1922105848789215)","('Human_Rights_And_Community_Relations', 0.10576280206441879)","('NON-ESG', 0.33715763688087463)","('NON-ESG', 0.1922105848789215)","('NON-ESG', 0.10576280206441879)"
Line 651,2 Represents new KPI added to 2021 ESG Action Report.,"('Systemic_Risk_Management', 0.24292130768299103)","('Business_Model_Resilience', 0.2147713154554367)","('Management_Of_Legal_And_Regulatory_Framework', 0.18765650689601898)","('NON-ESG', 0.24292130768299103)","('NON-ESG', 0.2147713154554367)","('NON-ESG', 0.18765650689601898)"
Line 652,Philanthropic Donations are cash donations made by AbbVie Corporate and the AbbVie Foundation to recognized 501 (c)(3) charitable organizations.,"('Management_Of_Legal_And_Regulatory_Framework', 0.844508945941925)","('Access_And_Affordability', 0.020349131897091866)","('Human_Rights_And_Community_Relations', 0.019122568890452385)","([], 0.844508945941925)","('NON-ESG', 0.020349131897091866)","('NON-ESG', 0.019122568890452385)"
Line 653,"Key Performance Indicators: Economic Activity, Volunteerism and PhilanthropyAbbVie supports the resiliency of the communities we operate in, contributing to trusted nonprofits and local programs.","('Business_Model_Resilience', 0.858640193939209)","('Human_Rights_And_Community_Relations', 0.02324577234685421)","('Employee_Engagement_Inclusion_And_Diversity', 0.016235588118433952)","(['Human Capital Development', 'Innovation Management'], 0.858640193939209)","('NON-ESG', 0.02324577234685421)","('NON-ESG', 0.016235588118433952)"
Line 654,The partnerships we build in the vicinity of our operations allow us to put our resources where they are most needed and where they can most have an impact.,"('Business_Model_Resilience', 0.3777419924736023)","('Systemic_Risk_Management', 0.09074270725250244)","('Human_Rights_And_Community_Relations', 0.06987884640693665)","('NON-ESG', 0.3777419924736023)","('NON-ESG', 0.09074270725250244)","('NON-ESG', 0.06987884640693665)"
Line 655,"At AbbVie, supporting our employees, our patients, and giving back to underserved communities is an important part of who we are.","('Access_And_Affordability', 0.9442003965377808)","('Human_Rights_And_Community_Relations', 0.005639973096549511)","('Critical_Incident_Risk_Management', 0.004830826073884964)","(['Access to Healthcare'], 0.9442003965377808)","('NON-ESG', 0.005639973096549511)","('NON-ESG', 0.004830826073884964)"
Line 656,"From the start of the COVID-19 pandemic in 2020, AbbVie quickly ramped up efforts to support COVID-19 relief for nonprofits focused on frontline healthcare workers and populations in hard-hit communities.","('Employee_Health_And_Safety', 0.30988532304763794)","('Critical_Incident_Risk_Management', 0.2334233522415161)","('Access_And_Affordability', 0.11072276532649994)","('NON-ESG', 0.30988532304763794)","('NON-ESG', 0.2334233522415161)","('NON-ESG', 0.11072276532649994)"
Line 657,"As vaccines became available, it was clear that mass inoculation would be critical to overcoming the pandemic.","('Critical_Incident_Risk_Management', 0.20248878002166748)","('Access_And_Affordability', 0.15331488847732544)","('Systemic_Risk_Management', 0.07318270951509476)","('NON-ESG', 0.20248878002166748)","('NON-ESG', 0.15331488847732544)","('NON-ESG', 0.07318270951509476)"
Line 658,"Therefore, in early 2021, AbbVie expanded its COVID-19 philanthropic support to vaccination efforts with a focus on marginalized communities disproportionately impacted by access barriers.","('Access_And_Affordability', 0.7715935111045837)","('Human_Rights_And_Community_Relations', 0.0741388201713562)","('Employee_Health_And_Safety', 0.016767919063568115)","(['Access to Healthcare'], 0.7715935111045837)","('NON-ESG', 0.0741388201713562)","('NON-ESG', 0.016767919063568115)"
Line 659,"AbbVie worked with Illinois Lake County Department of Public Health to launch a temporary vaccination clinic at the Greenbelt Cultural Center in North Chicago that vaccinated almost 6,000 seniors.","('Employee_Health_And_Safety', 0.4138462543487549)","('Access_And_Affordability', 0.20910042524337769)","('Employee_Engagement_Inclusion_And_Diversity', 0.05577707663178444)","('NON-ESG', 0.4138462543487549)","('NON-ESG', 0.20910042524337769)","('NON-ESG', 0.05577707663178444)"
Line 660,"AbbVie worked with local government and media to drive awareness of the vaccination clinic and partnered with trusted community partners to support grassroot education efforts, appointment scheduling and transportation to the clinic.","('Access_And_Affordability', 0.640915036201477)","('Employee_Health_And_Safety', 0.07894964516162872)","('Product_Quality_And_Safety', 0.04150769114494324)","(['Access to Healthcare'], 0.640915036201477)","('NON-ESG', 0.07894964516162872)","('NON-ESG', 0.04150769114494324)"
Line 661,Another key component of AbbVies COVID-19 philanthropic response in 2021 was empowering AbbVie employees to volunteer to support COVID-19 relief efforts.,"('Access_And_Affordability', 0.37074390053749084)","('Human_Rights_And_Community_Relations', 0.21250368654727936)","('Critical_Incident_Risk_Management', 0.11917231231927872)","('NON-ESG', 0.37074390053749084)","('NON-ESG', 0.21250368654727936)","('NON-ESG', 0.11917231231927872)"
Line 662,"In Illinois, nearly 600 AbbVie volunteers lent their medical and non-medical expertise to help administer more than 12,000 doses of the COVID-19 vaccine at a mass vaccination clinic in Lake County and contributed to an additional 7,000 vaccinations at a mass vaccination site in Chicago.","('Access_And_Affordability', 0.20014464855194092)","('Employee_Health_And_Safety', 0.18390589952468872)","('Product_Quality_And_Safety', 0.13787691295146942)","('NON-ESG', 0.20014464855194092)","('NON-ESG', 0.18390589952468872)","('NON-ESG', 0.13787691295146942)"
Line 663,"Additionally, in Puerto Rico, employees partnered with Direct Relief and VOCES Puerto Rico Immunization and Health Promotion Coalition to process 4,000 vaccination records to help local government efforts.","('Access_And_Affordability', 0.37858831882476807)","('Employee_Health_And_Safety', 0.2500920295715332)","('Product_Quality_And_Safety', 0.057366978377103806)","('NON-ESG', 0.37858831882476807)","('NON-ESG', 0.2500920295715332)","('NON-ESG', 0.057366978377103806)"
Line 664,The past year has been very difficult and so many people lost their lives.,"('Employee_Health_And_Safety', 0.6142644286155701)","('Critical_Incident_Risk_Management', 0.11963088810443878)","('Access_And_Affordability', 0.05683409795165062)","(['Health Outcome Contribution'], 0.6142644286155701)","('NON-ESG', 0.11963088810443878)","('NON-ESG', 0.05683409795165062)"
Line 665,"This is my opportunity to give back and I am very happy that Im relieving the frontline workers for one day at least.""","('Labor_Practices', 0.854921817779541)","('Employee_Health_And_Safety', 0.031612083315849304)","('Supply_Chain_Management', 0.02674819342792034)","([], 0.854921817779541)","('NON-ESG', 0.031612083315849304)","('NON-ESG', 0.02674819342792034)"
Line 666,"AbbVie Safety Data Scientist Surya Jayanti on why she signed up to volunteer at the Lake County Fairgrounds.of employees certified in Code of Business Conduct99%2021 Highlights countries in which we have suppliers based143 small and diverse suppliers1,770 48 2021 ESG Action Report 2021 ESG Action Report 49 Our board of directors is committed to strong corporate governance to enhance long-term stockholder value.","('Product_Quality_And_Safety', 0.4998839199542999)","('Employee_Health_And_Safety', 0.2680826783180237)","('Supply_Chain_Management', 0.03349291905760765)","('NON-ESG', 0.4998839199542999)","('NON-ESG', 0.2680826783180237)","('NON-ESG', 0.03349291905760765)"
Line 667,"Eleven of our twelve directors are independent, including the chairs and all members of the Audit, Compensation, Public Policy and Nominations and Governance Committees.","('Director_Removal', 0.5091755390167236)","('Management_Of_Legal_And_Regulatory_Framework', 0.2309037148952484)","('Business_Ethics', 0.06541208177804947)","(['Business Ethics'], 0.5091755390167236)","('NON-ESG', 0.2309037148952484)","('NON-ESG', 0.06541208177804947)"
Line 668,"Since our inception, we have had a lead independent director with robust and specific responsibilities who ensures the appropriate mix of oversight and independence is applied to all board decisions.","('Director_Removal', 0.6814797520637512)","('Management_Of_Legal_And_Regulatory_Framework', 0.07781712710857391)","('Business_Ethics', 0.048557352274656296)","(['Business Ethics'], 0.6814797520637512)","('NON-ESG', 0.07781712710857391)","('NON-ESG', 0.048557352274656296)"
Line 669,The lead independent director is chosen by and from the independent members of the board of directors.,"('Director_Removal', 0.7819110751152039)","('Data_Security', 0.02024894952774048)","('Management_Of_Legal_And_Regulatory_Framework', 0.01824435219168663)","(['Business Ethics'], 0.7819110751152039)","('NON-ESG', 0.02024894952774048)","('NON-ESG', 0.01824435219168663)"
Line 670,"Each board committee follows a charter that details its purpose, authority and responsibilities.","('Director_Removal', 0.5924713611602783)","('Management_Of_Legal_And_Regulatory_Framework', 0.11428791284561157)","('Human_Rights_And_Community_Relations', 0.025308892130851746)","(['Business Ethics'], 0.5924713611602783)","('NON-ESG', 0.11428791284561157)","('NON-ESG', 0.025308892130851746)"
Line 671,Corporate Governance AbbVies board and its committees have risk oversight responsibility for AbbVie.,"('Management_Of_Legal_And_Regulatory_Framework', 0.519108772277832)","('Director_Removal', 0.19788989424705505)","('Business_Ethics', 0.07836528867483139)","([], 0.519108772277832)","('NON-ESG', 0.19788989424705505)","('NON-ESG', 0.07836528867483139)"
Line 672,"In 2021, the board continued to focus on overseeing the companys response to COVID-19, including the impact on and resources for AbbVie employees.","('Employee_Health_And_Safety', 0.1827099770307541)","('Employee_Engagement_Inclusion_And_Diversity', 0.1390608847141266)","('Human_Rights_And_Community_Relations', 0.0885402262210846)","('NON-ESG', 0.1827099770307541)","('NON-ESG', 0.1390608847141266)","('NON-ESG', 0.0885402262210846)"
Line 673,"The board and its committees regularly review ESG topics that are meaningful to AbbVie, such as equity, equality, diversity and inclusion, environmental sustainability, and access.","('Employee_Engagement_Inclusion_And_Diversity', 0.9651986360549927)","('Human_Rights_And_Community_Relations', 0.004154877737164497)","('Employee_Health_And_Safety', 0.002420401433482766)","(['Talent Attraction & Retention'], 0.9651986360549927)","('NON-ESG', 0.004154877737164497)","('NON-ESG', 0.002420401433482766)"
Line 674,"ESG touches the entire company and as such, each of the boards committees, as well as the full board itself, oversees specific aspects of AbbVies ESG framework and strategy.","('Director_Removal', 0.4692898094654083)","('Management_Of_Legal_And_Regulatory_Framework', 0.1201048418879509)","('Business_Model_Resilience', 0.09316421300172806)","('NON-ESG', 0.4692898094654083)","('NON-ESG', 0.1201048418879509)","('NON-ESG', 0.09316421300172806)"
Line 675,"For more information on the oversight responsibilities of each committee, please see AbbVies annual proxy statement .","('Management_Of_Legal_And_Regulatory_Framework', 0.7563527822494507)","('Director_Removal', 0.07196151465177536)","('Business_Ethics', 0.019100535660982132)","([], 0.7563527822494507)","('NON-ESG', 0.07196151465177536)","('NON-ESG', 0.019100535660982132)"
Line 676,"To ensure continued and effective oversight, the board and its committees annually conduct detailed, anonymous self-evaluations.","('Director_Removal', 0.4578206241130829)","('Management_Of_Legal_And_Regulatory_Framework', 0.28414031863212585)","('Business_Ethics', 0.04230017587542534)","('NON-ESG', 0.4578206241130829)","('NON-ESG', 0.28414031863212585)","('NON-ESG', 0.04230017587542534)"
Line 677,"The full board, led by the lead independent director, discusses these evaluations to determine what, if any, actions or improvements should be undertaken.","('Director_Removal', 0.4514960050582886)","('Management_Of_Legal_And_Regulatory_Framework', 0.22381100058555603)","('Business_Model_Resilience', 0.043008483946323395)","('NON-ESG', 0.4514960050582886)","('NON-ESG', 0.22381100058555603)","('NON-ESG', 0.043008483946323395)"
Line 678,The board is also committed to AbbVies robust engagement with investors.,"('Business_Model_Resilience', 0.3067733943462372)","('Management_Of_Legal_And_Regulatory_Framework', 0.19708436727523804)","('Director_Removal', 0.07079096883535385)","('NON-ESG', 0.3067733943462372)","('NON-ESG', 0.19708436727523804)","('NON-ESG', 0.07079096883535385)"
Line 679,AbbVies annual investor engagement program includes outreach to stockholders representing nearly 40% of outstanding shares to seek feedback on AbbVies practices.,"('Management_Of_Legal_And_Regulatory_Framework', 0.185548797249794)","('Systemic_Risk_Management', 0.16146092116832733)","('Business_Model_Resilience', 0.15931104123592377)","('NON-ESG', 0.185548797249794)","('NON-ESG', 0.16146092116832733)","('NON-ESG', 0.15931104123592377)"
Line 680,This stockholder feedback is used to continually improve AbbVies practices and disclosures.,"('Systemic_Risk_Management', 0.40250301361083984)","('Business_Model_Resilience', 0.15519845485687256)","('Management_Of_Legal_And_Regulatory_Framework', 0.09741811454296112)","('NON-ESG', 0.40250301361083984)","('NON-ESG', 0.15519845485687256)","('NON-ESG', 0.09741811454296112)"
Line 681,"AbbVie is committed to a board with a diversity of experiences, identities and perspectives.","('Employee_Engagement_Inclusion_And_Diversity', 0.9598703980445862)","('Human_Rights_And_Community_Relations', 0.0034566668327897787)","('Employee_Health_And_Safety', 0.0029961441177874804)","(['Talent Attraction & Retention'], 0.9598703980445862)","('NON-ESG', 0.0034566668327897787)","('NON-ESG', 0.0029961441177874804)"
Line 682,"Diversity on the board, and throughout our workforce, strengthens AbbVies business and the oversight of the company.","('Employee_Engagement_Inclusion_And_Diversity', 0.9704867601394653)","('Employee_Health_And_Safety', 0.0027115826960653067)","('Human_Rights_And_Community_Relations', 0.0019692936912178993)","(['Talent Attraction & Retention'], 0.9704867601394653)","('NON-ESG', 0.0027115826960653067)","('NON-ESG', 0.0019692936912178993)"
Line 683,"Director nominees are based on a range of criteria, including diversity of race, ethnicity, gender, age and geography together with other volunteered identities.","('Employee_Engagement_Inclusion_And_Diversity', 0.9733673334121704)","('Employee_Health_And_Safety', 0.0019073832081630826)","('Customer_Privacy', 0.001817212556488812)","(['Talent Attraction & Retention'], 0.9733673334121704)","('NON-ESG', 0.0019073832081630826)","('NON-ESG', 0.001817212556488812)"
Line 684,"In the process of nominating individuals to serve as a member of the board of directors, the Nominations and Governance Committee considers the existing boards diversity and assesses the effectiveness of the recruitment process in achieving a diverse board.","('Employee_Engagement_Inclusion_And_Diversity', 0.7492992281913757)","('Director_Removal', 0.0913432389497757)","('Business_Model_Resilience', 0.02040041610598564)","(['Talent Attraction & Retention'], 0.7492992281913757)","('NON-ESG', 0.0913432389497757)","('NON-ESG', 0.02040041610598564)"
Line 685,"Currently, 25% of our board identify as women and 17% identify as ethnically or racially diverse.","('Employee_Engagement_Inclusion_And_Diversity', 0.9727544188499451)","('Human_Rights_And_Community_Relations', 0.001839538337662816)","('Customer_Privacy', 0.0017862280365079641)","(['Talent Attraction & Retention'], 0.9727544188499451)","('NON-ESG', 0.001839538337662816)","('NON-ESG', 0.0017862280365079641)"
Line 686,"Governance50 2021 ESG Action Report 2021 ESG Action Report 51 To make a positive, long-term impact for patients, we earn and maintain their trust by acting with integrity in everything we do.","('Management_Of_Legal_And_Regulatory_Framework', 0.3075679540634155)","('Business_Ethics', 0.2485477477312088)","('Human_Rights_And_Community_Relations', 0.11471622437238693)","('NON-ESG', 0.3075679540634155)","('NON-ESG', 0.2485477477312088)","('NON-ESG', 0.11471622437238693)"
Line 687,We follow all relevant laws and industry codes.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9621096253395081)","('Director_Removal', 0.003666816046461463)","('Business_Ethics', 0.002979105105623603)","([], 0.9621096253395081)","('NON-ESG', 0.003666816046461463)","('NON-ESG', 0.002979105105623603)"
Line 688,"Through our Code of Business Conduct , Supplier Code of Conduct and our internal anti-harassment and discrimination policy, we have clear expectations for appropriate behavior of everyone in AbbVies network.","('Employee_Engagement_Inclusion_And_Diversity', 0.4366520047187805)","('Business_Ethics', 0.22526344656944275)","('Employee_Health_And_Safety', 0.09266796708106995)","('NON-ESG', 0.4366520047187805)","('NON-ESG', 0.22526344656944275)","('NON-ESG', 0.09266796708106995)"
Line 689,Our Code of Business Conduct applies to all employees globally and is available in 31 languages.,"('Business_Ethics', 0.4469219446182251)","('Labor_Practices', 0.15024694800376892)","('Management_Of_Legal_And_Regulatory_Framework', 0.08310973644256592)","('NON-ESG', 0.4469219446182251)","('NON-ESG', 0.15024694800376892)","('NON-ESG', 0.08310973644256592)"
Line 690,"During the second quarter of each year, all employees are required to complete training on the Code and certify that they will adhere to it.","('Management_Of_Legal_And_Regulatory_Framework', 0.22350987792015076)","('Labor_Practices', 0.19000567495822906)","('Product_Quality_And_Safety', 0.14179010689258575)","('NON-ESG', 0.22350987792015076)","('NON-ESG', 0.19000567495822906)","('NON-ESG', 0.14179010689258575)"
Line 691,"Our compliance training is continually reviewed and updated, as necessary.","('Management_Of_Legal_And_Regulatory_Framework', 0.679057240486145)","('Business_Ethics', 0.126578688621521)","('Product_Quality_And_Safety', 0.033081550151109695)","([], 0.679057240486145)","('NON-ESG', 0.126578688621521)","('NON-ESG', 0.033081550151109695)"
Line 692,We also provide training to employees on anti-harassment and anti-discrimination policies and practices.,"('Employee_Engagement_Inclusion_And_Diversity', 0.6094185709953308)","('Labor_Practices', 0.1729578971862793)","('Employee_Health_And_Safety', 0.05775178223848343)","(['Talent Attraction & Retention'], 0.6094185709953308)","('NON-ESG', 0.1729578971862793)","('NON-ESG', 0.05775178223848343)"
Line 693,"Employees in particular functions take additional mandatory training on topics such as anti-corruption, anti- bribery, conflicts of interest and more.","('Business_Ethics', 0.9739500284194946)","('Management_Of_Legal_And_Regulatory_Framework', 0.003454651916399598)","('Competitive_Behavior', 0.002830056007951498)","(['Business Ethics'], 0.9739500284194946)","('NON-ESG', 0.003454651916399598)","('NON-ESG', 0.002830056007951498)"
Line 694,"In 2021, we added new modules to our conflicts of interest training.","('Management_Of_Legal_And_Regulatory_Framework', 0.5003706812858582)","('Competitive_Behavior', 0.23750492930412292)","('Business_Ethics', 0.07867374271154404)","([], 0.5003706812858582)","('NON-ESG', 0.23750492930412292)","('NON-ESG', 0.07867374271154404)"
Line 695,"As we more fully integrated Allergan into AbbVie, we educated employees on our standards through additional training.","('Employee_Engagement_Inclusion_And_Diversity', 0.3745570778846741)","('Labor_Practices', 0.17670661211013794)","('Product_Quality_And_Safety', 0.13985511660575867)","('NON-ESG', 0.3745570778846741)","('NON-ESG', 0.17670661211013794)","('NON-ESG', 0.13985511660575867)"
Line 696,"We are also committed to ethical marketing practices, as outlined in our Code of Business Conduct.","('Business_Ethics', 0.8906809687614441)","('Competitive_Behavior', 0.013991286046802998)","('Customer_Privacy', 0.013213475234806538)","(['Business Ethics'], 0.8906809687614441)","('NON-ESG', 0.013991286046802998)","('NON-ESG', 0.013213475234806538)"
Line 697,"For example, our advertising and promotion efforts focus on conveying useful product information to healthcare providers, patients and customers.","('Selling_Practices_And_Product_Labeling', 0.7055066823959351)","('Product_Design_And_Lifecycle_Management', 0.10008488595485687)","('Customer_Welfare', 0.04503969848155975)","(['Business Ethics'], 0.7055066823959351)","('NON-ESG', 0.10008488595485687)","('NON-ESG', 0.04503969848155975)"
Line 698,We only promote our pharmaceutical products for uses that have been approved or authorized by appropriate government or regulatory agencies.,"('Selling_Practices_And_Product_Labeling', 0.5008618831634521)","('Customer_Welfare', 0.18533843755722046)","('Product_Quality_And_Safety', 0.10734064877033234)","(['Business Ethics'], 0.5008618831634521)","('NON-ESG', 0.18533843755722046)","('NON-ESG', 0.10734064877033234)"
Line 699,"Our product claims are grounded in scientific evidence, accepted medical practice and government approved labeling rules in all countries where we operate.","('Selling_Practices_And_Product_Labeling', 0.8520604372024536)","('Customer_Welfare', 0.03991309925913811)","('Product_Quality_And_Safety', 0.026854658499360085)","(['Business Ethics'], 0.8520604372024536)","('NON-ESG', 0.03991309925913811)","('NON-ESG', 0.026854658499360085)"
Line 700,"AbbVies workplace environment supports a culture where employees can raise questions and concerns, helping us advance our commitment to ethical behavior.","('Business_Ethics', 0.9003690481185913)","('Human_Rights_And_Community_Relations', 0.016863953322172165)","('Competitive_Behavior', 0.010057833045721054)","(['Business Ethics'], 0.9003690481185913)","('NON-ESG', 0.016863953322172165)","('NON-ESG', 0.010057833045721054)"
Line 701,"We have established systems and processes for all employees to anonymously ask questions and report suspected or actual violations of our Code, policies and procedures.","('Business_Ethics', 0.9134768843650818)","('Customer_Privacy', 0.010539418086409569)","('Product_Quality_And_Safety', 0.007378811482340097)","(['Business Ethics'], 0.9134768843650818)","('NON-ESG', 0.010539418086409569)","('NON-ESG', 0.007378811482340097)"
Line 702,"We offer various reporting opportunities to employees, such as our Ethics and Compliance Helpline, a telephone and web-based hotline that is available 24/7 and can be used anonymously.","('Business_Ethics', 0.9349586367607117)","('Management_Of_Legal_And_Regulatory_Framework', 0.009632768109440804)","('Product_Quality_And_Safety', 0.007643772289156914)","(['Business Ethics'], 0.9349586367607117)","('NON-ESG', 0.009632768109440804)","('NON-ESG', 0.007643772289156914)"
Line 703,Employees may also contact the Office of Ethics and Compliance or Chief Ethics and Compliance Officer directly.,"('Business_Ethics', 0.9534801840782166)","('Management_Of_Legal_And_Regulatory_Framework', 0.007167893927544355)","('Product_Quality_And_Safety', 0.00480571947991848)","(['Business Ethics'], 0.9534801840782166)","('NON-ESG', 0.007167893927544355)","('NON-ESG', 0.00480571947991848)"
Line 704,All allegations are promptly investigated.,"('Business_Ethics', 0.8272389769554138)","('Management_Of_Legal_And_Regulatory_Framework', 0.01550732459872961)","('Customer_Privacy', 0.013853817246854305)","(['Business Ethics'], 0.8272389769554138)","('NON-ESG', 0.01550732459872961)","('NON-ESG', 0.013853817246854305)"
Line 705,"If we find that violations have occurred, we take corrective or disciplinary action as appropriate.","('Business_Ethics', 0.7219541072845459)","('Employee_Health_And_Safety', 0.07263018190860748)","('Management_Of_Legal_And_Regulatory_Framework', 0.0414881557226181)","(['Business Ethics'], 0.7219541072845459)","('NON-ESG', 0.07263018190860748)","('NON-ESG', 0.0414881557226181)"
Line 706,We do not tolerate retaliation against anyone who makes a good faith report.,"('Business_Ethics', 0.9043615460395813)","('Management_Of_Legal_And_Regulatory_Framework', 0.019223254173994064)","('Competitive_Behavior', 0.01379775907844305)","(['Business Ethics'], 0.9043615460395813)","('NON-ESG', 0.019223254173994064)","('NON-ESG', 0.01379775907844305)"
Line 707,We believe in the inherent dignity of every human being.,"('Human_Rights_And_Community_Relations', 0.5917116403579712)","('Labor_Practices', 0.05921575799584389)","('Employee_Engagement_Inclusion_And_Diversity', 0.05900188907980919)","([], 0.5917116403579712)","('NON-ESG', 0.05921575799584389)","('NON-ESG', 0.05900188907980919)"
Line 708,"We uphold and respect individual rights as set out in the Universal Declaration of Human Rights, focusing on preventing, mitigating and remedying any adverse human rights impacts across our value chain.","('Human_Rights_And_Community_Relations', 0.9645000696182251)","('Access_And_Affordability', 0.0032754335552453995)","('Labor_Practices', 0.002518759109079838)","([], 0.9645000696182251)","('NON-ESG', 0.0032754335552453995)","('NON-ESG', 0.002518759109079838)"
Line 709,"Our Commitment to Human Rights and the Code of Business Conduct describes the ways in which we ensure respect for all people, including our employees, contractors, suppliers and patients.","('Human_Rights_And_Community_Relations', 0.9425697922706604)","('Labor_Practices', 0.008692613802850246)","('Access_And_Affordability', 0.00566072529181838)","([], 0.9425697922706604)","('NON-ESG', 0.008692613802850246)","('NON-ESG', 0.00566072529181838)"
Line 710,"We absolutely prohibit child labor, forced labor, involuntary labor, human trafficking and unfair wages and benefits from our own operations and within our supply chain.","('Labor_Practices', 0.9774341583251953)","('Director_Removal', 0.0022236062213778496)","('Supply_Chain_Management', 0.0016376146813854575)","([], 0.9774341583251953)","('NON-ESG', 0.0022236062213778496)","('NON-ESG', 0.0016376146813854575)"
Line 711,"We do not tolerate harassment, discrimination or intimidation of any kind and are committed to maintaining a work environment free from intimidation, violence, or threats of violence.","('Employee_Engagement_Inclusion_And_Diversity', 0.2475803643465042)","('Employee_Health_And_Safety', 0.1949889361858368)","('Labor_Practices', 0.1710730344057083)","('NON-ESG', 0.2475803643465042)","('NON-ESG', 0.1949889361858368)","('NON-ESG', 0.1710730344057083)"
Line 712,"Additionally, our Global Privacy Policy protects the personal information of our employees, patients and customers.","('Customer_Privacy', 0.9604336619377136)","('Data_Security', 0.008636491373181343)","('Labor_Practices', 0.0021340881939977407)","([], 0.9604336619377136)","('NON-ESG', 0.008636491373181343)","('NON-ESG', 0.0021340881939977407)"
Line 713,We comply with each countrys labor laws and respect our employees rights to collective bargaining and freedom of association.,"('Labor_Practices', 0.9783786535263062)","('Director_Removal', 0.0024336366914212704)","('Air_Quality', 0.0014242391334846616)","([], 0.9783786535263062)","('NON-ESG', 0.0024336366914212704)","('NON-ESG', 0.0014242391334846616)"
Line 714,"In countries with collective bargaining agreements, we have regular conversations with representatives to maintain an open dialogue.","('Labor_Practices', 0.9711835980415344)","('Director_Removal', 0.002529889577999711)","('Employee_Engagement_Inclusion_And_Diversity', 0.001962861744686961)","([], 0.9711835980415344)","('NON-ESG', 0.002529889577999711)","('NON-ESG', 0.001962861744686961)"
Line 715,Twenty-four percent of our employees are represented by an independent trade union or covered by collective bargaining agreements.,"('Labor_Practices', 0.9767364263534546)","('Director_Removal', 0.002483053831383586)","('Supply_Chain_Management', 0.0015233006561174989)","([], 0.9767364263534546)","('NON-ESG', 0.002483053831383586)","('NON-ESG', 0.0015233006561174989)"
Line 716,"In Europe, our AbbVie European Employee Forum represents more than 10,000 employees and provides a forum to share information and build constructive dialogue with employee representatives across the regions countries.","('Employee_Engagement_Inclusion_And_Diversity', 0.6572784781455994)","('Employee_Health_And_Safety', 0.08596625179052353)","('Labor_Practices', 0.037112459540367126)","(['Talent Attraction & Retention'], 0.6572784781455994)","('NON-ESG', 0.08596625179052353)","('NON-ESG', 0.037112459540367126)"
Line 717,AbbVie is committed to ensuring the humane care and use of laboratory animals in the companys research and development programs.,"('Ecological_Impacts', 0.2620880901813507)","('Waste_And_Hazardous_Materials_Management', 0.20436528325080872)","('Employee_Health_And_Safety', 0.0862475112080574)","('NON-ESG', 0.2620880901813507)","('NON-ESG', 0.20436528325080872)","('NON-ESG', 0.0862475112080574)"
Line 718,"While research with animals is a regulatory requirement for the development of new medicines, AbbVies programs aim to exceed animal welfare agency standards.","('Management_Of_Legal_And_Regulatory_Framework', 0.5974087119102478)","('Product_Quality_And_Safety', 0.13154490292072296)","('Business_Ethics', 0.03575602546334267)","([], 0.5974087119102478)","('NON-ESG', 0.13154490292072296)","('NON-ESG', 0.03575602546334267)"
Line 719,Animals are only used when alternatives will not provide the data necessary to discover and develop safe and effective medicines.,"('Selling_Practices_And_Product_Labeling', 0.4379972815513611)","('Customer_Welfare', 0.18690507113933563)","('Product_Quality_And_Safety', 0.09722072631120682)","('NON-ESG', 0.4379972815513611)","('NON-ESG', 0.18690507113933563)","('NON-ESG', 0.09722072631120682)"
Line 720,"AbbVie programs are proudly supported by technical staff with state-of-the-art training and certifications in research animal care, board-certified veterinarians who are specialists in the care of research species and a Global Animal Welfare Program that assures the highest and most advanced industry welfare standards are maintained.","('Product_Quality_And_Safety', 0.1789807379245758)","('Ecological_Impacts', 0.15042565762996674)","('Management_Of_Legal_And_Regulatory_Framework', 0.08021548390388489)","('NON-ESG', 0.1789807379245758)","('NON-ESG', 0.15042565762996674)","('NON-ESG', 0.08021548390388489)"
Line 721,"We are committed to internationally accepted principles of the 3Rs (refinement, reduction, replacement).","('Management_Of_Legal_And_Regulatory_Framework', 0.6389240026473999)","('Human_Rights_And_Community_Relations', 0.10598205029964447)","('Competitive_Behavior', 0.038311608135700226)","([], 0.6389240026473999)","('NON-ESG', 0.10598205029964447)","('NON-ESG', 0.038311608135700226)"
Line 722,"In our research, we refine practices to minimize potential for pain or distress, reduce the number of animals required to achieve research objectives and replace animal studies with non- animal models or insentient species where possible.","('Employee_Health_And_Safety', 0.9343596696853638)","('Access_And_Affordability', 0.005458206404000521)","('Business_Ethics', 0.0054096318781375885)","(['Health Outcome Contribution'], 0.9343596696853638)","('NON-ESG', 0.005458206404000521)","('NON-ESG', 0.0054096318781375885)"
Line 723,"In 2021, 25 AbbVie research teams were rewarded internally for implementing animal welfare refinements, advanced technologies, improved modeling and non-animal in-vitro and in-silico platforms to reduce the number of animals required and, where appropriate, replace animal use.","('Customer_Welfare', 0.16817446053028107)","('Access_And_Affordability', 0.14937441051006317)","('GHG_Emissions', 0.12836161255836487)","('NON-ESG', 0.16817446053028107)","('NON-ESG', 0.14937441051006317)","('NON-ESG', 0.12836161255836487)"
Line 724,"In addition, following the 10-year anniversary of our canine socialization, play and adoption programs, volunteers throughout the company continue to show enthusiastic devotion to the socialization, outdoor exercise, enrichment and pre-adoption acclimation of our valuable research animals.","('Employee_Health_And_Safety', 0.2770693302154541)","('Access_And_Affordability', 0.22391435503959656)","('Employee_Engagement_Inclusion_And_Diversity', 0.14102505147457123)","('NON-ESG', 0.2770693302154541)","('NON-ESG', 0.22391435503959656)","('NON-ESG', 0.14102505147457123)"
Line 725,Ethical Conduct Human Rights Ethical Treatment of Animals We lead with ethical decision making.,"('Business_Ethics', 0.8071379661560059)","('Human_Rights_And_Community_Relations', 0.04821937158703804)","('Competitive_Behavior', 0.025153495371341705)","(['Business Ethics'], 0.8071379661560059)","('NON-ESG', 0.04821937158703804)","('NON-ESG', 0.025153495371341705)"
Line 726,"Good citizenship is good business, and good business ensures resilience and long-term success of the company.","('Business_Model_Resilience', 0.9056139588356018)","('Physical_Impacts_Of_Climate_Change', 0.009665134362876415)","('Product_Design_And_Lifecycle_Management', 0.009021147154271603)","(['Human Capital Development', 'Innovation Management'], 0.9056139588356018)","('NON-ESG', 0.009665134362876415)","('NON-ESG', 0.009021147154271603)"
Line 727,"We pursue the highest standardsoften exceeding legal and regulatory requirementsin quality, safety, compliance and performance.","('Product_Quality_And_Safety', 0.8061241507530212)","('Employee_Health_And_Safety', 0.077723428606987)","('Access_And_Affordability', 0.010739683173596859)","(['Product Quality & Recall Management'], 0.8061241507530212)","('NON-ESG', 0.077723428606987)","('NON-ESG', 0.010739683173596859)"
Line 728,"The foundation of our uncompromising integrity is our Code of Business Conduct, on which all employees must be trained and with which they agree to comply.","('Business_Ethics', 0.9613519310951233)","('Data_Security', 0.0038291809614747763)","('Customer_Privacy', 0.003162437118589878)","(['Business Ethics'], 0.9613519310951233)","('NON-ESG', 0.0038291809614747763)","('NON-ESG', 0.003162437118589878)"
Line 729,"Through this code, our employees have multiple avenues for the anonymous reporting of assumed or factual ethical violations.","('Business_Ethics', 0.9636640548706055)","('Product_Quality_And_Safety', 0.0034699696116149426)","('Management_Of_Legal_And_Regulatory_Framework', 0.0032113264314830303)","(['Business Ethics'], 0.9636640548706055)","('NON-ESG', 0.0034699696116149426)","('NON-ESG', 0.0032113264314830303)"
Line 730,We promptly review and respond to every allegation.,"('Business_Ethics', 0.892721951007843)","('Management_Of_Legal_And_Regulatory_Framework', 0.024591974914073944)","('Competitive_Behavior', 0.009129575453698635)","(['Business Ethics'], 0.892721951007843)","('NON-ESG', 0.024591974914073944)","('NON-ESG', 0.009129575453698635)"
Line 731,Protecting and ensuring the rights and dignity of each human are paramount to our ethical practices.,"('Human_Rights_And_Community_Relations', 0.9260610938072205)","('Labor_Practices', 0.009084374643862247)","('Business_Ethics', 0.007139943540096283)","([], 0.9260610938072205)","('NON-ESG', 0.009084374643862247)","('NON-ESG', 0.007139943540096283)"
Line 732,We absolutely prohibit any violations of human rights in our own operations and those of our suppliers.,"('Human_Rights_And_Community_Relations', 0.812960684299469)","('Labor_Practices', 0.03058646433055401)","('Business_Ethics', 0.022192828357219696)","([], 0.812960684299469)","('NON-ESG', 0.03058646433055401)","('NON-ESG', 0.022192828357219696)"
Line 733,Our treatment of animals is and will continue to be humane and compassionate.,"('Human_Rights_And_Community_Relations', 0.1501488834619522)","('Ecological_Impacts', 0.14189454913139343)","('Employee_Health_And_Safety', 0.1355823129415512)","('NON-ESG', 0.1501488834619522)","('NON-ESG', 0.14189454913139343)","('NON-ESG', 0.1355823129415512)"
Line 734,We adhere to international standards and all legal requirements in animal research practices.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8178892135620117)","('Business_Ethics', 0.05299157649278641)","('Product_Quality_And_Safety', 0.02460317313671112)","([], 0.8178892135620117)","('NON-ESG', 0.05299157649278641)","('NON-ESG', 0.02460317313671112)"
Line 735,"Our Code also outlines security and privacy practices as well, for both employee and patient data.","('Data_Security', 0.900966465473175)","('Customer_Privacy', 0.04419099912047386)","('Waste_And_Hazardous_Materials_Management', 0.005109796766191721)","([], 0.900966465473175)","('NON-ESG', 0.04419099912047386)","('NON-ESG', 0.005109796766191721)"
Line 736,"We comply with current regulations and look ahead to those in the pipeline around the world, preparing in advance.","('Management_Of_Legal_And_Regulatory_Framework', 0.9512380957603455)","('Human_Rights_And_Community_Relations', 0.004233867395669222)","('Energy_Management', 0.003726735943928361)","([], 0.9512380957603455)","('NON-ESG', 0.004233867395669222)","('NON-ESG', 0.003726735943928361)"
Line 737,Business Ethics 52 2021 ESG Action Report 2021 ESG Action Report 53 We established a multidisciplinary Global Digital Biomarkers Team (DBT) to explore novel applications of preclinical digital biomarkers.,"('Business_Ethics', 0.8912005424499512)","('Systemic_Risk_Management', 0.02739044837653637)","('Competitive_Behavior', 0.018481412902474403)","(['Business Ethics'], 0.8912005424499512)","('NON-ESG', 0.02739044837653637)","('NON-ESG', 0.018481412902474403)"
Line 738,"These technologies enable continuous, longitudinal and non-invasive monitoring of physiologic and behavioral parameters in rodents while they remain undisturbed in the comfort of their home environment.","('Ecological_Impacts', 0.7920846939086914)","('Employee_Health_And_Safety', 0.027035122737288475)","('Water_And_Wastewater_Management', 0.01736108772456646)","([], 0.7920846939086914)","('NON-ESG', 0.027035122737288475)","('NON-ESG', 0.01736108772456646)"
Line 739,We formed a centralized Microphysiological Systems (MPS) working group to advance development and internal application of these in vitro models.,"('Ecological_Impacts', 0.27191993594169617)","('Competitive_Behavior', 0.100348100066185)","('GHG_Emissions', 0.07780709862709045)","('NON-ESG', 0.27191993594169617)","('NON-ESG', 0.100348100066185)","('NON-ESG', 0.07780709862709045)"
Line 740,"MPS, such as organs- on-chips, are non-living systems designed to mimic physiologically relevant functions of human or animal organs and tissues and are becoming a valuable tool to accelerate drug development.","('Employee_Health_And_Safety', 0.21626509726047516)","('Ecological_Impacts', 0.16454988718032837)","('Employee_Engagement_Inclusion_And_Diversity', 0.09330872446298599)","('NON-ESG', 0.21626509726047516)","('NON-ESG', 0.16454988718032837)","('NON-ESG', 0.09330872446298599)"
Line 741,"Other innovative approaches include: Use of 3D-printed anatomic models and artificial tissues to replace in vivo animal models Development of extensive internal databases (e.g., gene sequencing, antibody promiscuity, absorption, and bioavailability data) to facilitate silico (computer-based) modeling capabilities Development and validation of specialized cellular models to replace in vivo animal models for drug candidate pre- screening and toxicity AbbVie is committed to ethical privacy practices and compliance with global privacy laws.","('Data_Security', 0.36624112725257874)","('Business_Ethics', 0.22423864901065826)","('Competitive_Behavior', 0.08919781446456909)","('NON-ESG', 0.36624112725257874)","('NON-ESG', 0.22423864901065826)","('NON-ESG', 0.08919781446456909)"
Line 742,"Other innovative approaches include: Use of 3D-printed anatomic models and artificial tissues to replace in vivo animal models Development of extensive internal databases (e.g., gene sequencing, antibody promiscuity, absorption, and bioavailability data) to facilitate silico (computer-based) modeling capabilities Development and validation of specialized cellular models to replace in vivo animal models for drug candidate pre- screening and toxicity AbbVie is committed to ethical privacy practices and compliance with global privacy laws.","('Data_Security', 0.6659063100814819)","('Customer_Privacy', 0.21603581309318542)","('Labor_Practices', 0.008608649484813213)","([], 0.6659063100814819)","('NON-ESG', 0.21603581309318542)","('NON-ESG', 0.008608649484813213)"
Line 743,AbbVie maintains a global privacy program with policies and procedures that are based on the European Unions influential General Data Protection Regulation (GDPR).,"('Data_Security', 0.8409513235092163)","('Customer_Privacy', 0.07155916094779968)","('Management_Of_Legal_And_Regulatory_Framework', 0.007087438367307186)","([], 0.8409513235092163)","('NON-ESG', 0.07155916094779968)","('NON-ESG', 0.007087438367307186)"
Line 744,"We continue to monitor the dozens of significant data privacy regulatory developments around the globe, including in the Middle East, China and the United States, and have developed an internal program to assess and implement these new laws into our global privacy program.","('Data_Security', 0.9221065640449524)","('Customer_Privacy', 0.020302824676036835)","('Business_Ethics', 0.0056020719930529594)","([], 0.9221065640449524)","('NON-ESG', 0.020302824676036835)","('NON-ESG', 0.0056020719930529594)"
Line 745,This allows us to improve and mature our global program while also providing the flexibility to address local requirements.,"('Management_Of_Legal_And_Regulatory_Framework', 0.7896105051040649)","('Human_Rights_And_Community_Relations', 0.03439443185925484)","('Competitive_Behavior', 0.022343242540955544)","([], 0.7896105051040649)","('NON-ESG', 0.03439443185925484)","('NON-ESG', 0.022343242540955544)"
Line 746,We continued the integration of AbbVie and Allergan privacy programs in 2021 as part of broader integration efforts.,"('Data_Security', 0.8851270079612732)","('Customer_Privacy', 0.042749594897031784)","('Business_Ethics', 0.007244741544127464)","([], 0.8851270079612732)","('NON-ESG', 0.042749594897031784)","('NON-ESG', 0.007244741544127464)"
Line 747,"We evaluated major programs worldwide, including privacy guidance for COVID-19 and multiple loyalty programs across our products.","('Customer_Privacy', 0.5583065748214722)","('Data_Security', 0.2132560908794403)","('Business_Ethics', 0.04290489852428436)","([], 0.5583065748214722)","('NON-ESG', 0.2132560908794403)","('NON-ESG', 0.04290489852428436)"
Line 748,"The global privacy team developed a monitoring program and conducted data classification training programs to emphasize the importance of properly classifying and protecting AbbVie data, as well as developed and released a global data subject request tool, found in our Privacy Center.","('Data_Security', 0.6906971335411072)","('Customer_Privacy', 0.22457392513751984)","('Director_Removal', 0.006522662006318569)","([], 0.6906971335411072)","('NON-ESG', 0.22457392513751984)","('NON-ESG', 0.006522662006318569)"
Line 749,These efforts continue to position AbbVie to fulfill its global privacy obligations and ethical duties regarding its collection and processing of personal data in performing its business functions.,"('Customer_Privacy', 0.9354051947593689)","('Data_Security', 0.023814070969820023)","('Business_Ethics', 0.00443717185407877)","([], 0.9354051947593689)","('NON-ESG', 0.023814070969820023)","('NON-ESG', 0.00443717185407877)"
Line 750,"In all our public policy engagements, we are transparent and compliant with our Code of Business Conduct.","('Management_Of_Legal_And_Regulatory_Framework', 0.8408578634262085)","('Business_Ethics', 0.0645439401268959)","('Director_Removal', 0.015003210864961147)","([], 0.8408578634262085)","('NON-ESG', 0.0645439401268959)","('NON-ESG', 0.015003210864961147)"
Line 751,"We pursue and advocate for policies that benefit patients, with a focus on improving access to medical advances and providing life-changing products to the patients who need them most.","('Product_Design_And_Lifecycle_Management', 0.5287942290306091)","('Access_And_Affordability', 0.1689995676279068)","('Customer_Welfare', 0.06227053329348564)","([], 0.5287942290306091)","('NON-ESG', 0.1689995676279068)","('NON-ESG', 0.06227053329348564)"
Line 752,AbbVie makes extensive disclosures regarding our political activities and political contributions as required by law and voluntarily discloses additional related information on our website.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8558700084686279)","('Director_Removal', 0.015943586826324463)","('Competitive_Behavior', 0.014781205914914608)","([], 0.8558700084686279)","('NON-ESG', 0.015943586826324463)","('NON-ESG', 0.014781205914914608)"
Line 753,"We have been recognized as a first-tier company, providing the highest level of political transparency and accountability, in the CPA-Zicklin Index from 2014-2021.","('Business_Ethics', 0.963880181312561)","('Systemic_Risk_Management', 0.004840631037950516)","('Management_Of_Legal_And_Regulatory_Framework', 0.004585771355777979)","(['Business Ethics'], 0.963880181312561)","('NON-ESG', 0.004840631037950516)","('NON-ESG', 0.004585771355777979)"
Line 754,We are an active member of trade associations and other membership organizations that are aligned with our business objectives.,"('Management_Of_Legal_And_Regulatory_Framework', 0.6534594297409058)","('Competitive_Behavior', 0.10144369304180145)","('Director_Removal', 0.03714466467499733)","([], 0.6534594297409058)","('NON-ESG', 0.10144369304180145)","('NON-ESG', 0.03714466467499733)"
Line 755,Data Privacy and Security Public Policy 2021 Percentage of employees certifying on the AbbVie Code of Business Conduct 99% Number of regulatory inspections of AbbVie commercial manufacturing facilities 57 Rate of expedited adverse event reporting EMA (European Medicines Agency) >99% Key Performance Indicators: Ethics and ComplianceRisk management is a key focus for AbbVie.,"('Business_Ethics', 0.9328902363777161)","('Data_Security', 0.019601404666900635)","('Customer_Privacy', 0.006497808266431093)","(['Business Ethics'], 0.9328902363777161)","('NON-ESG', 0.019601404666900635)","('NON-ESG', 0.006497808266431093)"
Line 756,Our board of directors reviews enterprise risks and discusses them with senior management on a regular basis.,"('Director_Removal', 0.6787369847297668)","('Business_Model_Resilience', 0.05046486482024193)","('Management_Of_Legal_And_Regulatory_Framework', 0.035117797553539276)","(['Business Ethics'], 0.6787369847297668)","('NON-ESG', 0.05046486482024193)","('NON-ESG', 0.035117797553539276)"
Line 757,The board receives regular reports from cross-functional leaders with subject matter expertise in risk management within their areas of responsibility.,"('Systemic_Risk_Management', 0.8490327000617981)","('Business_Model_Resilience', 0.03568800911307335)","('Physical_Impacts_Of_Climate_Change', 0.015448327176272869)","([], 0.8490327000617981)","('NON-ESG', 0.03568800911307335)","('NON-ESG', 0.015448327176272869)"
Line 758,Each member is responsible for proactively identifying and mitigating risks in their respective functions and providing feedback on these risks.,"('Systemic_Risk_Management', 0.8644230961799622)","('Physical_Impacts_Of_Climate_Change', 0.03451232612133026)","('Business_Model_Resilience', 0.01808478683233261)","([], 0.8644230961799622)","('NON-ESG', 0.03451232612133026)","('NON-ESG', 0.01808478683233261)"
Line 759,Specific risks are additionally overseen by our Risk Management and Global Security teams.,"('Systemic_Risk_Management', 0.8496712446212769)","('Data_Security', 0.05143529549241066)","('Business_Ethics', 0.018177883699536324)","([], 0.8496712446212769)","('NON-ESG', 0.05143529549241066)","('NON-ESG', 0.018177883699536324)"
Line 760,Our Executive Crisis Management Team (ECMT) anticipates and mitigates internal and external business risks.,"('Systemic_Risk_Management', 0.8831073045730591)","('Physical_Impacts_Of_Climate_Change', 0.034954119473695755)","('Critical_Incident_Risk_Management', 0.01311937253922224)","([], 0.8831073045730591)","('NON-ESG', 0.034954119473695755)","('NON-ESG', 0.01311937253922224)"
Line 761,"This team, led by our EVP, Operations, and consisting of functional leaders from across the enterprise, assesses each area of our business considering economic, environmental, and other risks with potential impacts to our facilities, employees and partners, and supply chains.","('Supply_Chain_Management', 0.9509837627410889)","('Labor_Practices', 0.004107252229005098)","('Physical_Impacts_Of_Climate_Change', 0.0038836966268718243)","([], 0.9509837627410889)","('NON-ESG', 0.004107252229005098)","('NON-ESG', 0.0038836966268718243)"
Line 762,With these inputs we establish risk management strategies and formal plans.,"('Systemic_Risk_Management', 0.7733066082000732)","('Management_Of_Legal_And_Regulatory_Framework', 0.05199132114648819)","('Business_Model_Resilience', 0.04795752093195915)","([], 0.7733066082000732)","('NON-ESG', 0.05199132114648819)","('NON-ESG', 0.04795752093195915)"
Line 763,"In 2021, we integrated Allergan into this planning.","('Customer_Welfare', 0.20193257927894592)","('GHG_Emissions', 0.11064466834068298)","('Energy_Management', 0.09340354800224304)","('NON-ESG', 0.20193257927894592)","('NON-ESG', 0.11064466834068298)","('NON-ESG', 0.09340354800224304)"
Line 764,"We routinely review and adjust plans to improve effectiveness and strengthen protection for our patients, employees and our business.","('Management_Of_Legal_And_Regulatory_Framework', 0.5146999359130859)","('Access_And_Affordability', 0.18927811086177826)","('Human_Rights_And_Community_Relations', 0.05280478298664093)","([], 0.5146999359130859)","('NON-ESG', 0.18927811086177826)","('NON-ESG', 0.05280478298664093)"
Line 765,AbbVies Global Security team conducts annual training with practice risk scenarios for our global and local Crisis Action Teams (CATs) on topics such as preparedness and resiliency for expected and unexpected crisis events.,"('Physical_Impacts_Of_Climate_Change', 0.42406636476516724)","('Critical_Incident_Risk_Management', 0.34241631627082825)","('Systemic_Risk_Management', 0.058821242302656174)","('NON-ESG', 0.42406636476516724)","('NON-ESG', 0.34241631627082825)","('NON-ESG', 0.058821242302656174)"
Line 766,"In 2020 and 2021, our CATs met regularly to address and manage the ongoing COVID-19 pandemic.","('Physical_Impacts_Of_Climate_Change', 0.28943517804145813)","('Air_Quality', 0.08266447484493256)","('GHG_Emissions', 0.08255418390035629)","('NON-ESG', 0.28943517804145813)","('NON-ESG', 0.08266447484493256)","('NON-ESG', 0.08255418390035629)"
Line 767,Our Business Technology Solutions team conducts cybersecurity awareness training across the entire employee network that focuses on educating employees how to identify and report cyber-threats.,"('Data_Security', 0.954304575920105)","('Physical_Impacts_Of_Climate_Change', 0.004484343808144331)","('Systemic_Risk_Management', 0.004383878782391548)","([], 0.954304575920105)","('NON-ESG', 0.004484343808144331)","('NON-ESG', 0.004383878782391548)"
Line 768,Our Global Anti-Counterfeiting Steering Committee is responsible for identifying and mitigating risks related to AbbVie medicines.,"('Data_Security', 0.36057740449905396)","('Business_Ethics', 0.17203371226787567)","('Systemic_Risk_Management', 0.09368060529232025)","('NON-ESG', 0.36057740449905396)","('NON-ESG', 0.17203371226787567)","('NON-ESG', 0.09368060529232025)"
Line 769,AbbVies Product Security Alert (PSA) Board is responsible for reviewing and reporting substandard and falsified medicines to the relevant authorities.,"('Business_Ethics', 0.2866331934928894)","('Data_Security', 0.2609447240829468)","('Product_Quality_And_Safety', 0.10693396627902985)","('NON-ESG', 0.2866331934928894)","('NON-ESG', 0.2609447240829468)","('NON-ESG', 0.10693396627902985)"
Line 770,"With the integration of Allergan, we expanded our work to prevent counterfeiting.","('Business_Ethics', 0.2824646830558777)","('Data_Security', 0.18144123256206512)","('Competitive_Behavior', 0.11566673964262009)","('NON-ESG', 0.2824646830558777)","('NON-ESG', 0.18144123256206512)","('NON-ESG', 0.11566673964262009)"
Line 771,"For example, together with the Chinese government, we worked to address counterfeit and diverted BOTOX and other Allergan products.","('Business_Ethics', 0.2774307131767273)","('Product_Quality_And_Safety', 0.15373405814170837)","('Competitive_Behavior', 0.1411471664905548)","('NON-ESG', 0.2774307131767273)","('NON-ESG', 0.15373405814170837)","('NON-ESG', 0.1411471664905548)"
Line 772,We also increased facility security at Allergan production sites to meet the highest-level standards to which AbbVie complies.,"('Business_Ethics', 0.5498301982879639)","('Product_Quality_And_Safety', 0.1388307809829712)","('Systemic_Risk_Management', 0.04970422014594078)","(['Business Ethics'], 0.5498301982879639)","('NON-ESG', 0.1388307809829712)","('NON-ESG', 0.04970422014594078)"
Line 773,"In 2020, we piloted a risk assessment exercise with select brand supply teams.","('Supply_Chain_Management', 0.9221070408821106)","('Product_Design_And_Lifecycle_Management', 0.01256604678928852)","('Energy_Management', 0.008024575188755989)","([], 0.9221070408821106)","('NON-ESG', 0.01256604678928852)","('NON-ESG', 0.008024575188755989)"
Line 774,"We introduced catastrophic events, like hurricanes that result in total inventory loss, to this pilot and identified the key nodes in each products supply chain to consider the full breadth of risk.","('Supply_Chain_Management', 0.9240345358848572)","('Systemic_Risk_Management', 0.012789802625775337)","('Physical_Impacts_Of_Climate_Change', 0.007500427775084972)","([], 0.9240345358848572)","('NON-ESG', 0.012789802625775337)","('NON-ESG', 0.007500427775084972)"
Line 775,"With its success, we rolled out the same assessment to our eight largest brands in 2021.A reliable supply chain allows AbbVie to deliver on our commitment to patients.","('Supply_Chain_Management', 0.9202376008033752)","('Product_Design_And_Lifecycle_Management', 0.01047421246767044)","('Energy_Management', 0.005265609826892614)","([], 0.9202376008033752)","('NON-ESG', 0.01047421246767044)","('NON-ESG', 0.005265609826892614)"
Line 776,"In 2021, we purchased goods and services valued at more than $15.6 billion from over 51,000 suppliers across 143 countries.","('Product_Design_And_Lifecycle_Management', 0.8500844836235046)","('Supply_Chain_Management', 0.04541778564453125)","('Energy_Management', 0.022548675537109375)","([], 0.8500844836235046)","('NON-ESG', 0.04541778564453125)","('NON-ESG', 0.022548675537109375)"
Line 777,Our supply chain strategy includes support for small and diverse businesses.,"('Supply_Chain_Management', 0.9378014802932739)","('Product_Design_And_Lifecycle_Management', 0.006005839444696903)","('Physical_Impacts_Of_Climate_Change', 0.005044668447226286)","([], 0.9378014802932739)","('NON-ESG', 0.006005839444696903)","('NON-ESG', 0.005044668447226286)"
Line 778,"In 2021, we spent $715 million working with approximately 1,770 small and diverse businesses the United States, including Puerto Rico.","('Employee_Engagement_Inclusion_And_Diversity', 0.946193516254425)","('Human_Rights_And_Community_Relations', 0.00548614701256156)","('Business_Model_Resilience', 0.003974826540797949)","(['Talent Attraction & Retention'], 0.946193516254425)","('NON-ESG', 0.00548614701256156)","('NON-ESG', 0.003974826540797949)"
Line 779,"With AbbVies investment, thousands of suppliers are met with business and growth opportunities, many of them working closely with AbbVie experts.","('Supply_Chain_Management', 0.9134267568588257)","('Product_Design_And_Lifecycle_Management', 0.010370285250246525)","('Energy_Management', 0.008552374318242073)","([], 0.9134267568588257)","('NON-ESG', 0.010370285250246525)","('NON-ESG', 0.008552374318242073)"
Line 780,"We expect our suppliers to espouse the same social and environmental values that we do: diversity and inclusion, sustainable business practices and human rights protections.","('Employee_Engagement_Inclusion_And_Diversity', 0.568885862827301)","('Human_Rights_And_Community_Relations', 0.30999454855918884)","('Access_And_Affordability', 0.012304459698498249)","(['Talent Attraction & Retention'], 0.568885862827301)","('NON-ESG', 0.30999454855918884)","('NON-ESG', 0.012304459698498249)"
Line 781,"To ensure alignment with these values, our suppliers are asked to comply with our Supplier Code of Conduct.","('Supply_Chain_Management', 0.9335691332817078)","('Labor_Practices', 0.009719916619360447)","('Product_Design_And_Lifecycle_Management', 0.004281595349311829)","([], 0.9335691332817078)","('NON-ESG', 0.009719916619360447)","('NON-ESG', 0.004281595349311829)"
Line 782,"Risk Management Supply Chain Sustainability54 2021 ESG Action Report 2021 ESG Action Report 55 A core goal of AbbVies is to ensure our medicines and products are available for patients who need them, when they need them.","('Supply_Chain_Management', 0.3990064263343811)","('Product_Design_And_Lifecycle_Management', 0.3751944899559021)","('Selling_Practices_And_Product_Labeling', 0.040746185928583145)","('NON-ESG', 0.3990064263343811)","('NON-ESG', 0.3751944899559021)","('NON-ESG', 0.040746185928583145)"
Line 783,"One way we achieve this is by maintaining an assurance of supply, requiring all suppliers of core inputs to be able to deliver quality products on time.","('Product_Design_And_Lifecycle_Management', 0.9349758625030518)","('Supply_Chain_Management', 0.015649784356355667)","('Product_Quality_And_Safety', 0.006625331938266754)","([], 0.9349758625030518)","('NON-ESG', 0.015649784356355667)","('NON-ESG', 0.006625331938266754)"
Line 784,We regularly track the business stability of crucial suppliers to preemptively mitigate any risk and develop solutions.,"('Supply_Chain_Management', 0.9485682249069214)","('Systemic_Risk_Management', 0.007934915833175182)","('Physical_Impacts_Of_Climate_Change', 0.005726061761379242)","([], 0.9485682249069214)","('NON-ESG', 0.007934915833175182)","('NON-ESG', 0.005726061761379242)"
Line 785,"In 2021, given the ongoing uncertainties of the COVID-19 pandemic, we conducted a pre-buy to purchase key materials to ensure we met patient needs throughout the year.","('Access_And_Affordability', 0.3470759093761444)","('Systemic_Risk_Management', 0.08436421304941177)","('Supply_Chain_Management', 0.08065147697925568)","('NON-ESG', 0.3470759093761444)","('NON-ESG', 0.08436421304941177)","('NON-ESG', 0.08065147697925568)"
Line 786,"During the pandemic we also supported a handful of our critical suppliers financially and strategically, to continue to meet our commitment to patients.","('Supply_Chain_Management', 0.829938530921936)","('Physical_Impacts_Of_Climate_Change', 0.0322236493229866)","('Systemic_Risk_Management', 0.02129681594669819)","([], 0.829938530921936)","('NON-ESG', 0.0322236493229866)","('NON-ESG', 0.02129681594669819)"
Line 787,"While backorders and shortages impacted multiple industries around the world, we were able to make our products available to our patients over 99% of the time.","('Product_Design_And_Lifecycle_Management', 0.8094696998596191)","('Product_Quality_And_Safety', 0.051035016775131226)","('Selling_Practices_And_Product_Labeling', 0.027795709669589996)","([], 0.8094696998596191)","('NON-ESG', 0.051035016775131226)","('NON-ESG', 0.027795709669589996)"
Line 788,"Assurance of Supply56 2021 ESG Action Report 2021 ESG Action Report 57 At In Case of Emergency (ICE) our mission is to ensure no person becomes ill, injured or loses a life at work.","('Employee_Health_And_Safety', 0.8358442187309265)","('Critical_Incident_Risk_Management', 0.12250691652297974)","('Access_And_Affordability', 0.0039225113578140736)","(['Health Outcome Contribution'], 0.8358442187309265)","('NON-ESG', 0.12250691652297974)","('NON-ESG', 0.0039225113578140736)"
Line 789,AbbVies mentorship program gave ICE the tools and resources to survive the COVID-19 pandemic.,"('Access_And_Affordability', 0.47667452692985535)","('Systemic_Risk_Management', 0.0586470402777195)","('Physical_Impacts_Of_Climate_Change', 0.053472068160772324)","('NON-ESG', 0.47667452692985535)","('NON-ESG', 0.0586470402777195)","('NON-ESG', 0.053472068160772324)"
Line 790,"The mentorship program paved the way to success for us and highlighted the organizations strengths, weaknesses, threats and opportunities.","('Data_Security', 0.35432901978492737)","('Systemic_Risk_Management', 0.28014546632766724)","('Business_Model_Resilience', 0.050555892288684845)","('NON-ESG', 0.35432901978492737)","('NON-ESG', 0.28014546632766724)","('NON-ESG', 0.050555892288684845)"
Line 791,"This helped us see that we can persevere and increase revenues even in the toughest of times.""","('Systemic_Risk_Management', 0.40793663263320923)","('Business_Model_Resilience', 0.13876251876354218)","('Competitive_Behavior', 0.12603239715099335)","('NON-ESG', 0.40793663263320923)","('NON-ESG', 0.13876251876354218)","('NON-ESG', 0.12603239715099335)"
Line 792,"Pamela Isom, President and CEO of ICE Safety Solutions Our Supplier Diversity Program enhances our competitiveness in the market by advancing opportunities to partner with small, woman- and minority-owned businesses.","('Supply_Chain_Management', 0.7154127359390259)","('Employee_Engagement_Inclusion_And_Diversity', 0.05384949967265129)","('Competitive_Behavior', 0.029353968799114227)","([], 0.7154127359390259)","('NON-ESG', 0.05384949967265129)","('NON-ESG', 0.029353968799114227)"
Line 793,"AbbVie continues to support our diverse suppliers including underrepresented populations, women, military veterans and the disabled communitythrough integration into our supply chain.","('Supply_Chain_Management', 0.9016751050949097)","('Product_Design_And_Lifecycle_Management', 0.013222971931099892)","('Labor_Practices', 0.008996831253170967)","([], 0.9016751050949097)","('NON-ESG', 0.013222971931099892)","('NON-ESG', 0.008996831253170967)"
Line 794,"Our Diverse Supplier Mentoring program, in partnership with the Diversity Alliance for Science, provides business owners with tools, resources and counsel.","('Employee_Engagement_Inclusion_And_Diversity', 0.9563128352165222)","('Access_And_Affordability', 0.003855923656374216)","('Employee_Health_And_Safety', 0.0036837405059486628)","(['Talent Attraction & Retention'], 0.9563128352165222)","('NON-ESG', 0.003855923656374216)","('NON-ESG', 0.0036837405059486628)"
Line 795,We also sponsor and provide scholarships for our diverse suppliers to participate in entrepreneurial education programs and conferences.,"('Employee_Engagement_Inclusion_And_Diversity', 0.5515581965446472)","('Access_And_Affordability', 0.1935001015663147)","('Human_Rights_And_Community_Relations', 0.04915900155901909)","(['Talent Attraction & Retention'], 0.5515581965446472)","('NON-ESG', 0.1935001015663147)","('NON-ESG', 0.04915900155901909)"
Line 796,We take a broad approach to discovering and connecting with these businesses.,"('Business_Model_Resilience', 0.4613363444805145)","('Product_Design_And_Lifecycle_Management', 0.0946231409907341)","('Employee_Engagement_Inclusion_And_Diversity', 0.08692078292369843)","('NON-ESG', 0.4613363444805145)","('NON-ESG', 0.0946231409907341)","('NON-ESG', 0.08692078292369843)"
Line 797,"AbbVie representatives participate in matchmaking events, trade fairs and conferences where we can understand the products and services of these diverse businesses.","('Product_Design_And_Lifecycle_Management', 0.8470458984375)","('Customer_Welfare', 0.031984247267246246)","('Selling_Practices_And_Product_Labeling', 0.026004986837506294)","([], 0.8470458984375)","('NON-ESG', 0.031984247267246246)","('NON-ESG', 0.026004986837506294)"
Line 798,"AbbVie works with suppliers who, like us, operate with the future in mind.","('Supply_Chain_Management', 0.8461243510246277)","('Product_Design_And_Lifecycle_Management', 0.036920685321092606)","('Business_Model_Resilience', 0.011223322711884975)","([], 0.8461243510246277)","('NON-ESG', 0.036920685321092606)","('NON-ESG', 0.011223322711884975)"
Line 799,"Our Supplier Social Responsibility Program requires our suppliers to maintain fair labor practices, foster worker safety, actively assess and manage their risk and maintain environmentally responsible manufacturing processes.","('Employee_Health_And_Safety', 0.552955687046051)","('Labor_Practices', 0.3355882465839386)","('Supply_Chain_Management', 0.013508598320186138)","(['Health Outcome Contribution'], 0.552955687046051)","('NON-ESG', 0.3355882465839386)","('NON-ESG', 0.013508598320186138)"
Line 800,"In 2021, AbbVie completed its biennial supplier sustainability survey with our top 200 suppliers by spend.","('Supply_Chain_Management', 0.9307650923728943)","('Product_Design_And_Lifecycle_Management', 0.010989162139594555)","('Labor_Practices', 0.004777586553245783)","([], 0.9307650923728943)","('NON-ESG', 0.010989162139594555)","('NON-ESG', 0.004777586553245783)"
Line 801,"This survey included sections on environmental sustainability, labor, ethics and cybersecurity.","('Business_Ethics', 0.955390989780426)","('Data_Security', 0.005453718360513449)","('Management_Of_Legal_And_Regulatory_Framework', 0.00500556081533432)","(['Business Ethics'], 0.955390989780426)","('NON-ESG', 0.005453718360513449)","('NON-ESG', 0.00500556081533432)"
Line 802,"Should our suppliers need support to achieve compliance or have an interest in establishing higher standards, our Environmental, Health and Safety (EHS) team offers pro bono services, including EHS audits and sustainability training.","('Product_Quality_And_Safety', 0.5076615214347839)","('Supply_Chain_Management', 0.149668887257576)","('Employee_Health_And_Safety', 0.040866486728191376)","(['Product Quality & Recall Management'], 0.5076615214347839)","('NON-ESG', 0.149668887257576)","('NON-ESG', 0.040866486728191376)"
Line 803,"We outline our expectations and requirements to our suppliers through our Supplier Code of Conduct , all of whom must comply.","('Supply_Chain_Management', 0.9209789633750916)","('Labor_Practices', 0.014275246299803257)","('Product_Design_And_Lifecycle_Management', 0.005244142841547728)","([], 0.9209789633750916)","('NON-ESG', 0.014275246299803257)","('NON-ESG', 0.005244142841547728)"
Line 804,AbbVie conducts quality assessments and audits of our critical suppliers to ensure suppliers uphold our standards.,"('Supply_Chain_Management', 0.4858630299568176)","('Business_Ethics', 0.09195937216281891)","('Product_Quality_And_Safety', 0.0919155552983284)","('NON-ESG', 0.4858630299568176)","('NON-ESG', 0.09195937216281891)","('NON-ESG', 0.0919155552983284)"
Line 805,"Should AbbVie standards not be met, we conduct a detailed risk evaluation that considers the potential impact on product efficacy, safety, availability and patient experience.","('Product_Quality_And_Safety', 0.87277752161026)","('Product_Design_And_Lifecycle_Management', 0.027235308662056923)","('Selling_Practices_And_Product_Labeling', 0.021655233576893806)","(['Product Quality & Recall Management'], 0.87277752161026)","('NON-ESG', 0.027235308662056923)","('NON-ESG', 0.021655233576893806)"
Line 806,We conduct an in-depth audit of these critical suppliers at least once every three years.,"('Supply_Chain_Management', 0.9339733719825745)","('Systemic_Risk_Management', 0.010490979067981243)","('Physical_Impacts_Of_Climate_Change', 0.005351164378225803)","([], 0.9339733719825745)","('NON-ESG', 0.010490979067981243)","('NON-ESG', 0.005351164378225803)"
Line 807,"We take strong, proactive measures to maintain the security of our supply chain.","('Supply_Chain_Management', 0.9474194645881653)","('Labor_Practices', 0.004574310965836048)","('Product_Design_And_Lifecycle_Management', 0.004369540140032768)","([], 0.9474194645881653)","('NON-ESG', 0.004574310965836048)","('NON-ESG', 0.004369540140032768)"
Line 808,"Supplier Diversity Supplier Social Responsibility Program Supplier Risk Management 2021 Total supplier spend (worldwide) ($ millions) $15,600 Total spend with small and diverse U.","('Supply_Chain_Management', 0.923034131526947)","('Labor_Practices', 0.013511212542653084)","('Product_Design_And_Lifecycle_Management', 0.005216756835579872)","([], 0.923034131526947)","('NON-ESG', 0.013511212542653084)","('NON-ESG', 0.005216756835579872)"
Line 809,"S. suppliers ($ millions) $715 Number of supplier sites assessed in-depth for quality 470 Percentage of supplier sites with greatest impact on product quality and safety assessed in-depth 49%Key Performance Indicators: Supplier Spend and DiversityAbbVies mission is to make a remarkable impact on peoples lives today and advance groundbreaking science to address the medical challenges of tomorrow, while achieving top tier financial performance.","('Product_Quality_And_Safety', 0.38863587379455566)","('Product_Design_And_Lifecycle_Management', 0.291625052690506)","('Supply_Chain_Management', 0.09293245524168015)","('NON-ESG', 0.38863587379455566)","('NON-ESG', 0.291625052690506)","('NON-ESG', 0.09293245524168015)"
Line 810,"We will continue to live up to this mission by: Discovering and developing innovative medicines and products that solve serious health issues Nurturing diverse talent as a source of innovation Partnering and collaborating with healthcare systems, diverse suppliers and community organizations to deliver effective medicines and supportive strategies that advance science, improve health outcomes and strengthen our collective impact Our existing portfolio and promising pipeline of new medicines and treatments provide us with a strong outlook for 2022 and beyond.","('Customer_Welfare', 0.32717159390449524)","('Product_Design_And_Lifecycle_Management', 0.14222872257232666)","('Selling_Practices_And_Product_Labeling', 0.12555019557476044)","('NON-ESG', 0.32717159390449524)","('NON-ESG', 0.14222872257232666)","('NON-ESG', 0.12555019557476044)"
Line 811,"We will continue to live up to this mission by: Discovering and developing innovative medicines and products that solve serious health issues Nurturing diverse talent as a source of innovation Partnering and collaborating with healthcare systems, diverse suppliers and community organizations to deliver effective medicines and supportive strategies that advance science, improve health outcomes and strengthen our collective impact Our existing portfolio and promising pipeline of new medicines and treatments provide us with a strong outlook for 2022 and beyond.","('Business_Model_Resilience', 0.747136652469635)","('Systemic_Risk_Management', 0.048722680658102036)","('Physical_Impacts_Of_Climate_Change', 0.027776187285780907)","(['Human Capital Development', 'Innovation Management'], 0.747136652469635)","('NON-ESG', 0.048722680658102036)","('NON-ESG', 0.027776187285780907)"
Line 812,"As we approach our 10-year anniversary of being an independent company, we will continue to innovate with integrity and intention to advance the long-term health of our patients, our people and our planet.","('Business_Model_Resilience', 0.4387435019016266)","('Human_Rights_And_Community_Relations', 0.09770266711711884)","('Employee_Engagement_Inclusion_And_Diversity', 0.08869536966085434)","('NON-ESG', 0.4387435019016266)","('NON-ESG', 0.09770266711711884)","('NON-ESG', 0.08869536966085434)"
Line 813,"We are driven by our commitment to science, which is a commitment to better our society.","('Human_Rights_And_Community_Relations', 0.21453693509101868)","('Ecological_Impacts', 0.171098530292511)","('Access_And_Affordability', 0.1072540208697319)","('NON-ESG', 0.21453693509101868)","('NON-ESG', 0.171098530292511)","('NON-ESG', 0.1072540208697319)"
Line 814,"Looking Ahead58 2021 ESG Action Report 2021 ESG Action Report 5960 2021 ESG Action Report 2021 ESG Action Report 61 SDG Relevant sub-targets AbbVies role 3.2 End preventable deaths of newborns and children < 5 years ofage 3.3 End AIDS, tuberculosis, malaria and neglected tropical diseases; combat hepatitis, water-borne diseases and other communicable diseases 3.4 Reduce premature mortality from non- communicable diseases through prevention and treatment; promote mental health and well-beingOur medicines treat respiratory conditions in premature newborns, HIV and hepatitis C and cancer.","('Employee_Health_And_Safety', 0.5695334672927856)","('Access_And_Affordability', 0.22001773118972778)","('Product_Quality_And_Safety', 0.03244495764374733)","(['Health Outcome Contribution'], 0.5695334672927856)","('NON-ESG', 0.22001773118972778)","('NON-ESG', 0.03244495764374733)"
Line 815,"Looking Ahead58 2021 ESG Action Report 2021 ESG Action Report 5960 2021 ESG Action Report 2021 ESG Action Report 61 SDG Relevant sub-targets AbbVies role 3.2 End preventable deaths of newborns and children < 5 years ofage 3.3 End AIDS, tuberculosis, malaria and neglected tropical diseases; combat hepatitis, water-borne diseases and other communicable diseases 3.4 Reduce premature mortality from non- communicable diseases through prevention and treatment; promote mental health and well-beingOur medicines treat respiratory conditions in premature newborns, HIV and hepatitis C and cancer.","('Employee_Health_And_Safety', 0.5280988812446594)","('Access_And_Affordability', 0.14996901154518127)","('Employee_Engagement_Inclusion_And_Diversity', 0.04440777748823166)","(['Health Outcome Contribution'], 0.5280988812446594)","('NON-ESG', 0.14996901154518127)","('NON-ESG', 0.04440777748823166)"
Line 816,"Our research on neglected tropical diseases, tuberculosis and malaria will help to directly address these targets.","('Systemic_Risk_Management', 0.1797870695590973)","('Access_And_Affordability', 0.09997247904539108)","('Employee_Health_And_Safety', 0.0898771807551384)","('NON-ESG', 0.1797870695590973)","('NON-ESG', 0.09997247904539108)","('NON-ESG', 0.0898771807551384)"
Line 817,"In addition, our philanthropy work includes supporting and strengthening healthcare systems.","('Management_Of_Legal_And_Regulatory_Framework', 0.31701967120170593)","('Access_And_Affordability', 0.15161052346229553)","('Human_Rights_And_Community_Relations', 0.15041778981685638)","('NON-ESG', 0.31701967120170593)","('NON-ESG', 0.15161052346229553)","('NON-ESG', 0.15041778981685638)"
Line 818,Read more in the Product Innovation and Community & Partner Engagement and Impact sections of this report.,"('Product_Design_And_Lifecycle_Management', 0.9339993000030518)","('Business_Model_Resilience', 0.010471334680914879)","('Supply_Chain_Management', 0.007022174075245857)","([], 0.9339993000030518)","('NON-ESG', 0.010471334680914879)","('NON-ESG', 0.007022174075245857)"
Line 819,"4.1 Ensure all girls and boys complete free, equitable, qualityeducation 4.4 Increase the number of people who have relevant skills for employment, decent jobs and entrepreneurship 4.5 Eliminate gender disparities in education and ensure equal access to education and training for the vulnerable 4.a Build and upgrade education facilities that are child, disability and gender sensitive and provide safe, nonviolent, inclusive and effective learning environments for allSupporting effective educational programs for underserved school-age children is a philanthropic priority for AbbVie and the AbbVie Foundation.","('Access_And_Affordability', 0.5528439879417419)","('Employee_Engagement_Inclusion_And_Diversity', 0.2217836081981659)","('Human_Rights_And_Community_Relations', 0.04351744055747986)","(['Access to Healthcare'], 0.5528439879417419)","('NON-ESG', 0.2217836081981659)","('NON-ESG', 0.04351744055747986)"
Line 820,"4.1 Ensure all girls and boys complete free, equitable, qualityeducation 4.4 Increase the number of people who have relevant skills for employment, decent jobs and entrepreneurship 4.5 Eliminate gender disparities in education and ensure equal access to education and training for the vulnerable 4.a Build and upgrade education facilities that are child, disability and gender sensitive and provide safe, nonviolent, inclusive and effective learning environments for allSupporting effective educational programs for underserved school-age children is a philanthropic priority for AbbVie and the AbbVie Foundation.","('Access_And_Affordability', 0.9397299289703369)","('Product_Quality_And_Safety', 0.00613201130181551)","('Critical_Incident_Risk_Management', 0.005163467023521662)","(['Access to Healthcare'], 0.9397299289703369)","('NON-ESG', 0.00613201130181551)","('NON-ESG', 0.005163467023521662)"
Line 821,"By leveraging our highly skilled workforce, we advance skill development for underserved students through mentorship, training and exposure to STEM projects.","('Access_And_Affordability', 0.9252332448959351)","('Product_Quality_And_Safety', 0.007824737578630447)","('Employee_Engagement_Inclusion_And_Diversity', 0.0073660993948578835)","(['Access to Healthcare'], 0.9252332448959351)","('NON-ESG', 0.007824737578630447)","('NON-ESG', 0.0073660993948578835)"
Line 822,Read more in Community & Partner Engagement and Impact.,"('Human_Rights_And_Community_Relations', 0.9479115009307861)","('Access_And_Affordability', 0.004821097478270531)","('Employee_Engagement_Inclusion_And_Diversity', 0.004191658925265074)","([], 0.9479115009307861)","('NON-ESG', 0.004821097478270531)","('NON-ESG', 0.004191658925265074)"
Line 823,"5.1 End all forms of discrimination against all women and girls 5.2 Eliminate all forms of violence against women and girls in the public and private spheres, including trafficking and sexual and other types of exploitation 5.5 Ensure womens full and effective participation and equal opportunities for leadership at all levels of decision-making in political, economic and public lifeOur five-year Equity, Equality, Diversity & Inclusion (EED&I) strategy is focused on creating a culture of equity & inclusion through education, removing barriers, creating differentiation and measurement.","('Employee_Engagement_Inclusion_And_Diversity', 0.9417087435722351)","('Labor_Practices', 0.00929362140595913)","('Human_Rights_And_Community_Relations', 0.008760015480220318)","(['Talent Attraction & Retention'], 0.9417087435722351)","('NON-ESG', 0.00929362140595913)","('NON-ESG', 0.008760015480220318)"
Line 824,"5.1 End all forms of discrimination against all women and girls 5.2 Eliminate all forms of violence against women and girls in the public and private spheres, including trafficking and sexual and other types of exploitation 5.5 Ensure womens full and effective participation and equal opportunities for leadership at all levels of decision-making in political, economic and public lifeOur five-year Equity, Equality, Diversity & Inclusion (EED&I) strategy is focused on creating a culture of equity & inclusion through education, removing barriers, creating differentiation and measurement.","('Employee_Engagement_Inclusion_And_Diversity', 0.44452524185180664)","('Competitive_Behavior', 0.10911748558282852)","('Business_Ethics', 0.08369752764701843)","('NON-ESG', 0.44452524185180664)","('NON-ESG', 0.10911748558282852)","('NON-ESG', 0.08369752764701843)"
Line 825,We work towards gender equity through activities such as our global Womens Leadership Journey development program to help women progress into senior roles.,"('Employee_Engagement_Inclusion_And_Diversity', 0.931775689125061)","('Labor_Practices', 0.013153715059161186)","('Human_Rights_And_Community_Relations', 0.009999053552746773)","(['Talent Attraction & Retention'], 0.931775689125061)","('NON-ESG', 0.013153715059161186)","('NON-ESG', 0.009999053552746773)"
Line 826,"Our anti-discrimination, anti-harassment and anti-violence policies extend through our organization and to our suppliers.","('Employee_Engagement_Inclusion_And_Diversity', 0.3663010001182556)","('Labor_Practices', 0.2522742450237274)","('Employee_Health_And_Safety', 0.12358691543340683)","('NON-ESG', 0.3663010001182556)","('NON-ESG', 0.2522742450237274)","('NON-ESG', 0.12358691543340683)"
Line 827,Read more in the Human Capital Management and Supply Chain Sustainability sections of this report.,"('Supply_Chain_Management', 0.9467088580131531)","('Product_Design_And_Lifecycle_Management', 0.00560166547074914)","('Physical_Impacts_Of_Climate_Change', 0.003924178425222635)","([], 0.9467088580131531)","('NON-ESG', 0.00560166547074914)","('NON-ESG', 0.003924178425222635)"
Line 828,"SDG Relevant sub-targets AbbVies role 6.4 By 2030, substantially increase water-use efficiency across all sectors and ensure sustainable withdrawals and supply of freshwater to address water scarcity and substantially reduce the number of people suffering from water scarcityAccess to clean water is crucial for health, and we are committed to using water responsibly and doing our part to protect this vital resource.","('Water_And_Wastewater_Management', 0.9777345061302185)","('GHG_Emissions', 0.0020864938851445913)","('Ecological_Impacts', 0.001667171367444098)","([], 0.9777345061302185)","('NON-ESG', 0.0020864938851445913)","('NON-ESG', 0.001667171367444098)"
Line 829,We have set an ambitious goal to halve our absolute water withdrawal by 2035 when compared with our 2015 baseline.,"('Water_And_Wastewater_Management', 0.9744320511817932)","('GHG_Emissions', 0.0035824384540319443)","('Energy_Management', 0.0020657239947468042)","([], 0.9744320511817932)","('NON-ESG', 0.0035824384540319443)","('NON-ESG', 0.0020657239947468042)"
Line 830,"To achieve this goal, we focus our efforts on reducing our total global water consumption and investing in innovative technologies that allow us to use water more efficiently.","('Water_And_Wastewater_Management', 0.9749759435653687)","('Energy_Management', 0.003067025914788246)","('GHG_Emissions', 0.0026858875062316656)","([], 0.9749759435653687)","('NON-ESG', 0.003067025914788246)","('NON-ESG', 0.0026858875062316656)"
Line 831,Read more in the Environmental Sustainability section of this report.,"('Ecological_Impacts', 0.26640552282333374)","('Product_Design_And_Lifecycle_Management', 0.12255191057920456)","('Business_Model_Resilience', 0.1035873219370842)","('NON-ESG', 0.26640552282333374)","('NON-ESG', 0.12255191057920456)","('NON-ESG', 0.1035873219370842)"
Line 832,"8.1 Sustain per capita economic growth in accordance with national circumstances 8.2 Achieve higher levels of economic productivity through diversification, technological upgrading and innovation 8.5 Achieve full and productive employment and decent work for all women and men, including for young people and persons with disabilities, and equal pay for work of equal valueWe have employees in more than 70 countries and purchase over $15.6B in goods and services from a supplier network spanning 143 countries and all 50 U.","('Labor_Practices', 0.9403097033500671)","('Employee_Engagement_Inclusion_And_Diversity', 0.009685294702649117)","('Human_Rights_And_Community_Relations', 0.004914921708405018)","([], 0.9403097033500671)","('NON-ESG', 0.009685294702649117)","('NON-ESG', 0.004914921708405018)"
Line 833,"8.1 Sustain per capita economic growth in accordance with national circumstances 8.2 Achieve higher levels of economic productivity through diversification, technological upgrading and innovation 8.5 Achieve full and productive employment and decent work for all women and men, including for young people and persons with disabilities, and equal pay for work of equal valueWe have employees in more than 70 countries and purchase over $15.6B in goods and services from a supplier network spanning 143 countries and all 50 U.","('Management_Of_Legal_And_Regulatory_Framework', 0.7211688160896301)","('Competitive_Behavior', 0.05814081057906151)","('Systemic_Risk_Management', 0.025894731283187866)","([], 0.7211688160896301)","('NON-ESG', 0.05814081057906151)","('NON-ESG', 0.025894731283187866)"
Line 834,S. states.,"('Management_Of_Legal_And_Regulatory_Framework', 0.4789767861366272)","('Competitive_Behavior', 0.06717659533023834)","('GHG_Emissions', 0.04775585979223251)","('NON-ESG', 0.4789767861366272)","('NON-ESG', 0.06717659533023834)","('NON-ESG', 0.04775585979223251)"
Line 835,We recruit and hire from historically underrepresented groups and provide economic opportunity and technical support to small and diverse suppliers.,"('Employee_Engagement_Inclusion_And_Diversity', 0.8645066618919373)","('Supply_Chain_Management', 0.018428560346364975)","('Access_And_Affordability', 0.01306557934731245)","(['Talent Attraction & Retention'], 0.8645066618919373)","('NON-ESG', 0.018428560346364975)","('NON-ESG', 0.01306557934731245)"
Line 836,Supporting communities is also a priority of the AbbVie Foundation.,"('Human_Rights_And_Community_Relations', 0.9196676015853882)","('Access_And_Affordability', 0.02019692398607731)","('Ecological_Impacts', 0.0074041374027729034)","([], 0.9196676015853882)","('NON-ESG', 0.02019692398607731)","('NON-ESG', 0.0074041374027729034)"
Line 837,"We partner with nonprofit organizations and engage our employees to support learning and workforce readiness programs, particularly in underserved communities.","('Access_And_Affordability', 0.9447156190872192)","('Human_Rights_And_Community_Relations', 0.005006983410567045)","('Product_Quality_And_Safety', 0.004813745617866516)","(['Access to Healthcare'], 0.9447156190872192)","('NON-ESG', 0.005006983410567045)","('NON-ESG', 0.004813745617866516)"
Line 838,"Read more in the Supply Chain Sustainability, Human Capital Management, and Community & Partner Engagement and Impact sections of this report.","('Supply_Chain_Management', 0.9475011825561523)","('Product_Design_And_Lifecycle_Management', 0.005175500176846981)","('Physical_Impacts_Of_Climate_Change', 0.003964094910770655)","([], 0.9475011825561523)","('NON-ESG', 0.005175500176846981)","('NON-ESG', 0.003964094910770655)"
Line 839,"9.4 By 2030, upgrade infrastructure and retrofit industries to make them sustainable, with increased resource-use efficiency and greater adoption of clean and environmentally sound technologies and industrial processes, with all countries taking action in accordance with their respective capabilities 9.5 Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spendingIntegrating sustainability into our design, planning and development allows us to embed environmental sustainability into our business activities, supporting our environmental targets and sustainable business growth.","('Product_Design_And_Lifecycle_Management', 0.8050320148468018)","('Energy_Management', 0.06937996298074722)","('Business_Model_Resilience', 0.01193558145314455)","([], 0.8050320148468018)","('NON-ESG', 0.06937996298074722)","('NON-ESG', 0.01193558145314455)"
Line 840,"9.4 By 2030, upgrade infrastructure and retrofit industries to make them sustainable, with increased resource-use efficiency and greater adoption of clean and environmentally sound technologies and industrial processes, with all countries taking action in accordance with their respective capabilities 9.5 Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spendingIntegrating sustainability into our design, planning and development allows us to embed environmental sustainability into our business activities, supporting our environmental targets and sustainable business growth.","('Product_Design_And_Lifecycle_Management', 0.2697364389896393)","('Business_Model_Resilience', 0.18987266719341278)","('Ecological_Impacts', 0.15972372889518738)","('NON-ESG', 0.2697364389896393)","('NON-ESG', 0.18987266719341278)","('NON-ESG', 0.15972372889518738)"
Line 841,"In 2021, we rolled out refreshed Global Facility Design Guidelines to our facility designers and engineers across the globe.","('Product_Design_And_Lifecycle_Management', 0.31605324149131775)","('Business_Model_Resilience', 0.12584251165390015)","('Energy_Management', 0.05949745699763298)","('NON-ESG', 0.31605324149131775)","('NON-ESG', 0.12584251165390015)","('NON-ESG', 0.05949745699763298)"
Line 842,These design guidelines include over 100 sustainable design concepts that can be incorporated into new facility design and upgrades.,"('Product_Design_And_Lifecycle_Management', 0.77019864320755)","('Business_Model_Resilience', 0.03753891587257385)","('Energy_Management', 0.03222532570362091)","([], 0.77019864320755)","('NON-ESG', 0.03753891587257385)","('NON-ESG', 0.03222532570362091)"
Line 843,"Most of our design concepts were integrated into our new R&D facility located in South San Francisco, a LEED Platinum building.","('Product_Design_And_Lifecycle_Management', 0.5803543925285339)","('Business_Model_Resilience', 0.07651612907648087)","('Product_Quality_And_Safety', 0.052170634269714355)","([], 0.5803543925285339)","('NON-ESG', 0.07651612907648087)","('NON-ESG', 0.052170634269714355)"
Line 844,"Opened in 2021, the building includes energy efficient lighting and lighting controls, as well as a rainwater harvesting system.","('Water_And_Wastewater_Management', 0.7158867716789246)","('Energy_Management', 0.1420988291501999)","('GHG_Emissions', 0.020040877163410187)","([], 0.7158867716789246)","('NON-ESG', 0.1420988291501999)","('NON-ESG', 0.020040877163410187)"
Line 845,"AbbVie employs over 11,000 professionals worldwide in Research & Development.","('Employee_Engagement_Inclusion_And_Diversity', 0.41597315669059753)","('Supply_Chain_Management', 0.07041916996240616)","('Human_Rights_And_Community_Relations', 0.06240609660744667)","('NON-ESG', 0.41597315669059753)","('NON-ESG', 0.07041916996240616)","('NON-ESG', 0.06240609660744667)"
Line 846,Read more in the Environmental Sustainability and Product Innovation sections of this report.,"('Product_Design_And_Lifecycle_Management', 0.9633116126060486)","('Product_Quality_And_Safety', 0.004451379645615816)","('Supply_Chain_Management', 0.00305324699729681)","([], 0.9633116126060486)","('NON-ESG', 0.004451379645615816)","('NON-ESG', 0.00305324699729681)"
Line 847,We are committed to contributing to the United Nations Sustainable Development Goals (SDGs).,"('Human_Rights_And_Community_Relations', 0.44989389181137085)","('Business_Model_Resilience', 0.14720936119556427)","('Ecological_Impacts', 0.08116153627634048)","('NON-ESG', 0.44989389181137085)","('NON-ESG', 0.14720936119556427)","('NON-ESG', 0.08116153627634048)"
Line 848,We have identified ten SDGs that align closely with our actions.,"('Management_Of_Legal_And_Regulatory_Framework', 0.4055137634277344)","('Human_Rights_And_Community_Relations', 0.23652878403663635)","('Business_Model_Resilience', 0.05762597918510437)","('NON-ESG', 0.4055137634277344)","('NON-ESG', 0.23652878403663635)","('NON-ESG', 0.05762597918510437)"
Line 849,"Our Contribution to the UN SDGsIndexes62 2021 ESG Action Report 2021 ESG Action Report 63 SDG Relevant sub-targets AbbVies role 10.2 Sustain per capita economic growth in accordance with national circumstances 10.4 Achieve higher levels of economic productivity through diversification, technological upgrading and innovationEquality of opportunity is very important to us.","('Systemic_Risk_Management', 0.33117687702178955)","('Competitive_Behavior', 0.24120700359344482)","('Business_Model_Resilience', 0.21225620806217194)","('NON-ESG', 0.33117687702178955)","('NON-ESG', 0.24120700359344482)","('NON-ESG', 0.21225620806217194)"
Line 850,"After our $50 million commitment in late 2020 to advance health and education equity in Black and historically marginalized communities, weve worked with our nonprofit partners to set the foundation for their programs and are accelerating measurable progress on health, education, and workforce disparities rooted in racism.","('Employee_Engagement_Inclusion_And_Diversity', 0.546129584312439)","('Access_And_Affordability', 0.18080471456050873)","('Human_Rights_And_Community_Relations', 0.10372532904148102)","(['Talent Attraction & Retention'], 0.546129584312439)","('NON-ESG', 0.18080471456050873)","('NON-ESG', 0.10372532904148102)"
Line 851,"Internally, through our five-year EEDI strategy that was established in 2019, we have developed new initiatives and continued our progress towards our objectives that aim to address historical inequities and provide equal opportunities for employment and advancements.","('Employee_Engagement_Inclusion_And_Diversity', 0.931311845779419)","('Labor_Practices', 0.010980360209941864)","('Human_Rights_And_Community_Relations', 0.009780404157936573)","(['Talent Attraction & Retention'], 0.931311845779419)","('NON-ESG', 0.010980360209941864)","('NON-ESG', 0.009780404157936573)"
Line 852,Read more in the Community & Partner Engagement and Impact and Human Capital Management sections of this report.,"('Human_Rights_And_Community_Relations', 0.9368096590042114)","('Business_Model_Resilience', 0.0065905810333788395)","('Access_And_Affordability', 0.0050111510790884495)","([], 0.9368096590042114)","('NON-ESG', 0.0065905810333788395)","('NON-ESG', 0.0050111510790884495)"
Line 853,"11.5 Reduce the number of people affected andsubstantially decrease the direct economic losses caused by disasters with a focus on protecting the poor and people in vulnerable situations 11.6 By 2030, reduce the adverse per capita environmental impact of cities, including by paying special attention to air quality and municipal and other waste managementOur philanthropic work is focused on investing in long-term solutions that build community strength and resilience.","('Air_Quality', 0.8622578978538513)","('Critical_Incident_Risk_Management', 0.0369277223944664)","('Physical_Impacts_Of_Climate_Change', 0.027080679312348366)","([], 0.8622578978538513)","('NON-ESG', 0.0369277223944664)","('NON-ESG', 0.027080679312348366)"
Line 854,"For example, we have been making long-term investments in Puerto Rico to assist in recovery efforts following natural disasters and be better prepared for future disasters.","('Critical_Incident_Risk_Management', 0.9248360395431519)","('Physical_Impacts_Of_Climate_Change', 0.028163019567728043)","('Air_Quality', 0.004872525576502085)","([], 0.9248360395431519)","('NON-ESG', 0.028163019567728043)","('NON-ESG', 0.004872525576502085)"
Line 855,"In addition, in 2021, we supported underserved communities in the US, Brazil and India by providing COVID-19 surge relief and vaccine access.","('Access_And_Affordability', 0.9454447627067566)","('Critical_Incident_Risk_Management', 0.004864280112087727)","('Human_Rights_And_Community_Relations', 0.004693778697401285)","(['Access to Healthcare'], 0.9454447627067566)","('NON-ESG', 0.004864280112087727)","('NON-ESG', 0.004693778697401285)"
Line 856,"As a pharmaceutical company, we produce hazardous and non-hazardous waste at our manufacturing and research sites.","('Waste_And_Hazardous_Materials_Management', 0.9844748973846436)","('Data_Security', 0.0010926821269094944)","('Employee_Health_And_Safety', 0.0010681945132091641)","([], 0.9844748973846436)","('NON-ESG', 0.0010926821269094944)","('NON-ESG', 0.0010681945132091641)"
Line 857,We recognize the importance of minimizing waste and using appropriate disposal methods.,"('Waste_And_Hazardous_Materials_Management', 0.9838427305221558)","('Water_And_Wastewater_Management', 0.0014170658541843295)","('Air_Quality', 0.0010917691979557276)","([], 0.9838427305221558)","('NON-ESG', 0.0014170658541843295)","('NON-ESG', 0.0010917691979557276)"
Line 858,"Whenever possible, we avoid landfills and continuously evaluate opportunities to reduce, reuse, and recycle our waste materials.","('Waste_And_Hazardous_Materials_Management', 0.9829599857330322)","('Water_And_Wastewater_Management', 0.001512389280833304)","('Data_Security', 0.0011700628092512488)","([], 0.9829599857330322)","('NON-ESG', 0.001512389280833304)","('NON-ESG', 0.0011700628092512488)"
Line 859,"In 2016, we set a goal to send zero waste to landfill by 2035.","('Waste_And_Hazardous_Materials_Management', 0.98311448097229)","('Water_And_Wastewater_Management', 0.0016268834006041288)","('Air_Quality', 0.0013370889937505126)","([], 0.98311448097229)","('NON-ESG', 0.0016268834006041288)","('NON-ESG', 0.0013370889937505126)"
Line 860,"As of 2021, were 89% of the way to achieving this goal.","('Management_Of_Legal_And_Regulatory_Framework', 0.4257076680660248)","('Human_Rights_And_Community_Relations', 0.14400725066661835)","('Business_Model_Resilience', 0.03876082971692085)","('NON-ESG', 0.4257076680660248)","('NON-ESG', 0.14400725066661835)","('NON-ESG', 0.03876082971692085)"
Line 861,Read more in the Community & Partner Engagement and Impact and Environmental Sustainability sections of this report.,"('Human_Rights_And_Community_Relations', 0.7839069366455078)","('Ecological_Impacts', 0.08866238594055176)","('Business_Model_Resilience', 0.016106752678751945)","([], 0.7839069366455078)","('NON-ESG', 0.08866238594055176)","('NON-ESG', 0.016106752678751945)"
Line 862,"12.2 Achieve sustainable management and efficient use of naturalresources 12.4 Achieve environmentally sound management of chemicals and wastes; significantly reduce their release to air, water and soil to minimize adverse impacts on health and the environment 12.5 Reduce waste generation through prevention, reduction, recycling and reuse 12.6 Encourage companies to adopt sustainable practices andintegrate sustainability information into their reporting cycleTo operate sustainably, we must use natural resources efficiently and manage waste in a way that preserves the health of our environment.","('Waste_And_Hazardous_Materials_Management', 0.970496416091919)","('Product_Design_And_Lifecycle_Management', 0.004491712432354689)","('Water_And_Wastewater_Management', 0.0025040232576429844)","([], 0.970496416091919)","('NON-ESG', 0.004491712432354689)","('NON-ESG', 0.0025040232576429844)"
Line 863,"12.2 Achieve sustainable management and efficient use of naturalresources 12.4 Achieve environmentally sound management of chemicals and wastes; significantly reduce their release to air, water and soil to minimize adverse impacts on health and the environment 12.5 Reduce waste generation through prevention, reduction, recycling and reuse 12.6 Encourage companies to adopt sustainable practices andintegrate sustainability information into their reporting cycleTo operate sustainably, we must use natural resources efficiently and manage waste in a way that preserves the health of our environment.","('Waste_And_Hazardous_Materials_Management', 0.9839023947715759)","('Water_And_Wastewater_Management', 0.0013669623294845223)","('Air_Quality', 0.0013379908632487059)","([], 0.9839023947715759)","('NON-ESG', 0.0013669623294845223)","('NON-ESG', 0.0013379908632487059)"
Line 864,"We have set absolute targets for reduction of our carbon emissions, water consumption and waste generation and are actively taking steps to meet them.","('Water_And_Wastewater_Management', 0.5649020075798035)","('Waste_And_Hazardous_Materials_Management', 0.1675281971693039)","('Energy_Management', 0.10657713562250137)","([], 0.5649020075798035)","('NON-ESG', 0.1675281971693039)","('NON-ESG', 0.10657713562250137)"
Line 865,Read more in the Environmental Sustainability section of this report.,"('Ecological_Impacts', 0.26640552282333374)","('Product_Design_And_Lifecycle_Management', 0.12255191057920456)","('Business_Model_Resilience', 0.1035873219370842)","('NON-ESG', 0.26640552282333374)","('NON-ESG', 0.12255191057920456)","('NON-ESG', 0.1035873219370842)"
Line 866,SDG Relevant sub-targets AbbVies role 13.1 Strengthen resilience and adaptive capacity to climate-related hazards and natural disasters in all countriesClimate change will increasingly impact health and well-being globally.,"('Physical_Impacts_Of_Climate_Change', 0.8681002259254456)","('Business_Model_Resilience', 0.06006326898932457)","('Supply_Chain_Management', 0.008047763258218765)","([], 0.8681002259254456)","('NON-ESG', 0.06006326898932457)","('NON-ESG', 0.008047763258218765)"
Line 867,We continually evaluate the impact of climate change on our business.,"('Physical_Impacts_Of_Climate_Change', 0.953826904296875)","('Business_Model_Resilience', 0.008036731742322445)","('Critical_Incident_Risk_Management', 0.0037842481397092342)","([], 0.953826904296875)","('NON-ESG', 0.008036731742322445)","('NON-ESG', 0.0037842481397092342)"
Line 868,"As a provider of essential medicines, we must minimize the impacts on our continuity of supply and have a governance approach in place to do so.","('Supply_Chain_Management', 0.7978929281234741)","('Water_And_Wastewater_Management', 0.029608672484755516)","('Selling_Practices_And_Product_Labeling', 0.021712766960263252)","([], 0.7978929281234741)","('NON-ESG', 0.029608672484755516)","('NON-ESG', 0.021712766960263252)"
Line 869,We anticipate climate-related risks and act proactively to mitigate them.,"('Physical_Impacts_Of_Climate_Change', 0.9298089742660522)","('Business_Model_Resilience', 0.015172786079347134)","('Systemic_Risk_Management', 0.012117804028093815)","([], 0.9298089742660522)","('NON-ESG', 0.015172786079347134)","('NON-ESG', 0.012117804028093815)"
Line 870,We also support disaster relief partners to help to strengthen community resilience and recovery from climate- related hazards.,"('Critical_Incident_Risk_Management', 0.9692772626876831)","('Physical_Impacts_Of_Climate_Change', 0.0038763617631047964)","('Air_Quality', 0.0027441619895398617)","([], 0.9692772626876831)","('NON-ESG', 0.0038763617631047964)","('NON-ESG', 0.0027441619895398617)"
Line 871,We committed to join the Science Based Targets initiative (SBTi) and are working on setting ambitious science-based emissions reduction targets.,"('GHG_Emissions', 0.6928555965423584)","('Air_Quality', 0.13783858716487885)","('Energy_Management', 0.05947861820459366)","(['Operational Eco-Efficiency'], 0.6928555965423584)","('NON-ESG', 0.13783858716487885)","('NON-ESG', 0.05947861820459366)"
Line 872,Read more in the Environmental Sustainability and Community & Partner Engagement and Impact sections of this report.,"('Human_Rights_And_Community_Relations', 0.8180067539215088)","('Ecological_Impacts', 0.0657953992486)","('Business_Model_Resilience', 0.01598709262907505)","([], 0.8180067539215088)","('NON-ESG', 0.0657953992486)","('NON-ESG', 0.01598709262907505)"
Line 873,"64 2021 ESG Action Report 2021 ESG Action Report 65 Safety of Clinical Trial Participants HC-BP-210a.1 Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials We require all our clinical studies to be conducted in a manner consistent with the ethical principles outlined in the World Medical Associations Declaration of Helsinki and to adhere to applicable standards set by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).","('Product_Quality_And_Safety', 0.8622820973396301)","('Customer_Welfare', 0.01658713072538376)","('Employee_Health_And_Safety', 0.013094935566186905)","(['Product Quality & Recall Management'], 0.8622820973396301)","('NON-ESG', 0.01658713072538376)","('NON-ESG', 0.013094935566186905)"
Line 874,"64 2021 ESG Action Report 2021 ESG Action Report 65 Safety of Clinical Trial Participants HC-BP-210a.1 Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials We require all our clinical studies to be conducted in a manner consistent with the ethical principles outlined in the World Medical Associations Declaration of Helsinki and to adhere to applicable standards set by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).","('Customer_Welfare', 0.3688969016075134)","('Selling_Practices_And_Product_Labeling', 0.21481145918369293)","('Product_Quality_And_Safety', 0.09265472739934921)","('NON-ESG', 0.3688969016075134)","('NON-ESG', 0.21481145918369293)","('NON-ESG', 0.09265472739934921)"
Line 875,"This includes adherence to Good Clinical Practice, Good Laboratory Practice and Good Manufacturing Practice standards, which provide assurance that the rights, safety, well- being and ethical treatment of trial participants are protected.","('Product_Quality_And_Safety', 0.9105257391929626)","('Employee_Health_And_Safety', 0.010742400772869587)","('Selling_Practices_And_Product_Labeling', 0.008891814388334751)","(['Product Quality & Recall Management'], 0.9105257391929626)","('NON-ESG', 0.010742400772869587)","('NON-ESG', 0.008891814388334751)"
Line 876,Read more in the Clinical Trials section of this report.,"('Competitive_Behavior', 0.12196899950504303)","('Access_And_Affordability', 0.09936060011386871)","('Customer_Welfare', 0.09370606392621994)","('NON-ESG', 0.12196899950504303)","('NON-ESG', 0.09936060011386871)","('NON-ESG', 0.09370606392621994)"
Line 877,Conduct of Clinical Trials & Postmarketing Commitments Registration of protocols & results reporting Clinical Trials Our Commitment to Bioethics HC-BP-210a.2 Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) U.,"('Competitive_Behavior', 0.3023155927658081)","('Management_Of_Legal_And_Regulatory_Framework', 0.10284151136875153)","('Customer_Welfare', 0.0824301615357399)","('NON-ESG', 0.3023155927658081)","('NON-ESG', 0.10284151136875153)","('NON-ESG', 0.0824301615357399)"
Line 878,S. Food & Drug Administration Inspection Classification Database HC-BP-210a.3 Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries Not reported.,"('Management_Of_Legal_And_Regulatory_Framework', 0.3862753212451935)","('Competitive_Behavior', 0.10014847666025162)","('Product_Quality_And_Safety', 0.10008556395769119)","('NON-ESG', 0.3862753212451935)","('NON-ESG', 0.10014847666025162)","('NON-ESG', 0.10008556395769119)"
Line 879,"Access to Medicines HC-BP-240a.1 Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index At AbbVie, we believe patients need access to quality and affordable medicines.","('Access_And_Affordability', 0.7835646867752075)","('Customer_Welfare', 0.026037471368908882)","('Product_Quality_And_Safety', 0.025811277329921722)","(['Access to Healthcare'], 0.7835646867752075)","('NON-ESG', 0.026037471368908882)","('NON-ESG', 0.025811277329921722)"
Line 880,"We continuously strive to improve health outcomes and increase access to healthcare services and our medicines for patients around the world, including through agreements with the Medicines Patent Pool.","('Access_And_Affordability', 0.4247629642486572)","('Customer_Welfare', 0.12266446650028229)","('Selling_Practices_And_Product_Labeling', 0.07124192267656326)","('NON-ESG', 0.4247629642486572)","('NON-ESG', 0.12266446650028229)","('NON-ESG', 0.07124192267656326)"
Line 881,"AbbVie partners with stakeholders on interventions to help build healthcare capacity, increase the quality and frequency of health worker training and educate patients about disease awareness, symptom management and treatment options.","('Employee_Health_And_Safety', 0.43970465660095215)","('Access_And_Affordability', 0.2982414662837982)","('Product_Quality_And_Safety', 0.03657214343547821)","('NON-ESG', 0.43970465660095215)","('NON-ESG', 0.2982414662837982)","('NON-ESG', 0.03657214343547821)"
Line 882,Making Medicine Accessible Our Commitment to Access to Medicine AbbVie Contribution to Combatting Neglected Tropical Diseases AbbVie MPP HCV Agreement AbbVie MPP HIV Agreement HC-BP-240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) World Health Organization Prequalification of Medical ProductsCounterfeit Drugs HC-BP-260a.1 Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting Specific risks are overseen by our Risk Management and Global Security teams.,"('Product_Design_And_Lifecycle_Management', 0.5666748881340027)","('Customer_Welfare', 0.11349783837795258)","('Selling_Practices_And_Product_Labeling', 0.10697492212057114)","([], 0.5666748881340027)","('NON-ESG', 0.11349783837795258)","('NON-ESG', 0.10697492212057114)"
Line 883,Making Medicine Accessible Our Commitment to Access to Medicine AbbVie Contribution to Combatting Neglected Tropical Diseases AbbVie MPP HCV Agreement AbbVie MPP HIV Agreement HC-BP-240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) World Health Organization Prequalification of Medical ProductsCounterfeit Drugs HC-BP-260a.1 Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting Specific risks are overseen by our Risk Management and Global Security teams.,"('Data_Security', 0.436523973941803)","('Business_Ethics', 0.22448228299617767)","('Systemic_Risk_Management', 0.0845734253525734)","('NON-ESG', 0.436523973941803)","('NON-ESG', 0.22448228299617767)","('NON-ESG', 0.0845734253525734)"
Line 884,Our Global Anti-Counterfeiting Steering Committee is responsible for identifying and mitigating risks related to AbbVie medicines.,"('Data_Security', 0.36057740449905396)","('Business_Ethics', 0.17203371226787567)","('Systemic_Risk_Management', 0.09368060529232025)","('NON-ESG', 0.36057740449905396)","('NON-ESG', 0.17203371226787567)","('NON-ESG', 0.09368060529232025)"
Line 885,They coordinate proactive strategies for preventing counterfeiting and diversion of our medicines and conduct routine monitoring to identify signals of possible counterfeiting or diversion.,"('Business_Ethics', 0.5680791735649109)","('Competitive_Behavior', 0.11941450089216232)","('Data_Security', 0.09058699011802673)","(['Business Ethics'], 0.5680791735649109)","('NON-ESG', 0.11941450089216232)","('NON-ESG', 0.09058699011802673)"
Line 886,"In 2021, the Office of Ethics and Compliance worked with external consulting firms to review AbbVies policies, systems and controls related to high-risk business areas/activities.","('Business_Ethics', 0.9711138606071472)","('Management_Of_Legal_And_Regulatory_Framework', 0.004522813484072685)","('Product_Quality_And_Safety', 0.002582699991762638)","(['Business Ethics'], 0.9711138606071472)","('NON-ESG', 0.004522813484072685)","('NON-ESG', 0.002582699991762638)"
Line 887,"Read more in the Risk Management, Product Quality and Safety and Supply Chain Sustainability sections of this report.","('Product_Design_And_Lifecycle_Management', 0.6910906434059143)","('Supply_Chain_Management', 0.1659187376499176)","('Product_Quality_And_Safety', 0.02359674498438835)","([], 0.6910906434059143)","('NON-ESG', 0.1659187376499176)","('NON-ESG', 0.02359674498438835)"
Line 888,"See AbbVie Supplier Code of Conduct HC-BP-260a.2 Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products AbbVie has established and maintains systems for global reporting of events and deviations, including counterfeit products.","('Product_Design_And_Lifecycle_Management', 0.2638814151287079)","('Product_Quality_And_Safety', 0.22413240373134613)","('Selling_Practices_And_Product_Labeling', 0.08973919600248337)","('NON-ESG', 0.2638814151287079)","('NON-ESG', 0.22413240373134613)","('NON-ESG', 0.08973919600248337)"
Line 889,Any possible events will be submitted accurately and timely per the pertinent regulations.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9543722867965698)","('Physical_Impacts_Of_Climate_Change', 0.004436402581632137)","('Director_Removal', 0.0035929838195443153)","([], 0.9543722867965698)","('NON-ESG', 0.004436402581632137)","('NON-ESG', 0.0035929838195443153)"
Line 890,"See AbbVie Supplier Code of Conduct HC-BP-260a.3 Number of actions that led to raids, seizure, arrests and/or filing or criminal charges related to counterfeit products Not reported.","('Business_Ethics', 0.22418974339962006)","('Product_Quality_And_Safety', 0.21833132207393646)","('Selling_Practices_And_Product_Labeling', 0.12325528264045715)","('NON-ESG', 0.22418974339962006)","('NON-ESG', 0.21833132207393646)","('NON-ESG', 0.12325528264045715)"
Line 891,"Affordability & Pricing HC-BP-240b.1 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period If there are material legal proceedings associated with ANDA litigation and public disclosure criteria are met, details would be included in 2021 Annual Report on Form 10-K and in Quarterly Reports on Form 10-Q.","('Competitive_Behavior', 0.5131598711013794)","('Customer_Welfare', 0.10855119675397873)","('Selling_Practices_And_Product_Labeling', 0.09507656842470169)","([], 0.5131598711013794)","('NON-ESG', 0.10855119675397873)","('NON-ESG', 0.09507656842470169)"
Line 892,HC-BP-240b.2 Percentage change in: (1) average list price and (2) average net price across U.,"('Competitive_Behavior', 0.6376466155052185)","('Systemic_Risk_Management', 0.06704984605312347)","('Energy_Management', 0.04263804480433464)","([], 0.6376466155052185)","('NON-ESG', 0.06704984605312347)","('NON-ESG', 0.04263804480433464)"
Line 893,S product portfolio compared to previous year Not reported.,"('Product_Design_And_Lifecycle_Management', 0.8799683451652527)","('Business_Model_Resilience', 0.016276441514492035)","('Supply_Chain_Management', 0.013772629201412201)","([], 0.8799683451652527)","('NON-ESG', 0.016276441514492035)","('NON-ESG', 0.013772629201412201)"
Line 894,HC-BP-240b.3 Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year Not reported.,"('Product_Design_And_Lifecycle_Management', 0.6177200675010681)","('Selling_Practices_And_Product_Labeling', 0.09543345868587494)","('Customer_Welfare', 0.06033685803413391)","([], 0.6177200675010681)","('NON-ESG', 0.09543345868587494)","('NON-ESG', 0.06033685803413391)"
Line 895,Drug Safety HC-BP-250a.1 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period U.,"('Product_Quality_And_Safety', 0.38347864151000977)","('Competitive_Behavior', 0.2353084236383438)","('Selling_Practices_And_Product_Labeling', 0.08259117603302002)","('NON-ESG', 0.38347864151000977)","('NON-ESG', 0.2353084236383438)","('NON-ESG', 0.08259117603302002)"
Line 896,S. Food & Drug Administration (FDA) Med Watch Safety Alerts for Human Medical Products HC-BP-250a.2 Percentage change in: (1) average list price and (2) average net price across U.,"('Product_Quality_And_Safety', 0.7449617981910706)","('Selling_Practices_And_Product_Labeling', 0.08034758269786835)","('Customer_Welfare', 0.03024485893547535)","(['Product Quality & Recall Management'], 0.7449617981910706)","('NON-ESG', 0.08034758269786835)","('NON-ESG', 0.03024485893547535)"
Line 897,S product portfolio compared to previous year U.,"('Product_Design_And_Lifecycle_Management', 0.8885747790336609)","('Customer_Welfare', 0.013200187124311924)","('Business_Model_Resilience', 0.012592200189828873)","([], 0.8885747790336609)","('NON-ESG', 0.013200187124311924)","('NON-ESG', 0.012592200189828873)"
Line 898,S Food & Drug Administration (FDA)Adverse Event Reporting System (FEARS) Public Dashboard HC-BP-250a.3 Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year FDA Class I Recalls: 0 FDA Class II Product Recalls: 1 Read more in the Product Quality and Safety section of this report.,"('Product_Quality_And_Safety', 0.8752481937408447)","('Selling_Practices_And_Product_Labeling', 0.02494179829955101)","('Competitive_Behavior', 0.008416460826992989)","(['Product Quality & Recall Management'], 0.8752481937408447)","('NON-ESG', 0.02494179829955101)","('NON-ESG', 0.008416460826992989)"
Line 899,U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.14571937918663025)","('Product_Design_And_Lifecycle_Management', 0.12332227826118469)","('Employee_Engagement_Inclusion_And_Diversity', 0.06306221336126328)","('NON-ESG', 0.14571937918663025)","('NON-ESG', 0.12332227826118469)","('NON-ESG', 0.06306221336126328)"
Line 900,"S Food & Drug Administration (FDA)Adverse Event Reporting System (FEARS) Public Dashboard HC-BP-250a.4 Total amount of product accepted for takeback, reuse, or disposal Not reported.","('Product_Quality_And_Safety', 0.5480575561523438)","('Selling_Practices_And_Product_Labeling', 0.2024967074394226)","('Product_Design_And_Lifecycle_Management', 0.06141170486807823)","(['Product Quality & Recall Management'], 0.5480575561523438)","('NON-ESG', 0.2024967074394226)","('NON-ESG', 0.06141170486807823)"
Line 901,HC-BP-250a.5 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type Not reported.,"('Management_Of_Legal_And_Regulatory_Framework', 0.5068101286888123)","('Business_Ethics', 0.2501804828643799)","('Product_Quality_And_Safety', 0.07775217294692993)","([], 0.5068101286888123)","('NON-ESG', 0.2501804828643799)","('NON-ESG', 0.07775217294692993)"
Line 902,"SASB Index: Biotechnology & Pharmaceuticals66 2021 ESG Action Report 2021 ESG Action Report 67 Ethical Marketing HC-BP-270a.1 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims If there are material legal proceedings associated with false marketing claims and public disclosure criteria are met, monetary losses as a result of legal proceedings would be included in 2021 Annual Report Form 10-K and in Quarterly Reports on Form 10-Q.","('Business_Ethics', 0.8127733469009399)","('Competitive_Behavior', 0.033736370503902435)","('Product_Quality_And_Safety', 0.027732133865356445)","(['Business Ethics'], 0.8127733469009399)","('NON-ESG', 0.033736370503902435)","('NON-ESG', 0.027732133865356445)"
Line 903,HC-BP-270a.2 Description of code of ethics governing promotion of off-label use of products AbbVie only promotes our pharmaceutical products for uses that have been approved or authorized by appropriate government or regulatory agencies.,"('Selling_Practices_And_Product_Labeling', 0.7457671165466309)","('Customer_Welfare', 0.07960774004459381)","('Product_Quality_And_Safety', 0.05423944070935249)","(['Business Ethics'], 0.7457671165466309)","('NON-ESG', 0.07960774004459381)","('NON-ESG', 0.05423944070935249)"
Line 904,"AbbVie product claims are grounded in scientific evidence, accepted medical practice and government-approved labeling rules in all countries where we operate.","('Selling_Practices_And_Product_Labeling', 0.8602914214134216)","('Customer_Welfare', 0.03546316921710968)","('Product_Quality_And_Safety', 0.02510625496506691)","(['Business Ethics'], 0.8602914214134216)","('NON-ESG', 0.03546316921710968)","('NON-ESG', 0.02510625496506691)"
Line 905,See AbbVie Code of Business Conduct for more information.,"('Business_Ethics', 0.8444218039512634)","('Management_Of_Legal_And_Regulatory_Framework', 0.03758286312222481)","('Systemic_Risk_Management', 0.01444323267787695)","(['Business Ethics'], 0.8444218039512634)","('NON-ESG', 0.03758286312222481)","('NON-ESG', 0.01444323267787695)"
Line 906,"Employee Recruitment, Development & Retention HC-BP-330a.1 Discussion of talent recruitment and retention efforts for scientists and research and development personnel We strive to ensure every employee is aware of, and has access to, opportunities for learning, growth and advancement.","('Employee_Engagement_Inclusion_And_Diversity', 0.9692299962043762)","('Employee_Health_And_Safety', 0.003342229872941971)","('Customer_Welfare', 0.0018403682624921203)","(['Talent Attraction & Retention'], 0.9692299962043762)","('NON-ESG', 0.003342229872941971)","('NON-ESG', 0.0018403682624921203)"
Line 907,"We believe in self- directed growth and development, where employees set the objectives that they want to achieve.","('Human_Rights_And_Community_Relations', 0.45060282945632935)","('Employee_Engagement_Inclusion_And_Diversity', 0.10715770721435547)","('Business_Model_Resilience', 0.09730905294418335)","('NON-ESG', 0.45060282945632935)","('NON-ESG', 0.10715770721435547)","('NON-ESG', 0.09730905294418335)"
Line 908,We supplement this individualized approach with company-wide education and an investment in emerging leaders.,"('Employee_Engagement_Inclusion_And_Diversity', 0.48335179686546326)","('Access_And_Affordability', 0.1364162415266037)","('Business_Model_Resilience', 0.0450826957821846)","('NON-ESG', 0.48335179686546326)","('NON-ESG', 0.1364162415266037)","('NON-ESG', 0.0450826957821846)"
Line 909,"We also conduct annual Talent Management Reviews, driven from the organizational perspective and led by our leaders across all functions.","('Employee_Engagement_Inclusion_And_Diversity', 0.9520673155784607)","('Business_Model_Resilience', 0.0041917734779417515)","('Employee_Health_And_Safety', 0.003617189358919859)","(['Talent Attraction & Retention'], 0.9520673155784607)","('NON-ESG', 0.0041917734779417515)","('NON-ESG', 0.003617189358919859)"
Line 910,Read more in the Developing and Engaging Diverse Talent and Developing Our People section of this report.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9338106513023376)","('Human_Rights_And_Community_Relations', 0.008842743001878262)","('Employee_Health_And_Safety', 0.005100331734865904)","(['Talent Attraction & Retention'], 0.9338106513023376)","('NON-ESG', 0.008842743001878262)","('NON-ESG', 0.005100331734865904)"
Line 911,"HC-BP-330a.2 (1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others Overall turnover rate in 2021: 10.7% Voluntary turnover rate in 2021: 8.1% Please see KPIs in the Human Capital Management section.","('Employee_Engagement_Inclusion_And_Diversity', 0.23185306787490845)","('Labor_Practices', 0.2111407220363617)","('Director_Removal', 0.13835066556930542)","('NON-ESG', 0.23185306787490845)","('NON-ESG', 0.2111407220363617)","('NON-ESG', 0.13835066556930542)"
Line 912,"Supply Chain Sustainability HC-BP-430a.1 Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients See AbbVie Supplier Code of Conduct Business Ethics HC-BP-510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery If there are material legal proceedings associated with corruption and bribery and public disclosure criteria are met, monetary losses would be included in AbbVies 2021 Annual Report Form 10-K and in Quarterly Reports on Form 10-Q .","('Business_Ethics', 0.9329567551612854)","('Labor_Practices', 0.006595331709831953)","('Product_Quality_And_Safety', 0.005136383231729269)","(['Business Ethics'], 0.9329567551612854)","('NON-ESG', 0.006595331709831953)","('NON-ESG', 0.005136383231729269)"
Line 913,"Supply Chain Sustainability HC-BP-430a.1 Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients See AbbVie Supplier Code of Conduct Business Ethics HC-BP-510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery If there are material legal proceedings associated with corruption and bribery and public disclosure criteria are met, monetary losses would be included in AbbVies 2021 Annual Report Form 10-K and in Quarterly Reports on Form 10-Q .","('Business_Ethics', 0.9764366149902344)","('Management_Of_Legal_And_Regulatory_Framework', 0.0022864092607051134)","('Data_Security', 0.001751432428136468)","(['Business Ethics'], 0.9764366149902344)","('NON-ESG', 0.0022864092607051134)","('NON-ESG', 0.001751432428136468)"
Line 914,HC-BP-510a.2 Description of code of ethics governing interactions with healthcare professionals AbbVie is fair and open in our interactions with healthcare professionals.,"('Business_Ethics', 0.9569230079650879)","('Management_Of_Legal_And_Regulatory_Framework', 0.006332760211080313)","('Product_Quality_And_Safety', 0.0046166349202394485)","(['Business Ethics'], 0.9569230079650879)","('NON-ESG', 0.006332760211080313)","('NON-ESG', 0.0046166349202394485)"
Line 915,AbbVie does not offer or give gifts or other items or services of value to earn favor for our products or to sway medical judgement.,"('Product_Design_And_Lifecycle_Management', 0.40293699502944946)","('Selling_Practices_And_Product_Labeling', 0.29493510723114014)","('Customer_Welfare', 0.04793691635131836)","('NON-ESG', 0.40293699502944946)","('NON-ESG', 0.29493510723114014)","('NON-ESG', 0.04793691635131836)"
Line 916,AbbVie relies on product quality and healthcare outcomes to influence purchasing and prescribing practices.,"('Selling_Practices_And_Product_Labeling', 0.24159370362758636)","('Product_Design_And_Lifecycle_Management', 0.22283999621868134)","('Customer_Welfare', 0.2153112143278122)","('NON-ESG', 0.24159370362758636)","('NON-ESG', 0.22283999621868134)","('NON-ESG', 0.2153112143278122)"
Line 917,"See Business Ethics section of the report and AbbVie Code of Business Conduct Activity Metrics HC-BP-000.A Number of patients treated Approximately 62 million HC-BP-000.B Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3) AbbVie medicines and devices treat more than 60 conditions across infant, adolescent, adult and senior stages of life.","('Business_Ethics', 0.7068958282470703)","('Product_Quality_And_Safety', 0.07697144895792007)","('Access_And_Affordability', 0.030643973499536514)","(['Business Ethics'], 0.7068958282470703)","('NON-ESG', 0.07697144895792007)","('NON-ESG', 0.030643973499536514)"
Line 918,"AbbVies pipeline currently includes more than 90 compounds, devices or indications in development individually or under collaboration or license agreements.","('GHG_Emissions', 0.26699545979499817)","('Customer_Welfare', 0.10582990944385529)","('Competitive_Behavior', 0.081614650785923)","('NON-ESG', 0.26699545979499817)","('NON-ESG', 0.10582990944385529)","('NON-ESG', 0.081614650785923)"
Line 919,"Of these programs, more than 50 are in mid- and late-stage development.","('Access_And_Affordability', 0.658031165599823)","('Employee_Engagement_Inclusion_And_Diversity', 0.04914715513586998)","('Customer_Welfare', 0.03229820728302002)","(['Access to Healthcare'], 0.658031165599823)","('NON-ESG', 0.04914715513586998)","('NON-ESG', 0.03229820728302002)"
Line 920,"AbbVie Inc. 1 North Waukegan Road North Chicago, IL 60064 U.","('Business_Model_Resilience', 0.15109314024448395)","('Supply_Chain_Management', 0.0806078389286995)","('Competitive_Behavior', 0.07249407470226288)","('NON-ESG', 0.15109314024448395)","('NON-ESG', 0.0806078389286995)","('NON-ESG', 0.07249407470226288)"
Line 921,S.A. abbvie.com 2022 AbbVie.,"('Management_Of_Legal_And_Regulatory_Framework', 0.16880114376544952)","('Business_Model_Resilience', 0.1526499092578888)","('Customer_Privacy', 0.11732108891010284)","('NON-ESG', 0.16880114376544952)","('NON-ESG', 0.1526499092578888)","('NON-ESG', 0.11732108891010284)"
Line 922,All rights reserved.,"('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 923,"For more information, visit: abbvie.com abbvie.com/societalimpact","('Management_Of_Legal_And_Regulatory_Framework', 0.2725054621696472)","('Business_Ethics', 0.06297139078378677)","('Competitive_Behavior', 0.05835680663585663)","('NON-ESG', 0.2725054621696472)","('NON-ESG', 0.06297139078378677)","('NON-ESG', 0.05835680663585663)"
